<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) - Ruospo, M - 2018 | Cochrane Library</title> <meta content="Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) - Ruospo, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006023.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) - Ruospo, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006023.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006023.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD)" name="citation_title"/> <meta content="Marinella Ruospo" name="citation_author"/> <meta content="Diaverum" name="citation_author_institution"/> <meta content="marinella.ruospo@gmail.com" name="citation_author_email"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Patrizia Natale" name="citation_author"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Mariacristina Vecchio" name="citation_author"/> <meta content="Danone Research" name="citation_author_institution"/> <meta content="Grahame J Elder" name="citation_author"/> <meta content="Giovanni FM Strippoli" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006023.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/08/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006023.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006023.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006023.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Calcium [blood]; Calcium Compounds [adverse effects, *therapeutic use]; Cause of Death; Chelating Agents [adverse effects, *therapeutic use]; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder [blood, *drug therapy, *prevention &amp; control]; Disease Progression; Fibroblast Growth Factor-23; Hypercalcemia [chemically induced]; Iron Compounds [adverse effects, therapeutic use]; Lanthanum [adverse effects, therapeutic use]; Parathyroid Hormone [blood]; Phosphorus [*blood]; Polyamines [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Renal Dialysis [statistics &amp; numerical data]; Sevelamer [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006023.pub3&amp;doi=10.1002/14651858.CD006023.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="fw9sVDQH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006023\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006023\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006023.pub3",title:"Phosphate binders for preventing and treating chronic kidney disease\\u2010mineral and bone disorder (CKD\\u2010MBD)",firstPublishedDate:"Aug 22, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006023.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006023.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006023.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006023.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006023.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006023.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006023.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006023.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006023.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006023.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13692 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006023.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-sec-0136"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-sec-0127"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/appendices#CD006023-sec-0141"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/table_n/CD006023StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/table_n/CD006023StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#CD006023-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marinella Ruospo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#CD006023-cr-0003">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#CD006023-cr-0004">Patrizia Natale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#CD006023-cr-0005">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#CD006023-cr-0006">Mariacristina Vecchio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#CD006023-cr-0007">Grahame J Elder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information#CD006023-cr-0008">Giovanni FM Strippoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information/en#CD006023-sec-0146">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 August 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006023.pub3">https://doi.org/10.1002/14651858.CD006023.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006023-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006023-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006023-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006023-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006023-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006023-abs-0001" lang="en"> <section id="CD006023-sec-0001"> <h3 class="title" id="CD006023-sec-0001">Background</h3> <p>Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD) with the aim to prevent progression of chronic kidney disease‐mineral and bone disorder (CKD‐MBD). This is an update of a review first published in 2011. </p> </section> <section id="CD006023-sec-0002"> <h3 class="title" id="CD006023-sec-0002">Objectives</h3> <p>The aim of this review was to assess the benefits and harms of phosphate binders for people with CKD with particular reference to relevant biochemical end‐points, musculoskeletal and cardiovascular morbidity, hospitalisation, and death. </p> </section> <section id="CD006023-sec-0003"> <h3 class="title" id="CD006023-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 12 July 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD006023-sec-0004"> <h3 class="title" id="CD006023-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) or quasi‐RCTs of adults with CKD of any GFR category comparing a phosphate binder to another phosphate binder, placebo or usual care to lower serum phosphate. Outcomes included all‐cause and cardiovascular death, myocardial infarction, stroke, adverse events, vascular calcification and bone fracture, and surrogates for such outcomes including serum phosphate, parathyroid hormone (PTH), and FGF23. </p> </section> <section id="CD006023-sec-0005"> <h3 class="title" id="CD006023-sec-0005">Data collection and analysis</h3> <p>Two authors independently selected studies for inclusion and extracted study data. We applied the Cochrane 'Risk of Bias' tool and used the GRADE process to assess evidence certainty. We estimated treatment effects using random‐effects meta‐analysis. Results were expressed as risk ratios (RR) for dichotomous outcomes together with 95% confidence intervals (CI) or mean differences (MD) or standardised MD (SMD) for continuous outcomes. </p> </section> <section id="CD006023-sec-0006"> <h3 class="title" id="CD006023-sec-0006">Main results</h3> <p>We included 104 studies involving 13,744 adults. Sixty‐nine new studies were added to this 2018 update. </p> <p>Most placebo or usual care controlled studies were among participants with CKD G2 to G5 not requiring dialysis (15/25 studies involving 1467 participants) while most head to head studies involved participants with CKD G5D treated with dialysis (74/81 studies involving 10,364 participants). Overall, seven studies compared sevelamer with placebo or usual care (667 participants), seven compared lanthanum to placebo or usual care (515 participants), three compared iron to placebo or usual care (422 participants), and four compared calcium to placebo or usual care (278 participants). Thirty studies compared sevelamer to calcium (5424 participants), and fourteen studies compared lanthanum to calcium (1690 participants). No study compared iron‐based binders to calcium. The remaining studies evaluated comparisons between sevelamer (hydrochloride or carbonate), sevelamer plus calcium, lanthanum, iron (ferric citrate, sucroferric oxyhydroxide, stabilised polynuclear iron(III)‐oxyhydroxide), calcium (acetate, ketoglutarate, carbonate), bixalomer, colestilan, magnesium (carbonate), magnesium plus calcium, aluminium hydroxide, sucralfate, the inhibitor of phosphate absorption nicotinamide, placebo, or usual care without binder. In 82 studies, treatment was evaluated among adults with CKD G5D treated with haemodialysis or peritoneal dialysis, while in 22 studies, treatment was evaluated among participants with CKD G2 to G5. The duration of study follow‐up ranged from 8 weeks to 36 months (median 3.7 months). The sample size ranged from 8 to 2103 participants (median 69). The mean age ranged between 42.6 and 68.9 years. </p> <p>Random sequence generation and allocation concealment were low risk in 25 and 15 studies, respectively. Twenty‐seven studies reported low risk methods for blinding of participants, investigators, and outcome assessors. Thirty‐one studies were at low risk of attrition bias and 69 studies were at low risk of selective reporting bias. </p> <p>In CKD G2 to G5, compared with placebo or usual care, sevelamer, lanthanum, iron and calcium‐based phosphate binders had uncertain or inestimable effects on death (all causes), cardiovascular death, myocardial infarction, stroke, fracture, or coronary artery calcification. Sevelamer may lead to constipation (RR 6.92, CI 2.24 to 21.4; <i>low certainty</i> ) and lanthanum (RR 2.98, CI 1.21 to 7.30, <i>moderate certainty</i> ) and iron‐based binders (RR 2.66, CI 1.15 to 6.12, <i>moderate certainty</i> ) probably increased constipation compared with placebo or usual care. Lanthanum may result in vomiting (RR 3.72, CI 1.36 to 10.18, <i>low certainty</i> ). Iron‐based binders probably result in diarrhoea (RR 2.81, CI 1.18 to 6.68, <i>high certainty</i>), while the risks of other adverse events for all binders were uncertain. </p> <p>In CKD G5D sevelamer may lead to lower death (all causes) (RR 0.53, CI 0.30 to 0.91, <i>low certainty</i> ) and induce less hypercalcaemia (RR 0.30, CI 0.20 to 0.43, <i>low certainty</i> ) when compared with calcium‐based binders, and has uncertain or inestimable effects on cardiovascular death, myocardial infarction, stroke, fracture, or coronary artery calcification. The finding of lower death with sevelamer compared with calcium was present when the analysis was restricted to studies at low risk of bias (RR 0.50, CI 0.32 to 0.77). In absolute terms, sevelamer may lower risk of death (all causes) from 210 per 1000 to 105 per 1000 over a follow‐up of up to 36 months, compared to calcium‐based binders. Compared with calcium‐based binders, lanthanum had uncertain effects with respect to all‐cause or cardiovascular death, myocardial infarction, stroke, fracture, or coronary artery calcification and probably had reduced risks of treatment‐related hypercalcaemia (RR 0.16, CI 0.06 to 0.43, <i>low certainty</i>). There were no head‐to‐head studies of iron‐based binders compared with calcium. The paucity of placebo‐controlled studies in CKD G5D has led to uncertainty about the effects of phosphate binders on patient‐important outcomes compared with placebo. </p> <p>It is uncertain whether the effects of binders on clinically‐relevant outcomes were different for patients who were and were not treated with dialysis in subgroup analyses. </p> </section> <section id="CD006023-sec-0007"> <h3 class="title" id="CD006023-sec-0007">Authors' conclusions</h3> <p>In studies of adults with CKD G5D treated with dialysis, sevelamer may lower death (all causes) compared to calcium‐based binders and incur less treatment‐related hypercalcaemia, while we found no clinically important benefits of any phosphate binder on cardiovascular death, myocardial infarction, stroke, fracture or coronary artery calcification. The effects of binders on patient‐important outcomes compared to placebo are uncertain. In patients with CKD G2 to G5, the effects of sevelamer, lanthanum, and iron‐based phosphate binders on cardiovascular, vascular calcification, and bone outcomes compared to placebo or usual care, are also uncertain and they may incur constipation, while iron‐based binders may lead to diarrhoea. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006023-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006023-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006023-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006023-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006023-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006023-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006023-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006023-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006023-abs-0004" lang="en"> <h3>Phosphate binders to prevent complications of chronic kidney disease</h3> <p><b>What is the issue?</b> </p> <p>People with chronic kidney disease (CKD) have a reduction in their capacity to remove phosphate from the body via the kidneys, so that phosphate levels in the blood and in body tissues increase as kidney function decreases. This may lead to the development of deposits comprised of calcium plus phosphate in blood vessels and other tissues, together with damage to the skeleton, worsening of kidney failure and an increased risk of cardiovascular disease, bone pain, fractures, and death. </p> <p>Phosphate binders are often prescribed with meals to people with kidney disease, with the intention of reducing the absorption of dietary phosphate from the gastrointestinal tract. </p> <p><b>What did we do?</b><br/> This review asked whether phosphate binders influence damage to blood vessels and soft tissues, skeletal changes, kidney function, and risks of cardiovascular disease, bone pain, fractures, and death that accompany worsening kidney failure. We included all clinical studies in which people with CKD were given different phosphate binders (by random chance) for at least eight weeks. We also checked the quality of the information in the studies to learn how certain we could be about the results. </p> <p><b>What did we find?</b> </p> <p>We identified 104 studies of phosphate binders that included 13,744 people. Some studies gave treatment for only eight weeks while some studies treated participants for three years. People in the studies had a range of kidney function, and many were on dialysis. Overall we could not be certain of a number of important outcomes because many of the clinical studies we included had important flaws in their design. </p> <p>Sevelamer treatment may have decreased death for those patients given this medication when taken instead of calcium. The phosphate binders probably caused constipation, but we could not be very certain about the risks of other side‐effects. We were not very certain whether phosphate binders reduced heart complications, stroke, bone pain, or calcification of blood vessels. </p> <p><b>Conclusions</b> </p> <p>Overall, we are not very sure whether specific phosphate binders are beneficial to patients with CKD. There is a possibility that sevelamer may prevent death compared to calcium‐based binders, but we don't know whether this may be caused by an increased risk of calcium‐based binders, a lower risk with sevelamer treatment, or the possibility that both may be true. Patients need to know that it is not certain whether phosphate binders help to prevent complications of kidney disease, but sevelamer may be preferred to calcium binders. </p> <p>We did not find differences in the effects of treatment for patients on dialysis and those not on dialysis, although most studies evaluating treatment with calcium‐based binders were among dialysis patients and those comparing binders with placebo were among people not treated with dialysis. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006023-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006023-sec-0136"></div> <h3 class="title" id="CD006023-sec-0137">Implications for practice</h3> <section id="CD006023-sec-0137"> <p>The superiority of phosphate binders over placebo has not been demonstrated across the range of GFR categories. The current evidence for phosphate binders supports the use of sevelamer compared with calcium‐based agents based on lower death (all causes) with sevelamer for adults with CKD G5D. Whether this finding is due to avoidance of calcium loading from calcium‐based binders, or a direct beneficial effect of sevelamer on lowering phosphate balance or both is not known. It is not possible to definitively establish whether this possible benefit of sevelamer on death (all causes) when compared with calcium‐based binders extends to other non‐calcium‐based binders including lanthanum and iron‐based binders as studies for these agents have not evaluated death and cardiovascular outcomes. However, the <a href="./references#CD006023-bbs2-0209" title="OgataH , FugakawaM , HidekiH , KanedaH , KagimuraT , AkizawaT , et al. Design and baseline characteristics of the LANDMARK study. Clinical &amp; Experimental Nephrology2017;21(3):531‐7. [MEDLINE: 27405619] ">LANDMARK 2017</a> is near to reporting. The impact of sevelamer or other non‐calcium‐based binders on cardiovascular events and death, bone symptoms, or vascular calcification is uncertain. There is very limited evidence for phosphate binders compared with placebo or usual care in the dialysis setting. As such, the superiority of phosphate‐binding therapies over placebo has not been demonstrated across the range of CKD GFR categories. </p> <p>For patients with CKD G2 to G5 not requiring dialysis, there is very limited evidence for phosphate binders compared with placebo or usual care. The impact of phosphate binder therapy on cardiovascular complications and bone and skeletal symptoms is uncertain for this group of patients. </p> <p>Overall, there are very few data for the comparative effects of individual phosphate binders including iron‐based binders and sevelamer hydrochloride versus sevelamer bicarbonate. </p> <p>Patients across the range of GFR categories should be informed about the low‐ to very‐low certainty evidence for use of phosphate binders with respect to death and cardiovascular outcomes and of the potential for phosphate binders to cause harm. Patients in CKD GFR categories G2 to G5 not treated with dialysis may reasonably choose not to receive or limit phosphate binder therapy based on the lack of clear evidence for improved clinical outcomes and potential side‐effects. Patients who are on dialysis should be informed of the balance between the potential benefits and adverse effects of phosphate binders, including possible differences in these benefits and adverse events between binder classes as well as the lack of evidence of phosphate binders compared with placebo. Patients treated with dialysis may reasonably wish to avoid or to limit calcium‐based binders due to the potential for higher treatment‐related death and may reasonably choose not to receive or limit phosphate binder therapy due to the low or very low certainty evidence. </p> </section> <h3 class="title" id="CD006023-sec-0138">Implications for research</h3> <section id="CD006023-sec-0138"> <p>Based on limitations in existing studies and a paucity of evidence for specific clinical questions, further research is likely to change the estimated effects of different phosphate binders in CKD and increase our certainty in the evidence. </p> <p>Current research does not provide high‐quality evidence for the long‐term benefits of lanthanum or iron‐based binders compared with either placebo or calcium‐based treatment. The <a href="./references#CD006023-bbs2-0209" title="OgataH , FugakawaM , HidekiH , KanedaH , KagimuraT , AkizawaT , et al. Design and baseline characteristics of the LANDMARK study. Clinical &amp; Experimental Nephrology2017;21(3):531‐7. [MEDLINE: 27405619] ">LANDMARK 2017</a> comparing lanthanum carbonate versus calcium carbonate among &gt;2300 patients is due to report and may offer higher certainty for the effects of lanthanum carbonate for people with ESKD treated with dialysis. It will be important to update this Cochrane review when the LANDMARK study results are reported. A similar study of an iron‐based binder such as ferric citrate or sucroferric oxyhydroxide compared with a calcium‐based binder or placebo and designed to evaluate death and cardiovascular events would inform contemporary clinical decision‐making. </p> <p>The present body of evidence for phosphate binders includes over 100 studies involving over 13,000 patients. Despite this, evidence for the use of phosphate binders is low or very low certainty because of the dominance of small studies, the short duration of follow‐up for many studies, and the incomplete reporting of core outcomes that are most relevant to clinical care. Future phosphate binder studies should be designed to evaluate patient‐centred core outcomes based on <a href="http://songinitiative.org/projects/song-hd/" target="_blank">SONG‐HD</a> together with systematic reporting of adverse events and specific outcomes related to CKD‐MBD, such as bone pain, inability to participate in life and work, health‐related quality of life, and impaired mobility. It would be very informative if future studies could incorporate cost‐effectiveness analyses as part of the study design. </p> <p>Studies comparing non‐calcium phosphate binders with calcium binders are principally in patients treated with dialysis. Future large‐scale placebo‐controlled studies of sevelamer, lanthanum, or iron‐based binders particularly involving patients treated with dialysis are critical to informing clinical across the range of CKD GFR categories would inform clinical care. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006023-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006023-sec-0022"></div> <div class="table" id="CD006023-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Sevelamer versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Sevelamer versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> most studies involved people with CKD not requiring dialysis </p> <p><b>Intervention:</b> sevelamer versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sevelamer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Death (all causes)</p> <p>Follow‐up: 3 to 24 months (median 10 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.16</b> </p> <p>(0.20 to 22.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>248 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>A single study reported 1 or more events. The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>17 per 1000</b> </p> <p>(2 to 183)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.90 (0.12 to 29.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported 1 event in each group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p>Follow‐up: 2 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>30 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> <p>(2 to 673)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b> </p> <p>(0.07 to 22.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>370 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 2.8 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> </p> <p>(3 to 173)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.09</b> </p> <p>(0.26 to 16.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 2 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> <p>(23 to 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 6.92</b> </p> <p>(2.24 to 21.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>430 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 2 to 10 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>4.48 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the sevelamer group was<br/> <b>0.28 mg/dL lower</b> (0.39 higher to 0.94 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>483 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> <p>Follow‐up: 24 months (both studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcium score in the placebo group was <b>945</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcium score in the sevelamer group was</p> <p><b>70 lower</b> (362 lower to 222 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006023-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: Lanthanum versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Lanthanum versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> most studies involved people with CKD not requiring dialysis </p> <p><b>Intervention:</b> lanthanum versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or standard care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lanthanum</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Death (all causes)</p> <p>Follow‐up: 1.8 to 12 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.63</b> </p> <p>(0.07 to 37.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>214 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5,6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>A single death was reported among three studies. The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p>Follow‐up: 1.8 to 12 months (median 2 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>87 per 1000</b> </p> <p>(32 to 237)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.72</b> </p> <p>(1.36 to 10.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 1.8 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>89 per 1000</b> </p> <p>(13 to 601)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.76</b> </p> <p>(0.41 to 18.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 1.8 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>35 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>104 per 1000</b> </p> <p>(42 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.98</b> </p> <p>(1.21 to 7.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>299 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 1.8 to 12 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>4.7 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the lanthanum group was <b>0.48 mg/dL lower</b> </p> <p>(0.05 to 0.90 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the placebo group was <b>23 mm<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the lanthanum group was<b>3 mm<sup>3</sup> higher</b> (9.86 lower to 15.86 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006023-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: Iron versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Iron versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> dialysis (1 study) and CKD (2 studies) </p> <p><b>Intervention:</b> iron versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or standard care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Iron</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (all causes)</p> <p>Follow‐up: 2.75 to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> <p>(1 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.52</b> </p> <p>(0.06 to 4.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypercalcaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>67 per 1000</b> </p> <p>(20 to 221)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> (0.30 to 3.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 1.8 to 3 months (median 2.75 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>114 per 1000</b> </p> <p>(49 to 262)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.66</b> </p> <p>(1.15 to 6.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 1.8 to 3 months (median 2.75 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>5.8 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate in the iron group was</p> <p><b>1.33 mg/dL lower</b> </p> <p>(0.41 to 2.25 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006023-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: Calcium versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Calcium versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> Most studies involved people with CKD not requiring dialysis </p> <p><b>Intervention</b>: calcium versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Calcium</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (all causes)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> </p> <p>(2 to 203)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.46</b> </p> <p>(0.05 to 4.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 3 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>56 per 1000</b> </p> <p>(13 to 248)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 7.28</b> </p> <p>(1.64 to 32.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p>Follow‐up: 3 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> <p>(10 to 144)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.58</b> </p> <p>(0.15 to 2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 3 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>161 per 1000</b> </p> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.44</b> </p> <p>(0.32 to 18.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 5.5 to 24 months (median 9 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>5.0 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the calcium group was <b>0.18 mg/dL lower</b> (0.95 higher to 1.30 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the placebo group was <b>473</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the calcium group was <b>74 lower</b> (443 lower to 295 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006023-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: Sevelamer versus calcium</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sevelamer versus calcium for preventing and treating bone disease people with in chronic kidney disease (CKD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting</b>: most studies involved people treated with dialysis </p> <p><b>Intervention:</b> sevelamer versus calcium </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Calcium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sevelamer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Death (all causes)</b> </p> <p>Follow‐up: 1.8 to 36 months (median 5.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk population (CKD G2 to G5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>RR 0.53</b> </p> <p>(0.30 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>3688 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> <p>(27 to 227)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High risk population (CKD G5D)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>210 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>105 per 1000</b> </p> <p>(55 to 199)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Follow‐up: 3 to 36 months (median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk population (CKD G2 to G5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> </p> <p>(0.11 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2829 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b> </p> <p>(1 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High risk population (CKD G5D)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>132 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>112 per 1000</b> </p> <p>(11 to 177)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 1.8 to 36 months (median 5.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (28 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.30</b> </p> <p>(0.20 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4084 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> <p>Follow‐up: 2 to 12 months (median 9 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/> (70 to 214) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> </p> <p>(0.56 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 9 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>158 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>150 per 1000</b> </p> <p>(85 to 267)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.95</b> </p> <p>(0.54 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Constipation</b> </p> <p>Follow‐up: 2 to 20 months (median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/> (9 to 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> </p> <p>(0.71 to 2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2652 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 1.8 to 36 months (median 5.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the calcium group was <b>5.39 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the sevelamer group was<br/> <b>0.06 mg/dL higher</b> </p> <p>(0.11 lower to 0.23 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4360 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcium score</b> </p> <p>Follow‐up: 12‐24 months (median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the calcium group was <b>923</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the sevelamer group was</p> <p><b>25 lower</b> (76 lower to 26 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the median incidence of the event in the control arm of included studies. Where there was a wide range of reported incidence (for example, Death (all causes) ranged from 10 per 1000 to 340 per 1000), two levels of risk (high and low) were generated for calculation of absolute risks </p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006023-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings ‐ Lanthanum versus calcium</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lanthanum versus calcium for preventing and treating bone disease people with in chronic kidney disease (CKD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with CKD </p> <p><b>Setting</b>: most studies involved people treated with dialysis </p> <p><b>Intervention:</b> lanthanum versus calcium </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Calcium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lanthanum</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death (all causes)</p> <p>Follow‐up: 1.8 to 18 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population (CKD G5D)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> </p> <p>(0.18 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>505 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The studies were in CKD G5D</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> <p>(3 to 48)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 1.8 to 12 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/> (14 to 103) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.16</b> </p> <p>(0.06 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1347 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> <p>Follow‐up: 1.8 to 12 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><br/> (84 to 254) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b> </p> <p>(0.95 to 2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1191 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 1.8 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b> </p> <p>(37 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.88</b> </p> <p>(0.48 to 31.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1058 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,3,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Constipation</b> </p> <p>Follow‐up: 1.8 to 18 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><br/> (33 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p>(0.50 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1213 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 3 to 12 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the calcium group was <b>5.39 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the lanthanum group was<br/> <b>0.01 mg/dL lower</b><br/> (0.42 higher to 0.43 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to assess for publication bias due to substantial between‐study heterogeneity. The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary artery calcium score</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the calcium group was <b>1640</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the lanthanum group was <b>57</b> lower (1308 lower to 5 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A single study reported 1 or more events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of the control arm of included studies. Where there was a wide range of reported incidence (for example, Death (all causes) ranged from 10 per 1000 to 340 per 1000), two levels of risk (high and low) were generated for calculation of absolute risks. </p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006023-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006023-sec-0023"></div> <section id="CD006023-sec-0024"> <h3 class="title" id="CD006023-sec-0024">Description of the condition</h3> <p>People with chronic kidney disease (CKD) develop impaired excretion of their dietary phosphate load (<a href="./references#CD006023-bbs2-0225" title="HruskaKA , MathewS , LundR , QiuP , PrattR . Hyperphosphatemia of chronic kidney disease. Kidney International2008;74(2):148‐57. [MEDLINE: 18449174] ">Hruska 2008</a>) leading to positive phosphate balance. Hyperphosphataemia leads to a rise in fibroblast growth factor‐23 (FGF23) levels that provide a compensatory increase of renal phosphate excretion and inhibit 1,25 dihydroxy‐vitamin D production and increase its catabolism (<a href="./references#CD006023-bbs2-0219" title="GutiérrezO , IsakovaT , RheeE , ShahA , HolmesJ , ColleroneG , et al. Fibroblast growth factor‐23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Journal of the American Society of Nephrology2005;16(7):2205‐15. [MEDLINE: 15917335] ">Gutiérrez 2005</a>). However, in the presence of further reductions in kidney function, these initial homeostatic responses fail and further increases in serum phosphate and reductions in serum 1,25‐dihydroxy‐vitamin D contribute to an increase in parathyroid hormone (PTH), the actions of which will initially restore calcium and phosphate values toward their normal ranges (<a href="./references#CD006023-bbs2-0214" title="CozzolinoM , BrancaccioD , GallieniM , SlatopolskyE . Pathogenesis of vascular calcification in chronic kidney disease. Kidney International2005;68(2):429‐36. [MEDLINE: 16014020] ">Cozzolino 2005</a>; <a href="./references#CD006023-bbs2-0225" title="HruskaKA , MathewS , LundR , QiuP , PrattR . Hyperphosphatemia of chronic kidney disease. Kidney International2008;74(2):148‐57. [MEDLINE: 18449174] ">Hruska 2008</a>; <a href="./references#CD006023-bbs2-0244" title="SilverJ , LeviR . Cellular and molecular mechanisms of secondary hyperparathyroidism. Clinical Nephrology2005;63(2):119‐26. [MEDLINE: 15730054] ">Silver 2005</a>). With progression of CKD, these homeostatic responses fail and result in increased risks for hypocalcaemia and hyperphosphataemia that increase PTH release via the calcium‐sensing receptor on parathyroid cells. Prolonged low serum calcium levels lead to stabilisation of mRNA encoding PTH. Reduced 1,25 dihydroxy‐vitamin D levels allow increased transcription of the PTH gene (<a href="./references#CD006023-bbs2-0232" title="KumarR , ThompsonJR . The regulation of parathyroid hormone secretion and synthesis. Journal of the American Society of Nephrology2011;22(2):216‐24. [MEDLINE: 21164021] ">Kumar 2011</a>). Abnormal serum levels of PTH are observed in 10% of people with a glomerular filtration rate (GFR) above 80 mL/min and in 80% of people with a GFR below 20 mL/min (<a href="./references#CD006023-bbs2-0233" title="LevinA , BakrisGL , MolitchM , SmuldersM , TianJ , WilliamsLA , et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.[Erratum appears in Kidney Int. 2009 Jun;75(11):1237]. Kidney International2007;71(1):31‐8. [MEDLINE: 17091124] ">Levin 2007</a>). Serum levels of calcium and phosphate tend to be within the normal range with a GFR above 40 mL/min and tend to remain stable until the GFR is below 20 mL/min (<a href="./references#CD006023-bbs2-0233" title="LevinA , BakrisGL , MolitchM , SmuldersM , TianJ , WilliamsLA , et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.[Erratum appears in Kidney Int. 2009 Jun;75(11):1237]. Kidney International2007;71(1):31‐8. [MEDLINE: 17091124] ">Levin 2007</a>). </p> <p>Together, these changes may contribute to the development of a cluster of inter‐related conditions described as chronic kidney disease‐mineral and bone disorder (CKD‐MBD). This systemic disorder manifests in a number of ways. In bone, there are alterations of bone turnover, mineralization, and volume that may be accompanied by marrow fibrosis. These changes can cause altered bone growth and strength, leading to bone pain. In the cardiovascular system, excess vascular and other soft‐tissue calcification leads to occlusive arterial disease and cardiac valvular abnormalities. </p> <p>Commonly measured laboratory abnormalities that accompany the development of CKD‐MBD include values of serum calcium, phosphate, vitamin D metabolites, PTH, markers of bone turnover, and FGF23. Epidemiological data have increasingly demonstrated an association between abnormal values of serum phosphate, PTH, calcium, and FGF23 caused by CKD and increased cardiovascular events and death, hospitalisation, reduced quality of life, and increased costs of care (<a href="./references#CD006023-bbs2-0210" title="BlockGA , Hulbert‐ShearonTE , LevinNW , PortFK . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Diseases1998;31(4):607‐17. [MEDLINE: 9531176] ">Block 1998</a>; <a href="./references#CD006023-bbs2-0211" title="BlockGA , KlassenPS , LazarusJM , OfsthunN , LowrieEG , ChertowGM . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology2004;15(8):2208‐18. [MEDLINE: 15284307] ">Block 2004</a>; <a href="./references#CD006023-bbs2-0220" title="GutiérrezOM , MannstadtM , IsakovaT , Rauh‐HainJA , TamezH , ShahA , et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New England Journal of Medicine2008;359(6):584‐92. [MEDLINE: 18687639] ">Gutiérrez 2008</a>; <a href="./references#CD006023-bbs2-0249" title="TentoriF , BlayneyMJ , AlbertJM , GillespieBW , KerrPG , BommerJ , et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases2008;52(3):519‐30. [MEDLINE: 18514987] ">Tentori 2008</a>). </p> </section> <section id="CD006023-sec-0025"> <h3 class="title" id="CD006023-sec-0025">Description of the intervention</h3> <p>Over the past few decades, cardiovascular disease has accounted for over half of the deaths in people receiving dialysis (<a href="./references#CD006023-bbs2-0251" title="United States Renal Data System(USRDS) . Costs of ESRD. www.usrds.org/2009/pdf/V2_11_09.pdf(accessed July 2018). ">USRDS 2009</a>). The development of CKD‐MBD causing vascular calcification in the media of arterial vessels and soft tissues is recognised as a major contributing factor (<a href="./references#CD006023-bbs2-0218" title="GuerinAP , BlacherJ , PannierB , MarchaisSJ , SafarME , LondonGM . Impact of aortic stiffness attenuation on survival of patients in end‐stage renal failure. Circulation2001;103(7):987‐92. [MEDLINE: 11181474] ">Guerin 2001</a>; <a href="./references#CD006023-bbs2-0248" title="StevensLA , DjurdjevO , CardewS , CameronEC , LevinA . Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. Journal of the American Society of Nephrology2004;15(3):770‐9. [MEDLINE: 14978180] ">Stevens 2004</a>) to this increased death. </p> <p>Several agents such as phosphate binders, vitamin D compounds, and calcimimetics are widely used to retard the development and progression of CKD‐MBD complications by acting to reduce dietary phosphate absorption and uptake, treat hyperphosphataemia and hypocalcaemia, increase low 1,25 dihydroxy‐vitamin D levels, and attenuate PTH secretion. </p> </section> <section id="CD006023-sec-0026"> <h3 class="title" id="CD006023-sec-0026">How the intervention might work</h3> <p>Several phosphate binders, including aluminium‐ and calcium‐based agents, have been widely used since 1970. Non‐calcium and non‐aluminium‐based agents, such as sevelamer hydrochloride and lanthanum carbonate, subsequently became available, and more recently, iron‐based compounds have been developed. The use of sevelamer, lanthanum, and iron‐based compounds is increasing in nephrology practice, although they incur greater cost than the older phosphate binders (<a href="./references#CD006023-bbs2-0245" title="StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] ">St Peter 2008</a>; <a href="./references#CD006023-bbs2-0246" title="StPeterW , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] ">St Peter 2009</a>; <a href="./references#CD006023-bbs2-0251" title="United States Renal Data System(USRDS) . Costs of ESRD. www.usrds.org/2009/pdf/V2_11_09.pdf(accessed July 2018). ">USRDS 2009</a>). </p> <p>The avoidance of calcium‐based agents in CKD theoretically avoids the risks associated with positive calcium balance and the consequent acceleration of vascular calcification and cardiovascular events. For control of hyperphosphataemia, the 2003 National Kidney Foundation Kidney Disease Outcomes Quality Initiatives (NKF‐KDOQI) recommended calcium‐based binders in CKD stages 3 and 4 (glomerular filtration rate (GFR) 30 to 59 mL/min/1.73 m<sup>2</sup> and 15 to 29 mL/min/1.73 m<sup>2</sup>, respectively), and both calcium‐based and calcium‐ and aluminium‐free binders in CKD stages 5 and 5D (GFR &lt; 15 mL/min/1.73 m<sup>2</sup> and dialysis) (<a href="./references#CD006023-bbs2-0228" title="National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American Journal of Kidney Diseases2003;42(4 Suppl 3):70‐7. [MEDLINE: 14520607] ">K/DOQI 2003</a>). However, more recently, the Kidney Disease: Improving Global Outcomes (KDIGO) 2017 update suggests that for patients with CKD G3a‐G5D, elevated phosphate levels should be lowered toward the normal range rather than normalised, while avoiding hypercalcaemia for adult patients (<a href="./references#CD006023-bbs2-0231" title="Kidney Disease: Improving Glogal Outcomes (KDIGO) CKD‐MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD). Kidney International ‐ Supplement2017;7(3):1‐59. [EMBASE: 617012703] ">KDIGO 2017</a>). The 2017 KDIGO update suggested restricting the dose of calcium‐based phosphate binders and tolerance of mild and asymptomatic hypocalcaemia, in order to avoid exogenous calcium loading. These guidelines offered a more conservative approach to the use of phosphate binders in patients with CKD G3a to G4, due to insufficient evidence that targeting normal range serum phosphate values improved clinical outcomes, and based upon the safety and side effects of the therapeutic interventions. </p> </section> <section id="CD006023-sec-0027"> <h3 class="title" id="CD006023-sec-0027">Why it is important to do this review</h3> <p>The utility of calcium‐free phosphate binders in reducing clinical events in CKD, balanced against their cost and potential harms has been controversial (<a href="./references#CD006023-bbs2-0239" title="SaluskyIB . A new era in phosphate binder therapy: what are the options?. Kidney International ‐ Supplement2006, (105):S10‐5. [MEDLINE: 17136110] ">Salusky 2006</a>; <a href="./references#CD006023-bbs2-0246" title="StPeterW , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] ">St Peter 2009</a>). The KDIGO guidelines of 2009 recommended restricting the use of calcium‐based binders in people with persistent or recurrent hypercalcaemia or arterial calcification, or both (<a href="./references#CD006023-bbs2-0229" title="Kidney Disease: Improving Global Outcomes (KDIGO) CKD‐MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease‐mineral and bone disorder (CKD‐MBD). Kidney International ‐ Supplement 209;76(113):S1‐130. [MEDLINE: 19644521] ">KDIGO 2009</a>) and that phosphate binders might be used in patients with CKD G3‐5 and on dialysis (CKD G5D) to achieve improvements in serum phosphate levels toward the normal range. However, citing new trial evidence, the KDIGO 2017 guidelines suggest that phosphate binders have an insufficient evidence base for efficacy and safety among patients with CKD G3a to G5 not on dialysis and that phosphate binders be limited to patients with "progressive or persistent" hyperphosphataemia (<a href="./references#CD006023-bbs2-0231" title="Kidney Disease: Improving Glogal Outcomes (KDIGO) CKD‐MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD). Kidney International ‐ Supplement2017;7(3):1‐59. [EMBASE: 617012703] ">KDIGO 2017</a>). The 2017 KDIGO guidelines have suggested that not all phosphate binders are interchangeable, and that excess exposure to calcium, as calcium‐based binders, may be harmful across all GFR categories, however there has remained some uncertainty about the evidence that calcium‐free agents are superior to calcium‐based agents for prevention of adverse clinical outcomes. </p> <p>In addition, non‐calcium binders may increase healthcare costs. Subsidisation of non‐calcium based phosphate binders in Australia led to increased medication costs from AUD 12.85 per patient per week to AUD 59.85 per patient per week (an additional AUD 2444 per patient per years) (<a href="./references#CD006023-bbs2-0217" title="GrayNA , KrishnasamyR , VardeshDL , HollettPR , AnsteyCM . Impact of non‐traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost. Nephrology2011;16(8):688‐96. [MEDLINE: 21649793] ">Gray 2011</a>). Medicare costs for phosphate binders among dialysis patients in the US were in excess of USD 1.5 billion in 2015 (<a href="./references#CD006023-bbs2-0247" title="StPeterWL , WaznyLD , WeinhandlED . Phosphate‐binder use in US dialysis patients: prevalence, costs, evidence, and policies. American Journal of Kidney Diseases2018;71(2):246‐53. [MEDLINE: 29195858] ">St. Peter 2018</a>). </p> <p>Current guidelines suggest the restriction of calcium‐based phosphate binders for patients treated with dialysis, and a more tolerant approach to higher phosphate levels among patients with CKD G3a to 5 not requiring dialysis, likely to lead to less phosphate binder use for these patients. Because of these factors and the emergence of new studies since the 2011 Cochrane review, we have updated the evidence to address the use of phosphate binder for patients with CKD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006023-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006023-sec-0028"></div> <p>The aim of this review was to assess the benefits and harms of phosphate binders for people with CKD with particular reference to relevant biochemical end‐points, musculoskeletal and cardiovascular morbidity, hospitalisation, and death. </p> <p>In particular we aimed to evaluate the effects of aluminium‐, calcium‐, sevelamer‐, lanthanum‐, iron‐, bixalomer‐, colestilan‐, and magnesium‐based phosphate binders, and nicotinamide, on: </p> <p> <ol id="CD006023-list-0001"> <li> <p>Relevant biochemical end‐points: serum PTH, calcium, phosphate and FGF23</p> </li> <li> <p>Symptoms: pruritis and bone pain</p> </li> <li> <p>Bone structure and function: bone mineral density (BMD) assessed by dual‐energy X‐ray absorptiometry (DEXA) or quantitative computerised tomography (QCT), bone turnover and mineralisation based on biochemical bone turnover markers, turnover and volume based on histomorphometry, and fracture events </p> </li> <li> <p>Clinical outcomes: cardiovascular events, number of hospital admissions, and cardiovascular and death (all causes) </p> </li> <li> <p>Vascular calcification</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>We also aimed to identify whether treatment efficacy differed based on GFR categories (CKD G5D and CKD G2 to G5) and whether individual phosphate binders within each class had different effects. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006023-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006023-sec-0029"></div> <section id="CD006023-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006023-sec-0031"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth, or other predictable methods) of phosphate binders used for CKD (any GFR category). Studies of phosphate binders, alone or in combination with other (non‐randomised) co‐interventions (for example vitamin D compounds) were included. The first phase of randomised cross‐over studies was included, or both study phases, if appropriate statistical analyses were reported. There were no language restrictions. </p> </section> <section id="CD006023-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD006023-sec-0033"> <h5 class="title">Inclusion criteria</h5> <p>Adults with CKD (any category) including G2 to G5 (GFR 15 to 90 mL/min) and G5D (dialysis) (<a href="./references#CD006023-bbs2-0230" title="Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International ‐ Supplement2013;3(1):1‐150. [EMBASE: 369856107] ">KDIGO 2012</a>). </p> </section> <section id="CD006023-sec-0034"> <h5 class="title">Exclusion criteria</h5> <p>Studies of participants with a kidney transplant (CKD 5T) were excluded as these studies have been reviewed in a separate Cochrane review (<a href="./references#CD006023-bbs2-0235" title="PalmerSC , McGregorDO , StrippoliGF . Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD005015.pub3] ">Palmer 2007</a>) that is currently being updated. Studies evaluating treatment in children were excluded as these have been evaluated in a separate Cochrane review (<a href="./references#CD006023-bbs2-0222" title="HahnD , HodsonEM , CraigJC . Interventions for metabolic bone disease in children with chronic kidney disease. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD008327.pub2] ">Hahn 2015</a>). </p> </section> </section> <section id="CD006023-sec-0035"> <h4 class="title">Types of interventions</h4> <p>We included studies with follow‐up of at least eight weeks evaluating phosphate binders (including: sevelamer‐, lanthanum‐, calcium‐, iron‐, bixalomer‐, colestilan‐ (colestimide), magnesium‐, and aluminium‐ based binders) and nicotinamide (nicotinic acid), compared with another phosphate binder or placebo or usual care without phosphate binder. </p> </section> <section id="CD006023-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD006023-sec-0037"> <h5 class="title">Primary outcomes</h5> <p>Death (all causes)</p> </section> <section id="CD006023-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD006023-list-0002"> <li> <p>Cardiovascular death</p> </li> <li> <p>Hospitalisation</p> </li> <li> <p>Nonfatal myocardial infarction</p> </li> <li> <p>Nonfatal stroke</p> </li> <li> <p>Fracture (incidence of fracture at any site; vertebral compression fractures; fracture of femur, hip, and any long bones identified by radiographic studies) </p> </li> <li> <p>Pruritus</p> </li> <li> <p>Calciphylaxis</p> </li> <li> <p>Adverse effects: including gastrointestinal (nausea, diarrhoea, constipation, abdominal bloating, abdominal pain), electrolyte imbalance (hyperkalaemia) </p> </li> <li> <p>Hypercalcaemia (defined as serum calcium level &gt; 10.2 mg/dL (2.6 mmol/L) or as defined by the study investigators) </p> </li> <li> <p>Serum phosphate (mg/dL), serum calcium (mg/dL), calcium‐by‐phosphate product (mg<sup>2</sup>/dL<sup>2</sup>), PTH (intact (iPTH), or PTH (1‐84)); alkaline phosphatase (IU/L), serum bicarbonate (mEq/L), fibroblast growth factor 23 (FGF23), fetuin‐A, and Klotho (any form) </p> </li> <li> <p>Vascular calcification, soft tissue or valvular calcification</p> </li> <li> <p>Bone mineral density assessed by dual energy X‐ray absorptiometry (DXA) or quantitative computed tomography (QCT) (change in bone mineral density using Z‐scores, T‐scores, or g/cm<sup>2</sup> (DXA) or g/cm<sup>3</sup> (QCT) at the lumbar spine, femoral neck, or radius) </p> </li> <li> <p>Estimated GFR (eGFR); end‐stage kidney disease (ESKD) (defined as eGFR &lt; 15 mL/min/1.73 m<sup>2</sup>, or commencing dialysis, or as defined by investigators). </p> </li> </ol> </p> </section> </section> </section> <section id="CD006023-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006023-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 12 July 2018 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources: </p> <p> <ol id="CD006023-list-0003"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the <i>Specialised Register</i> section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD006023-sec-0142">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD006023-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD006023-list-0004"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD006023-sec-0042"> <h3 class="title" id="CD006023-sec-0042">Data collection and analysis</h3> <section id="CD006023-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may have been relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. Studies and reviews that might have included relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD006023-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Data were extracted on the characteristics of participants, interventions, comparisons, and the outcomes listed above. Authors were contacted if data relating to death, phosphate, calcium, PTH, or calcium‐by‐phosphate product were not available or not reported in the published reports. Discrepancies between the assessments of the two data extractors were resolved by discussion with an arbitrator. </p> </section> <section id="CD006023-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were assessed independently by two authors using the risk of bias assessment tool (<a href="./references#CD006023-bbs2-0224" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD006023-sec-0143">Appendix 2</a>). </p> <p> <ul id="CD006023-list-0005"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD006023-list-0006"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD006023-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>Dichotomous data were analysed using the risk ratio (RR) and its 95% confidence interval (CI). Where continuous measurements of outcomes were used, the mean difference (MD) and its 95% CI were computed. </p> </section> <section id="CD006023-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>Any further information (relating to serum phosphate, calcium, PTH, and death) required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review. </p> </section> <section id="CD006023-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I<sup>2</sup> statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD006023-bbs2-0223" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). A guide to the interpretation of I<sup>2</sup> values was as follows: </p> <p> <ul id="CD006023-list-0007"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity <br/></p> </li> </ul> </p> <p>The importance of the observed value of I<sup>2</sup> depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>) (<a href="./references#CD006023-bbs2-0224" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD006023-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>We had planned to examine for publication bias using evidence of asymmetry in a funnel plot in the absence of between‐study statistical heterogeneity (Higgins 201). </p> </section> <section id="CD006023-sec-0050"> <h4 class="title">Data synthesis</h4> <p>Risk estimates from individual studies were pooled using the inverse variance random‐effects model. </p> </section> <section id="CD006023-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Sources of heterogeneity that were explored in the subgroup analyses for the primary outcome (death (all causes)) were: age (older than 60 years and 60 years or younger), CKD stage (stages 1‐4 and stage 5D), baseline serum phosphate (above or below 4.5 mg/dL (1.5 mmol/L)), study duration (above and below 12 months), and methodological quality (low risk of bias for allocation concealment and high or unclear risk of bias). We did not complete planned subgroup analyses for older versus newer agents as most binder types are well‐established. We have also not included subgroup analysis based on number of participants. We have now included subgroup analyses based on age and CKD category, which were not pre‐defined in the previous protocol for this review. </p> <section id="CD006023-sec-0052"> <h5 class="title">'Summary of findings' tables</h5> <p>The main results are presented in the 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD006023-bbs2-0240" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD006023-bbs2-0215" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>; <a href="./references#CD006023-bbs2-0216" title="GuyattG , OxmanA D , AklE A , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64:383‐94. [MEDLINE: 22818160] ">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD006023-bbs2-0241" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We present the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD006023-list-0008"> <li> <p>Death (all causes)</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Hypercalcaemia</p> </li> <li> <p>Nausea</p> </li> <li> <p>Vomiting</p> </li> <li> <p>Constipation</p> </li> <li> <p>Serum phosphate</p> </li> <li> <p>Vascular calcification</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006023-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006023-sec-0053"></div> <section id="CD006023-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD006023-sec-0055"> <h4 class="title">Results of the search</h4> <p>Search results are shown in <a href="#CD006023-fig-0001">Figure 1</a>. For this 2018 review update, we identified 404 new reports. Sixty‐nine new studies in 138 reports were eligible (<a href="./references#CD006023-sec-0152" title="">Characteristics of included studies</a>). Ninety‐two additional reports of 20 studies included in the 2011 review were identified in the updated search and added to the review. Our search identified three studies that have not yet been completed (<a href="./references#CD006023-bbs2-0207" title="GassmanJJ . The COMBINE Study: the CKD optimal management with BInders and NicotinamidE. www.clinicaltrials.gov/show/NCT02258074 (first received 7 October 2014). ">COMBINE 2014</a>; <a href="./references#CD006023-bbs2-0208" title="ToussaintND , PedagogosE . IMPROVE: IMpact of Phosphate Reduction On Vascular End‐points in chronic kidney disease. www.anzctr.org.au/trial_view aspx?id=335812 (first received 10 August 2010). ">IMPROVE‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0209" title="OgataH , FugakawaM , HidekiH , KanedaH , KagimuraT , AkizawaT , et al. Design and baseline characteristics of the LANDMARK study. Clinical &amp; Experimental Nephrology2017;21(3):531‐7. [MEDLINE: 27405619] ">LANDMARK 2017</a>) according to details held within the www.ClinicalTrials.gov registry. Three studies were identified as completed without published results and have been categorised as "Awaiting Classification" (<a href="./references#CD006023-bbs2-0204" title="RoeS . Efficacy and safety study of magnesium iron hydroxycarbonate for the reduction of high blood phosphate in hemodialysis patients. www.clinicalTrials.gov/show/NCT00317694 (first received 25 April 2006). ">NCT00317694</a>; <a href="./references#CD006023-bbs2-0205" title="SaluskyIB . Regulation of bone formation in renal osteodystrophy. www.clinicaltrials.gov/show/NCT00560300 (first received 19 November 2007). ">NCT00560300</a>; <a href="./references#CD006023-bbs2-0206" title="NCT01968759 . Sevelamer in proteinuric CKD. www.clinicalTrials.gov/show/NCT01968759 (first received 24 October 2013). ">NCT01968759</a>). These three studies are reported as completed within www.ClinicalTrials.gov, but no results have been published or were available directly from the investigators. Twenty‐three studies in 24 reports were removed from the 2011 review during the update process as the studies did not have eight weeks follow‐up or longer (<a href="./references#CD006023-bbs2-0109" title="Al‐BaajF , HutchisonAJ , UK Lanthanum Study Group. Lanthanum carbonate: a novel non‐calcaemic phosphate binder in dialysis patients [abstract]. Journal of the American Society of Nephrology2000;11(Sept):557A. Al‐BaajF , SpeakeM , HutchinsonJ . Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short‐term, placebo‐controlled study. Nephrology Dialysis Transplantation2005;20(4):775‐82. [MEDLINE: 15703206] HutchisonAJ , GillM , CopleyJB , PooleL , WilsonRJ . Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients. BMC Nephrology2013;14:40. [MEDLINE: 23418668] HutchisonAJ , UK Lanthanum Study Group. Lanthanum carbonate: a novel non‐calcaemic phosphate binder in dialysis patients. [abstract]. Nephrology Dialysis Transplantation2000;15(9):A113. [CENTRAL: CN‐00550562] ">Al‐Baaj 2005</a>; <a href="./references#CD006023-bbs2-0115" title="ChertowGM , BurkeSK , LazarusMJ , StenzelKH , WomboltD , GoldbergD , et al. Poly(allylamine hydrochloride) (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. American Journal of Kidney Diseases1997;29(1):66‐71. [MEDLINE: 9002531] ">Chertow 1997</a>; <a href="./references#CD006023-bbs2-0116" title="ChiangSS , ChenJB , YangWC . Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end‐stage renal disease. Clinical Nephrology2005;63(6):461‐70. [MEDLINE: 15960148] WebsterI , LooB . The novel phosphate binder lanthanum carbonate is preferred to conventional agents in a Chinese population [abstract]. Nephrology Nursing Journal2004;31(2):142. YangW , ChiangS , ChenJ . Efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in Chinese chronic renal failure patients [abstract no: F‐PO652]. Journal of the American Society of Nephrology2003;14(Nov):204A. [CENTRAL: CN‐00583787] ">Chiang 2005</a>; <a href="./references#CD006023-bbs2-0119" title="d'Almeida FilhoEJ , daCruzEA , HoetteM , RuzanyF , KeenLN , LugonJR . Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients. Revista Paulista de Medicina [Sao Paulo Medical Journal]2000;118(6):179‐84. [MEDLINE: 11120549] ">d'Almeida Filho 2000</a>; <a href="./references#CD006023-bbs2-0122" title="EmmettM , SirmonMD , KirkpatrickGW , NolanC , SchmittGW , ClevelandMB . Calcium acetate control of serum phosphorus in hemodialysis patients. American Journal of Kidney Diseases1991;17(5):544‐50. [MEDLINE: 2024656] EmmettM , SirmonMD , KirkpatrickWG , NolanCR , SchmittGW , ClevelandMB . Calcium acetate control of serum phosphorus in hemodialysis patients [abstract]. Kidney International1990;37(1):449. [CENTRAL: CN‐00583353] ">Emmett 1991</a>; <a href="./references#CD006023-bbs2-0124" title="FanS , RossC , MitraS , KalraP , HeatonJ , HunterJ , et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Nephrology Dialysis Transplantation2009;24(12):3794‐9. [MEDLINE: 19666658] ">Fan 2009</a>; <a href="./references#CD006023-bbs2-0137" title="FinnWF , JoyMS , WebsterI . Efficacy and tolerability of lanthanum carbonate, a new phosphate binder for the treatment of hyperphosphatemia [abstract]. Nephrology Nursing Journal2003;30(2):150. FinnWF , JoyMS , WebsterI . Lanthanum carbonate, a novel phosphate binder, is effective and has a good safety profile in the long‐term treatment of hyperphosphatemia in end‐stage renal disease [abstract]. Nephrology Nursing Journal2003;30(2):151. FinnWF , JoyMS , LAM‐308 Study Group. A long‐term, open‐label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Current Medical Research &amp; Opinion2005;21(5):657‐64. [MEDLINE: 15969865] JoyMS , FinnWF , LAM‐302 Study Group. Randomized, double‐blind, placebo‐controlled, dose‐titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. American Journal of Kidney Diseases2003;42(1):96‐107. [MEDLINE: 12830461] ">Joy 2003</a>; <a href="./references#CD006023-bbs2-0140" title="KoiwaF , OnodaN , KatoH , TokumotoA , OkadaT , FukagawaM , et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Therapeutic Apheresis &amp; Dialysis2005;9(4):340‐6. [MEDLINE: 16076379] ">Koiwa 2005a</a>; <a href="./references#CD006023-bbs2-0143" title="KuriharaS , TsurutaY , AkizawaT . Effect of MCI‐196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double‐blind, placebo‐controlled, short‐term trial. Nephrology Dialysis Transplantation2005;20(2):424‐30. [MEDLINE: 15673691] KuriharaS , TsurutaY , AkizawaT . Effect of MCI‐196 (colestilan) on hyperphosphatemia in hemodialysis patients [abstract no: F‐PO662]. Journal of the American Society of Nephrology2003;14(Nov):206A. [CENTRAL: CN‐00626036] ">Kurihara 2005</a>; <a href="./references#CD006023-bbs2-0125" title="FinnWF , JoyMS . Lanthanum carbonate (FosrenolTM) significantly reduces serum phosphorus levels and calcium X phosphorus product values in a dose‐ranging study [abstract no: PS1‐20]. Nephrology2003;8(Suppl 1):A29. FinnWF , JoyMS , HladikG , Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clinical Nephrology2004;62(3):193‐201. [MEDLINE: 15481851] FinnWF , JoyMS , WebsterI , GillM . Long‐term treatment with lanthanum carbonate (Fosrenol) is safe and effective in haemodialysis patients [abstract no:W434]. Nephrology Dialysis Transplantation2003;18(Suppl 4):685. FinnWF , JoyMS , LAM‐308 Study Group. A long‐term, open‐label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Current Medical Research &amp; Opinion2005;21(5):657‐64. [MEDLINE: 15969865] ">Finn 2004</a>; <a href="./references#CD006023-bbs2-0149" title="McIntyreC , PaiP , WarwickG , WilkieM , ToftA , HutchinsonA . Iron‐magnesium hydroxycarbonate (alpharen): a novel non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: FP452]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi171. [CENTRAL: CN‐00690654] McIntyreCW , PaiP , WarwickG , WilkieM , ToftA . Alpharen is a novel effective non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: F‐PO108]. Journal of the American Society of Nephrology2006;17(Abstracts):359A. [CENTRAL: CN‐00688970] McIntyreCW , PaiP , WarwickG , WilkieM , ToftAJ , HutchisonAJ . Iron‐magnesium hydroxycarbonate (alpharen): a novel non calcium containing phosphate binder for the treatment of hyperphosphataemia in chronic haemodialysis patients [abstract no: 142]. American Journal of Kidney Diseases2007;49(4):A60. McIntyreCW , PaiP , WarwickG , WilkieM , ToftAJ , HutchisonAJ . Iron‐magnesium hydroxycarbonate (fermagate): a novel non‐calcium‐containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(2):401‐9. [MEDLINE: 19158369] ">McIntyre 2009</a>; <a href="./references#CD006023-bbs2-0171" title="PflanzS , HendersonIS , McElduffN , JonesMC . Calcium acetate versus calcium carbonate as phosphate‐binding agents in chronic haemodialysis. Nephrology Dialysis Transplantation1994;9(8):1121‐4. [MEDLINE: 7800211] PflanzS , HendersonIS , McElduffN , JonesMC . Calcium acetate versus calcium carbonate as phosphate‐binding agents in chronic haemodialysis [abstract]. Nephrology Dialysis Transplantation1993;8(11):1301. [CENTRAL: CN‐00447209] ">Pflanz 1994</a>; <a href="./references#CD006023-bbs2-0175" title="RingT , NielsenC , AndersenSP , BehrensJK , SodemannB , KornerupHJ . Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. Nephrology Dialysis Transplantation1993;8(4):341‐6. [MEDLINE: 8390009] ">Ring 1993</a>; <a href="./references#CD006023-bbs2-0182" title="SchaeferK , ScheerJ , AsmusG , UmlaufE , HagemannJ , vonHerrathD . The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrology Dialysis Transplantation1991;6(3):170‐5. [MEDLINE: 1866045] ">Schaefer 1991</a>; <a href="./references#CD006023-bbs2-0191" title="KrauseR , SpragueS , ZhangP , QiuP , RossE . Lanthanum carbonate provides greater phosphate reduction than sevelamer hydrochloride over a 4 week treatment period in patients on dialysis [abstract no: SU579]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. SpragueSM , RossEA , NathSD , ZhangP , PrattRD , KrauseR . Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clinical Nephrology2009;72(4):252‐8. [MEDLINE: 19825330] ">Sprague 2009b</a>; <a href="./references#CD006023-bbs2-0202" title="YangWC , YangCS , HouCC , WuTH , ChengYR , YoungEW , et al. An open‐label, crossover study of a new phosphate binding agent in hemodialysis patients: ferric citrate [abstract]. 8th Asian Pacific Congress of Nephrology; 2000 Mar 26‐30; Taipei, Taiwan. 2000:187. [CENTRAL: CN‐00462027] YangWC , YangCS , HouCC , WuTH , YoungEW , HsuCH . An open‐label, crossover study of a new phosphate‐binding agent in haemodialysis patients: ferric citrate. Nephrology Dialysis Transplantation2002;17(2):265‐70. [MEDLINE: 11812877] ">Yang 2002</a>), included non‐randomised patients (<a href="./references#CD006023-bbs2-0114" title="BorregoJ , Perez del BarrioP , SerranoP , Garcia CortesMJ , Sanchez PeralesMC , BorregoFJ , et al. A comparison of phosphorus‐chelating effect of calcium carbonate versus calcium acetate before dialysis [Comparacion del efecto quelante del fosforo de carbonato vs acetato calcico en predialisis]. Nefrologia2000;20(4):348‐54. [MEDLINE: 11039260] ">Borrego 2000</a>), did not evaluate an eligible intervention (<a href="./references#CD006023-bbs2-0126" title="FischerD , ClineK , PloneM , DillonM , BurkeS , BlairA . A randomized, cross‐over study to compare once a day with three times per day sevelamer dosing [abstract no: SP221]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v93. FischerD , ClineK , PloneMA , DillonM , BurkeSK , BlairAT . Results of a randomized crossover study comparing once daily and thrice‐daily sevelamer dosing. American Journal of Kidney Diseases2006;48(3):437‐44. [MEDLINE: 16931217] ">Fischer 2006</a>; <a href="./references#CD006023-bbs2-0127" title="MehrotraR . A new formulation of lanthanum carbonate is preferred by patients and physicians [abstract no: SP396]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv147. [CENTRAL: CN‐00653769] MehrotraR . Efficacy and safety of higher‐strength lanthanum carbonate [abstract no: F‐PO095]. Journal of the American Society of Nephrology2006;17(Abstracts):356A. [CENTRAL: CN‐00653768] MehrotraR . Patient and physician preference and satisfaction with a new formulation of lanthanum carbonate (LC) [abstract no: SA‐PO803]. Journal of the American Society of Nephrology2005;16:732A. [CENTRAL: CN‐00653767] MehrotraR . Preference and satisfaction with reformulated higher‐dosage strength lanthanum carbonate [abstract no: F‐PO094]. Journal of the American Society of Nephrology2006;17(Abstracts):356A. [CENTRAL: CN‐00653770] MehrotraR , MartinKJ , FishbaneS , SpragueSM , ZeigS , AngerM , et al. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clinical Journal of the American Society of Nephrology: CJASN2008;3(5):1437‐45. [MEDLINE: 18579668] ">FORESEE 2008</a>; <a href="./references#CD006023-bbs2-0135" title="IttelTH , SchferC , SchmittH , GladziwaU , SieberthHG . Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric‐coated preparation and effect of additional Aluminium hydroxide on hyperaluminaemia. Klinische Wochenschrift1991;69(2):59‐67. [MEDLINE: 2027271] ">Ittel 1991</a>; <a href="./references#CD006023-bbs2-0172" title="PhelpsKR , SternM , SlingerlandA , HeraviM , StrogatzDS , HaqqieSS . Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure. American Journal of Nephrology2002;22(5‐6):445‐54. [MEDLINE: 12381942] ">Phelps 2002</a>), evaluated treatment in children (<a href="./references#CD006023-bbs2-0178" title="GoodmanWG , CoburnJW , FoleyJ , SaluskyIB . Prospective assessment of aluminum retention in dialyzed patients given calcium carbonate or aluminum hydroxide [abstract]. Kidney International1990;37(1):328. [CENTRAL: CN‐00626083] SaluskyIB , CoburnJW , FoleyJ , SlatopolskyE , GoodmanWG . Prospective trial of calcium carbonate versus aluminum hydroxide with oral calcitriol therapy in renal osteodystrophy [abstract]. Kidney International1990;37(1):451. SaluskyIB , FoleyJ , GoodmanWG . Calcium carbonate versus aluminum hydroxide with oral calcitriol therapy in pediatric renal osteodystrophy [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:416A. SaluskyIB , FoleyJ , NelsonP , GoodmanWG . Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. New England Journal of Medicine1991;324(8):527‐31. [MEDLINE: 1992306] ">Salusky 1991</a>), or were a secondary publication of an existing excluded study. </p> <div class="figure" id="CD006023-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD006023-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> <p>This 2018 review update therefore includes 104 studies (272 reports) involving 13,744 adult participants. </p> </section> <section id="CD006023-sec-0056"> <h4 class="title">Included studies</h4> <p>The characteristics of the participants and the interventions in included studies are detailed in the <a href="./references#CD006023-sec-0152" title="">Characteristics of included studies</a>. </p> <section id="CD006023-sec-0057"> <h5 class="title">Study design, setting, and characteristics</h5> <p>Study duration varied from 8 weeks to 36 months (median 3.7 months). Twenty studies were a cross‐over study design in which participants were administered each of the study interventions sequentially with or without a washout period. </p> <p>Studies were conducted in twenty‐nine different countries or regions including Australia (<a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>), Belgium (<a href="./references#CD006023-bbs2-0093" title="TielmansC , KnoopC , DoutrelepontJM , TimmermansD , Even‐AdinD , VanherweghemJL . Superiority of calcium acetate (ACET) over carbonate (CARB) to bind phosphorus (P) in hemodialysis patients (HDP) [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:219A. ">Tielmans 1990</a>), Brazil (<a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a>), China (<a href="./references#CD006023-bbs2-0021" title="ChenN , WuX , DingX , MeiC , FuP , JiangG , et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double‐blind, placebo‐controlled, dose‐titration study. Nephrology Dialysis Transplantation2014;29(1):152‐60. [MEDLINE: 24151017] ">Chen 2014</a>; <a href="./references#CD006023-bbs2-0087" title="SongFR , ChengH , ZhaoDM , YuJ , GaoY . Effects of lanthanum carbonate on serum calcium and phosphorus of CAPD patients with chronic renal failure receiving calcitriol pulse therapy due to secondary hyperparathyroidism. Chinese Journal of Evidence‐Based Medicine2014;14(6):651‐4. [EMBASE: 2014574871] ">Song 2014</a>; <a href="./references#CD006023-bbs2-0099" title="WangXH , ZhangX , MuCJ , HeY , PengQP , YangGS , et al. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients. Journal of Huazhong University of Science and Technology. Medical Sciences2015;35(4):508‐13. [MEDLINE: 26223918] ">Wang 2015b</a>; <a href="./references#CD006023-bbs2-0103" title="ZhaoH , WangJ , ZhaoDM , DongYM , GaoY . Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end‐stage renal disease: a randomized controlled trial. Chinese Journal of Evidence‐Based Medicine2014;14(11):1293‐8. [EMBASE: 2014948885] ">Zhao 2014</a>), Denmark (<a href="./references#CD006023-bbs2-0014" title="BroS , RasmussenRA , HandbergJ , OlgaardK , Feld‐RasmussenB . Randomized crossover study comparing the phosphate‐binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. American Journal of Kidney Diseases1998;31(2):257‐62. [MEDLINE: 9469496] ">Bro 1998</a>; <a href="./references#CD006023-bbs2-0051" title="JespersenB , JensenJD , NielsenHK , LauridsenIN , AndersenMJ , PoulsenJH , et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1‐84), and bone mineral content in dialysis patients. Nephrology Dialysis Transplantation1991;6(2):98‐104. [MEDLINE: 1857534] ">Jespersen 1991</a>; <a href="./references#CD006023-bbs2-0076" title="RudnickiM , HyldstrupL , PetersenLJ , HojstedJ , TranbolI . Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double‐blind placebo‐controlled study. Mineral &amp; Electrolyte Metabolism1994;20(3):130‐4. [MEDLINE: 7816001] ">Rudnicki 1994</a>), Egypt (<a href="./references#CD006023-bbs2-0005" title="AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadministration of nicotinamide and calcium‐based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis. Advances in Natural Science2012;5(1):1‐9. [DOI: 10.3968/j.ans.1715787020120501.1001] AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadminstration of nicotinamide and calcium‐based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]. Value in Health2012;15(4):A152. [EMBASE: 70763798] ElSharkawyMM , KamelM , ElhamamsyM , AllamS . Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i253. [EMBASE: 71075759] ">Allam 2012</a>) multiple European countries (<a href="./references#CD006023-bbs2-0016" title="CovicA , Passlick‐DeetjenJ , KroczakM , Buschges‐SeraphinB , GhenuA , PonceP , et al. A comparison of calcium acetate/magnesium carbonate and sevelamer‐hydrochloride effects on fibroblast growth factor‐23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation2013;28(9):2383‐92. [MEDLINE: 23787550] PaschA , deFranciscoALM , CovicA , MarzellB , ArensHJ , Passlick‐DeetjenJ , et al. Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate/ magnesium carbonate containing phosphate binder [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii40. [EMBASE: 71491561] deFranciscoAL , LeidigM , CovicAC , KettelerM , Benedyk‐LorensE , MircescuGM , et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrology Dialysis Transplantation2010;25(11):3707‐17. [MEDLINE: 20530499] ">CALMAG 2010</a>; <a href="./references#CD006023-bbs2-0033" title="EvenepoelP , SelgasR , CaputoF , FoggensteinerL , HeafJG , OrtizA , et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2009;24(1):278‐85. [MEDLINE: 18820280] EvenepoelP , SelgasR , DuggalA , KellyA , FanSL . Effects of sevelamer hydrochloride (Renagel®) and calcium acetate on controlling serum phosphorus in peritoneal dialysis patients [abstract no: MP580]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv496. [CENTRAL: CN‐00671825] EvenepoelP , SelgasR , DuggalA , KellyAL , FanSL . Comparative effects of sevelamer hydrochloride (Renagel®) and calcium acetate on markers of mineral metabolism in peritoneal dialysis patients [abstract no: TH‐PO778]. Journal of the American Society of Nephrology2006;17(Abstracts):272A. [CENTRAL: CN‐00671824] ">Evenepoel 2009</a>; <a href="./references#CD006023-bbs2-0044" title="GillM , WebsterI , SegarsL . Efficacy and safety of lanthanum carbonate, the novel phosphate binder, in Chinese patients with chronic kidney disease [abstract]. Nephrology Nursing Journal2004;31(2):141. HutchisonA , Lanthanum Study Group. Analysis of haematology data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract no: SP219]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v92‐3. HutchisonA , Lanthanum Study Group. No adverse effects of haematological parameters during lanthanum carbonate treatment in over 2000 patients [abstract no: W‐PO40068]. Nephrology2005;10(Suppl):A297. HutchisonA , SPD405‐301 Lanthanum Study Group. Long‐term safety, efficacy, and tolerability of lanthanum carbonate: results from a 3.5‐year study [abstract no: W‐PO40065]. Nephrology2005;10(Suppl 1):A297. HutchisonA , WebsterI . Lanthanum carbonate versus calcium carbonate: effect on parathyroid hormone (PTH) levels [abstract no: F‐PO656]. Journal of the American Society of Nephrology2003;14(Nov):205A. HutchisonA , WebsterI . Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenal®) during long‐term therapy in hemodialysis patients. [abstract no: SU‐PO1039]. Journal of the American Society of Nephrology2003;14(Nov):764A. HutchisonA , WebsterI . Safety and efficacy data for lanthanum carbonate: a summary from three studies [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:107. HutchisonA , WebsterI , GillM , SchmiederR . Safety and tolerability of lanthanum carbonate in haemodialysis patients: a 12‐month study [abstract no: W431]. Nephrology Dialysis Transplantation2003;18(Suppl 4):684. HutchisonA , Lanthanum Study Group. No evidence of hepatoxicity with lanthanum carbonate ‐ clinical trial data from 2000 dialysis patients [abstract no: W‐PO40069]. Nephrology2005;10(Suppl):A298. HutchisonAJ . Lanthanum carbonate (FosrenolTM), a novel, nonaluminum, noncalcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract no: PS1‐22]. Nephrology2003;8(Suppl 1):A29. HutchisonAJ , GillM . A demographic analysis of lanthanum carbonate phase II and III studies [abstract no: 271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106‐7. [CENTRAL: CN‐00509244] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6‐month, randomized, comparative trial versus calcium carbonate. Nephron2005;100(1):c8‐19. [MEDLINE: 15809508] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Long‐term efficacy and tolerability of lanthanum carbonate: results from a 3‐year study. Nephron2006;102(2):c61‐71. [MEDLINE: 16224198] HutchisonAJ , Lanthanum Study Group. The novel, non‐aluminium, non‐calcium phosphate binder, fosrenol, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract no: SA‐PO599]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):385A‐6A. [CENTRAL: CN‐00445823] SpeakeM , HutchisonAJ , WebsterI . Lanthanum carbonate, a novel, non‐aluminum, non‐calcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract]. Nephrology Nursing Journal2003;30(2):149. [CENTRAL: CN‐00644297] SpeakeM , WebsterI . Long‐term safety, tolerability, and efficacy of lanthanum carbonate therapy [abstract]. Nephrology Nursing Journal2004;31(2):143. [CENTRAL: CN‐00644295] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WebsterI , GillM . Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients [abstract no: SP267]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105. [CENTRAL: CN‐00509557] ">Hutchison 2005</a>), France (<a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0069" title="LengletA , LiabeufS , ElEsperN , BrissetS , MansourJ , Lemaire‐HurtelAS , et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation2017;32(5):870‐9. [MEDLINE: 24599830] ">NICOREN 2017</a>; <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a>; <a href="./references#CD006023-bbs2-0078" title="SadekT , MazouzH , BahlouH , OprisiuR , ElEsperN , ElEsperI , et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open‐label, randomized study. Nephrology Dialysis Transplantation2003;18(3):582‐9. [MEDLINE: 12584283] ">Sadek 2003</a>), Germany (<a href="./references#CD006023-bbs2-0008" title="BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross‐over study. Nephrology Dialysis Transplantation1999;14(6):1475‐9. [MEDLINE: 10383011] BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium‐ketoglutarate vs. calcium‐acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):552A. [CENTRAL: CN‐00444439] ">Birck 1999</a>; <a href="./references#CD006023-bbs2-0032" title="DeuberH . Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract no: W422]. Nephrology Dialysis Transplantation2003;18(Suppl 4):680‐1. [CENTRAL: CN‐00445085] DeuberHJ . Combined use of calcium acetate and magnesium carbonate as phosphate binder [Kombinierter einsatz von kalziumazetat und magnesiumkarbonat als orale phosphatbinder]. Nieren und Hochdruckkrankheiten2004;33(8):403‐8. [EMBASE: 39150178] ">Deuber 2004</a>), Greece (<a href="./references#CD006023-bbs2-0054" title="KatopodisKP , AndrikosEK , GouvaCD , BairaktariET , NikolopoulosPM , TakouliLK , et al. Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients. Peritoneal Dialysis International2006;26(3):320‐7. [MEDLINE: 16722024] ">Katopodis 2006</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>), Iran (<a href="./references#CD006023-bbs2-0082" title="ShahbazianH , ZafarMA , GhorbaniA , AbbaspourMR , Belladi MusaviSS , HayatiF , et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double‐blind randomized clinical trial. Nefrologia2011;31(1):58‐65. [MEDLINE: 21270914] ">Shahbazian 2011</a>), Italy (<a href="./references#CD006023-bbs2-0031" title="DeSantoNG , FrangiosaA , AnastasioP , MarinoA , CorrealeG , PernaA , et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. Journal of Nephrology2006;19 Suppl 9:S108‐14. [MEDLINE: 16736432] ">De Santo 2006</a>; <a href="./references#CD006023-bbs2-0041" title="GallieniM , CicchettiT , SalvadoriM , SorbaG , StalteriA , TarchiniR , et al. Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial ‐ Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]. Journal of the American Society of Nephrology2005;16:746A. [CENTRAL: CN‐00583853] ">Gallieni 2005</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0046" title="BellasiA , CozzolinoM , RussoD , MolonyD , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology2016;86(9):113‐24. [MEDLINE: 27443567] BellasiA , CozzolinoM , RussoD , MolonyDA , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii588. [EMBASE: 72207961] DiIorioB . In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'. American Journal of Kidney Diseases2014;63(1):164‐5. [MEDLINE: 24377649] DiIorioB , MolonyD , BellC , CuccinielloE , BellizziV , RussoD , et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. American Journal of Kidney Diseases2013;62(4):771‐8. [MEDLINE: 23684755] DiIorioBR , CuccinielloE , BellizziV . Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan‐Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar‐Apr;26(2):419]. Journal of Nephrology2009;22(6):694‐8. [MEDLINE: 19967647] MolonyD , BellasiA , BellizziV , RussoD , DiIorioB . Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii54. [EMBASE: 70765453] ObiY , HamanoT . The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. American Journal of Kidney Diseases2014;63(1):164. [MEDLINE: 24377650] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593‐602; PMID: 25027030]. Journal of Nephrology2014;27(6):717. [MEDLINE: 25098354] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]. Journal of Nephrology2015;28(5):593‐602. [MEDLINE: 25027030] ">INDEPENDENT‐HD 2009</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>), Japan (<a href="./references#CD006023-bbs2-0002" title="AkizawaT , KinugasaE , NagaiT , NiikuraK , KuriharaS , SuzukiM , et al. Effect of sevelamer hydrochloride (PB‐94) on hyperphosphatemia in Japanese hemodialysis (HD) patients [abstract no: A2940]. Journal of the American Society of Nephrology2000;11(Sept):557A. [CENTRAL: CN‐00550506] KinugasaE , KoshikawaS , PB‐94 Study Group. Effects of PB‐94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients ‐ a randomized, open label, dose titration study of PB‐94 versus caltan® tablet 500 (calcium carbonate) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):755A. [CENTRAL: CN‐00626049] ">Akizawa 2000</a>; <a href="./references#CD006023-bbs2-0003" title="AkizawaT , OrigasaH , KameokaC , KanekoY , KawasakiS , Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Therapeutic Apheresis &amp; Dialysis2014;18(2):122‐31. [MEDLINE: 24720402] ">Akizawa 2014a</a>; <a href="./references#CD006023-bbs2-0004" title="AkizawaT , OrigasaH , KameokaC , TsukadaJ , KuroishiK , YamaguchiY . Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Therapeutic Apheresis &amp; Dialysis2016;20(6):588‐97. [MEDLINE: 27896908] ">Akizawa 2016</a>; <a href="./references#CD006023-bbs2-0039" title="FujiiH , KonoK , GotoS , NakaiK , WatanabeS , WatanabeK , et al. Effect of lanthanum carbonate on cardiac abnormalities in patients new to hemodialysis [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii645. [EMBASE: 617289957] FujiiH , NakaiK , KonoK , GotoS , KitamuraK , YonekuraY , et al. Effect of lanthanum carbonate on coronary artery calcification during the early period after the initiation of haemodialysis [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i252. [EMBASE: 72326579] ">Fujii 2017</a>; <a href="./references#CD006023-bbs2-0040" title="FujimoriA , OhkawaS , OkadaS , MizobuchiN , SakaiM , HasuikeY , et al. Comparison of the suppressive effects on fibroblast growth factor 23 between ferric citrate and lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii244‐5. [EMBASE: 617291229] ">Fujimori 2017</a>; <a href="./references#CD006023-bbs2-0048" title="ItohK , TanakaM , HashiguchiJ , FunakoshiS , NakanoH , KuboH , et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp; Dialysis2008;12(2):126‐32. [MEDLINE: 18387160] ">Itoh 2008</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>; <a href="./references#CD006023-bbs2-0053" title="KasaiS , SatoK , MurataY , KinoshitaY . Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(4):341‐9. [EMBASE: 2012432570] ">Kasai 2012</a>; <a href="./references#CD006023-bbs2-0066" title="MatsushimaH , YasudaT , OyamaA , MiyataM . Efficacy and safety of iron‐based phosphate binders, ferric citrate hydrate versus sucroferric oxyhydroxide, on hyperphosphatemia in chronic hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii679. [EMBASE: 617290946] ">Matsushima 2017</a>; <a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a>; <a href="./references#CD006023-bbs2-0084" title="ShibataK , IwamotoT , MurakamiT , HirawaS , YasudaG , ToyaY , et al. A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone [abstract no: SAP245]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi245. ShibataK , IwamotoT , OnoS , MurakamiT , YanagiM , KoguchiN , et al. A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone. Three‐years follow up [abstract no: SU500]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Shibata 2007</a>; <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a>; <a href="./references#CD006023-bbs2-0092" title="TakaharaY , MatsudaY , TakahashiS , ShigematsuT , Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre‐dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical Nephrology2014;82(3):181‐90. [MEDLINE: 25079863] ">Takahara 2014</a>; <a href="./references#CD006023-bbs2-0098" title="WadaK , WadaY . Evaluation of aortic calcification with lanthanum carbonate vs. calcium‐based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open‐label randomized controlled trial. Therapeutic Apheresis &amp; Dialysis2014;18(4):353‐60. [MEDLINE: 24417760] ">Wada 2014</a>; <a href="./references#CD006023-bbs2-0100" title="YokoyamaK , HirakataH , AkibaT , FukagawaM , NakayamaM , SawadaK , et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis‐dependent CKD. Clinical Journal of The American Society of Nephrology: CJASN2014;9(3):543‐52. [MEDLINE: 24408120] ">Yokoyama 2014</a>; <a href="./references#CD006023-bbs2-0101" title="YokoyamaK , AkibaT , FukagawaM , NakayamaM , SawadaK , KumagaiY , et al. A randomized trial of JTT‐751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology Dialysis Transplantation2014;29(5):1053‐60. [MEDLINE: 24376274] ">Yokoyama 2014a</a>), Japan and Taiwan (<a href="./references#CD006023-bbs2-0020" title="ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: a 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology2011;16(8):743‐50. [MEDLINE: 21854503] ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08‐08]. Nephrology2010;15(Suppl 3):51. [EMBASE: 70467427] ChenJB , ChiangSS , HenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]. NDT Plus2010;3(Suppl 3):iii238. [EMBASE: 70484048] ">Chen 2011b</a>; <a href="./references#CD006023-bbs2-0094" title="ToidaT , FukudomeK , FujimotoS , YamadaK , SatoY , ChiyotandaS , et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clinical Nephrology2012;78(3):216‐23. [MEDLINE: 22874110] ">Toida 2012</a>), Republic of Korea (<a href="./references#CD006023-bbs2-0055" title="KoYS , RyuJW , LeeJH , YiJH , HanSW , KimHJ . Efficacy of lanthanum carbonate and calcium carbonate in Korean dialysis patients. Korean Journal of Nephrology2010;29(1):64‐72. [CENTRAL: CN‐01045527] ">Ko 2010</a>; <a href="./references#CD006023-bbs2-0057" title="LeeYK , ChoiHY , ShinSK , LeeHY . Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clinical Nephrology2013;79(2):136‐42. [MEDLINE: 23211335] ">Lee 2013</a>), Macedonia (<a href="./references#CD006023-bbs2-0089" title="SikoleA , SpasovskiG , GelevS , AmitovV , StojcevN , GrozdanovskiR . Lanthanum carbonate ‐ a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v95‐6. SikoleA , SpasovskiG , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]. Nephrology Dialysis Transplantation2002;17(Suppl 12):67. [CENTRAL: CN‐00509481] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients ‐ single center experience [abstract no: w436]. Nephrology Dialysis Transplantation2003;18(Suppl 4):685‐6. [CENTRAL: CN‐00447817] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]. International Journal of Artificial Organs2003;26(7):630. [CENTRAL: CN‐00583691] SpasovskiG , SikoleA , GelevS , MasinJ , FreemontT , WebsterI , et al. The evolution of renal bone disease in dialysis patients ‐ comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105‐6. [CENTRAL: CN‐00509488] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , GrozdanovskiR , et al. Comparative, bone biopsy‐based, 3 years follow‐up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]. Nephrology Dialysis Transplantation2005;20(6 Suppl):v376. [CENTRAL: CN‐00583693] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , PolenakovicB , WebsterI , et al. The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA‐PO842]. Journal of the American Society of Nephrology2005;16(Oct):741A. [CENTRAL: CN‐00583697] SpasovskiGB , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]. Hemodialysis International2003;7(1):87. [CENTRAL: CN‐00461778] SpasovskiGB , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , WebsterI , et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow‐up. Nephrology Dialysis Transplantation2006;21(8):2217‐24. [MEDLINE: 16595583] ">Spasovski 2006</a>), multinational (<a href="./references#CD006023-bbs2-0027" title="D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International ‐ Supplement2003;85:S73‐8. [MEDLINE: 12753271] D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. Multi‐centre study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients [abstract no: PS1‐15]. Nephrology2003;8(Suppl 1):A28. DeBroeME , D'HaesePC , FreemontTJ , WebsterI , GillM , SpasovskiGB . Comparative effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients: results from a large, long‐term clinical trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):682. [CENTRAL: CN‐00445015] FreemontA . The effects of lanthanum carbonate and calcium carbonate on bone in patients with chronic kidney disease [abstract no: 33]. American Journal of Kidney Diseases2004;43(4):A23. [CENTRAL: CN‐00644282] FreemontA , JonesC . The effects of the phosphate binders lanthanum carbonate and calcium carbonate on bone: a comparative study in patients with chronic kidney disease [abstract no:SP270]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106. [CENTRAL: CN‐00509202] FreemontAJ , HoylandJA , DentonJ , Lanthanum Carbonate SPD405‐303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end‐stage renal disease. Clinical Nephrology2005;64(6):428‐37. [MEDLINE: 16370155] FreemontT , MallucheHH . Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clinical Nephrology2005;63(2):138‐45. [MEDLINE: 15730056] TorresA , DeBroeME , D'HaesePC , HutchisonA , JonesC . One‐year, randomized, open‐label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol®) and calcium carbonate in dialysis patients [abstract no: SU‐PO1041]. Journal of the American Society of Nephrology2003;14(Nov):764A. [CENTRAL: CN‐00583261] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WilsonR . Spica Consultants Ltd. Personal communication2005. WilsonR , CopleyJB , PooleL . Lower serum phosphorus can be attained by increasing the dose of lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii496. [EMBASE: 70766788] ">D'Haese 2003</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>; <a href="./references#CD006023-bbs2-0065" title="LocatelliF , SpasovskiG , DimkovicN , WannerC , DellannaF , PontorieroG . The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1‐year prospective randomized study. Nephrology Dialysis Transplantation2014;29(5):1061‐73. [MEDLINE: 24302608] ">Locatelli 2014</a>; <a href="./references#CD006023-bbs2-0068" title="NCT00542815 . A study of MCI‐196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia. ClinicalTrials.gov/show/NCT00542815 (first received 12 October 2007). ">NCT00542815</a>), Pakistan (<a href="./references#CD006023-bbs2-0001" title="AhmedW , Rizwan‐Ul‐HagAM , KhanS , HaiderS , Abad‐Ur‐Reham . Comparative efficacy of sevelamer hydrochloride versus calcium acetate on bone biomarkers in patients with end stage renal disease on hemodialysis. Pakistan Journal of Medical &amp; Health Sciences2014;8(3):769‐71. [EMBASE: 600071132] ">Ahmed 2014</a>; <a href="./references#CD006023-bbs2-0079" title="SaifI , HalimA , AltafA , SaifM , KhalidM , AhmadD , et al. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis. Journal of Ayub Medical College, Abbottabad: JAMC2007;19(4):26‐8. [MEDLINE: 18693591] ">Saif 2007</a>), Poland (<a href="./references#CD006023-bbs2-0104" title="ZwiechR , DryjaP , LacinaD , KroliczakV , ChrulS , KacprzykF . The influence of short‐term magnesium carbonate treatment on calcium‐phosphorus balance in dialysis patients [Wplyw krotkoterminowego leczenia weglanem magnezu na gospodarke wapniowo‐fosforanowa u chorych przewlekle hemodializowanych]. Wiadomosci Lekarskie2011;64(1):9‐14. [MEDLINE: 21812357] ">Zwiech 2011</a>), Portugal (<a href="./references#CD006023-bbs2-0035" title="FerreiraA , FrazãoJM , Monier‐FaugereMC , GilC , GalvaoJ , OliveiraC , et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. Journal of the American Society of Nephrology2008;19(2):405‐12. [MEDLINE: 18199805] ">Ferreira 2008</a>), Saudi Arabia (<a href="./references#CD006023-bbs2-0083" title="ShaheenA , AkeelNM , BadawiLS , SouqiyyehMZ . Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Medical Journal2004;25(6):785‐91. [MEDLINE: 15195212] ">Shaheen 2004</a>), Spain (<a href="./references#CD006023-bbs2-0006" title="AlmirallJ , VecianaL , LlibreJ . Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):976. [CENTRAL: CN‐00260851] AlmirallJ , VecianaL , LlibreJ . Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. American Journal of Nephrology1994;14(3):192‐6. [MEDLINE: 7977479] ">Almirall 1994</a>; <a href="./references#CD006023-bbs2-0017" title="CaravacaF , SantosI , CuberoJJ , EsparragoJF , ArrobasM , PizarroJL , et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron1992;60(4):423‐7. [MEDLINE: 1584317] CaravacaF , SantosI , RoblesR , CuberoJ , EsparragoJ , ArrobasM , et al. Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1990;5(8):729. [CENTRAL: CN‐00260555] ">Caravaca 1992</a>; <a href="./references#CD006023-bbs2-0038" title="ForasterA , GonzalezMT , CarrerasJ , PrietoML , SampietroJ , BonninR , et al. Calcium acetate. A good alternative to calcium carbonate for treating hyperphosphoremia in chronic hemodialysis patients with high risk of hypercalcemia [Acetato calcico. Una buena alternativa al carbonato calcico, como quelante del fosforo, en los pacientes en hemodialisis con riesgo de hipercalcemia]. Nefrologia1998;18(4):296‐301. [EMBASE: 1998302471] ">Foraster 1998</a>; <a href="./references#CD006023-bbs2-0043" title="HervasJG , PradosD , CerezoS . Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney International ‐ Supplement2003;85:69‐72. [MEDLINE: 12753270] ">Hervas 2003</a>; <a href="./references#CD006023-bbs2-0067" title="Navarro‐GonzalezJF , Mora‐FernandezC , Muros de FuentesM , Donate‐CorreaJ , Cazana‐PerezV , Garcia‐PerezJ . Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2011;6(9):2272‐9. [MEDLINE: 21784820] ">Navarro‐Gonzalez 2011</a>; <a href="./references#CD006023-bbs2-0088" title="SorianoS , OjedaR , RodriguezM , AlmadenY , RodriguezM , Martin‐MaloA , et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clinical Nephrology2013;80(1):17‐22. [MEDLINE: 23391319] ">Soriano 2013</a>), Taiwan (<a href="./references#CD006023-bbs2-0058" title="LeeCT , WuIW , ChiangSS , PengYS , ShuKH , WuMJ , et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double‐blind, placebo‐controlled study. Journal of Nephrology2015;28(1):105‐13. [EMBASE: 2015735302] ">Lee 2015b</a>; <a href="./references#CD006023-bbs2-0061" title="LinYF , ChenYM , HungKY , ChuTS , KanWC , HuangCY , et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. Journal of the Formosan Medical Association2010;109(9):663‐72. [MEDLINE: 20863994] LinYF , ChienCT , KanWC , ChenYM , ChuTS , HungKY , et al. Pleiotropic effects of sevelamer beyond phosphate binding in end‐stage renal disease patients: a randomized, open‐label, parallel‐group study. Clinical Drug Investigation2011;31(4):257‐67. [MEDLINE: 21299254] ">Lin 2010</a>; <a href="./references#CD006023-bbs2-0062" title="LinHH , LiouHH , WuMS , HuangCC . Factors associated with serum fetuin‐A concentrations after long‐term use of different phosphate binders in hemodialysis patients. BMC Nephrology2016;17:33. [MEDLINE: 27007989] LinHH , LiouHH , WuMS , LinCY , HuangCC . Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology2014;19(11):672‐8. [MEDLINE: 25113414] ">Lin 2014a</a>; <a href="./references#CD006023-bbs2-0063" title="HuangC , YuC , LiuY . Effect of sevelamer on homocysteinemia and lipid profile in patients undergoing maintenance hemodialysis ‐ a randomized clinical trial [abstract no: F‐PO610]. Journal of the American Society of Nephrology2005;16:467A. [CENTRAL: CN‐00756400] LiuYL , LinHH , YuCC , KuoHL , YangYF , ChouCY , et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Renal Failure2006;28(8):701‐7. [MEDLINE: 17162430] ">Liu 2006</a>), Thailand (<a href="./references#CD006023-bbs2-0007" title="AramwitP , SrisawadwongR , SupasyndhO . Effectiveness and safety of extended‐release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Journal of Nephrology2012;25(3):354‐62. [MEDLINE: 21748722] ">Aramwit 2012</a>), The Netherlands (<a href="./references#CD006023-bbs2-0049" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients. Nephrology Dialysis Transplantation1995;10(12):2321‐4. [MEDLINE: 8808233] ">Janssen 1995</a>; <a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a>), Turkey (<a href="./references#CD006023-bbs2-0015" title="CaglarK , YilmazMI , SaglamM , CakirE , AcikelC , EyiletenT , et al. Short‐term treatment with sevelamer increases serum fetuin‐a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clinical Journal of the American Society of Nephrology: CJASN2008;3(1):61‐8. [MEDLINE: 18057307] YilmazMI , SonmezA , SaglamM , YamanH , KilicS , EyiletenT , et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. American Journal of Kidney Diseases2012;59(2):177‐85. [MEDLINE: 22137672] ">Caglar 2008</a>; <a href="./references#CD006023-bbs2-0081" title="SezerS , KarakanS , AcarNO . Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]. NDT Plus2010;3(Suppl 3):iii196. [EMBASE: 70483939] ">Sezer 2010</a>), the USA (<a href="./references#CD006023-bbs2-0009" title="BleyerAJ , BurkeSK , DillonM , GarrettB , KantKS , LynchD , et al. A comparison of the calcium‐free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases1999;33(4):694‐701. [MEDLINE: 10196011] BleyerAJ , GarrettB , KantKS , LynchD , RahmanN , SchoenfeldP , et al. An open label, cross‐over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):548a. [CENTRAL: CN‐00444452] ">Bleyer 1999</a>; <a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0019" title="BudoffMJ , KesslerP , GaoYL , QunibiW , MoustafaM , MaoSS . The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)‐2 study. Academic Radiology2008;15(1):58‐61. [MEDLINE: 18078907] QunibiW , HorwithG , KesslerP , MoustafaM , CARE‐2 Investigators. Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation‐2 (CARE‐2) study [abstract no: PUB386]. Journal of the American Society of Nephrology2005;16(Oct Abstracts Issue):866A. [CENTRAL: CN‐00602064] QunibiW , MoustafaM , KesslerP , BortleyE , MuenzL , BudoffM . Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study [abstract no: FP386]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi148. [CENTRAL: CN‐00691160] QunibiW , MoustafaM , KesslerP , MuenzLR , BudoffM . Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: TH‐PO845]. Journal of the American Society of Nephrology2006;17(Abstracts):286A. [CENTRAL: CN‐00602067] QunibiW , MoustafaM , MuenzLR , HeDY , KesslerPD , Diaz‐BuxoJA , et al. A 1‐year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study. American Journal of Kidney Diseases2008;51(6):952‐65. [MEDLINE: 18423809] QunibiW , MuenzLR , Diaz‐BuxoJA . The CARE‐2 study results: setting the record straight. Nephrology Dialysis Transplantation2008;23(12):4081‐2. [MEDLINE: 18820282] QunibiWY , MoustafaM , KesslerP , BorteyE , MuenzLR , BudoffM . Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: S‐PO‐0376]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:150. QunibiWY , MoustafaM , KesslerP , MuenzLR , Diaz‐BuxoJ , BudoffM , et al. Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation‐2 (CARE‐2) study [abstract no: TH‐FC043]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. ">CARE‐2 2008</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0022" title="ChengSC , YoungDO , DelmezJA , CoyneDW . The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]. Journal of the American Society of Nephrology2007;18(Abstracts):924A. ChengSC , YoungDO , HuangY , DelmezJA , CoyneDW . A randomized, double‐blind, placebo‐controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):1131‐8. [MEDLINE: 18385391] ">Cheng 2008</a>; <a href="./references#CD006023-bbs2-0023" title="ChennasamudramSP , NoorT , VasylyevaTL . Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. Journal of Renal Care2013;39(2):82‐9. [MEDLINE: 23574727] ">Chennasamudram 2013</a>; <a href="./references#CD006023-bbs2-0024" title="ChertowGM , DillonM , BurkeSK , StegM , BleyerAJ , GarrettBN , et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clinical Nephrology1999;51(1):18‐26. [MEDLINE: 9988142] ">Chertow 1999</a>; <a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a>; <a href="./references#CD006023-bbs2-0029" title="DelmezJA , KelberJ , NorwoodKY , GilesKS , SlatopolskyE . The clinical evaluation of magnesium carbonate (MgCo3) as a phosphorous (P) binder in the suppression of secondary hyperparathyroidism [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:416. DelmezJA , KelberJ , NorwordKY , GilesKS , SlatopolskyE . Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney International1996;49(1):163‐7. [MEDLINE: 8770963] ">Delmez 1996</a>; <a href="./references#CD006023-bbs2-0030" title="DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. A randomized, double‐blind cross‐over design study of sevelamer hydrochloride (SH, Renegel®) and sevelamer carbonate (SC) in chronic kidney disease patients on hemodialysis [abstract no: 48]. American Journal of Kidney Diseases2007;49(4):A36. [CENTRAL: CN‐00671791] DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. Results of a randomized, double‐blind, cross‐over design study of sevelamer hydrochloride (Renagel®) and sevelamer carbonate in chronic kidney disease patients on hemodialysis [abstract no: SaP377]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi361. [CENTRAL: CN‐00671790] DelmezJ , BlockG , RobertsonJ , Chasan‐TaberS , BlairA , DillonM , et al. A randomized, double‐blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clinical Nephrology2007;68(6):386‐91. [MEDLINE: 18184521] ">Delmez 2007</a>; <a href="./references#CD006023-bbs2-0036" title="FishbaneS , DelmezJ , SukiW , HariacharS , MoeS , HeatonJ . Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open‐label study in chronic kidney disease patients on hemodialysis [abstract no: M621]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. FishbaneS , DelmezJ , SukiWN , HariacharS , MoeS . A randomized, parallel, open‐label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):936A. [CENTRAL: CN‐00747271] FishbaneS , DelmezJ , SukiWN , HariacharSK , HeatonJ , Chasan‐TaberS , et al. A randomized, parallel, open‐label study to compare once‐daily sevelamer carbonate powder dosing with thrice‐daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. American Journal of Kidney Diseases2010;55(2):307‐15. [MEDLINE: 20042256] ">Fishbane 2010</a>; <a href="./references#CD006023-bbs2-0042" title="GreenbergS , ShapiroW , PoruchJG . Calcium acetate (aa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:472. [CENTRAL: CN‐00509217] GreenbergS , ShapiroW , PorushJG . Calcium acetate (caa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. Journal of the American Society of Nephrology1994;5(3):492. ">Greenberg 1994</a>; <a href="./references#CD006023-bbs2-0047" title="IsakovaT , Barchi‐ChungA , EnfieldG , SmithK , VargasG , HoustonJ , et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD. Clinical Journal of The American Society of Nephrology: CJASN2013;8(6):1009‐18. [MEDLINE: 23471131] IsakovaT , Barchi‐ChungA , EnfieldG , SmithKT , VargasGS , HoustonJ , et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR‐OR068]. Journal of the American Society of Nephrology2012;23:45A. ">Isakova 2013</a>; <a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a>; <a href="./references#CD006023-bbs2-0075" title="RoxeDM , MistovichM , BarchDH . Phosphate‐binding effects of sucralfate in patients with chronic renal failure. American Journal of Kidney Diseases1989;13(3):194‐9. [MEDLINE: 2919600] ">Roxe 1989</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0090" title="SpiegelDM , FarmerB . Long‐term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodialysis International2009;13(4):453‐9. [MEDLINE: 19469885] SpiegelDM , FarmerB , ChoncholM . Magnesium carbonate ‐ an effective phosphate binder [abstract no: 152]. American Journal of Kidney Diseases2006;47(4):A56. [CENTRAL: CN‐00653706] SpiegelDM , FarmerB , SmitsG , ChoncholM . Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition2007;17(6):416‐22. [MEDLINE: 17971314] ">Spiegel 2007</a>; <a href="./references#CD006023-bbs2-0091" title="SpragueS , FinnW , AbboudH , QiuP , SPD405‐206 Study Investigators. Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00757113] SpragueSM , AbboudH , QuiP , DauphinM , ZhangP , FinnW . Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):178‐85. [MEDLINE: 19056618] SpragueSM , FinnWF , QiuP , Study 206 Investigators. Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi‐center trial [abstract no: PUB442]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):927A. [CENTRAL: CN‐00756891] ">Sprague 2009a</a>; <a href="./references#CD006023-bbs2-0097" title="VlassaraH , UribarriJ , CaiW , GoodmanS , PyzikR , PostJ , et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2012;7(6):934‐42. [MEDLINE: 22461535] Yubero‐SerranoEM , WoodwardM , PoretskyL , VlassaraH , StrikerGE . Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro‐oxidant status in patients with diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2015;10(5):759‐66. [MEDLINE: 25710801] ">Vlassara 2012</a>; <a href="./references#CD006023-bbs2-0102" title="YoungDO , ChengSC , DelmezJA , CoyneDW . The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International2009;29(5):562‐7. [MEDLINE: 19776051] ">Young 2009a</a>), and the USA and Europe (<a href="./references#CD006023-bbs2-0025" title='AsmusHG , BraunJ , KrauseR , BrunkhorstR , HolzerH , SchulzW , et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrology Dialysis Transplantation2005;20(8):1653‐61. [MEDLINE: 15930018] BommerJ , AsmusG , BraunJ , BrunkhorstR , HolzerH , KrauseR , et al. Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]. Nephrology Dialysis Transplantation2002;17(Suppl 1):32. [CENTRAL: CN‐00509096] BommerJ , European Renagel Investigators Group. Lipid lowering effect of renagel, a novel phosphate binder [abstract]. Nephrology Dialysis Transplantation2001;16(6):A122. [CENTRAL: CN‐00444477] BraunJ , AsmusHG , HolzerH , BrunkhorstR , KrauseR , SchulzW , et al. Long‐term comparison of a calcium‐free phosphate binder and calcium carbonate‐‐phosphorus metabolism and cardiovascular calcification. Clinical Nephrology2004;62(2):104‐15. [MEDLINE: 15356967] ChertowGM , BurkeSK , RaggiP , Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International2002;62(1):245‐52. [MEDLINE: 12081584] ChertowGM , Chasan‐TaberS , RaggiP . The "tip of the iceberg" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):433a. [CENTRAL: CN‐00444789] ChertowGM , DillonMA , AminN , BommerJ , BurkeSK . Sevelamer is more effective at controlling disorders of mineral metabolism than calcium‐based phosphate binders in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):195‐6A. [CENTRAL: CN‐00444790] ChertowGM , GoodmanWG , TotoRD , RaggiP . In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL‐C, APO‐B, and HS‐CRP compared with calcium acetate (PHOSLO) [abstract no: SA‐PO603]. Journal of the American Society of Nephrology2002;13(Sept, Program &amp; Abstracts):386a. [CENTRAL: CN‐00444791] ChertowGM , RaggiP , Chasan‐TaberS , BommerJ , HolzerH , BurkeSK . Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation2004;19(6):1489‐96. [MEDLINE: 15102961] ChertowGM , RaggiP , McCarthyJT , SchulmanG , SilberzweigJ , KuhlikA , et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. American Journal of Nephrology2003;23(5):307‐14. [MEDLINE: 12915774] FerramoscaE , BurkeS , Chasan‐TaberS , RattiC , ChertowGM , RaggiP . Potential antiatherogenic and anti‐inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal2005;149(5):820‐5. [MEDLINE: 15894962] GargJP , Chasan‐TaberS , BlairA , PloneM , BommerJ , RaggiP , et al. Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis &amp; Rheumatism2005;52(1):290‐5. [MEDLINE: 15641045] JamesG , RaggiP , BoulayA , BurkeS , Chasan‐TaberS , ChertowG , et al. Thoracic vertebral bone density increases with renagel and decreases with calcium‐based phosphate binder therapy ‐ a two year study [abstract no: W423]. Nephrology Dialysis Transplantation2003;18(Suppl 4):681. [CENTRAL: CN‐00445894] RaggiP , BommerJ , ChertowGM . Valvular calcification in hemodialysis patients randomized to calcium‐based phosphorus binders or sevelamer. Journal of Heart Valve Disease2004;13(1):134‐41. [MEDLINE: 14765851] RaggiP , BurkeS , Chasen‐TaberS , ChertowG , HolzerH , BommerJ . Sevelamer preserves trabecular bone mineral density [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:103‐4. [CENTRAL: CN‐00509430] RaggiP , BurkeSK , Chasen‐TaberS , ChertowGM , HolzerH , BommerJ . Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA‐PO924]. Journal of the American Society of Nephrology2003;14(Nov):502A. [CENTRAL: CN‐00583411] RaggiP , BurkeSK , DillonMA , AminN , BommerJ , ChertowGM . Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):239A. [CENTRAL: CN‐00447325] RaggiP , JamesG , BurkeSK , BommerS , Chasan‐TaberS , HolzerH , et al. Decrease in thoracic vertebral bone attenuation with calcium‐based phosphate binders in hemodialysis. Journal of Bone &amp; Mineral Research2005;20(5):764‐72. [MEDLINE: 15824849] '>Chertow 2002</a>). Forty‐six studies received at least some funding from companies that manufacture phosphate binders, while 41 studies provided no specific details about funding sources. </p> </section> <section id="CD006023-sec-0058"> <h5 class="title">Study participants</h5> <p>The 104 studies included 13,744 randomised participants. Most studies involved participants with CKD G5D ((83 studies). Of these, 73 were among participants treated with haemodialysis, two involved participants treated with haemodialysis or peritoneal dialysis, and eight involved participants treated with peritoneal dialysis. Twenty studies involved participants with CKD G2 to G5 not requiring dialysis. In one study, the GFR category of CKD was not reported. The sample size varied from eight participants (<a href="./references#CD006023-bbs2-0031" title="DeSantoNG , FrangiosaA , AnastasioP , MarinoA , CorrealeG , PernaA , et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. Journal of Nephrology2006;19 Suppl 9:S108‐14. [MEDLINE: 16736432] ">De Santo 2006</a>) to 2013 participants (<a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a>). The median number of participants was 69. The inclusion criteria included specific serum phosphate levels in 40 studies; the requirement for a phosphate binder in 26 studies; and was not specified in the remaining 38 studies. The mean study age ranged from 42.6 years (<a href="./references#CD006023-bbs2-0079" title="SaifI , HalimA , AltafA , SaifM , KhalidM , AhmadD , et al. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis. Journal of Ayub Medical College, Abbottabad: JAMC2007;19(4):26‐8. [MEDLINE: 18693591] ">Saif 2007</a>) to 68.9 years (<a href="./references#CD006023-bbs2-0099" title="WangXH , ZhangX , MuCJ , HeY , PengQP , YangGS , et al. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients. Journal of Huazhong University of Science and Technology. Medical Sciences2015;35(4):508‐13. [MEDLINE: 26223918] ">Wang 2015b</a>), with a median of 57.2 years. </p> </section> <section id="CD006023-sec-0059"> <h5 class="title">Interventions</h5> <p>Details of interventions in each study are presented in the <a href="./references#CD006023-sec-0152" title="">Characteristics of included studies</a>. Twenty‐eight studies compared a phosphate binder with placebo or usual care (not including phosphate binder), 49 studies compared a calcium‐free binder with a calcium‐based binder, 16 studies compared a calcium‐free binder with a second calcium‐free binder class, and 14 studies compared two different drugs within the same binder class. In 77 studies, the phosphate binder was titrated to specific levels of serum phosphate, while in 25 studies, a fixed dose of phosphate binder was used. Specific approaches to phosphate binder therapy were not reported in two studies. Most placebo or usual care controlled studies were among participants with CKD G2 to G5 not requiring dialysis (15/25 studies involving 1467 participants) while most head to head studies involved participants with CKD G5D treated with dialysis (74/81 studies involving 10,364 participants). </p> <section id="CD006023-sec-0060"> <h6 class="title">Phosphate binder versus placebo or usual care</h6> <section id="CD006023-sec-0061"> <p><b>Sevelamer versus placebo or usual care (677 participants)</b></p> <p>Sevelamer hydrochloride or carbonate was compared with placebo or usual care in seven studies involving 667 participants (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0021" title="ChenN , WuX , DingX , MeiC , FuP , JiangG , et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double‐blind, placebo‐controlled, dose‐titration study. Nephrology Dialysis Transplantation2014;29(1):152‐60. [MEDLINE: 24151017] ">Chen 2014</a>; <a href="./references#CD006023-bbs2-0026" title="ChueCD , TownendJN , MoodyWE , ZehnderD , WallNA , HarperL , et al. Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology2013;24(5):842‐52. [MEDLINE: 23599381] ChueCD , TownendJN , SteedsRP , FerroCJ . Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB‐PHOS randomised controlled trial. Trials [Electronic Resource]2011;12(1):30. [MEDLINE: 21288351] ">CRIB‐PHOS 2011</a>; <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>). Six of the seven studies involved participants with CKD G2 to G5 not requiring dialysis. Treatment duration and follow‐up ranged between 2 and 24 months with a median of 3 months. </p> </section> <section id="CD006023-sec-0062"> <p><b>Lanthanum versus placebo or usual care (515 participants)</b></p> <p>Lanthanum carbonate was compared with placebo or usual care in seven studies involving 515 participants (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0047" title="IsakovaT , Barchi‐ChungA , EnfieldG , SmithK , VargasG , HoustonJ , et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD. Clinical Journal of The American Society of Nephrology: CJASN2013;8(6):1009‐18. [MEDLINE: 23471131] IsakovaT , Barchi‐ChungA , EnfieldG , SmithKT , VargasGS , HoustonJ , et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR‐OR068]. Journal of the American Society of Nephrology2012;23:45A. ">Isakova 2013</a>; <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0091" title="SpragueS , FinnW , AbboudH , QiuP , SPD405‐206 Study Investigators. Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00757113] SpragueSM , AbboudH , QuiP , DauphinM , ZhangP , FinnW . Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):178‐85. [MEDLINE: 19056618] SpragueSM , FinnWF , QiuP , Study 206 Investigators. Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi‐center trial [abstract no: PUB442]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):927A. [CENTRAL: CN‐00756891] ">Sprague 2009a</a>; <a href="./references#CD006023-bbs2-0092" title="TakaharaY , MatsudaY , TakahashiS , ShigematsuT , Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre‐dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical Nephrology2014;82(3):181‐90. [MEDLINE: 25079863] ">Takahara 2014</a>; <a href="./references#CD006023-bbs2-0099" title="WangXH , ZhangX , MuCJ , HeY , PengQP , YangGS , et al. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients. Journal of Huazhong University of Science and Technology. Medical Sciences2015;35(4):508‐13. [MEDLINE: 26223918] ">Wang 2015b</a>). Six of the seven studies evaluated therapy for participants with CKD G2 to G5 not requiring dialysis. Treatment and follow‐up ranged between 3 and 12 months with a median of 3 months. </p> </section> <section id="CD006023-sec-0063"> <p><b>Iron versus placebo or usual care (422 participants)</b></p> <p>An iron‐based binder (ferric citrate, previously designated as JTT‐751) was compared with placebo or usual care in three studies involving 422 participants (<a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0058" title="LeeCT , WuIW , ChiangSS , PengYS , ShuKH , WuMJ , et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double‐blind, placebo‐controlled study. Journal of Nephrology2015;28(1):105‐13. [EMBASE: 2015735302] ">Lee 2015b</a>; <a href="./references#CD006023-bbs2-0100" title="YokoyamaK , HirakataH , AkibaT , FukagawaM , NakayamaM , SawadaK , et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis‐dependent CKD. Clinical Journal of The American Society of Nephrology: CJASN2014;9(3):543‐52. [MEDLINE: 24408120] ">Yokoyama 2014</a>). Two of the three studies involved adults with CKD G2 to G5 not requiring dialysis. Treatment and follow‐up ranged between 1.8 and 3 months with a median of 2.75 months. </p> </section> <section id="CD006023-sec-0064"> <p><b>Calcium versus placebo or usual care (278 participants)</b></p> <p>Calcium carbonate was compared with placebo in four studies (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a>; <a href="./references#CD006023-bbs2-0076" title="RudnickiM , HyldstrupL , PetersenLJ , HojstedJ , TranbolI . Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double‐blind placebo‐controlled study. Mineral &amp; Electrolyte Metabolism1994;20(3):130‐4. [MEDLINE: 7816001] ">Rudnicki 1994</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>) involving 278 participants. Three of the four studies evaluated treatment in patients with CKD G2 to G5 not requiring dialysis. Treatment and follow‐up ranged between 3 and 9 months with a median of 7 months. </p> </section> <section id="CD006023-sec-0065"> <p><b>Bixalomer versus placebo or usual care (163 participants)</b></p> <p>Bixalomer is a non‐calcium, metal‐free non‐absorbable polymer which has been compared with placebo for 3 months among 163 participants with CKD G2 to G5 not requiring dialysis (<a href="./references#CD006023-bbs2-0004" title="AkizawaT , OrigasaH , KameokaC , TsukadaJ , KuroishiK , YamaguchiY . Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Therapeutic Apheresis &amp; Dialysis2016;20(6):588‐97. [MEDLINE: 27896908] ">Akizawa 2016</a>). </p> </section> <section id="CD006023-sec-0066"> <p><b>Nicotinamide versus placebo or usual care (219 participants)</b></p> <p>Nicotinamide (also known as nicotinic acid), while not a phosphate binder, inhibits active phosphate absorption from the gut. Nicotinamide was compared with placebo or usual care in six studies involving 219 participants (<a href="./references#CD006023-bbs2-0005" title="AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadministration of nicotinamide and calcium‐based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis. Advances in Natural Science2012;5(1):1‐9. [DOI: 10.3968/j.ans.1715787020120501.1001] AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadminstration of nicotinamide and calcium‐based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]. Value in Health2012;15(4):A152. [EMBASE: 70763798] ElSharkawyMM , KamelM , ElhamamsyM , AllamS . Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i253. [EMBASE: 71075759] ">Allam 2012</a>; <a href="./references#CD006023-bbs2-0007" title="AramwitP , SrisawadwongR , SupasyndhO . Effectiveness and safety of extended‐release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Journal of Nephrology2012;25(3):354‐62. [MEDLINE: 21748722] ">Aramwit 2012</a>; <a href="./references#CD006023-bbs2-0022" title="ChengSC , YoungDO , DelmezJA , CoyneDW . The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]. Journal of the American Society of Nephrology2007;18(Abstracts):924A. ChengSC , YoungDO , HuangY , DelmezJA , CoyneDW . A randomized, double‐blind, placebo‐controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):1131‐8. [MEDLINE: 18385391] ">Cheng 2008</a>; <a href="./references#CD006023-bbs2-0082" title="ShahbazianH , ZafarMA , GhorbaniA , AbbaspourMR , Belladi MusaviSS , HayatiF , et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double‐blind randomized clinical trial. Nefrologia2011;31(1):58‐65. [MEDLINE: 21270914] ">Shahbazian 2011</a>; <a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a>; <a href="./references#CD006023-bbs2-0102" title="YoungDO , ChengSC , DelmezJA , CoyneDW . The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International2009;29(5):562‐7. [MEDLINE: 19776051] ">Young 2009a</a>). All studies involved participants with CKD G5D. Treatment and follow‐up ranged between 1.8 and 3.7 months with a median of 2.4 months. </p> </section> <section id="CD006023-sec-0067"> <p><b>Colestilan versus placebo or usual care (642 participants)</b></p> <p>Colestilan (also known as colestimide) was compared with placebo for three months in a single study involving 642 haemodialysis patients (<a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>). </p> </section> </section> <section id="CD006023-sec-0068"> <h6 class="title">Non‐calcium phosphate binder versus calcium phosphate binder</h6> <section id="CD006023-sec-0069"> <p><b>Sevelamer versus calcium (5424 participants)</b></p> <p>Thirty studies (5424 participants) compared sevelamer hydrochloride or sevelamer carbonate with calcium carbonate or acetate (<a href="./references#CD006023-bbs2-0001" title="AhmedW , Rizwan‐Ul‐HagAM , KhanS , HaiderS , Abad‐Ur‐Reham . Comparative efficacy of sevelamer hydrochloride versus calcium acetate on bone biomarkers in patients with end stage renal disease on hemodialysis. Pakistan Journal of Medical &amp; Health Sciences2014;8(3):769‐71. [EMBASE: 600071132] ">Ahmed 2014</a>; <a href="./references#CD006023-bbs2-0002" title="AkizawaT , KinugasaE , NagaiT , NiikuraK , KuriharaS , SuzukiM , et al. Effect of sevelamer hydrochloride (PB‐94) on hyperphosphatemia in Japanese hemodialysis (HD) patients [abstract no: A2940]. Journal of the American Society of Nephrology2000;11(Sept):557A. [CENTRAL: CN‐00550506] KinugasaE , KoshikawaS , PB‐94 Study Group. Effects of PB‐94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients ‐ a randomized, open label, dose titration study of PB‐94 versus caltan® tablet 500 (calcium carbonate) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):755A. [CENTRAL: CN‐00626049] ">Akizawa 2000</a>; <a href="./references#CD006023-bbs2-0009" title="BleyerAJ , BurkeSK , DillonM , GarrettB , KantKS , LynchD , et al. A comparison of the calcium‐free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases1999;33(4):694‐701. [MEDLINE: 10196011] BleyerAJ , GarrettB , KantKS , LynchD , RahmanN , SchoenfeldP , et al. An open label, cross‐over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):548a. [CENTRAL: CN‐00444452] ">Bleyer 1999</a>; <a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0015" title="CaglarK , YilmazMI , SaglamM , CakirE , AcikelC , EyiletenT , et al. Short‐term treatment with sevelamer increases serum fetuin‐a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clinical Journal of the American Society of Nephrology: CJASN2008;3(1):61‐8. [MEDLINE: 18057307] YilmazMI , SonmezA , SaglamM , YamanH , KilicS , EyiletenT , et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. American Journal of Kidney Diseases2012;59(2):177‐85. [MEDLINE: 22137672] ">Caglar 2008</a>; <a href="./references#CD006023-bbs2-0019" title="BudoffMJ , KesslerP , GaoYL , QunibiW , MoustafaM , MaoSS . The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)‐2 study. Academic Radiology2008;15(1):58‐61. [MEDLINE: 18078907] QunibiW , HorwithG , KesslerP , MoustafaM , CARE‐2 Investigators. Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation‐2 (CARE‐2) study [abstract no: PUB386]. Journal of the American Society of Nephrology2005;16(Oct Abstracts Issue):866A. [CENTRAL: CN‐00602064] QunibiW , MoustafaM , KesslerP , BortleyE , MuenzL , BudoffM . Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study [abstract no: FP386]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi148. [CENTRAL: CN‐00691160] QunibiW , MoustafaM , KesslerP , MuenzLR , BudoffM . Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: TH‐PO845]. Journal of the American Society of Nephrology2006;17(Abstracts):286A. [CENTRAL: CN‐00602067] QunibiW , MoustafaM , MuenzLR , HeDY , KesslerPD , Diaz‐BuxoJA , et al. A 1‐year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study. American Journal of Kidney Diseases2008;51(6):952‐65. [MEDLINE: 18423809] QunibiW , MuenzLR , Diaz‐BuxoJA . The CARE‐2 study results: setting the record straight. Nephrology Dialysis Transplantation2008;23(12):4081‐2. [MEDLINE: 18820282] QunibiWY , MoustafaM , KesslerP , BorteyE , MuenzLR , BudoffM . Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: S‐PO‐0376]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:150. QunibiWY , MoustafaM , KesslerP , MuenzLR , Diaz‐BuxoJ , BudoffM , et al. Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation‐2 (CARE‐2) study [abstract no: TH‐FC043]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. ">CARE‐2 2008</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0023" title="ChennasamudramSP , NoorT , VasylyevaTL . Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. Journal of Renal Care2013;39(2):82‐9. [MEDLINE: 23574727] ">Chennasamudram 2013</a>; <a href="./references#CD006023-bbs2-0025" title='AsmusHG , BraunJ , KrauseR , BrunkhorstR , HolzerH , SchulzW , et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrology Dialysis Transplantation2005;20(8):1653‐61. [MEDLINE: 15930018] BommerJ , AsmusG , BraunJ , BrunkhorstR , HolzerH , KrauseR , et al. Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]. Nephrology Dialysis Transplantation2002;17(Suppl 1):32. [CENTRAL: CN‐00509096] BommerJ , European Renagel Investigators Group. Lipid lowering effect of renagel, a novel phosphate binder [abstract]. Nephrology Dialysis Transplantation2001;16(6):A122. [CENTRAL: CN‐00444477] BraunJ , AsmusHG , HolzerH , BrunkhorstR , KrauseR , SchulzW , et al. Long‐term comparison of a calcium‐free phosphate binder and calcium carbonate‐‐phosphorus metabolism and cardiovascular calcification. Clinical Nephrology2004;62(2):104‐15. [MEDLINE: 15356967] ChertowGM , BurkeSK , RaggiP , Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International2002;62(1):245‐52. [MEDLINE: 12081584] ChertowGM , Chasan‐TaberS , RaggiP . The "tip of the iceberg" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):433a. [CENTRAL: CN‐00444789] ChertowGM , DillonMA , AminN , BommerJ , BurkeSK . Sevelamer is more effective at controlling disorders of mineral metabolism than calcium‐based phosphate binders in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):195‐6A. [CENTRAL: CN‐00444790] ChertowGM , GoodmanWG , TotoRD , RaggiP . In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL‐C, APO‐B, and HS‐CRP compared with calcium acetate (PHOSLO) [abstract no: SA‐PO603]. Journal of the American Society of Nephrology2002;13(Sept, Program &amp; Abstracts):386a. [CENTRAL: CN‐00444791] ChertowGM , RaggiP , Chasan‐TaberS , BommerJ , HolzerH , BurkeSK . Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation2004;19(6):1489‐96. [MEDLINE: 15102961] ChertowGM , RaggiP , McCarthyJT , SchulmanG , SilberzweigJ , KuhlikA , et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. American Journal of Nephrology2003;23(5):307‐14. [MEDLINE: 12915774] FerramoscaE , BurkeS , Chasan‐TaberS , RattiC , ChertowGM , RaggiP . Potential antiatherogenic and anti‐inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal2005;149(5):820‐5. [MEDLINE: 15894962] GargJP , Chasan‐TaberS , BlairA , PloneM , BommerJ , RaggiP , et al. Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis &amp; Rheumatism2005;52(1):290‐5. [MEDLINE: 15641045] JamesG , RaggiP , BoulayA , BurkeS , Chasan‐TaberS , ChertowG , et al. Thoracic vertebral bone density increases with renagel and decreases with calcium‐based phosphate binder therapy ‐ a two year study [abstract no: W423]. Nephrology Dialysis Transplantation2003;18(Suppl 4):681. [CENTRAL: CN‐00445894] RaggiP , BommerJ , ChertowGM . Valvular calcification in hemodialysis patients randomized to calcium‐based phosphorus binders or sevelamer. Journal of Heart Valve Disease2004;13(1):134‐41. [MEDLINE: 14765851] RaggiP , BurkeS , Chasen‐TaberS , ChertowG , HolzerH , BommerJ . Sevelamer preserves trabecular bone mineral density [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:103‐4. [CENTRAL: CN‐00509430] RaggiP , BurkeSK , Chasen‐TaberS , ChertowGM , HolzerH , BommerJ . Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA‐PO924]. Journal of the American Society of Nephrology2003;14(Nov):502A. [CENTRAL: CN‐00583411] RaggiP , BurkeSK , DillonMA , AminN , BommerJ , ChertowGM . Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):239A. [CENTRAL: CN‐00447325] RaggiP , JamesG , BurkeSK , BommerS , Chasan‐TaberS , HolzerH , et al. Decrease in thoracic vertebral bone attenuation with calcium‐based phosphate binders in hemodialysis. Journal of Bone &amp; Mineral Research2005;20(5):764‐72. [MEDLINE: 15824849] '>Chertow 2002</a>; <a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a>; <a href="./references#CD006023-bbs2-0031" title="DeSantoNG , FrangiosaA , AnastasioP , MarinoA , CorrealeG , PernaA , et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. Journal of Nephrology2006;19 Suppl 9:S108‐14. [MEDLINE: 16736432] ">De Santo 2006</a>; <a href="./references#CD006023-bbs2-0033" title="EvenepoelP , SelgasR , CaputoF , FoggensteinerL , HeafJG , OrtizA , et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2009;24(1):278‐85. [MEDLINE: 18820280] EvenepoelP , SelgasR , DuggalA , KellyA , FanSL . Effects of sevelamer hydrochloride (Renagel®) and calcium acetate on controlling serum phosphorus in peritoneal dialysis patients [abstract no: MP580]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv496. [CENTRAL: CN‐00671825] EvenepoelP , SelgasR , DuggalA , KellyAL , FanSL . Comparative effects of sevelamer hydrochloride (Renagel®) and calcium acetate on markers of mineral metabolism in peritoneal dialysis patients [abstract no: TH‐PO778]. Journal of the American Society of Nephrology2006;17(Abstracts):272A. [CENTRAL: CN‐00671824] ">Evenepoel 2009</a>; <a href="./references#CD006023-bbs2-0035" title="FerreiraA , FrazãoJM , Monier‐FaugereMC , GilC , GalvaoJ , OliveiraC , et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. Journal of the American Society of Nephrology2008;19(2):405‐12. [MEDLINE: 18199805] ">Ferreira 2008</a>; <a href="./references#CD006023-bbs2-0041" title="GallieniM , CicchettiT , SalvadoriM , SorbaG , StalteriA , TarchiniR , et al. Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial ‐ Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]. Journal of the American Society of Nephrology2005;16:746A. [CENTRAL: CN‐00583853] ">Gallieni 2005</a>; <a href="./references#CD006023-bbs2-0043" title="HervasJG , PradosD , CerezoS . Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney International ‐ Supplement2003;85:69‐72. [MEDLINE: 12753270] ">Hervas 2003</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0046" title="BellasiA , CozzolinoM , RussoD , MolonyD , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology2016;86(9):113‐24. [MEDLINE: 27443567] BellasiA , CozzolinoM , RussoD , MolonyDA , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii588. [EMBASE: 72207961] DiIorioB . In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'. American Journal of Kidney Diseases2014;63(1):164‐5. [MEDLINE: 24377649] DiIorioB , MolonyD , BellC , CuccinielloE , BellizziV , RussoD , et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. American Journal of Kidney Diseases2013;62(4):771‐8. [MEDLINE: 23684755] DiIorioBR , CuccinielloE , BellizziV . Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan‐Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar‐Apr;26(2):419]. Journal of Nephrology2009;22(6):694‐8. [MEDLINE: 19967647] MolonyD , BellasiA , BellizziV , RussoD , DiIorioB . Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii54. [EMBASE: 70765453] ObiY , HamanoT . The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. American Journal of Kidney Diseases2014;63(1):164. [MEDLINE: 24377650] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593‐602; PMID: 25027030]. Journal of Nephrology2014;27(6):717. [MEDLINE: 25098354] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]. Journal of Nephrology2015;28(5):593‐602. [MEDLINE: 25027030] ">INDEPENDENT‐HD 2009</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>; <a href="./references#CD006023-bbs2-0061" title="LinYF , ChenYM , HungKY , ChuTS , KanWC , HuangCY , et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. Journal of the Formosan Medical Association2010;109(9):663‐72. [MEDLINE: 20863994] LinYF , ChienCT , KanWC , ChenYM , ChuTS , HungKY , et al. Pleiotropic effects of sevelamer beyond phosphate binding in end‐stage renal disease patients: a randomized, open‐label, parallel‐group study. Clinical Drug Investigation2011;31(4):257‐67. [MEDLINE: 21299254] ">Lin 2010</a>; <a href="./references#CD006023-bbs2-0062" title="LinHH , LiouHH , WuMS , HuangCC . Factors associated with serum fetuin‐A concentrations after long‐term use of different phosphate binders in hemodialysis patients. BMC Nephrology2016;17:33. [MEDLINE: 27007989] LinHH , LiouHH , WuMS , LinCY , HuangCC . Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology2014;19(11):672‐8. [MEDLINE: 25113414] ">Lin 2014a</a>; <a href="./references#CD006023-bbs2-0063" title="HuangC , YuC , LiuY . Effect of sevelamer on homocysteinemia and lipid profile in patients undergoing maintenance hemodialysis ‐ a randomized clinical trial [abstract no: F‐PO610]. Journal of the American Society of Nephrology2005;16:467A. [CENTRAL: CN‐00756400] LiuYL , LinHH , YuCC , KuoHL , YangYF , ChouCY , et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Renal Failure2006;28(8):701‐7. [MEDLINE: 17162430] ">Liu 2006</a>; <a href="./references#CD006023-bbs2-0067" title="Navarro‐GonzalezJF , Mora‐FernandezC , Muros de FuentesM , Donate‐CorreaJ , Cazana‐PerezV , Garcia‐PerezJ . Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2011;6(9):2272‐9. [MEDLINE: 21784820] ">Navarro‐Gonzalez 2011</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>; <a href="./references#CD006023-bbs2-0078" title="SadekT , MazouzH , BahlouH , OprisiuR , ElEsperN , ElEsperI , et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open‐label, randomized study. Nephrology Dialysis Transplantation2003;18(3):582‐9. [MEDLINE: 12584283] ">Sadek 2003</a>; <a href="./references#CD006023-bbs2-0081" title="SezerS , KarakanS , AcarNO . Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]. NDT Plus2010;3(Suppl 3):iii196. [EMBASE: 70483939] ">Sezer 2010</a>; <a href="./references#CD006023-bbs2-0083" title="ShaheenA , AkeelNM , BadawiLS , SouqiyyehMZ . Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Medical Journal2004;25(6):785‐91. [MEDLINE: 15195212] ">Shaheen 2004</a>; <a href="./references#CD006023-bbs2-0097" title="VlassaraH , UribarriJ , CaiW , GoodmanS , PyzikR , PostJ , et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2012;7(6):934‐42. [MEDLINE: 22461535] Yubero‐SerranoEM , WoodwardM , PoretskyL , VlassaraH , StrikerGE . Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro‐oxidant status in patients with diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2015;10(5):759‐66. [MEDLINE: 25710801] ">Vlassara 2012</a>; <a href="./references#CD006023-bbs2-0103" title="ZhaoH , WangJ , ZhaoDM , DongYM , GaoY . Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end‐stage renal disease: a randomized controlled trial. Chinese Journal of Evidence‐Based Medicine2014;14(11):1293‐8. [EMBASE: 2014948885] ">Zhao 2014</a>). The duration of treatment ranged between 1.8 and 24 months with a median of 5.5 months. Nearly all studies (25) involved participants with CKD G5D treated with haemodialysis (24 studies) or peritoneal dialysis (1 study). </p> </section> <section id="CD006023-sec-0070"> <p><b>Lanthanum versus calcium (1690 participants)</b></p> <p>Fourteen studies (1690 participants) compared lanthanum carbonate with calcium carbonate or acetate (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0027" title="D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International ‐ Supplement2003;85:S73‐8. [MEDLINE: 12753271] D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. Multi‐centre study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients [abstract no: PS1‐15]. Nephrology2003;8(Suppl 1):A28. DeBroeME , D'HaesePC , FreemontTJ , WebsterI , GillM , SpasovskiGB . Comparative effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients: results from a large, long‐term clinical trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):682. [CENTRAL: CN‐00445015] FreemontA . The effects of lanthanum carbonate and calcium carbonate on bone in patients with chronic kidney disease [abstract no: 33]. American Journal of Kidney Diseases2004;43(4):A23. [CENTRAL: CN‐00644282] FreemontA , JonesC . The effects of the phosphate binders lanthanum carbonate and calcium carbonate on bone: a comparative study in patients with chronic kidney disease [abstract no:SP270]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106. [CENTRAL: CN‐00509202] FreemontAJ , HoylandJA , DentonJ , Lanthanum Carbonate SPD405‐303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end‐stage renal disease. Clinical Nephrology2005;64(6):428‐37. [MEDLINE: 16370155] FreemontT , MallucheHH . Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clinical Nephrology2005;63(2):138‐45. [MEDLINE: 15730056] TorresA , DeBroeME , D'HaesePC , HutchisonA , JonesC . One‐year, randomized, open‐label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol®) and calcium carbonate in dialysis patients [abstract no: SU‐PO1041]. Journal of the American Society of Nephrology2003;14(Nov):764A. [CENTRAL: CN‐00583261] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WilsonR . Spica Consultants Ltd. Personal communication2005. WilsonR , CopleyJB , PooleL . Lower serum phosphorus can be attained by increasing the dose of lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii496. [EMBASE: 70766788] ">D'Haese 2003</a>; <a href="./references#CD006023-bbs2-0039" title="FujiiH , KonoK , GotoS , NakaiK , WatanabeS , WatanabeK , et al. Effect of lanthanum carbonate on cardiac abnormalities in patients new to hemodialysis [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii645. [EMBASE: 617289957] FujiiH , NakaiK , KonoK , GotoS , KitamuraK , YonekuraY , et al. Effect of lanthanum carbonate on coronary artery calcification during the early period after the initiation of haemodialysis [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i252. [EMBASE: 72326579] ">Fujii 2017</a>; <a href="./references#CD006023-bbs2-0044" title="GillM , WebsterI , SegarsL . Efficacy and safety of lanthanum carbonate, the novel phosphate binder, in Chinese patients with chronic kidney disease [abstract]. Nephrology Nursing Journal2004;31(2):141. HutchisonA , Lanthanum Study Group. Analysis of haematology data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract no: SP219]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v92‐3. HutchisonA , Lanthanum Study Group. No adverse effects of haematological parameters during lanthanum carbonate treatment in over 2000 patients [abstract no: W‐PO40068]. Nephrology2005;10(Suppl):A297. HutchisonA , SPD405‐301 Lanthanum Study Group. Long‐term safety, efficacy, and tolerability of lanthanum carbonate: results from a 3.5‐year study [abstract no: W‐PO40065]. Nephrology2005;10(Suppl 1):A297. HutchisonA , WebsterI . Lanthanum carbonate versus calcium carbonate: effect on parathyroid hormone (PTH) levels [abstract no: F‐PO656]. Journal of the American Society of Nephrology2003;14(Nov):205A. HutchisonA , WebsterI . Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenal®) during long‐term therapy in hemodialysis patients. [abstract no: SU‐PO1039]. Journal of the American Society of Nephrology2003;14(Nov):764A. HutchisonA , WebsterI . Safety and efficacy data for lanthanum carbonate: a summary from three studies [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:107. HutchisonA , WebsterI , GillM , SchmiederR . Safety and tolerability of lanthanum carbonate in haemodialysis patients: a 12‐month study [abstract no: W431]. Nephrology Dialysis Transplantation2003;18(Suppl 4):684. HutchisonA , Lanthanum Study Group. No evidence of hepatoxicity with lanthanum carbonate ‐ clinical trial data from 2000 dialysis patients [abstract no: W‐PO40069]. Nephrology2005;10(Suppl):A298. HutchisonAJ . Lanthanum carbonate (FosrenolTM), a novel, nonaluminum, noncalcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract no: PS1‐22]. Nephrology2003;8(Suppl 1):A29. HutchisonAJ , GillM . A demographic analysis of lanthanum carbonate phase II and III studies [abstract no: 271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106‐7. [CENTRAL: CN‐00509244] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6‐month, randomized, comparative trial versus calcium carbonate. Nephron2005;100(1):c8‐19. [MEDLINE: 15809508] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Long‐term efficacy and tolerability of lanthanum carbonate: results from a 3‐year study. Nephron2006;102(2):c61‐71. [MEDLINE: 16224198] HutchisonAJ , Lanthanum Study Group. The novel, non‐aluminium, non‐calcium phosphate binder, fosrenol, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract no: SA‐PO599]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):385A‐6A. [CENTRAL: CN‐00445823] SpeakeM , HutchisonAJ , WebsterI . Lanthanum carbonate, a novel, non‐aluminum, non‐calcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract]. Nephrology Nursing Journal2003;30(2):149. [CENTRAL: CN‐00644297] SpeakeM , WebsterI . Long‐term safety, tolerability, and efficacy of lanthanum carbonate therapy [abstract]. Nephrology Nursing Journal2004;31(2):143. [CENTRAL: CN‐00644295] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WebsterI , GillM . Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients [abstract no: SP267]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105. [CENTRAL: CN‐00509557] ">Hutchison 2005</a>; <a href="./references#CD006023-bbs2-0055" title="KoYS , RyuJW , LeeJH , YiJH , HanSW , KimHJ . Efficacy of lanthanum carbonate and calcium carbonate in Korean dialysis patients. Korean Journal of Nephrology2010;29(1):64‐72. [CENTRAL: CN‐01045527] ">Ko 2010</a>; <a href="./references#CD006023-bbs2-0057" title="LeeYK , ChoiHY , ShinSK , LeeHY . Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clinical Nephrology2013;79(2):136‐42. [MEDLINE: 23211335] ">Lee 2013</a>; <a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a>; <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a>; <a href="./references#CD006023-bbs2-0087" title="SongFR , ChengH , ZhaoDM , YuJ , GaoY . Effects of lanthanum carbonate on serum calcium and phosphorus of CAPD patients with chronic renal failure receiving calcitriol pulse therapy due to secondary hyperparathyroidism. Chinese Journal of Evidence‐Based Medicine2014;14(6):651‐4. [EMBASE: 2014574871] ">Song 2014</a>; <a href="./references#CD006023-bbs2-0088" title="SorianoS , OjedaR , RodriguezM , AlmadenY , RodriguezM , Martin‐MaloA , et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clinical Nephrology2013;80(1):17‐22. [MEDLINE: 23391319] ">Soriano 2013</a>; <a href="./references#CD006023-bbs2-0089" title="SikoleA , SpasovskiG , GelevS , AmitovV , StojcevN , GrozdanovskiR . Lanthanum carbonate ‐ a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v95‐6. SikoleA , SpasovskiG , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]. Nephrology Dialysis Transplantation2002;17(Suppl 12):67. [CENTRAL: CN‐00509481] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients ‐ single center experience [abstract no: w436]. Nephrology Dialysis Transplantation2003;18(Suppl 4):685‐6. [CENTRAL: CN‐00447817] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]. International Journal of Artificial Organs2003;26(7):630. [CENTRAL: CN‐00583691] SpasovskiG , SikoleA , GelevS , MasinJ , FreemontT , WebsterI , et al. The evolution of renal bone disease in dialysis patients ‐ comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105‐6. [CENTRAL: CN‐00509488] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , GrozdanovskiR , et al. Comparative, bone biopsy‐based, 3 years follow‐up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]. Nephrology Dialysis Transplantation2005;20(6 Suppl):v376. [CENTRAL: CN‐00583693] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , PolenakovicB , WebsterI , et al. The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA‐PO842]. Journal of the American Society of Nephrology2005;16(Oct):741A. [CENTRAL: CN‐00583697] SpasovskiGB , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]. Hemodialysis International2003;7(1):87. [CENTRAL: CN‐00461778] SpasovskiGB , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , WebsterI , et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow‐up. Nephrology Dialysis Transplantation2006;21(8):2217‐24. [MEDLINE: 16595583] ">Spasovski 2006</a>; <a href="./references#CD006023-bbs2-0094" title="ToidaT , FukudomeK , FujimotoS , YamadaK , SatoY , ChiyotandaS , et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clinical Nephrology2012;78(3):216‐23. [MEDLINE: 22874110] ">Toida 2012</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>; <a href="./references#CD006023-bbs2-0098" title="WadaK , WadaY . Evaluation of aortic calcification with lanthanum carbonate vs. calcium‐based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open‐label randomized controlled trial. Therapeutic Apheresis &amp; Dialysis2014;18(4):353‐60. [MEDLINE: 24417760] ">Wada 2014</a>). The duration of treatment ranged between 1.8 and 18 months with a median of 6 months. All but three studies involved participants with CKD G5D treated with haemodialysis (9 studies) or peritoneal dialysis (3 studies). </p> </section> <section id="CD006023-sec-0071"> <p><b>Sevelamer plus calcium versus calcium (35 participants)</b></p> <p>Sevelamer hydrochloride plus calcium carbonate was compared with calcium carbonate for 36 months in 35 patients with CKD G5D treatment with haemodialysis (<a href="./references#CD006023-bbs2-0084" title="ShibataK , IwamotoT , MurakamiT , HirawaS , YasudaG , ToyaY , et al. A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone [abstract no: SAP245]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi245. ShibataK , IwamotoT , OnoS , MurakamiT , YanagiM , KoguchiN , et al. A comparative study of the effects on pulse wave velocity (PWV) in hemodialysis (HD) patients treated by sevelamer with low dose calcium carbonate or calcium carbonate alone. Three‐years follow up [abstract no: SU500]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. ">Shibata 2007</a>). </p> </section> <section id="CD006023-sec-0072"> <p><b>Sevelamer versus calcium plus magnesium (255 participants)</b></p> <p>Sevelamer hydrochloride was compared with calcium acetate plus magnesium carbonate for six months in 255 participants with CKD G5D treated with haemodialysis (<a href="./references#CD006023-bbs2-0016" title="CovicA , Passlick‐DeetjenJ , KroczakM , Buschges‐SeraphinB , GhenuA , PonceP , et al. A comparison of calcium acetate/magnesium carbonate and sevelamer‐hydrochloride effects on fibroblast growth factor‐23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation2013;28(9):2383‐92. [MEDLINE: 23787550] PaschA , deFranciscoALM , CovicA , MarzellB , ArensHJ , Passlick‐DeetjenJ , et al. Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate/ magnesium carbonate containing phosphate binder [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii40. [EMBASE: 71491561] deFranciscoAL , LeidigM , CovicAC , KettelerM , Benedyk‐LorensE , MircescuGM , et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrology Dialysis Transplantation2010;25(11):3707‐17. [MEDLINE: 20530499] ">CALMAG 2010</a>). </p> </section> <section id="CD006023-sec-0073"> <p><b>Sevelamer versus sevelamer plus calcium (71 participants)</b></p> <p>Sevelamer hydrochloride was compared with sevelamer hydrochloride plus calcium for 2.8 months in one study of 71 patients with CKD 5D treated with haemodialysis (<a href="./references#CD006023-bbs2-0024" title="ChertowGM , DillonM , BurkeSK , StegM , BleyerAJ , GarrettBN , et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clinical Nephrology1999;51(1):18‐26. [MEDLINE: 9988142] ">Chertow 1999</a>). </p> </section> <section id="CD006023-sec-0074"> <p><b>Magnesium versus calcium (30 participants)</b></p> <p><a href="./references#CD006023-bbs2-0090" title="SpiegelDM , FarmerB . Long‐term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodialysis International2009;13(4):453‐9. [MEDLINE: 19469885] SpiegelDM , FarmerB , ChoncholM . Magnesium carbonate ‐ an effective phosphate binder [abstract no: 152]. American Journal of Kidney Diseases2006;47(4):A56. [CENTRAL: CN‐00653706] SpiegelDM , FarmerB , SmitsG , ChoncholM . Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition2007;17(6):416‐22. [MEDLINE: 17971314] ">Spiegel 2007</a> evaluated magnesium carbonate versus calcium carbonate treatment for 2.8 months among 30 dialysis patients. </p> </section> <section id="CD006023-sec-0075"> <p><b>Magnesium plus calcium versus magnesium (157 participants)</b></p> <p>Combined magnesium and calcium therapy was compared with calcium alone in four studies (157 participants) (<a href="./references#CD006023-bbs2-0032" title="DeuberH . Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract no: W422]. Nephrology Dialysis Transplantation2003;18(Suppl 4):680‐1. [CENTRAL: CN‐00445085] DeuberHJ . Combined use of calcium acetate and magnesium carbonate as phosphate binder [Kombinierter einsatz von kalziumazetat und magnesiumkarbonat als orale phosphatbinder]. Nieren und Hochdruckkrankheiten2004;33(8):403‐8. [EMBASE: 39150178] ">Deuber 2004</a>; <a href="./references#CD006023-bbs2-0034" title="EvsanaaB , LiuI , AliazardehB , MahdaviS , BajwaG , GulaJ , et al. MgCaCO3 versus CaCO3 in peritoneal dialysis patients‐‐a cross‐over pilot trial. Peritoneal Dialysis International2015;35(1):31‐4. [MEDLINE: 24584605] ">Evsanaa 2015</a>; <a href="./references#CD006023-bbs2-0090" title="SpiegelDM , FarmerB . Long‐term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodialysis International2009;13(4):453‐9. [MEDLINE: 19469885] SpiegelDM , FarmerB , ChoncholM . Magnesium carbonate ‐ an effective phosphate binder [abstract no: 152]. American Journal of Kidney Diseases2006;47(4):A56. [CENTRAL: CN‐00653706] SpiegelDM , FarmerB , SmitsG , ChoncholM . Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition2007;17(6):416‐22. [MEDLINE: 17971314] ">Spiegel 2007</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>). All studies involved participants with CKD 5D treated with long‐term haemodialysis or peritoneal dialysis. Follow‐up ranged from three months to 30 months, with a median of 7.5 months. </p> </section> <section id="CD006023-sec-0076"> <p><b>Aluminium versus calcium (67 participants)</b></p> <p>Aluminium hydroxide was compared with calcium carbonate or acetate over 6 to 12 months among 67 haemodialysis patients (<a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a>; <a href="./references#CD006023-bbs2-0051" title="JespersenB , JensenJD , NielsenHK , LauridsenIN , AndersenMJ , PoulsenJH , et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1‐84), and bone mineral content in dialysis patients. Nephrology Dialysis Transplantation1991;6(2):98‐104. [MEDLINE: 1857534] ">Jespersen 1991</a>). </p> </section> </section> <section id="CD006023-sec-0077"> <h6 class="title">Non‐calcium phosphate binder versus non‐calcium phosphate binder</h6> <section id="CD006023-sec-0078"> <p><b>Sevelamer versus lanthanum (197 participants)</b></p> <p>Sevelamer hydrochloride or carbonate was compared with lanthanum carbonate in three studies (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0053" title="KasaiS , SatoK , MurataY , KinoshitaY . Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(4):341‐9. [EMBASE: 2012432570] ">Kasai 2012</a>; <a href="./references#CD006023-bbs2-0071" title="PrattR , SmythM . Effective reduction of serum phosphorus using carbonate, with fewer tablets than sevelamer hydrochloride [abstract no: FP486]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi183. ">Pratt 2007</a>) involving 197 participants. Two of the three studies involved participants with CKD 5D treated with haemodialysis. Follow‐up ranged from 2 months to 12 months. </p> </section> <section id="CD006023-sec-0079"> <p><b>Sevelamer versus iron (1704 participants)</b></p> <p>Sevelamer hydrochloride or carbonate was compared with iron‐based binders (SBR759 (iron (III) starch/saccharose complex); sucroferric oxyhydroxide; ferric citrate) in four studies involving 1704 participants (<a href="./references#CD006023-bbs2-0020" title="ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: a 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology2011;16(8):743‐50. [MEDLINE: 21854503] ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08‐08]. Nephrology2010;15(Suppl 3):51. [EMBASE: 70467427] ChenJB , ChiangSS , HenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]. NDT Plus2010;3(Suppl 3):iii238. [EMBASE: 70484048] ">Chen 2011b</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0056" title="KoiwaF , YokoyamaK , FukagawaM , TeraoA , AkizawaT . Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrology2017;22(4):293‐300. [MEDLINE: 27496336] ">Koiwa 2017</a>; <a href="./references#CD006023-bbs2-0101" title="YokoyamaK , AkibaT , FukagawaM , NakayamaM , SawadaK , KumagaiY , et al. A randomized trial of JTT‐751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology Dialysis Transplantation2014;29(5):1053‐60. [MEDLINE: 24376274] ">Yokoyama 2014a</a>). Three of the four studies involved participants with CKD G5D. Follow‐up ranged between 3 and 6 months, with a median of 3 months. </p> </section> <section id="CD006023-sec-0080"> <p><b>Sevelamer versus bixalomer (110 participants)</b></p> <p><a href="./references#CD006023-bbs2-0003" title="AkizawaT , OrigasaH , KameokaC , KanekoY , KawasakiS , Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Therapeutic Apheresis &amp; Dialysis2014;18(2):122‐31. [MEDLINE: 24720402] ">Akizawa 2014a</a> evaluated sevelamer hydrochloride versus bixalomer over three months in 110 participants with CKD G5D treated with haemodialysis. </p> </section> <section id="CD006023-sec-0081"> <p><b>Sevelamer versus nicotinamide (100 participants)</b></p> <p>Sevelamer hydrochloride was compared with nicotinamide for six months in one study (<a href="./references#CD006023-bbs2-0069" title="LengletA , LiabeufS , ElEsperN , BrissetS , MansourJ , Lemaire‐HurtelAS , et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation2017;32(5):870‐9. [MEDLINE: 24599830] ">NICOREN 2017</a>) involving 100 participants with CKD G5D treated with haemodialysis. </p> </section> <section id="CD006023-sec-0082"> <p><b>Sevelamer versus colestilan (598 participants)</b></p> <p>Sevelamer was compared with colestilan in three studies involving 598 participants (<a href="./references#CD006023-bbs2-0048" title="ItohK , TanakaM , HashiguchiJ , FunakoshiS , NakanoH , KuboH , et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp; Dialysis2008;12(2):126‐32. [MEDLINE: 18387160] ">Itoh 2008</a>; <a href="./references#CD006023-bbs2-0065" title="LocatelliF , SpasovskiG , DimkovicN , WannerC , DellannaF , PontorieroG . The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1‐year prospective randomized study. Nephrology Dialysis Transplantation2014;29(5):1061‐73. [MEDLINE: 24302608] ">Locatelli 2014</a>; <a href="./references#CD006023-bbs2-0068" title="NCT00542815 . A study of MCI‐196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia. ClinicalTrials.gov/show/NCT00542815 (first received 12 October 2007). ">NCT00542815</a>). All participants had CKD G5D treated with haemodialysis or peritoneal dialysis. Treatment and follow‐up continued for 1.9 to 12 months. </p> </section> <section id="CD006023-sec-0083"> <p><b>Sevelamer versus aluminium (30 participants)</b></p> <p>Sevelamer hydrochloride was compared with aluminium hydroxide during treatment over 16 months in 30 participants with CKD G5D treated with peritoneal dialysis (<a href="./references#CD006023-bbs2-0054" title="KatopodisKP , AndrikosEK , GouvaCD , BairaktariET , NikolopoulosPM , TakouliLK , et al. Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients. Peritoneal Dialysis International2006;26(3):320‐7. [MEDLINE: 16722024] ">Katopodis 2006</a>). </p> </section> <section id="CD006023-sec-0084"> <p><b>Sevelamer versus magnesium (40 participants)</b></p> <p><a href="./references#CD006023-bbs2-0104" title="ZwiechR , DryjaP , LacinaD , KroliczakV , ChrulS , KacprzykF . The influence of short‐term magnesium carbonate treatment on calcium‐phosphorus balance in dialysis patients [Wplyw krotkoterminowego leczenia weglanem magnezu na gospodarke wapniowo‐fosforanowa u chorych przewlekle hemodializowanych]. Wiadomosci Lekarskie2011;64(1):9‐14. [MEDLINE: 21812357] ">Zwiech 2011</a> compared sevelamer hydrochloride with magnesium carbonate during treatment of 3 months in 40 participants with CKD G5D treated with haemodialysis. </p> </section> <section id="CD006023-sec-0085"> <p><b>Lanthanum versus iron (18 participants)</b></p> <p><a href="./references#CD006023-bbs2-0040" title="FujimoriA , OhkawaS , OkadaS , MizobuchiN , SakaiM , HasuikeY , et al. Comparison of the suppressive effects on fibroblast growth factor 23 between ferric citrate and lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii244‐5. [EMBASE: 617291229] ">Fujimori 2017</a> evaluated lanthanum carbonate versus ferric citrate for 3 months in 18 participants with CKD G5D treated with haemodialysis. </p> </section> <section id="CD006023-sec-0086"> <p><b>Aluminium versus sucralfate (27 participants)</b></p> <p>Aluminium hydroxide was compared with sucralfate (not used in current clinical care) for 1.8 months in 27 participants with CKD G5D treated with haemodialysis (<a href="./references#CD006023-bbs2-0075" title="RoxeDM , MistovichM , BarchDH . Phosphate‐binding effects of sucralfate in patients with chronic renal failure. American Journal of Kidney Diseases1989;13(3):194‐9. [MEDLINE: 2919600] ">Roxe 1989</a>). </p> </section> </section> <section id="CD006023-sec-0087"> <h6 class="title">Phosphate binder class</h6> <section id="CD006023-sec-0088"> <p><b>Sevelamer hydrochloride versus sevelamer carbonate (296 participants)</b></p> <p>Sevelamer hydrochloride was compared with sevelamer carbonate in two studies involving 296 participants with CKD G5D treated with haemodialysis (<a href="./references#CD006023-bbs2-0030" title="DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. A randomized, double‐blind cross‐over design study of sevelamer hydrochloride (SH, Renegel®) and sevelamer carbonate (SC) in chronic kidney disease patients on hemodialysis [abstract no: 48]. American Journal of Kidney Diseases2007;49(4):A36. [CENTRAL: CN‐00671791] DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. Results of a randomized, double‐blind, cross‐over design study of sevelamer hydrochloride (Renagel®) and sevelamer carbonate in chronic kidney disease patients on hemodialysis [abstract no: SaP377]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi361. [CENTRAL: CN‐00671790] DelmezJ , BlockG , RobertsonJ , Chasan‐TaberS , BlairA , DillonM , et al. A randomized, double‐blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clinical Nephrology2007;68(6):386‐91. [MEDLINE: 18184521] ">Delmez 2007</a>; <a href="./references#CD006023-bbs2-0036" title="FishbaneS , DelmezJ , SukiW , HariacharS , MoeS , HeatonJ . Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open‐label study in chronic kidney disease patients on hemodialysis [abstract no: M621]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. FishbaneS , DelmezJ , SukiWN , HariacharS , MoeS . A randomized, parallel, open‐label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):936A. [CENTRAL: CN‐00747271] FishbaneS , DelmezJ , SukiWN , HariacharSK , HeatonJ , Chasan‐TaberS , et al. A randomized, parallel, open‐label study to compare once‐daily sevelamer carbonate powder dosing with thrice‐daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. American Journal of Kidney Diseases2010;55(2):307‐15. [MEDLINE: 20042256] ">Fishbane 2010</a>). Treatment and follow‐up was for 5.5 and 12 months, respectively. </p> </section> <section id="CD006023-sec-0089"> <p><b>Calcium‐based binder versus calcium‐based binder (320 participants)</b></p> <p>Calcium carbonate was compared with calcium acetate in eight studies (209 participants) (<a href="./references#CD006023-bbs2-0006" title="AlmirallJ , VecianaL , LlibreJ . Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):976. [CENTRAL: CN‐00260851] AlmirallJ , VecianaL , LlibreJ . Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. American Journal of Nephrology1994;14(3):192‐6. [MEDLINE: 7977479] ">Almirall 1994</a>; <a href="./references#CD006023-bbs2-0017" title="CaravacaF , SantosI , CuberoJJ , EsparragoJF , ArrobasM , PizarroJL , et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron1992;60(4):423‐7. [MEDLINE: 1584317] CaravacaF , SantosI , RoblesR , CuberoJ , EsparragoJ , ArrobasM , et al. Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1990;5(8):729. [CENTRAL: CN‐00260555] ">Caravaca 1992</a>; <a href="./references#CD006023-bbs2-0038" title="ForasterA , GonzalezMT , CarrerasJ , PrietoML , SampietroJ , BonninR , et al. Calcium acetate. A good alternative to calcium carbonate for treating hyperphosphoremia in chronic hemodialysis patients with high risk of hypercalcemia [Acetato calcico. Una buena alternativa al carbonato calcico, como quelante del fosforo, en los pacientes en hemodialisis con riesgo de hipercalcemia]. Nefrologia1998;18(4):296‐301. [EMBASE: 1998302471] ">Foraster 1998</a>; <a href="./references#CD006023-bbs2-0042" title="GreenbergS , ShapiroW , PoruchJG . Calcium acetate (aa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:472. [CENTRAL: CN‐00509217] GreenbergS , ShapiroW , PorushJG . Calcium acetate (caa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. Journal of the American Society of Nephrology1994;5(3):492. ">Greenberg 1994</a>; <a href="./references#CD006023-bbs2-0049" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients. Nephrology Dialysis Transplantation1995;10(12):2321‐4. [MEDLINE: 8808233] ">Janssen 1995</a>; <a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a>; <a href="./references#CD006023-bbs2-0093" title="TielmansC , KnoopC , DoutrelepontJM , TimmermansD , Even‐AdinD , VanherweghemJL . Superiority of calcium acetate (ACET) over carbonate (CARB) to bind phosphorus (P) in hemodialysis patients (HDP) [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:219A. ">Tielmans 1990</a>). Calcium ketoglutarate was compared with calcium acetate or carbonate in two studies involving 47 participants (<a href="./references#CD006023-bbs2-0008" title="BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross‐over study. Nephrology Dialysis Transplantation1999;14(6):1475‐9. [MEDLINE: 10383011] BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium‐ketoglutarate vs. calcium‐acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):552A. [CENTRAL: CN‐00444439] ">Birck 1999</a>; <a href="./references#CD006023-bbs2-0014" title="BroS , RasmussenRA , HandbergJ , OlgaardK , Feld‐RasmussenB . Randomized crossover study comparing the phosphate‐binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. American Journal of Kidney Diseases1998;31(2):257‐62. [MEDLINE: 9469496] ">Bro 1998</a>). All studies involved participants with CKD G5D treated with haemodialysis. Treatment and follow‐up ranged between 2 and 12 months with a median of 3 months. </p> </section> <section id="CD006023-sec-0090"> <p><b>Ferric citrate versus sucroferric oxyhydroxide (43 participants)</b></p> <p>Ferric citrate was compared with sucroferric oxyhydroxide during three months of treatment among 43 participants with CKD G5D treated with haemodialysis (<a href="./references#CD006023-bbs2-0066" title="MatsushimaH , YasudaT , OyamaA , MiyataM . Efficacy and safety of iron‐based phosphate binders, ferric citrate hydrate versus sucroferric oxyhydroxide, on hyperphosphatemia in chronic hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii679. [EMBASE: 617290946] ">Matsushima 2017</a>). </p> </section> </section> </section> </section> <section id="CD006023-sec-0091"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded 99 studies (in 193 reports) as studies were not RCTs, were studies involving children, did not evaluate two different phosphate binders, or had follow‐up of less than eight weeks (<a href="./references#CD006023-sec-0153" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD006023-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias for studies overall are summarised in <a href="#CD006023-fig-0002">Figure 2</a> and the risk of bias in each individual study is reported in Figure 3. </p> <div class="figure" id="CD006023-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006023-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD006023-sec-0093"> <h4 class="title">Allocation</h4> <p>Methods for generating the random sequence were deemed to be at low risk of bias in 25 studies (<a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0019" title="BudoffMJ , KesslerP , GaoYL , QunibiW , MoustafaM , MaoSS . The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)‐2 study. Academic Radiology2008;15(1):58‐61. [MEDLINE: 18078907] QunibiW , HorwithG , KesslerP , MoustafaM , CARE‐2 Investigators. Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation‐2 (CARE‐2) study [abstract no: PUB386]. Journal of the American Society of Nephrology2005;16(Oct Abstracts Issue):866A. [CENTRAL: CN‐00602064] QunibiW , MoustafaM , KesslerP , BortleyE , MuenzL , BudoffM . Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study [abstract no: FP386]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi148. [CENTRAL: CN‐00691160] QunibiW , MoustafaM , KesslerP , MuenzLR , BudoffM . Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: TH‐PO845]. Journal of the American Society of Nephrology2006;17(Abstracts):286A. [CENTRAL: CN‐00602067] QunibiW , MoustafaM , MuenzLR , HeDY , KesslerPD , Diaz‐BuxoJA , et al. A 1‐year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study. American Journal of Kidney Diseases2008;51(6):952‐65. [MEDLINE: 18423809] QunibiW , MuenzLR , Diaz‐BuxoJA . The CARE‐2 study results: setting the record straight. Nephrology Dialysis Transplantation2008;23(12):4081‐2. [MEDLINE: 18820282] QunibiWY , MoustafaM , KesslerP , BorteyE , MuenzLR , BudoffM . Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: S‐PO‐0376]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:150. QunibiWY , MoustafaM , KesslerP , MuenzLR , Diaz‐BuxoJ , BudoffM , et al. Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation‐2 (CARE‐2) study [abstract no: TH‐FC043]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. ">CARE‐2 2008</a>; <a href="./references#CD006023-bbs2-0025" title='AsmusHG , BraunJ , KrauseR , BrunkhorstR , HolzerH , SchulzW , et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrology Dialysis Transplantation2005;20(8):1653‐61. [MEDLINE: 15930018] BommerJ , AsmusG , BraunJ , BrunkhorstR , HolzerH , KrauseR , et al. Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]. Nephrology Dialysis Transplantation2002;17(Suppl 1):32. [CENTRAL: CN‐00509096] BommerJ , European Renagel Investigators Group. Lipid lowering effect of renagel, a novel phosphate binder [abstract]. Nephrology Dialysis Transplantation2001;16(6):A122. [CENTRAL: CN‐00444477] BraunJ , AsmusHG , HolzerH , BrunkhorstR , KrauseR , SchulzW , et al. Long‐term comparison of a calcium‐free phosphate binder and calcium carbonate‐‐phosphorus metabolism and cardiovascular calcification. Clinical Nephrology2004;62(2):104‐15. [MEDLINE: 15356967] ChertowGM , BurkeSK , RaggiP , Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International2002;62(1):245‐52. [MEDLINE: 12081584] ChertowGM , Chasan‐TaberS , RaggiP . The "tip of the iceberg" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):433a. [CENTRAL: CN‐00444789] ChertowGM , DillonMA , AminN , BommerJ , BurkeSK . Sevelamer is more effective at controlling disorders of mineral metabolism than calcium‐based phosphate binders in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):195‐6A. [CENTRAL: CN‐00444790] ChertowGM , GoodmanWG , TotoRD , RaggiP . In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL‐C, APO‐B, and HS‐CRP compared with calcium acetate (PHOSLO) [abstract no: SA‐PO603]. Journal of the American Society of Nephrology2002;13(Sept, Program &amp; Abstracts):386a. [CENTRAL: CN‐00444791] ChertowGM , RaggiP , Chasan‐TaberS , BommerJ , HolzerH , BurkeSK . Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation2004;19(6):1489‐96. [MEDLINE: 15102961] ChertowGM , RaggiP , McCarthyJT , SchulmanG , SilberzweigJ , KuhlikA , et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. American Journal of Nephrology2003;23(5):307‐14. [MEDLINE: 12915774] FerramoscaE , BurkeS , Chasan‐TaberS , RattiC , ChertowGM , RaggiP . Potential antiatherogenic and anti‐inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal2005;149(5):820‐5. [MEDLINE: 15894962] GargJP , Chasan‐TaberS , BlairA , PloneM , BommerJ , RaggiP , et al. Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis &amp; Rheumatism2005;52(1):290‐5. [MEDLINE: 15641045] JamesG , RaggiP , BoulayA , BurkeS , Chasan‐TaberS , ChertowG , et al. Thoracic vertebral bone density increases with renagel and decreases with calcium‐based phosphate binder therapy ‐ a two year study [abstract no: W423]. Nephrology Dialysis Transplantation2003;18(Suppl 4):681. [CENTRAL: CN‐00445894] RaggiP , BommerJ , ChertowGM . Valvular calcification in hemodialysis patients randomized to calcium‐based phosphorus binders or sevelamer. Journal of Heart Valve Disease2004;13(1):134‐41. [MEDLINE: 14765851] RaggiP , BurkeS , Chasen‐TaberS , ChertowG , HolzerH , BommerJ . Sevelamer preserves trabecular bone mineral density [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:103‐4. [CENTRAL: CN‐00509430] RaggiP , BurkeSK , Chasen‐TaberS , ChertowGM , HolzerH , BommerJ . Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA‐PO924]. Journal of the American Society of Nephrology2003;14(Nov):502A. [CENTRAL: CN‐00583411] RaggiP , BurkeSK , DillonMA , AminN , BommerJ , ChertowGM . Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):239A. [CENTRAL: CN‐00447325] RaggiP , JamesG , BurkeSK , BommerS , Chasan‐TaberS , HolzerH , et al. Decrease in thoracic vertebral bone attenuation with calcium‐based phosphate binders in hemodialysis. Journal of Bone &amp; Mineral Research2005;20(5):764‐72. [MEDLINE: 15824849] '>Chertow 2002</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0042" title="GreenbergS , ShapiroW , PoruchJG . Calcium acetate (aa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:472. [CENTRAL: CN‐00509217] GreenbergS , ShapiroW , PorushJG . Calcium acetate (caa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. Journal of the American Society of Nephrology1994;5(3):492. ">Greenberg 1994</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0054" title="KatopodisKP , AndrikosEK , GouvaCD , BairaktariET , NikolopoulosPM , TakouliLK , et al. Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients. Peritoneal Dialysis International2006;26(3):320‐7. [MEDLINE: 16722024] ">Katopodis 2006</a>; <a href="./references#CD006023-bbs2-0056" title="KoiwaF , YokoyamaK , FukagawaM , TeraoA , AkizawaT . Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrology2017;22(4):293‐300. [MEDLINE: 27496336] ">Koiwa 2017</a>; <a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a>; <a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>; <a href="./references#CD006023-bbs2-0065" title="LocatelliF , SpasovskiG , DimkovicN , WannerC , DellannaF , PontorieroG . The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1‐year prospective randomized study. Nephrology Dialysis Transplantation2014;29(5):1061‐73. [MEDLINE: 24302608] ">Locatelli 2014</a>; <a href="./references#CD006023-bbs2-0067" title="Navarro‐GonzalezJF , Mora‐FernandezC , Muros de FuentesM , Donate‐CorreaJ , Cazana‐PerezV , Garcia‐PerezJ . Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2011;6(9):2272‐9. [MEDLINE: 21784820] ">Navarro‐Gonzalez 2011</a>; <a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0076" title="RudnickiM , HyldstrupL , PetersenLJ , HojstedJ , TranbolI . Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double‐blind placebo‐controlled study. Mineral &amp; Electrolyte Metabolism1994;20(3):130‐4. [MEDLINE: 7816001] ">Rudnicki 1994</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a>; <a href="./references#CD006023-bbs2-0087" title="SongFR , ChengH , ZhaoDM , YuJ , GaoY . Effects of lanthanum carbonate on serum calcium and phosphorus of CAPD patients with chronic renal failure receiving calcitriol pulse therapy due to secondary hyperparathyroidism. Chinese Journal of Evidence‐Based Medicine2014;14(6):651‐4. [EMBASE: 2014574871] ">Song 2014</a>; <a href="./references#CD006023-bbs2-0094" title="ToidaT , FukudomeK , FujimotoS , YamadaK , SatoY , ChiyotandaS , et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clinical Nephrology2012;78(3):216‐23. [MEDLINE: 22874110] ">Toida 2012</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>). The sequence did not appear to be random in one study, in which treatment group may have been based on serum phosphate levels (<a href="./references#CD006023-bbs2-0039" title="FujiiH , KonoK , GotoS , NakaiK , WatanabeS , WatanabeK , et al. Effect of lanthanum carbonate on cardiac abnormalities in patients new to hemodialysis [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii645. [EMBASE: 617289957] FujiiH , NakaiK , KonoK , GotoS , KitamuraK , YonekuraY , et al. Effect of lanthanum carbonate on coronary artery calcification during the early period after the initiation of haemodialysis [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i252. [EMBASE: 72326579] ">Fujii 2017</a>). In the remaining 78 studies, the method for generating the random sequence was unclear. </p> <p>Allocation concealment was adjudicated as low risk of bias in 15 studies (<a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0042" title="GreenbergS , ShapiroW , PoruchJG . Calcium acetate (aa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:472. [CENTRAL: CN‐00509217] GreenbergS , ShapiroW , PorushJG . Calcium acetate (caa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. Journal of the American Society of Nephrology1994;5(3):492. ">Greenberg 1994</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>; <a href="./references#CD006023-bbs2-0056" title="KoiwaF , YokoyamaK , FukagawaM , TeraoA , AkizawaT . Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrology2017;22(4):293‐300. [MEDLINE: 27496336] ">Koiwa 2017</a>; <a href="./references#CD006023-bbs2-0069" title="LengletA , LiabeufS , ElEsperN , BrissetS , MansourJ , Lemaire‐HurtelAS , et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation2017;32(5):870‐9. [MEDLINE: 24599830] ">NICOREN 2017</a>; <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>). The method to conceal allocation was deemed to be high risk in one study in which some participants could choose their treatment group (<a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>). The risk of bias for allocation concealment was unclear in the remaining 88 studies. </p> </section> <section id="CD006023-sec-0094"> <h4 class="title">Blinding</h4> <p>Twenty‐seven studies were blinded and considered to be at low risk of bias for performance bias (<a href="./references#CD006023-bbs2-0004" title="AkizawaT , OrigasaH , KameokaC , TsukadaJ , KuroishiK , YamaguchiY . Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Therapeutic Apheresis &amp; Dialysis2016;20(6):588‐97. [MEDLINE: 27896908] ">Akizawa 2016</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0021" title="ChenN , WuX , DingX , MeiC , FuP , JiangG , et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double‐blind, placebo‐controlled, dose‐titration study. Nephrology Dialysis Transplantation2014;29(1):152‐60. [MEDLINE: 24151017] ">Chen 2014</a>; <a href="./references#CD006023-bbs2-0022" title="ChengSC , YoungDO , DelmezJA , CoyneDW . The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]. Journal of the American Society of Nephrology2007;18(Abstracts):924A. ChengSC , YoungDO , HuangY , DelmezJA , CoyneDW . A randomized, double‐blind, placebo‐controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):1131‐8. [MEDLINE: 18385391] ">Cheng 2008</a>; <a href="./references#CD006023-bbs2-0026" title="ChueCD , TownendJN , MoodyWE , ZehnderD , WallNA , HarperL , et al. Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology2013;24(5):842‐52. [MEDLINE: 23599381] ChueCD , TownendJN , SteedsRP , FerroCJ . Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB‐PHOS randomised controlled trial. Trials [Electronic Resource]2011;12(1):30. [MEDLINE: 21288351] ">CRIB‐PHOS 2011</a>; <a href="./references#CD006023-bbs2-0034" title="EvsanaaB , LiuI , AliazardehB , MahdaviS , BajwaG , GulaJ , et al. MgCaCO3 versus CaCO3 in peritoneal dialysis patients‐‐a cross‐over pilot trial. Peritoneal Dialysis International2015;35(1):31‐4. [MEDLINE: 24584605] ">Evsanaa 2015</a>; <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0047" title="IsakovaT , Barchi‐ChungA , EnfieldG , SmithK , VargasG , HoustonJ , et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD. Clinical Journal of The American Society of Nephrology: CJASN2013;8(6):1009‐18. [MEDLINE: 23471131] IsakovaT , Barchi‐ChungA , EnfieldG , SmithKT , VargasGS , HoustonJ , et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR‐OR068]. Journal of the American Society of Nephrology2012;23:45A. ">Isakova 2013</a>; <a href="./references#CD006023-bbs2-0058" title="LeeCT , WuIW , ChiangSS , PengYS , ShuKH , WuMJ , et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double‐blind, placebo‐controlled study. Journal of Nephrology2015;28(1):105‐13. [EMBASE: 2015735302] ">Lee 2015b</a>; <a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>; <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a>; <a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0076" title="RudnickiM , HyldstrupL , PetersenLJ , HojstedJ , TranbolI . Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double‐blind placebo‐controlled study. Mineral &amp; Electrolyte Metabolism1994;20(3):130‐4. [MEDLINE: 7816001] ">Rudnicki 1994</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0082" title="ShahbazianH , ZafarMA , GhorbaniA , AbbaspourMR , Belladi MusaviSS , HayatiF , et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double‐blind randomized clinical trial. Nefrologia2011;31(1):58‐65. [MEDLINE: 21270914] ">Shahbazian 2011</a>; <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a>; <a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a>; <a href="./references#CD006023-bbs2-0091" title="SpragueS , FinnW , AbboudH , QiuP , SPD405‐206 Study Investigators. Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00757113] SpragueSM , AbboudH , QuiP , DauphinM , ZhangP , FinnW . Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):178‐85. [MEDLINE: 19056618] SpragueSM , FinnWF , QiuP , Study 206 Investigators. Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi‐center trial [abstract no: PUB442]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):927A. [CENTRAL: CN‐00756891] ">Sprague 2009a</a>; <a href="./references#CD006023-bbs2-0092" title="TakaharaY , MatsudaY , TakahashiS , ShigematsuT , Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre‐dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical Nephrology2014;82(3):181‐90. [MEDLINE: 25079863] ">Takahara 2014</a>; <a href="./references#CD006023-bbs2-0093" title="TielmansC , KnoopC , DoutrelepontJM , TimmermansD , Even‐AdinD , VanherweghemJL . Superiority of calcium acetate (ACET) over carbonate (CARB) to bind phosphorus (P) in hemodialysis patients (HDP) [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:219A. ">Tielmans 1990</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>; <a href="./references#CD006023-bbs2-0100" title="YokoyamaK , HirakataH , AkibaT , FukagawaM , NakayamaM , SawadaK , et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis‐dependent CKD. Clinical Journal of The American Society of Nephrology: CJASN2014;9(3):543‐52. [MEDLINE: 24408120] ">Yokoyama 2014</a>; <a href="./references#CD006023-bbs2-0102" title="YoungDO , ChengSC , DelmezJA , CoyneDW . The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International2009;29(5):562‐7. [MEDLINE: 19776051] ">Young 2009a</a>). Blinding was unclear in four studies (<a href="./references#CD006023-bbs2-0006" title="AlmirallJ , VecianaL , LlibreJ . Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):976. [CENTRAL: CN‐00260851] AlmirallJ , VecianaL , LlibreJ . Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. American Journal of Nephrology1994;14(3):192‐6. [MEDLINE: 7977479] ">Almirall 1994</a>; <a href="./references#CD006023-bbs2-0007" title="AramwitP , SrisawadwongR , SupasyndhO . Effectiveness and safety of extended‐release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Journal of Nephrology2012;25(3):354‐62. [MEDLINE: 21748722] ">Aramwit 2012</a>; <a href="./references#CD006023-bbs2-0066" title="MatsushimaH , YasudaT , OyamaA , MiyataM . Efficacy and safety of iron‐based phosphate binders, ferric citrate hydrate versus sucroferric oxyhydroxide, on hyperphosphatemia in chronic hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii679. [EMBASE: 617290946] ">Matsushima 2017</a>; <a href="./references#CD006023-bbs2-0081" title="SezerS , KarakanS , AcarNO . Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]. NDT Plus2010;3(Suppl 3):iii196. [EMBASE: 70483939] ">Sezer 2010</a>). The remaining 73 studies were not blinded and were considered at high risk of performance bias. </p> <p>As most studies were based on laboratory assessment or patient‐centred outcomes including death, all studies were considered at low risk of bias for blinding of outcome assessment. </p> </section> <section id="CD006023-sec-0095"> <h4 class="title">Incomplete outcome data</h4> <p>Thirty‐one studies met criteria for low risk of attrition bias (<a href="./references#CD006023-bbs2-0006" title="AlmirallJ , VecianaL , LlibreJ . Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):976. [CENTRAL: CN‐00260851] AlmirallJ , VecianaL , LlibreJ . Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. American Journal of Nephrology1994;14(3):192‐6. [MEDLINE: 7977479] ">Almirall 1994</a>; <a href="./references#CD006023-bbs2-0007" title="AramwitP , SrisawadwongR , SupasyndhO . Effectiveness and safety of extended‐release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Journal of Nephrology2012;25(3):354‐62. [MEDLINE: 21748722] ">Aramwit 2012</a>; <a href="./references#CD006023-bbs2-0009" title="BleyerAJ , BurkeSK , DillonM , GarrettB , KantKS , LynchD , et al. A comparison of the calcium‐free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases1999;33(4):694‐701. [MEDLINE: 10196011] BleyerAJ , GarrettB , KantKS , LynchD , RahmanN , SchoenfeldP , et al. An open label, cross‐over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):548a. [CENTRAL: CN‐00444452] ">Bleyer 1999</a>; <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0015" title="CaglarK , YilmazMI , SaglamM , CakirE , AcikelC , EyiletenT , et al. Short‐term treatment with sevelamer increases serum fetuin‐a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clinical Journal of the American Society of Nephrology: CJASN2008;3(1):61‐8. [MEDLINE: 18057307] YilmazMI , SonmezA , SaglamM , YamanH , KilicS , EyiletenT , et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. American Journal of Kidney Diseases2012;59(2):177‐85. [MEDLINE: 22137672] ">Caglar 2008</a>; <a href="./references#CD006023-bbs2-0020" title="ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: a 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology2011;16(8):743‐50. [MEDLINE: 21854503] ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08‐08]. Nephrology2010;15(Suppl 3):51. [EMBASE: 70467427] ChenJB , ChiangSS , HenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]. NDT Plus2010;3(Suppl 3):iii238. [EMBASE: 70484048] ">Chen 2011b</a>; <a href="./references#CD006023-bbs2-0021" title="ChenN , WuX , DingX , MeiC , FuP , JiangG , et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double‐blind, placebo‐controlled, dose‐titration study. Nephrology Dialysis Transplantation2014;29(1):152‐60. [MEDLINE: 24151017] ">Chen 2014</a>; <a href="./references#CD006023-bbs2-0022" title="ChengSC , YoungDO , DelmezJA , CoyneDW . The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]. Journal of the American Society of Nephrology2007;18(Abstracts):924A. ChengSC , YoungDO , HuangY , DelmezJA , CoyneDW . A randomized, double‐blind, placebo‐controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):1131‐8. [MEDLINE: 18385391] ">Cheng 2008</a>; <a href="./references#CD006023-bbs2-0026" title="ChueCD , TownendJN , MoodyWE , ZehnderD , WallNA , HarperL , et al. Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology2013;24(5):842‐52. [MEDLINE: 23599381] ChueCD , TownendJN , SteedsRP , FerroCJ . Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB‐PHOS randomised controlled trial. Trials [Electronic Resource]2011;12(1):30. [MEDLINE: 21288351] ">CRIB‐PHOS 2011</a>; <a href="./references#CD006023-bbs2-0030" title="DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. A randomized, double‐blind cross‐over design study of sevelamer hydrochloride (SH, Renegel®) and sevelamer carbonate (SC) in chronic kidney disease patients on hemodialysis [abstract no: 48]. American Journal of Kidney Diseases2007;49(4):A36. [CENTRAL: CN‐00671791] DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. Results of a randomized, double‐blind, cross‐over design study of sevelamer hydrochloride (Renagel®) and sevelamer carbonate in chronic kidney disease patients on hemodialysis [abstract no: SaP377]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi361. [CENTRAL: CN‐00671790] DelmezJ , BlockG , RobertsonJ , Chasan‐TaberS , BlairA , DillonM , et al. A randomized, double‐blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clinical Nephrology2007;68(6):386‐91. [MEDLINE: 18184521] ">Delmez 2007</a>; <a href="./references#CD006023-bbs2-0034" title="EvsanaaB , LiuI , AliazardehB , MahdaviS , BajwaG , GulaJ , et al. MgCaCO3 versus CaCO3 in peritoneal dialysis patients‐‐a cross‐over pilot trial. Peritoneal Dialysis International2015;35(1):31‐4. [MEDLINE: 24584605] ">Evsanaa 2015</a>; <a href="./references#CD006023-bbs2-0043" title="HervasJG , PradosD , CerezoS . Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney International ‐ Supplement2003;85:69‐72. [MEDLINE: 12753270] ">Hervas 2003</a>; <a href="./references#CD006023-bbs2-0046" title="BellasiA , CozzolinoM , RussoD , MolonyD , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology2016;86(9):113‐24. [MEDLINE: 27443567] BellasiA , CozzolinoM , RussoD , MolonyDA , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii588. [EMBASE: 72207961] DiIorioB . In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'. American Journal of Kidney Diseases2014;63(1):164‐5. [MEDLINE: 24377649] DiIorioB , MolonyD , BellC , CuccinielloE , BellizziV , RussoD , et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. American Journal of Kidney Diseases2013;62(4):771‐8. [MEDLINE: 23684755] DiIorioBR , CuccinielloE , BellizziV . Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan‐Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar‐Apr;26(2):419]. Journal of Nephrology2009;22(6):694‐8. [MEDLINE: 19967647] MolonyD , BellasiA , BellizziV , RussoD , DiIorioB . Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii54. [EMBASE: 70765453] ObiY , HamanoT . The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. American Journal of Kidney Diseases2014;63(1):164. [MEDLINE: 24377650] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593‐602; PMID: 25027030]. Journal of Nephrology2014;27(6):717. [MEDLINE: 25098354] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]. Journal of Nephrology2015;28(5):593‐602. [MEDLINE: 25027030] ">INDEPENDENT‐HD 2009</a>; <a href="./references#CD006023-bbs2-0047" title="IsakovaT , Barchi‐ChungA , EnfieldG , SmithK , VargasG , HoustonJ , et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD. Clinical Journal of The American Society of Nephrology: CJASN2013;8(6):1009‐18. [MEDLINE: 23471131] IsakovaT , Barchi‐ChungA , EnfieldG , SmithKT , VargasGS , HoustonJ , et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR‐OR068]. Journal of the American Society of Nephrology2012;23:45A. ">Isakova 2013</a>; <a href="./references#CD006023-bbs2-0053" title="KasaiS , SatoK , MurataY , KinoshitaY . Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(4):341‐9. [EMBASE: 2012432570] ">Kasai 2012</a>; <a href="./references#CD006023-bbs2-0063" title="HuangC , YuC , LiuY . Effect of sevelamer on homocysteinemia and lipid profile in patients undergoing maintenance hemodialysis ‐ a randomized clinical trial [abstract no: F‐PO610]. Journal of the American Society of Nephrology2005;16:467A. [CENTRAL: CN‐00756400] LiuYL , LinHH , YuCC , KuoHL , YangYF , ChouCY , et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Renal Failure2006;28(8):701‐7. [MEDLINE: 17162430] ">Liu 2006</a>; <a href="./references#CD006023-bbs2-0067" title="Navarro‐GonzalezJF , Mora‐FernandezC , Muros de FuentesM , Donate‐CorreaJ , Cazana‐PerezV , Garcia‐PerezJ . Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2011;6(9):2272‐9. [MEDLINE: 21784820] ">Navarro‐Gonzalez 2011</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0076" title="RudnickiM , HyldstrupL , PetersenLJ , HojstedJ , TranbolI . Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double‐blind placebo‐controlled study. Mineral &amp; Electrolyte Metabolism1994;20(3):130‐4. [MEDLINE: 7816001] ">Rudnicki 1994</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>; <a href="./references#CD006023-bbs2-0081" title="SezerS , KarakanS , AcarNO . Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]. NDT Plus2010;3(Suppl 3):iii196. [EMBASE: 70483939] ">Sezer 2010</a>; <a href="./references#CD006023-bbs2-0082" title="ShahbazianH , ZafarMA , GhorbaniA , AbbaspourMR , Belladi MusaviSS , HayatiF , et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double‐blind randomized clinical trial. Nefrologia2011;31(1):58‐65. [MEDLINE: 21270914] ">Shahbazian 2011</a>; <a href="./references#CD006023-bbs2-0083" title="ShaheenA , AkeelNM , BadawiLS , SouqiyyehMZ . Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Medical Journal2004;25(6):785‐91. [MEDLINE: 15195212] ">Shaheen 2004</a>; <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a>; <a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a>; <a href="./references#CD006023-bbs2-0089" title="SikoleA , SpasovskiG , GelevS , AmitovV , StojcevN , GrozdanovskiR . Lanthanum carbonate ‐ a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v95‐6. SikoleA , SpasovskiG , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]. Nephrology Dialysis Transplantation2002;17(Suppl 12):67. [CENTRAL: CN‐00509481] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients ‐ single center experience [abstract no: w436]. Nephrology Dialysis Transplantation2003;18(Suppl 4):685‐6. [CENTRAL: CN‐00447817] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]. International Journal of Artificial Organs2003;26(7):630. [CENTRAL: CN‐00583691] SpasovskiG , SikoleA , GelevS , MasinJ , FreemontT , WebsterI , et al. The evolution of renal bone disease in dialysis patients ‐ comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105‐6. [CENTRAL: CN‐00509488] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , GrozdanovskiR , et al. Comparative, bone biopsy‐based, 3 years follow‐up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]. Nephrology Dialysis Transplantation2005;20(6 Suppl):v376. [CENTRAL: CN‐00583693] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , PolenakovicB , WebsterI , et al. The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA‐PO842]. Journal of the American Society of Nephrology2005;16(Oct):741A. [CENTRAL: CN‐00583697] SpasovskiGB , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]. Hemodialysis International2003;7(1):87. [CENTRAL: CN‐00461778] SpasovskiGB , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , WebsterI , et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow‐up. Nephrology Dialysis Transplantation2006;21(8):2217‐24. [MEDLINE: 16595583] ">Spasovski 2006</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>; <a href="./references#CD006023-bbs2-0098" title="WadaK , WadaY . Evaluation of aortic calcification with lanthanum carbonate vs. calcium‐based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open‐label randomized controlled trial. Therapeutic Apheresis &amp; Dialysis2014;18(4):353‐60. [MEDLINE: 24417760] ">Wada 2014</a>; <a href="./references#CD006023-bbs2-0099" title="WangXH , ZhangX , MuCJ , HeY , PengQP , YangGS , et al. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients. Journal of Huazhong University of Science and Technology. Medical Sciences2015;35(4):508‐13. [MEDLINE: 26223918] ">Wang 2015b</a>; <a href="./references#CD006023-bbs2-0102" title="YoungDO , ChengSC , DelmezJA , CoyneDW . The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International2009;29(5):562‐7. [MEDLINE: 19776051] ">Young 2009a</a>; <a href="./references#CD006023-bbs2-0103" title="ZhaoH , WangJ , ZhaoDM , DongYM , GaoY . Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end‐stage renal disease: a randomized controlled trial. Chinese Journal of Evidence‐Based Medicine2014;14(11):1293‐8. [EMBASE: 2014948885] ">Zhao 2014</a>). Fifty‐two studies were considered at high risk of attrition bias when there was differential loss to follow‐up between treatment groups, high attrition rates (&gt; 10%), or when adverse events were substantially higher in one or both treatment groups (<a href="./references#CD006023-bbs2-0003" title="AkizawaT , OrigasaH , KameokaC , KanekoY , KawasakiS , Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Therapeutic Apheresis &amp; Dialysis2014;18(2):122‐31. [MEDLINE: 24720402] ">Akizawa 2014a</a>; <a href="./references#CD006023-bbs2-0004" title="AkizawaT , OrigasaH , KameokaC , TsukadaJ , KuroishiK , YamaguchiY . Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Therapeutic Apheresis &amp; Dialysis2016;20(6):588‐97. [MEDLINE: 27896908] ">Akizawa 2016</a>; <a href="./references#CD006023-bbs2-0005" title="AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadministration of nicotinamide and calcium‐based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis. Advances in Natural Science2012;5(1):1‐9. [DOI: 10.3968/j.ans.1715787020120501.1001] AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadminstration of nicotinamide and calcium‐based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]. Value in Health2012;15(4):A152. [EMBASE: 70763798] ElSharkawyMM , KamelM , ElhamamsyM , AllamS . Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i253. [EMBASE: 71075759] ">Allam 2012</a>; <a href="./references#CD006023-bbs2-0008" title="BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross‐over study. Nephrology Dialysis Transplantation1999;14(6):1475‐9. [MEDLINE: 10383011] BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium‐ketoglutarate vs. calcium‐acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):552A. [CENTRAL: CN‐00444439] ">Birck 1999</a>; <a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0014" title="BroS , RasmussenRA , HandbergJ , OlgaardK , Feld‐RasmussenB . Randomized crossover study comparing the phosphate‐binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. American Journal of Kidney Diseases1998;31(2):257‐62. [MEDLINE: 9469496] ">Bro 1998</a>; <a href="./references#CD006023-bbs2-0016" title="CovicA , Passlick‐DeetjenJ , KroczakM , Buschges‐SeraphinB , GhenuA , PonceP , et al. A comparison of calcium acetate/magnesium carbonate and sevelamer‐hydrochloride effects on fibroblast growth factor‐23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation2013;28(9):2383‐92. [MEDLINE: 23787550] PaschA , deFranciscoALM , CovicA , MarzellB , ArensHJ , Passlick‐DeetjenJ , et al. Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate/ magnesium carbonate containing phosphate binder [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii40. [EMBASE: 71491561] deFranciscoAL , LeidigM , CovicAC , KettelerM , Benedyk‐LorensE , MircescuGM , et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrology Dialysis Transplantation2010;25(11):3707‐17. [MEDLINE: 20530499] ">CALMAG 2010</a>; <a href="./references#CD006023-bbs2-0017" title="CaravacaF , SantosI , CuberoJJ , EsparragoJF , ArrobasM , PizarroJL , et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron1992;60(4):423‐7. [MEDLINE: 1584317] CaravacaF , SantosI , RoblesR , CuberoJ , EsparragoJ , ArrobasM , et al. Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1990;5(8):729. [CENTRAL: CN‐00260555] ">Caravaca 1992</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0019" title="BudoffMJ , KesslerP , GaoYL , QunibiW , MoustafaM , MaoSS . The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)‐2 study. Academic Radiology2008;15(1):58‐61. [MEDLINE: 18078907] QunibiW , HorwithG , KesslerP , MoustafaM , CARE‐2 Investigators. Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation‐2 (CARE‐2) study [abstract no: PUB386]. Journal of the American Society of Nephrology2005;16(Oct Abstracts Issue):866A. [CENTRAL: CN‐00602064] QunibiW , MoustafaM , KesslerP , BortleyE , MuenzL , BudoffM . Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study [abstract no: FP386]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi148. [CENTRAL: CN‐00691160] QunibiW , MoustafaM , KesslerP , MuenzLR , BudoffM . Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: TH‐PO845]. Journal of the American Society of Nephrology2006;17(Abstracts):286A. [CENTRAL: CN‐00602067] QunibiW , MoustafaM , MuenzLR , HeDY , KesslerPD , Diaz‐BuxoJA , et al. A 1‐year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study. American Journal of Kidney Diseases2008;51(6):952‐65. [MEDLINE: 18423809] QunibiW , MuenzLR , Diaz‐BuxoJA . The CARE‐2 study results: setting the record straight. Nephrology Dialysis Transplantation2008;23(12):4081‐2. [MEDLINE: 18820282] QunibiWY , MoustafaM , KesslerP , BorteyE , MuenzLR , BudoffM . Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: S‐PO‐0376]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:150. QunibiWY , MoustafaM , KesslerP , MuenzLR , Diaz‐BuxoJ , BudoffM , et al. Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation‐2 (CARE‐2) study [abstract no: TH‐FC043]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. ">CARE‐2 2008</a>; <a href="./references#CD006023-bbs2-0027" title="D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International ‐ Supplement2003;85:S73‐8. [MEDLINE: 12753271] D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. Multi‐centre study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients [abstract no: PS1‐15]. Nephrology2003;8(Suppl 1):A28. DeBroeME , D'HaesePC , FreemontTJ , WebsterI , GillM , SpasovskiGB . Comparative effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients: results from a large, long‐term clinical trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):682. [CENTRAL: CN‐00445015] FreemontA . The effects of lanthanum carbonate and calcium carbonate on bone in patients with chronic kidney disease [abstract no: 33]. American Journal of Kidney Diseases2004;43(4):A23. [CENTRAL: CN‐00644282] FreemontA , JonesC . The effects of the phosphate binders lanthanum carbonate and calcium carbonate on bone: a comparative study in patients with chronic kidney disease [abstract no:SP270]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106. [CENTRAL: CN‐00509202] FreemontAJ , HoylandJA , DentonJ , Lanthanum Carbonate SPD405‐303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end‐stage renal disease. Clinical Nephrology2005;64(6):428‐37. [MEDLINE: 16370155] FreemontT , MallucheHH . Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clinical Nephrology2005;63(2):138‐45. [MEDLINE: 15730056] TorresA , DeBroeME , D'HaesePC , HutchisonA , JonesC . One‐year, randomized, open‐label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol®) and calcium carbonate in dialysis patients [abstract no: SU‐PO1041]. Journal of the American Society of Nephrology2003;14(Nov):764A. [CENTRAL: CN‐00583261] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WilsonR . Spica Consultants Ltd. Personal communication2005. WilsonR , CopleyJB , PooleL . Lower serum phosphorus can be attained by increasing the dose of lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii496. [EMBASE: 70766788] ">D'Haese 2003</a>; <a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a>; <a href="./references#CD006023-bbs2-0033" title="EvenepoelP , SelgasR , CaputoF , FoggensteinerL , HeafJG , OrtizA , et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2009;24(1):278‐85. [MEDLINE: 18820280] EvenepoelP , SelgasR , DuggalA , KellyA , FanSL . Effects of sevelamer hydrochloride (Renagel®) and calcium acetate on controlling serum phosphorus in peritoneal dialysis patients [abstract no: MP580]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv496. [CENTRAL: CN‐00671825] EvenepoelP , SelgasR , DuggalA , KellyAL , FanSL . Comparative effects of sevelamer hydrochloride (Renagel®) and calcium acetate on markers of mineral metabolism in peritoneal dialysis patients [abstract no: TH‐PO778]. Journal of the American Society of Nephrology2006;17(Abstracts):272A. [CENTRAL: CN‐00671824] ">Evenepoel 2009</a>; <a href="./references#CD006023-bbs2-0035" title="FerreiraA , FrazãoJM , Monier‐FaugereMC , GilC , GalvaoJ , OliveiraC , et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. Journal of the American Society of Nephrology2008;19(2):405‐12. [MEDLINE: 18199805] ">Ferreira 2008</a>; <a href="./references#CD006023-bbs2-0036" title="FishbaneS , DelmezJ , SukiW , HariacharS , MoeS , HeatonJ . Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open‐label study in chronic kidney disease patients on hemodialysis [abstract no: M621]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. FishbaneS , DelmezJ , SukiWN , HariacharS , MoeS . A randomized, parallel, open‐label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):936A. [CENTRAL: CN‐00747271] FishbaneS , DelmezJ , SukiWN , HariacharSK , HeatonJ , Chasan‐TaberS , et al. A randomized, parallel, open‐label study to compare once‐daily sevelamer carbonate powder dosing with thrice‐daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. American Journal of Kidney Diseases2010;55(2):307‐15. [MEDLINE: 20042256] ">Fishbane 2010</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0040" title="FujimoriA , OhkawaS , OkadaS , MizobuchiN , SakaiM , HasuikeY , et al. Comparison of the suppressive effects on fibroblast growth factor 23 between ferric citrate and lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii244‐5. [EMBASE: 617291229] ">Fujimori 2017</a>; <a href="./references#CD006023-bbs2-0044" title="GillM , WebsterI , SegarsL . Efficacy and safety of lanthanum carbonate, the novel phosphate binder, in Chinese patients with chronic kidney disease [abstract]. Nephrology Nursing Journal2004;31(2):141. HutchisonA , Lanthanum Study Group. Analysis of haematology data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract no: SP219]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v92‐3. HutchisonA , Lanthanum Study Group. No adverse effects of haematological parameters during lanthanum carbonate treatment in over 2000 patients [abstract no: W‐PO40068]. Nephrology2005;10(Suppl):A297. HutchisonA , SPD405‐301 Lanthanum Study Group. Long‐term safety, efficacy, and tolerability of lanthanum carbonate: results from a 3.5‐year study [abstract no: W‐PO40065]. Nephrology2005;10(Suppl 1):A297. HutchisonA , WebsterI . Lanthanum carbonate versus calcium carbonate: effect on parathyroid hormone (PTH) levels [abstract no: F‐PO656]. Journal of the American Society of Nephrology2003;14(Nov):205A. HutchisonA , WebsterI . Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenal®) during long‐term therapy in hemodialysis patients. [abstract no: SU‐PO1039]. Journal of the American Society of Nephrology2003;14(Nov):764A. HutchisonA , WebsterI . Safety and efficacy data for lanthanum carbonate: a summary from three studies [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:107. HutchisonA , WebsterI , GillM , SchmiederR . Safety and tolerability of lanthanum carbonate in haemodialysis patients: a 12‐month study [abstract no: W431]. Nephrology Dialysis Transplantation2003;18(Suppl 4):684. HutchisonA , Lanthanum Study Group. No evidence of hepatoxicity with lanthanum carbonate ‐ clinical trial data from 2000 dialysis patients [abstract no: W‐PO40069]. Nephrology2005;10(Suppl):A298. HutchisonAJ . Lanthanum carbonate (FosrenolTM), a novel, nonaluminum, noncalcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract no: PS1‐22]. Nephrology2003;8(Suppl 1):A29. HutchisonAJ , GillM . A demographic analysis of lanthanum carbonate phase II and III studies [abstract no: 271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106‐7. [CENTRAL: CN‐00509244] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6‐month, randomized, comparative trial versus calcium carbonate. Nephron2005;100(1):c8‐19. [MEDLINE: 15809508] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Long‐term efficacy and tolerability of lanthanum carbonate: results from a 3‐year study. Nephron2006;102(2):c61‐71. [MEDLINE: 16224198] HutchisonAJ , Lanthanum Study Group. The novel, non‐aluminium, non‐calcium phosphate binder, fosrenol, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract no: SA‐PO599]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):385A‐6A. [CENTRAL: CN‐00445823] SpeakeM , HutchisonAJ , WebsterI . Lanthanum carbonate, a novel, non‐aluminum, non‐calcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract]. Nephrology Nursing Journal2003;30(2):149. [CENTRAL: CN‐00644297] SpeakeM , WebsterI . Long‐term safety, tolerability, and efficacy of lanthanum carbonate therapy [abstract]. Nephrology Nursing Journal2004;31(2):143. [CENTRAL: CN‐00644295] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WebsterI , GillM . Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients [abstract no: SP267]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105. [CENTRAL: CN‐00509557] ">Hutchison 2005</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0048" title="ItohK , TanakaM , HashiguchiJ , FunakoshiS , NakanoH , KuboH , et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp; Dialysis2008;12(2):126‐32. [MEDLINE: 18387160] ">Itoh 2008</a>; <a href="./references#CD006023-bbs2-0049" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients. Nephrology Dialysis Transplantation1995;10(12):2321‐4. [MEDLINE: 8808233] ">Janssen 1995</a>; <a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a>; <a href="./references#CD006023-bbs2-0051" title="JespersenB , JensenJD , NielsenHK , LauridsenIN , AndersenMJ , PoulsenJH , et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1‐84), and bone mineral content in dialysis patients. Nephrology Dialysis Transplantation1991;6(2):98‐104. [MEDLINE: 1857534] ">Jespersen 1991</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>; <a href="./references#CD006023-bbs2-0056" title="KoiwaF , YokoyamaK , FukagawaM , TeraoA , AkizawaT . Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrology2017;22(4):293‐300. [MEDLINE: 27496336] ">Koiwa 2017</a>; <a href="./references#CD006023-bbs2-0057" title="LeeYK , ChoiHY , ShinSK , LeeHY . Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clinical Nephrology2013;79(2):136‐42. [MEDLINE: 23211335] ">Lee 2013</a>; <a href="./references#CD006023-bbs2-0058" title="LeeCT , WuIW , ChiangSS , PengYS , ShuKH , WuMJ , et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double‐blind, placebo‐controlled study. Journal of Nephrology2015;28(1):105‐13. [EMBASE: 2015735302] ">Lee 2015b</a>; <a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a>; <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0061" title="LinYF , ChenYM , HungKY , ChuTS , KanWC , HuangCY , et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. Journal of the Formosan Medical Association2010;109(9):663‐72. [MEDLINE: 20863994] LinYF , ChienCT , KanWC , ChenYM , ChuTS , HungKY , et al. Pleiotropic effects of sevelamer beyond phosphate binding in end‐stage renal disease patients: a randomized, open‐label, parallel‐group study. Clinical Drug Investigation2011;31(4):257‐67. [MEDLINE: 21299254] ">Lin 2010</a>; <a href="./references#CD006023-bbs2-0062" title="LinHH , LiouHH , WuMS , HuangCC . Factors associated with serum fetuin‐A concentrations after long‐term use of different phosphate binders in hemodialysis patients. BMC Nephrology2016;17:33. [MEDLINE: 27007989] LinHH , LiouHH , WuMS , LinCY , HuangCC . Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology2014;19(11):672‐8. [MEDLINE: 25113414] ">Lin 2014a</a>; <a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>; <a href="./references#CD006023-bbs2-0065" title="LocatelliF , SpasovskiG , DimkovicN , WannerC , DellannaF , PontorieroG . The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1‐year prospective randomized study. Nephrology Dialysis Transplantation2014;29(5):1061‐73. [MEDLINE: 24302608] ">Locatelli 2014</a>; <a href="./references#CD006023-bbs2-0068" title="NCT00542815 . A study of MCI‐196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia. ClinicalTrials.gov/show/NCT00542815 (first received 12 October 2007). ">NCT00542815</a>; <a href="./references#CD006023-bbs2-0069" title="LengletA , LiabeufS , ElEsperN , BrissetS , MansourJ , Lemaire‐HurtelAS , et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation2017;32(5):870‐9. [MEDLINE: 24599830] ">NICOREN 2017</a>; <a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a>; <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a>; <a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a>; <a href="./references#CD006023-bbs2-0075" title="RoxeDM , MistovichM , BarchDH . Phosphate‐binding effects of sucralfate in patients with chronic renal failure. American Journal of Kidney Diseases1989;13(3):194‐9. [MEDLINE: 2919600] ">Roxe 1989</a>; <a href="./references#CD006023-bbs2-0078" title="SadekT , MazouzH , BahlouH , OprisiuR , ElEsperN , ElEsperI , et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open‐label, randomized study. Nephrology Dialysis Transplantation2003;18(3):582‐9. [MEDLINE: 12584283] ">Sadek 2003</a>; <a href="./references#CD006023-bbs2-0079" title="SaifI , HalimA , AltafA , SaifM , KhalidM , AhmadD , et al. Comparison of calcium acetate with calcium carbonate as phosphate binder in patients on maintenance haemodialysis. Journal of Ayub Medical College, Abbottabad: JAMC2007;19(4):26‐8. [MEDLINE: 18693591] ">Saif 2007</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0091" title="SpragueS , FinnW , AbboudH , QiuP , SPD405‐206 Study Investigators. Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00757113] SpragueSM , AbboudH , QuiP , DauphinM , ZhangP , FinnW . Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):178‐85. [MEDLINE: 19056618] SpragueSM , FinnWF , QiuP , Study 206 Investigators. Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi‐center trial [abstract no: PUB442]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):927A. [CENTRAL: CN‐00756891] ">Sprague 2009a</a>; <a href="./references#CD006023-bbs2-0092" title="TakaharaY , MatsudaY , TakahashiS , ShigematsuT , Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre‐dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical Nephrology2014;82(3):181‐90. [MEDLINE: 25079863] ">Takahara 2014</a>; <a href="./references#CD006023-bbs2-0094" title="ToidaT , FukudomeK , FujimotoS , YamadaK , SatoY , ChiyotandaS , et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clinical Nephrology2012;78(3):216‐23. [MEDLINE: 22874110] ">Toida 2012</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>; <a href="./references#CD006023-bbs2-0097" title="VlassaraH , UribarriJ , CaiW , GoodmanS , PyzikR , PostJ , et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2012;7(6):934‐42. [MEDLINE: 22461535] Yubero‐SerranoEM , WoodwardM , PoretskyL , VlassaraH , StrikerGE . Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro‐oxidant status in patients with diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2015;10(5):759‐66. [MEDLINE: 25710801] ">Vlassara 2012</a>; <a href="./references#CD006023-bbs2-0100" title="YokoyamaK , HirakataH , AkibaT , FukagawaM , NakayamaM , SawadaK , et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis‐dependent CKD. Clinical Journal of The American Society of Nephrology: CJASN2014;9(3):543‐52. [MEDLINE: 24408120] ">Yokoyama 2014</a>; <a href="./references#CD006023-bbs2-0101" title="YokoyamaK , AkibaT , FukagawaM , NakayamaM , SawadaK , KumagaiY , et al. A randomized trial of JTT‐751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology Dialysis Transplantation2014;29(5):1053‐60. [MEDLINE: 24376274] ">Yokoyama 2014a</a>). In the remaining 21 studies, attrition bias was considered unclear. Loss to follow‐up was commonly due to death, transplantation, withdrawal of consent, protocol violation, or adverse events. </p> </section> <section id="CD006023-sec-0096"> <h4 class="title">Selective reporting</h4> <p>Sixty‐nine studies reported expected and clinically‐relevant outcomes and were deemed to be at low risk of bias (<a href="./references#CD006023-bbs2-0002" title="AkizawaT , KinugasaE , NagaiT , NiikuraK , KuriharaS , SuzukiM , et al. Effect of sevelamer hydrochloride (PB‐94) on hyperphosphatemia in Japanese hemodialysis (HD) patients [abstract no: A2940]. Journal of the American Society of Nephrology2000;11(Sept):557A. [CENTRAL: CN‐00550506] KinugasaE , KoshikawaS , PB‐94 Study Group. Effects of PB‐94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients ‐ a randomized, open label, dose titration study of PB‐94 versus caltan® tablet 500 (calcium carbonate) [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):755A. [CENTRAL: CN‐00626049] ">Akizawa 2000</a>; <a href="./references#CD006023-bbs2-0003" title="AkizawaT , OrigasaH , KameokaC , KanekoY , KawasakiS , Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Therapeutic Apheresis &amp; Dialysis2014;18(2):122‐31. [MEDLINE: 24720402] ">Akizawa 2014a</a>; <a href="./references#CD006023-bbs2-0004" title="AkizawaT , OrigasaH , KameokaC , TsukadaJ , KuroishiK , YamaguchiY . Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Therapeutic Apheresis &amp; Dialysis2016;20(6):588‐97. [MEDLINE: 27896908] ">Akizawa 2016</a>; <a href="./references#CD006023-bbs2-0005" title="AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadministration of nicotinamide and calcium‐based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis. Advances in Natural Science2012;5(1):1‐9. [DOI: 10.3968/j.ans.1715787020120501.1001] AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadminstration of nicotinamide and calcium‐based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]. Value in Health2012;15(4):A152. [EMBASE: 70763798] ElSharkawyMM , KamelM , ElhamamsyM , AllamS . Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i253. [EMBASE: 71075759] ">Allam 2012</a>; <a href="./references#CD006023-bbs2-0007" title="AramwitP , SrisawadwongR , SupasyndhO . Effectiveness and safety of extended‐release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Journal of Nephrology2012;25(3):354‐62. [MEDLINE: 21748722] ">Aramwit 2012</a>; <a href="./references#CD006023-bbs2-0009" title="BleyerAJ , BurkeSK , DillonM , GarrettB , KantKS , LynchD , et al. A comparison of the calcium‐free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases1999;33(4):694‐701. [MEDLINE: 10196011] BleyerAJ , GarrettB , KantKS , LynchD , RahmanN , SchoenfeldP , et al. An open label, cross‐over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):548a. [CENTRAL: CN‐00444452] ">Bleyer 1999</a>; <a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0014" title="BroS , RasmussenRA , HandbergJ , OlgaardK , Feld‐RasmussenB . Randomized crossover study comparing the phosphate‐binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. American Journal of Kidney Diseases1998;31(2):257‐62. [MEDLINE: 9469496] ">Bro 1998</a>; <a href="./references#CD006023-bbs2-0016" title="CovicA , Passlick‐DeetjenJ , KroczakM , Buschges‐SeraphinB , GhenuA , PonceP , et al. A comparison of calcium acetate/magnesium carbonate and sevelamer‐hydrochloride effects on fibroblast growth factor‐23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation2013;28(9):2383‐92. [MEDLINE: 23787550] PaschA , deFranciscoALM , CovicA , MarzellB , ArensHJ , Passlick‐DeetjenJ , et al. Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate/ magnesium carbonate containing phosphate binder [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii40. [EMBASE: 71491561] deFranciscoAL , LeidigM , CovicAC , KettelerM , Benedyk‐LorensE , MircescuGM , et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrology Dialysis Transplantation2010;25(11):3707‐17. [MEDLINE: 20530499] ">CALMAG 2010</a>; <a href="./references#CD006023-bbs2-0019" title="BudoffMJ , KesslerP , GaoYL , QunibiW , MoustafaM , MaoSS . The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)‐2 study. Academic Radiology2008;15(1):58‐61. [MEDLINE: 18078907] QunibiW , HorwithG , KesslerP , MoustafaM , CARE‐2 Investigators. Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation‐2 (CARE‐2) study [abstract no: PUB386]. Journal of the American Society of Nephrology2005;16(Oct Abstracts Issue):866A. [CENTRAL: CN‐00602064] QunibiW , MoustafaM , KesslerP , BortleyE , MuenzL , BudoffM . Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study [abstract no: FP386]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi148. [CENTRAL: CN‐00691160] QunibiW , MoustafaM , KesslerP , MuenzLR , BudoffM . Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: TH‐PO845]. Journal of the American Society of Nephrology2006;17(Abstracts):286A. [CENTRAL: CN‐00602067] QunibiW , MoustafaM , MuenzLR , HeDY , KesslerPD , Diaz‐BuxoJA , et al. A 1‐year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study. American Journal of Kidney Diseases2008;51(6):952‐65. [MEDLINE: 18423809] QunibiW , MuenzLR , Diaz‐BuxoJA . The CARE‐2 study results: setting the record straight. Nephrology Dialysis Transplantation2008;23(12):4081‐2. [MEDLINE: 18820282] QunibiWY , MoustafaM , KesslerP , BorteyE , MuenzLR , BudoffM . Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: S‐PO‐0376]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:150. QunibiWY , MoustafaM , KesslerP , MuenzLR , Diaz‐BuxoJ , BudoffM , et al. Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation‐2 (CARE‐2) study [abstract no: TH‐FC043]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. ">CARE‐2 2008</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0020" title="ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: a 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology2011;16(8):743‐50. [MEDLINE: 21854503] ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08‐08]. Nephrology2010;15(Suppl 3):51. [EMBASE: 70467427] ChenJB , ChiangSS , HenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]. NDT Plus2010;3(Suppl 3):iii238. [EMBASE: 70484048] ">Chen 2011b</a>; <a href="./references#CD006023-bbs2-0021" title="ChenN , WuX , DingX , MeiC , FuP , JiangG , et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double‐blind, placebo‐controlled, dose‐titration study. Nephrology Dialysis Transplantation2014;29(1):152‐60. [MEDLINE: 24151017] ">Chen 2014</a>; <a href="./references#CD006023-bbs2-0026" title="ChueCD , TownendJN , MoodyWE , ZehnderD , WallNA , HarperL , et al. Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology2013;24(5):842‐52. [MEDLINE: 23599381] ChueCD , TownendJN , SteedsRP , FerroCJ . Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB‐PHOS randomised controlled trial. Trials [Electronic Resource]2011;12(1):30. [MEDLINE: 21288351] ">CRIB‐PHOS 2011</a>; <a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a>; <a href="./references#CD006023-bbs2-0030" title="DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. A randomized, double‐blind cross‐over design study of sevelamer hydrochloride (SH, Renegel®) and sevelamer carbonate (SC) in chronic kidney disease patients on hemodialysis [abstract no: 48]. American Journal of Kidney Diseases2007;49(4):A36. [CENTRAL: CN‐00671791] DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. Results of a randomized, double‐blind, cross‐over design study of sevelamer hydrochloride (Renagel®) and sevelamer carbonate in chronic kidney disease patients on hemodialysis [abstract no: SaP377]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi361. [CENTRAL: CN‐00671790] DelmezJ , BlockG , RobertsonJ , Chasan‐TaberS , BlairA , DillonM , et al. A randomized, double‐blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clinical Nephrology2007;68(6):386‐91. [MEDLINE: 18184521] ">Delmez 2007</a>; <a href="./references#CD006023-bbs2-0033" title="EvenepoelP , SelgasR , CaputoF , FoggensteinerL , HeafJG , OrtizA , et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2009;24(1):278‐85. [MEDLINE: 18820280] EvenepoelP , SelgasR , DuggalA , KellyA , FanSL . Effects of sevelamer hydrochloride (Renagel®) and calcium acetate on controlling serum phosphorus in peritoneal dialysis patients [abstract no: MP580]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv496. [CENTRAL: CN‐00671825] EvenepoelP , SelgasR , DuggalA , KellyAL , FanSL . Comparative effects of sevelamer hydrochloride (Renagel®) and calcium acetate on markers of mineral metabolism in peritoneal dialysis patients [abstract no: TH‐PO778]. Journal of the American Society of Nephrology2006;17(Abstracts):272A. [CENTRAL: CN‐00671824] ">Evenepoel 2009</a>; <a href="./references#CD006023-bbs2-0036" title="FishbaneS , DelmezJ , SukiW , HariacharS , MoeS , HeatonJ . Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open‐label study in chronic kidney disease patients on hemodialysis [abstract no: M621]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. FishbaneS , DelmezJ , SukiWN , HariacharS , MoeS . A randomized, parallel, open‐label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):936A. [CENTRAL: CN‐00747271] FishbaneS , DelmezJ , SukiWN , HariacharSK , HeatonJ , Chasan‐TaberS , et al. A randomized, parallel, open‐label study to compare once‐daily sevelamer carbonate powder dosing with thrice‐daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. American Journal of Kidney Diseases2010;55(2):307‐15. [MEDLINE: 20042256] ">Fishbane 2010</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0041" title="GallieniM , CicchettiT , SalvadoriM , SorbaG , StalteriA , TarchiniR , et al. Comparison of sevelamer HCL and calcium carbonate in the treatment of hyperphosphatemia in dialysis patients: a randomized clinical trial ‐ Calcium Carbonate Sevelamer Evaluation (CaCSE) study [abstract]. Journal of the American Society of Nephrology2005;16:746A. [CENTRAL: CN‐00583853] ">Gallieni 2005</a>; <a href="./references#CD006023-bbs2-0044" title="GillM , WebsterI , SegarsL . Efficacy and safety of lanthanum carbonate, the novel phosphate binder, in Chinese patients with chronic kidney disease [abstract]. Nephrology Nursing Journal2004;31(2):141. HutchisonA , Lanthanum Study Group. Analysis of haematology data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract no: SP219]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v92‐3. HutchisonA , Lanthanum Study Group. No adverse effects of haematological parameters during lanthanum carbonate treatment in over 2000 patients [abstract no: W‐PO40068]. Nephrology2005;10(Suppl):A297. HutchisonA , SPD405‐301 Lanthanum Study Group. Long‐term safety, efficacy, and tolerability of lanthanum carbonate: results from a 3.5‐year study [abstract no: W‐PO40065]. Nephrology2005;10(Suppl 1):A297. HutchisonA , WebsterI . Lanthanum carbonate versus calcium carbonate: effect on parathyroid hormone (PTH) levels [abstract no: F‐PO656]. Journal of the American Society of Nephrology2003;14(Nov):205A. HutchisonA , WebsterI . Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenal®) during long‐term therapy in hemodialysis patients. [abstract no: SU‐PO1039]. Journal of the American Society of Nephrology2003;14(Nov):764A. HutchisonA , WebsterI . Safety and efficacy data for lanthanum carbonate: a summary from three studies [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:107. HutchisonA , WebsterI , GillM , SchmiederR . Safety and tolerability of lanthanum carbonate in haemodialysis patients: a 12‐month study [abstract no: W431]. Nephrology Dialysis Transplantation2003;18(Suppl 4):684. HutchisonA , Lanthanum Study Group. No evidence of hepatoxicity with lanthanum carbonate ‐ clinical trial data from 2000 dialysis patients [abstract no: W‐PO40069]. Nephrology2005;10(Suppl):A298. HutchisonAJ . Lanthanum carbonate (FosrenolTM), a novel, nonaluminum, noncalcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract no: PS1‐22]. Nephrology2003;8(Suppl 1):A29. HutchisonAJ , GillM . A demographic analysis of lanthanum carbonate phase II and III studies [abstract no: 271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106‐7. [CENTRAL: CN‐00509244] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6‐month, randomized, comparative trial versus calcium carbonate. Nephron2005;100(1):c8‐19. [MEDLINE: 15809508] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Long‐term efficacy and tolerability of lanthanum carbonate: results from a 3‐year study. Nephron2006;102(2):c61‐71. [MEDLINE: 16224198] HutchisonAJ , Lanthanum Study Group. The novel, non‐aluminium, non‐calcium phosphate binder, fosrenol, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract no: SA‐PO599]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):385A‐6A. [CENTRAL: CN‐00445823] SpeakeM , HutchisonAJ , WebsterI . Lanthanum carbonate, a novel, non‐aluminum, non‐calcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract]. Nephrology Nursing Journal2003;30(2):149. [CENTRAL: CN‐00644297] SpeakeM , WebsterI . Long‐term safety, tolerability, and efficacy of lanthanum carbonate therapy [abstract]. Nephrology Nursing Journal2004;31(2):143. [CENTRAL: CN‐00644295] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WebsterI , GillM . Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients [abstract no: SP267]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105. [CENTRAL: CN‐00509557] ">Hutchison 2005</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0046" title="BellasiA , CozzolinoM , RussoD , MolonyD , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology2016;86(9):113‐24. [MEDLINE: 27443567] BellasiA , CozzolinoM , RussoD , MolonyDA , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii588. [EMBASE: 72207961] DiIorioB . In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'. American Journal of Kidney Diseases2014;63(1):164‐5. [MEDLINE: 24377649] DiIorioB , MolonyD , BellC , CuccinielloE , BellizziV , RussoD , et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. American Journal of Kidney Diseases2013;62(4):771‐8. [MEDLINE: 23684755] DiIorioBR , CuccinielloE , BellizziV . Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan‐Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar‐Apr;26(2):419]. Journal of Nephrology2009;22(6):694‐8. [MEDLINE: 19967647] MolonyD , BellasiA , BellizziV , RussoD , DiIorioB . Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii54. [EMBASE: 70765453] ObiY , HamanoT . The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. American Journal of Kidney Diseases2014;63(1):164. [MEDLINE: 24377650] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593‐602; PMID: 25027030]. Journal of Nephrology2014;27(6):717. [MEDLINE: 25098354] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]. Journal of Nephrology2015;28(5):593‐602. [MEDLINE: 25027030] ">INDEPENDENT‐HD 2009</a>; <a href="./references#CD006023-bbs2-0047" title="IsakovaT , Barchi‐ChungA , EnfieldG , SmithK , VargasG , HoustonJ , et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD. Clinical Journal of The American Society of Nephrology: CJASN2013;8(6):1009‐18. [MEDLINE: 23471131] IsakovaT , Barchi‐ChungA , EnfieldG , SmithKT , VargasGS , HoustonJ , et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR‐OR068]. Journal of the American Society of Nephrology2012;23:45A. ">Isakova 2013</a>; <a href="./references#CD006023-bbs2-0049" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients. Nephrology Dialysis Transplantation1995;10(12):2321‐4. [MEDLINE: 8808233] ">Janssen 1995</a>; <a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>; <a href="./references#CD006023-bbs2-0053" title="KasaiS , SatoK , MurataY , KinoshitaY . Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(4):341‐9. [EMBASE: 2012432570] ">Kasai 2012</a>; <a href="./references#CD006023-bbs2-0054" title="KatopodisKP , AndrikosEK , GouvaCD , BairaktariET , NikolopoulosPM , TakouliLK , et al. Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients. Peritoneal Dialysis International2006;26(3):320‐7. [MEDLINE: 16722024] ">Katopodis 2006</a>; <a href="./references#CD006023-bbs2-0055" title="KoYS , RyuJW , LeeJH , YiJH , HanSW , KimHJ . Efficacy of lanthanum carbonate and calcium carbonate in Korean dialysis patients. Korean Journal of Nephrology2010;29(1):64‐72. [CENTRAL: CN‐01045527] ">Ko 2010</a>; <a href="./references#CD006023-bbs2-0056" title="KoiwaF , YokoyamaK , FukagawaM , TeraoA , AkizawaT . Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrology2017;22(4):293‐300. [MEDLINE: 27496336] ">Koiwa 2017</a>; <a href="./references#CD006023-bbs2-0057" title="LeeYK , ChoiHY , ShinSK , LeeHY . Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clinical Nephrology2013;79(2):136‐42. [MEDLINE: 23211335] ">Lee 2013</a>; <a href="./references#CD006023-bbs2-0058" title="LeeCT , WuIW , ChiangSS , PengYS , ShuKH , WuMJ , et al. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double‐blind, placebo‐controlled study. Journal of Nephrology2015;28(1):105‐13. [EMBASE: 2015735302] ">Lee 2015b</a>; <a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a>; <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0061" title="LinYF , ChenYM , HungKY , ChuTS , KanWC , HuangCY , et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. Journal of the Formosan Medical Association2010;109(9):663‐72. [MEDLINE: 20863994] LinYF , ChienCT , KanWC , ChenYM , ChuTS , HungKY , et al. Pleiotropic effects of sevelamer beyond phosphate binding in end‐stage renal disease patients: a randomized, open‐label, parallel‐group study. Clinical Drug Investigation2011;31(4):257‐67. [MEDLINE: 21299254] ">Lin 2010</a>; <a href="./references#CD006023-bbs2-0062" title="LinHH , LiouHH , WuMS , HuangCC . Factors associated with serum fetuin‐A concentrations after long‐term use of different phosphate binders in hemodialysis patients. BMC Nephrology2016;17:33. [MEDLINE: 27007989] LinHH , LiouHH , WuMS , LinCY , HuangCC . Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology2014;19(11):672‐8. [MEDLINE: 25113414] ">Lin 2014a</a>; <a href="./references#CD006023-bbs2-0063" title="HuangC , YuC , LiuY . Effect of sevelamer on homocysteinemia and lipid profile in patients undergoing maintenance hemodialysis ‐ a randomized clinical trial [abstract no: F‐PO610]. Journal of the American Society of Nephrology2005;16:467A. [CENTRAL: CN‐00756400] LiuYL , LinHH , YuCC , KuoHL , YangYF , ChouCY , et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Renal Failure2006;28(8):701‐7. [MEDLINE: 17162430] ">Liu 2006</a>; <a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>; <a href="./references#CD006023-bbs2-0065" title="LocatelliF , SpasovskiG , DimkovicN , WannerC , DellannaF , PontorieroG . The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1‐year prospective randomized study. Nephrology Dialysis Transplantation2014;29(5):1061‐73. [MEDLINE: 24302608] ">Locatelli 2014</a>; <a href="./references#CD006023-bbs2-0066" title="MatsushimaH , YasudaT , OyamaA , MiyataM . Efficacy and safety of iron‐based phosphate binders, ferric citrate hydrate versus sucroferric oxyhydroxide, on hyperphosphatemia in chronic hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii679. [EMBASE: 617290946] ">Matsushima 2017</a>; <a href="./references#CD006023-bbs2-0068" title="NCT00542815 . A study of MCI‐196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia. ClinicalTrials.gov/show/NCT00542815 (first received 12 October 2007). ">NCT00542815</a>; <a href="./references#CD006023-bbs2-0069" title="LengletA , LiabeufS , ElEsperN , BrissetS , MansourJ , Lemaire‐HurtelAS , et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation2017;32(5):870‐9. [MEDLINE: 24599830] ">NICOREN 2017</a>; <a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a>; <a href="./references#CD006023-bbs2-0071" title="PrattR , SmythM . Effective reduction of serum phosphorus using carbonate, with fewer tablets than sevelamer hydrochloride [abstract no: FP486]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi183. ">Pratt 2007</a>; <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a>; <a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0078" title="SadekT , MazouzH , BahlouH , OprisiuR , ElEsperN , ElEsperI , et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open‐label, randomized study. Nephrology Dialysis Transplantation2003;18(3):582‐9. [MEDLINE: 12584283] ">Sadek 2003</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0081" title="SezerS , KarakanS , AcarNO . Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]. NDT Plus2010;3(Suppl 3):iii196. [EMBASE: 70483939] ">Sezer 2010</a>; <a href="./references#CD006023-bbs2-0082" title="ShahbazianH , ZafarMA , GhorbaniA , AbbaspourMR , Belladi MusaviSS , HayatiF , et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double‐blind randomized clinical trial. Nefrologia2011;31(1):58‐65. [MEDLINE: 21270914] ">Shahbazian 2011</a>; <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a>; <a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a>; <a href="./references#CD006023-bbs2-0089" title="SikoleA , SpasovskiG , GelevS , AmitovV , StojcevN , GrozdanovskiR . Lanthanum carbonate ‐ a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v95‐6. SikoleA , SpasovskiG , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]. Nephrology Dialysis Transplantation2002;17(Suppl 12):67. [CENTRAL: CN‐00509481] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients ‐ single center experience [abstract no: w436]. Nephrology Dialysis Transplantation2003;18(Suppl 4):685‐6. [CENTRAL: CN‐00447817] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]. International Journal of Artificial Organs2003;26(7):630. [CENTRAL: CN‐00583691] SpasovskiG , SikoleA , GelevS , MasinJ , FreemontT , WebsterI , et al. The evolution of renal bone disease in dialysis patients ‐ comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105‐6. [CENTRAL: CN‐00509488] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , GrozdanovskiR , et al. Comparative, bone biopsy‐based, 3 years follow‐up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]. Nephrology Dialysis Transplantation2005;20(6 Suppl):v376. [CENTRAL: CN‐00583693] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , PolenakovicB , WebsterI , et al. The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA‐PO842]. Journal of the American Society of Nephrology2005;16(Oct):741A. [CENTRAL: CN‐00583697] SpasovskiGB , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]. Hemodialysis International2003;7(1):87. [CENTRAL: CN‐00461778] SpasovskiGB , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , WebsterI , et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow‐up. Nephrology Dialysis Transplantation2006;21(8):2217‐24. [MEDLINE: 16595583] ">Spasovski 2006</a>; <a href="./references#CD006023-bbs2-0091" title="SpragueS , FinnW , AbboudH , QiuP , SPD405‐206 Study Investigators. Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00757113] SpragueSM , AbboudH , QuiP , DauphinM , ZhangP , FinnW . Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):178‐85. [MEDLINE: 19056618] SpragueSM , FinnWF , QiuP , Study 206 Investigators. Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi‐center trial [abstract no: PUB442]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):927A. [CENTRAL: CN‐00756891] ">Sprague 2009a</a>; <a href="./references#CD006023-bbs2-0092" title="TakaharaY , MatsudaY , TakahashiS , ShigematsuT , Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre‐dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical Nephrology2014;82(3):181‐90. [MEDLINE: 25079863] ">Takahara 2014</a>; <a href="./references#CD006023-bbs2-0093" title="TielmansC , KnoopC , DoutrelepontJM , TimmermansD , Even‐AdinD , VanherweghemJL . Superiority of calcium acetate (ACET) over carbonate (CARB) to bind phosphorus (P) in hemodialysis patients (HDP) [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:219A. ">Tielmans 1990</a>; <a href="./references#CD006023-bbs2-0094" title="ToidaT , FukudomeK , FujimotoS , YamadaK , SatoY , ChiyotandaS , et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clinical Nephrology2012;78(3):216‐23. [MEDLINE: 22874110] ">Toida 2012</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>; <a href="./references#CD006023-bbs2-0097" title="VlassaraH , UribarriJ , CaiW , GoodmanS , PyzikR , PostJ , et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2012;7(6):934‐42. [MEDLINE: 22461535] Yubero‐SerranoEM , WoodwardM , PoretskyL , VlassaraH , StrikerGE . Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro‐oxidant status in patients with diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2015;10(5):759‐66. [MEDLINE: 25710801] ">Vlassara 2012</a>; <a href="./references#CD006023-bbs2-0098" title="WadaK , WadaY . Evaluation of aortic calcification with lanthanum carbonate vs. calcium‐based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open‐label randomized controlled trial. Therapeutic Apheresis &amp; Dialysis2014;18(4):353‐60. [MEDLINE: 24417760] ">Wada 2014</a>; <a href="./references#CD006023-bbs2-0100" title="YokoyamaK , HirakataH , AkibaT , FukagawaM , NakayamaM , SawadaK , et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis‐dependent CKD. Clinical Journal of The American Society of Nephrology: CJASN2014;9(3):543‐52. [MEDLINE: 24408120] ">Yokoyama 2014</a>; <a href="./references#CD006023-bbs2-0101" title="YokoyamaK , AkibaT , FukagawaM , NakayamaM , SawadaK , KumagaiY , et al. A randomized trial of JTT‐751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology Dialysis Transplantation2014;29(5):1053‐60. [MEDLINE: 24376274] ">Yokoyama 2014a</a>; <a href="./references#CD006023-bbs2-0103" title="ZhaoH , WangJ , ZhaoDM , DongYM , GaoY . Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end‐stage renal disease: a randomized controlled trial. Chinese Journal of Evidence‐Based Medicine2014;14(11):1293‐8. [EMBASE: 2014948885] ">Zhao 2014</a>). The remaining 35 studies did not report patient‐centred outcomes of death or adverse events. </p> </section> <section id="CD006023-sec-0097"> <h4 class="title">Other potential sources of bias</h4> <p>Forty studies appeared to be free from other sources of bias (<a href="./references#CD006023-bbs2-0005" title="AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadministration of nicotinamide and calcium‐based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis. Advances in Natural Science2012;5(1):1‐9. [DOI: 10.3968/j.ans.1715787020120501.1001] AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadminstration of nicotinamide and calcium‐based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]. Value in Health2012;15(4):A152. [EMBASE: 70763798] ElSharkawyMM , KamelM , ElhamamsyM , AllamS . Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i253. [EMBASE: 71075759] ">Allam 2012</a>; <a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a>; <a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0015" title="CaglarK , YilmazMI , SaglamM , CakirE , AcikelC , EyiletenT , et al. Short‐term treatment with sevelamer increases serum fetuin‐a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clinical Journal of the American Society of Nephrology: CJASN2008;3(1):61‐8. [MEDLINE: 18057307] YilmazMI , SonmezA , SaglamM , YamanH , KilicS , EyiletenT , et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. American Journal of Kidney Diseases2012;59(2):177‐85. [MEDLINE: 22137672] ">Caglar 2008</a>; <a href="./references#CD006023-bbs2-0016" title="CovicA , Passlick‐DeetjenJ , KroczakM , Buschges‐SeraphinB , GhenuA , PonceP , et al. A comparison of calcium acetate/magnesium carbonate and sevelamer‐hydrochloride effects on fibroblast growth factor‐23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation2013;28(9):2383‐92. [MEDLINE: 23787550] PaschA , deFranciscoALM , CovicA , MarzellB , ArensHJ , Passlick‐DeetjenJ , et al. Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate/ magnesium carbonate containing phosphate binder [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii40. [EMBASE: 71491561] deFranciscoAL , LeidigM , CovicAC , KettelerM , Benedyk‐LorensE , MircescuGM , et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrology Dialysis Transplantation2010;25(11):3707‐17. [MEDLINE: 20530499] ">CALMAG 2010</a>; <a href="./references#CD006023-bbs2-0017" title="CaravacaF , SantosI , CuberoJJ , EsparragoJF , ArrobasM , PizarroJL , et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron1992;60(4):423‐7. [MEDLINE: 1584317] CaravacaF , SantosI , RoblesR , CuberoJ , EsparragoJ , ArrobasM , et al. Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1990;5(8):729. [CENTRAL: CN‐00260555] ">Caravaca 1992</a>; <a href="./references#CD006023-bbs2-0019" title="BudoffMJ , KesslerP , GaoYL , QunibiW , MoustafaM , MaoSS . The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)‐2 study. Academic Radiology2008;15(1):58‐61. [MEDLINE: 18078907] QunibiW , HorwithG , KesslerP , MoustafaM , CARE‐2 Investigators. Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation‐2 (CARE‐2) study [abstract no: PUB386]. Journal of the American Society of Nephrology2005;16(Oct Abstracts Issue):866A. [CENTRAL: CN‐00602064] QunibiW , MoustafaM , KesslerP , BortleyE , MuenzL , BudoffM . Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study [abstract no: FP386]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi148. [CENTRAL: CN‐00691160] QunibiW , MoustafaM , KesslerP , MuenzLR , BudoffM . Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: TH‐PO845]. Journal of the American Society of Nephrology2006;17(Abstracts):286A. [CENTRAL: CN‐00602067] QunibiW , MoustafaM , MuenzLR , HeDY , KesslerPD , Diaz‐BuxoJA , et al. A 1‐year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study. American Journal of Kidney Diseases2008;51(6):952‐65. [MEDLINE: 18423809] QunibiW , MuenzLR , Diaz‐BuxoJA . The CARE‐2 study results: setting the record straight. Nephrology Dialysis Transplantation2008;23(12):4081‐2. [MEDLINE: 18820282] QunibiWY , MoustafaM , KesslerP , BorteyE , MuenzLR , BudoffM . Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: S‐PO‐0376]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:150. QunibiWY , MoustafaM , KesslerP , MuenzLR , Diaz‐BuxoJ , BudoffM , et al. Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation‐2 (CARE‐2) study [abstract no: TH‐FC043]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. ">CARE‐2 2008</a>; <a href="./references#CD006023-bbs2-0024" title="ChertowGM , DillonM , BurkeSK , StegM , BleyerAJ , GarrettBN , et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clinical Nephrology1999;51(1):18‐26. [MEDLINE: 9988142] ">Chertow 1999</a>; <a href="./references#CD006023-bbs2-0025" title='AsmusHG , BraunJ , KrauseR , BrunkhorstR , HolzerH , SchulzW , et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrology Dialysis Transplantation2005;20(8):1653‐61. [MEDLINE: 15930018] BommerJ , AsmusG , BraunJ , BrunkhorstR , HolzerH , KrauseR , et al. Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]. Nephrology Dialysis Transplantation2002;17(Suppl 1):32. [CENTRAL: CN‐00509096] BommerJ , European Renagel Investigators Group. Lipid lowering effect of renagel, a novel phosphate binder [abstract]. Nephrology Dialysis Transplantation2001;16(6):A122. [CENTRAL: CN‐00444477] BraunJ , AsmusHG , HolzerH , BrunkhorstR , KrauseR , SchulzW , et al. Long‐term comparison of a calcium‐free phosphate binder and calcium carbonate‐‐phosphorus metabolism and cardiovascular calcification. Clinical Nephrology2004;62(2):104‐15. [MEDLINE: 15356967] ChertowGM , BurkeSK , RaggiP , Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International2002;62(1):245‐52. [MEDLINE: 12081584] ChertowGM , Chasan‐TaberS , RaggiP . The "tip of the iceberg" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):433a. [CENTRAL: CN‐00444789] ChertowGM , DillonMA , AminN , BommerJ , BurkeSK . Sevelamer is more effective at controlling disorders of mineral metabolism than calcium‐based phosphate binders in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):195‐6A. [CENTRAL: CN‐00444790] ChertowGM , GoodmanWG , TotoRD , RaggiP . In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL‐C, APO‐B, and HS‐CRP compared with calcium acetate (PHOSLO) [abstract no: SA‐PO603]. Journal of the American Society of Nephrology2002;13(Sept, Program &amp; Abstracts):386a. [CENTRAL: CN‐00444791] ChertowGM , RaggiP , Chasan‐TaberS , BommerJ , HolzerH , BurkeSK . Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation2004;19(6):1489‐96. [MEDLINE: 15102961] ChertowGM , RaggiP , McCarthyJT , SchulmanG , SilberzweigJ , KuhlikA , et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. American Journal of Nephrology2003;23(5):307‐14. [MEDLINE: 12915774] FerramoscaE , BurkeS , Chasan‐TaberS , RattiC , ChertowGM , RaggiP . Potential antiatherogenic and anti‐inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal2005;149(5):820‐5. [MEDLINE: 15894962] GargJP , Chasan‐TaberS , BlairA , PloneM , BommerJ , RaggiP , et al. Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis &amp; Rheumatism2005;52(1):290‐5. [MEDLINE: 15641045] JamesG , RaggiP , BoulayA , BurkeS , Chasan‐TaberS , ChertowG , et al. Thoracic vertebral bone density increases with renagel and decreases with calcium‐based phosphate binder therapy ‐ a two year study [abstract no: W423]. Nephrology Dialysis Transplantation2003;18(Suppl 4):681. [CENTRAL: CN‐00445894] RaggiP , BommerJ , ChertowGM . Valvular calcification in hemodialysis patients randomized to calcium‐based phosphorus binders or sevelamer. Journal of Heart Valve Disease2004;13(1):134‐41. [MEDLINE: 14765851] RaggiP , BurkeS , Chasen‐TaberS , ChertowG , HolzerH , BommerJ . Sevelamer preserves trabecular bone mineral density [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:103‐4. [CENTRAL: CN‐00509430] RaggiP , BurkeSK , Chasen‐TaberS , ChertowGM , HolzerH , BommerJ . Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA‐PO924]. Journal of the American Society of Nephrology2003;14(Nov):502A. [CENTRAL: CN‐00583411] RaggiP , BurkeSK , DillonMA , AminN , BommerJ , ChertowGM . Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):239A. [CENTRAL: CN‐00447325] RaggiP , JamesG , BurkeSK , BommerS , Chasan‐TaberS , HolzerH , et al. Decrease in thoracic vertebral bone attenuation with calcium‐based phosphate binders in hemodialysis. Journal of Bone &amp; Mineral Research2005;20(5):764‐72. [MEDLINE: 15824849] '>Chertow 2002</a>; <a href="./references#CD006023-bbs2-0026" title="ChueCD , TownendJN , MoodyWE , ZehnderD , WallNA , HarperL , et al. Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology2013;24(5):842‐52. [MEDLINE: 23599381] ChueCD , TownendJN , SteedsRP , FerroCJ . Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB‐PHOS randomised controlled trial. Trials [Electronic Resource]2011;12(1):30. [MEDLINE: 21288351] ">CRIB‐PHOS 2011</a>; <a href="./references#CD006023-bbs2-0032" title="DeuberH . Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract no: W422]. Nephrology Dialysis Transplantation2003;18(Suppl 4):680‐1. [CENTRAL: CN‐00445085] DeuberHJ . Combined use of calcium acetate and magnesium carbonate as phosphate binder [Kombinierter einsatz von kalziumazetat und magnesiumkarbonat als orale phosphatbinder]. Nieren und Hochdruckkrankheiten2004;33(8):403‐8. [EMBASE: 39150178] ">Deuber 2004</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0044" title="GillM , WebsterI , SegarsL . Efficacy and safety of lanthanum carbonate, the novel phosphate binder, in Chinese patients with chronic kidney disease [abstract]. Nephrology Nursing Journal2004;31(2):141. HutchisonA , Lanthanum Study Group. Analysis of haematology data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract no: SP219]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v92‐3. HutchisonA , Lanthanum Study Group. No adverse effects of haematological parameters during lanthanum carbonate treatment in over 2000 patients [abstract no: W‐PO40068]. Nephrology2005;10(Suppl):A297. HutchisonA , SPD405‐301 Lanthanum Study Group. Long‐term safety, efficacy, and tolerability of lanthanum carbonate: results from a 3.5‐year study [abstract no: W‐PO40065]. Nephrology2005;10(Suppl 1):A297. HutchisonA , WebsterI . Lanthanum carbonate versus calcium carbonate: effect on parathyroid hormone (PTH) levels [abstract no: F‐PO656]. Journal of the American Society of Nephrology2003;14(Nov):205A. HutchisonA , WebsterI . Maintained safety, tolerability and efficacy of lanthanum carbonate (Fosrenal®) during long‐term therapy in hemodialysis patients. [abstract no: SU‐PO1039]. Journal of the American Society of Nephrology2003;14(Nov):764A. HutchisonA , WebsterI . Safety and efficacy data for lanthanum carbonate: a summary from three studies [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:107. HutchisonA , WebsterI , GillM , SchmiederR . Safety and tolerability of lanthanum carbonate in haemodialysis patients: a 12‐month study [abstract no: W431]. Nephrology Dialysis Transplantation2003;18(Suppl 4):684. HutchisonA , Lanthanum Study Group. No evidence of hepatoxicity with lanthanum carbonate ‐ clinical trial data from 2000 dialysis patients [abstract no: W‐PO40069]. Nephrology2005;10(Suppl):A298. HutchisonAJ . Lanthanum carbonate (FosrenolTM), a novel, nonaluminum, noncalcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract no: PS1‐22]. Nephrology2003;8(Suppl 1):A29. HutchisonAJ , GillM . A demographic analysis of lanthanum carbonate phase II and III studies [abstract no: 271]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106‐7. [CENTRAL: CN‐00509244] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: A 6‐month, randomized, comparative trial versus calcium carbonate. Nephron2005;100(1):c8‐19. [MEDLINE: 15809508] HutchisonAJ , MaesB , VanwalleghemJ , AsmusG , MohamedE , SchmiederR , et al. Long‐term efficacy and tolerability of lanthanum carbonate: results from a 3‐year study. Nephron2006;102(2):c61‐71. [MEDLINE: 16224198] HutchisonAJ , Lanthanum Study Group. The novel, non‐aluminium, non‐calcium phosphate binder, fosrenol, is an effective treatment for hyperphosphataemia and has a good safety profile [abstract no: SA‐PO599]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):385A‐6A. [CENTRAL: CN‐00445823] SpeakeM , HutchisonAJ , WebsterI . Lanthanum carbonate, a novel, non‐aluminum, non‐calcium phosphate binder, is effective and well tolerated in hyperphosphatemia [abstract]. Nephrology Nursing Journal2003;30(2):149. [CENTRAL: CN‐00644297] SpeakeM , WebsterI . Long‐term safety, tolerability, and efficacy of lanthanum carbonate therapy [abstract]. Nephrology Nursing Journal2004;31(2):143. [CENTRAL: CN‐00644295] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WebsterI , GillM . Lanthanum carbonate, a new phosphate binder, is well tolerated over a 3 year period in dialysis patients [abstract no: SP267]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105. [CENTRAL: CN‐00509557] ">Hutchison 2005</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0046" title="BellasiA , CozzolinoM , RussoD , MolonyD , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology2016;86(9):113‐24. [MEDLINE: 27443567] BellasiA , CozzolinoM , RussoD , MolonyDA , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii588. [EMBASE: 72207961] DiIorioB . In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'. American Journal of Kidney Diseases2014;63(1):164‐5. [MEDLINE: 24377649] DiIorioB , MolonyD , BellC , CuccinielloE , BellizziV , RussoD , et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. American Journal of Kidney Diseases2013;62(4):771‐8. [MEDLINE: 23684755] DiIorioBR , CuccinielloE , BellizziV . Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan‐Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar‐Apr;26(2):419]. Journal of Nephrology2009;22(6):694‐8. [MEDLINE: 19967647] MolonyD , BellasiA , BellizziV , RussoD , DiIorioB . Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii54. [EMBASE: 70765453] ObiY , HamanoT . The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. American Journal of Kidney Diseases2014;63(1):164. [MEDLINE: 24377650] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593‐602; PMID: 25027030]. Journal of Nephrology2014;27(6):717. [MEDLINE: 25098354] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]. Journal of Nephrology2015;28(5):593‐602. [MEDLINE: 25027030] ">INDEPENDENT‐HD 2009</a>; <a href="./references#CD006023-bbs2-0047" title="IsakovaT , Barchi‐ChungA , EnfieldG , SmithK , VargasG , HoustonJ , et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD. Clinical Journal of The American Society of Nephrology: CJASN2013;8(6):1009‐18. [MEDLINE: 23471131] IsakovaT , Barchi‐ChungA , EnfieldG , SmithKT , VargasGS , HoustonJ , et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR‐OR068]. Journal of the American Society of Nephrology2012;23:45A. ">Isakova 2013</a>; <a href="./references#CD006023-bbs2-0048" title="ItohK , TanakaM , HashiguchiJ , FunakoshiS , NakanoH , KuboH , et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp; Dialysis2008;12(2):126‐32. [MEDLINE: 18387160] ">Itoh 2008</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>; <a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a>; <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0061" title="LinYF , ChenYM , HungKY , ChuTS , KanWC , HuangCY , et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. Journal of the Formosan Medical Association2010;109(9):663‐72. [MEDLINE: 20863994] LinYF , ChienCT , KanWC , ChenYM , ChuTS , HungKY , et al. Pleiotropic effects of sevelamer beyond phosphate binding in end‐stage renal disease patients: a randomized, open‐label, parallel‐group study. Clinical Drug Investigation2011;31(4):257‐67. [MEDLINE: 21299254] ">Lin 2010</a>; <a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>; <a href="./references#CD006023-bbs2-0065" title="LocatelliF , SpasovskiG , DimkovicN , WannerC , DellannaF , PontorieroG . The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1‐year prospective randomized study. Nephrology Dialysis Transplantation2014;29(5):1061‐73. [MEDLINE: 24302608] ">Locatelli 2014</a>; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>; <a href="./references#CD006023-bbs2-0080" title="SeifertME , delas FuentesL , Davila‐RomanVG , HruskaKA . Early intervention in the CKD‐MDB affects vascular function [abstract no: LB‐PO3163]. Journal of the American Society of Nephrology2011;22(Abstracts):7B. SeifertME , delas FuentesL , RothsteinM , DietzenDJ , BierhalsAJ , ChengSC , et al. Effects of phosphate binder therapy on vascular stiffness in early‐stage chronic kidney disease. American Journal of Nephrology2013;38(2):158‐67. [MEDLINE: 23941761] ">Seifert 2013</a>; <a href="./references#CD006023-bbs2-0082" title="ShahbazianH , ZafarMA , GhorbaniA , AbbaspourMR , Belladi MusaviSS , HayatiF , et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double‐blind randomized clinical trial. Nefrologia2011;31(1):58‐65. [MEDLINE: 21270914] ">Shahbazian 2011</a>; <a href="./references#CD006023-bbs2-0087" title="SongFR , ChengH , ZhaoDM , YuJ , GaoY . Effects of lanthanum carbonate on serum calcium and phosphorus of CAPD patients with chronic renal failure receiving calcitriol pulse therapy due to secondary hyperparathyroidism. Chinese Journal of Evidence‐Based Medicine2014;14(6):651‐4. [EMBASE: 2014574871] ">Song 2014</a>; <a href="./references#CD006023-bbs2-0088" title="SorianoS , OjedaR , RodriguezM , AlmadenY , RodriguezM , Martin‐MaloA , et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clinical Nephrology2013;80(1):17‐22. [MEDLINE: 23391319] ">Soriano 2013</a>; <a href="./references#CD006023-bbs2-0090" title="SpiegelDM , FarmerB . Long‐term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodialysis International2009;13(4):453‐9. [MEDLINE: 19469885] SpiegelDM , FarmerB , ChoncholM . Magnesium carbonate ‐ an effective phosphate binder [abstract no: 152]. American Journal of Kidney Diseases2006;47(4):A56. [CENTRAL: CN‐00653706] SpiegelDM , FarmerB , SmitsG , ChoncholM . Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition2007;17(6):416‐22. [MEDLINE: 17971314] ">Spiegel 2007</a>; <a href="./references#CD006023-bbs2-0094" title="ToidaT , FukudomeK , FujimotoS , YamadaK , SatoY , ChiyotandaS , et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clinical Nephrology2012;78(3):216‐23. [MEDLINE: 22874110] ">Toida 2012</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>; <a href="./references#CD006023-bbs2-0097" title="VlassaraH , UribarriJ , CaiW , GoodmanS , PyzikR , PostJ , et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2012;7(6):934‐42. [MEDLINE: 22461535] Yubero‐SerranoEM , WoodwardM , PoretskyL , VlassaraH , StrikerGE . Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro‐oxidant status in patients with diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2015;10(5):759‐66. [MEDLINE: 25710801] ">Vlassara 2012</a>; <a href="./references#CD006023-bbs2-0098" title="WadaK , WadaY . Evaluation of aortic calcification with lanthanum carbonate vs. calcium‐based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open‐label randomized controlled trial. Therapeutic Apheresis &amp; Dialysis2014;18(4):353‐60. [MEDLINE: 24417760] ">Wada 2014</a>; <a href="./references#CD006023-bbs2-0099" title="WangXH , ZhangX , MuCJ , HeY , PengQP , YangGS , et al. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients. Journal of Huazhong University of Science and Technology. Medical Sciences2015;35(4):508‐13. [MEDLINE: 26223918] ">Wang 2015b</a>; <a href="./references#CD006023-bbs2-0101" title="YokoyamaK , AkibaT , FukagawaM , NakayamaM , SawadaK , KumagaiY , et al. A randomized trial of JTT‐751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology Dialysis Transplantation2014;29(5):1053‐60. [MEDLINE: 24376274] ">Yokoyama 2014a</a>; <a href="./references#CD006023-bbs2-0103" title="ZhaoH , WangJ , ZhaoDM , DongYM , GaoY . Efficacy of sevelamer carbonate for hyperphosphatemia in patients with end‐stage renal disease: a randomized controlled trial. Chinese Journal of Evidence‐Based Medicine2014;14(11):1293‐8. [EMBASE: 2014948885] ">Zhao 2014</a>). Forty‐three studies had other sources of bias (<a href="./references#CD006023-bbs2-0001" title="AhmedW , Rizwan‐Ul‐HagAM , KhanS , HaiderS , Abad‐Ur‐Reham . Comparative efficacy of sevelamer hydrochloride versus calcium acetate on bone biomarkers in patients with end stage renal disease on hemodialysis. Pakistan Journal of Medical &amp; Health Sciences2014;8(3):769‐71. [EMBASE: 600071132] ">Ahmed 2014</a>; <a href="./references#CD006023-bbs2-0003" title="AkizawaT , OrigasaH , KameokaC , KanekoY , KawasakiS , Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Therapeutic Apheresis &amp; Dialysis2014;18(2):122‐31. [MEDLINE: 24720402] ">Akizawa 2014a</a>; <a href="./references#CD006023-bbs2-0004" title="AkizawaT , OrigasaH , KameokaC , TsukadaJ , KuroishiK , YamaguchiY . Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Therapeutic Apheresis &amp; Dialysis2016;20(6):588‐97. [MEDLINE: 27896908] ">Akizawa 2016</a>; <a href="./references#CD006023-bbs2-0006" title="AlmirallJ , VecianaL , LlibreJ . Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):976. [CENTRAL: CN‐00260851] AlmirallJ , VecianaL , LlibreJ . Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. American Journal of Nephrology1994;14(3):192‐6. [MEDLINE: 7977479] ">Almirall 1994</a>; <a href="./references#CD006023-bbs2-0007" title="AramwitP , SrisawadwongR , SupasyndhO . Effectiveness and safety of extended‐release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Journal of Nephrology2012;25(3):354‐62. [MEDLINE: 21748722] ">Aramwit 2012</a>; <a href="./references#CD006023-bbs2-0008" title="BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross‐over study. Nephrology Dialysis Transplantation1999;14(6):1475‐9. [MEDLINE: 10383011] BirckR , ZimmermannE , WassmerS , NowackR , van derWoudeFJ . Calcium‐ketoglutarate vs. calcium‐acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):552A. [CENTRAL: CN‐00444439] ">Birck 1999</a>; <a href="./references#CD006023-bbs2-0009" title="BleyerAJ , BurkeSK , DillonM , GarrettB , KantKS , LynchD , et al. A comparison of the calcium‐free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases1999;33(4):694‐701. [MEDLINE: 10196011] BleyerAJ , GarrettB , KantKS , LynchD , RahmanN , SchoenfeldP , et al. An open label, cross‐over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):548a. [CENTRAL: CN‐00444452] ">Bleyer 1999</a>; <a href="./references#CD006023-bbs2-0014" title="BroS , RasmussenRA , HandbergJ , OlgaardK , Feld‐RasmussenB . Randomized crossover study comparing the phosphate‐binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. American Journal of Kidney Diseases1998;31(2):257‐62. [MEDLINE: 9469496] ">Bro 1998</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0020" title="ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: a 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology2011;16(8):743‐50. [MEDLINE: 21854503] ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08‐08]. Nephrology2010;15(Suppl 3):51. [EMBASE: 70467427] ChenJB , ChiangSS , HenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]. NDT Plus2010;3(Suppl 3):iii238. [EMBASE: 70484048] ">Chen 2011b</a>; <a href="./references#CD006023-bbs2-0021" title="ChenN , WuX , DingX , MeiC , FuP , JiangG , et al. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double‐blind, placebo‐controlled, dose‐titration study. Nephrology Dialysis Transplantation2014;29(1):152‐60. [MEDLINE: 24151017] ">Chen 2014</a>; <a href="./references#CD006023-bbs2-0022" title="ChengSC , YoungDO , DelmezJA , CoyneDW . The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]. Journal of the American Society of Nephrology2007;18(Abstracts):924A. ChengSC , YoungDO , HuangY , DelmezJA , CoyneDW . A randomized, double‐blind, placebo‐controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):1131‐8. [MEDLINE: 18385391] ">Cheng 2008</a>; <a href="./references#CD006023-bbs2-0023" title="ChennasamudramSP , NoorT , VasylyevaTL . Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis. Journal of Renal Care2013;39(2):82‐9. [MEDLINE: 23574727] ">Chennasamudram 2013</a>; <a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a>; <a href="./references#CD006023-bbs2-0029" title="DelmezJA , KelberJ , NorwoodKY , GilesKS , SlatopolskyE . The clinical evaluation of magnesium carbonate (MgCo3) as a phosphorous (P) binder in the suppression of secondary hyperparathyroidism [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:416. DelmezJA , KelberJ , NorwordKY , GilesKS , SlatopolskyE . Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney International1996;49(1):163‐7. [MEDLINE: 8770963] ">Delmez 1996</a>; <a href="./references#CD006023-bbs2-0030" title="DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. A randomized, double‐blind cross‐over design study of sevelamer hydrochloride (SH, Renegel®) and sevelamer carbonate (SC) in chronic kidney disease patients on hemodialysis [abstract no: 48]. American Journal of Kidney Diseases2007;49(4):A36. [CENTRAL: CN‐00671791] DelmezJ , BlockG , BleyerA , RobertsonJ , Chasan‐TaberS , DillonM , et al. Results of a randomized, double‐blind, cross‐over design study of sevelamer hydrochloride (Renagel®) and sevelamer carbonate in chronic kidney disease patients on hemodialysis [abstract no: SaP377]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi361. [CENTRAL: CN‐00671790] DelmezJ , BlockG , RobertsonJ , Chasan‐TaberS , BlairA , DillonM , et al. A randomized, double‐blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clinical Nephrology2007;68(6):386‐91. [MEDLINE: 18184521] ">Delmez 2007</a>; <a href="./references#CD006023-bbs2-0031" title="DeSantoNG , FrangiosaA , AnastasioP , MarinoA , CorrealeG , PernaA , et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. Journal of Nephrology2006;19 Suppl 9:S108‐14. [MEDLINE: 16736432] ">De Santo 2006</a>; <a href="./references#CD006023-bbs2-0033" title="EvenepoelP , SelgasR , CaputoF , FoggensteinerL , HeafJG , OrtizA , et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2009;24(1):278‐85. [MEDLINE: 18820280] EvenepoelP , SelgasR , DuggalA , KellyA , FanSL . Effects of sevelamer hydrochloride (Renagel®) and calcium acetate on controlling serum phosphorus in peritoneal dialysis patients [abstract no: MP580]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv496. [CENTRAL: CN‐00671825] EvenepoelP , SelgasR , DuggalA , KellyAL , FanSL . Comparative effects of sevelamer hydrochloride (Renagel®) and calcium acetate on markers of mineral metabolism in peritoneal dialysis patients [abstract no: TH‐PO778]. Journal of the American Society of Nephrology2006;17(Abstracts):272A. [CENTRAL: CN‐00671824] ">Evenepoel 2009</a>; <a href="./references#CD006023-bbs2-0034" title="EvsanaaB , LiuI , AliazardehB , MahdaviS , BajwaG , GulaJ , et al. MgCaCO3 versus CaCO3 in peritoneal dialysis patients‐‐a cross‐over pilot trial. Peritoneal Dialysis International2015;35(1):31‐4. [MEDLINE: 24584605] ">Evsanaa 2015</a>; <a href="./references#CD006023-bbs2-0035" title="FerreiraA , FrazãoJM , Monier‐FaugereMC , GilC , GalvaoJ , OliveiraC , et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. Journal of the American Society of Nephrology2008;19(2):405‐12. [MEDLINE: 18199805] ">Ferreira 2008</a>; <a href="./references#CD006023-bbs2-0036" title="FishbaneS , DelmezJ , SukiW , HariacharS , MoeS , HeatonJ . Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open‐label study in chronic kidney disease patients on hemodialysis [abstract no: M621]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. FishbaneS , DelmezJ , SukiWN , HariacharS , MoeS . A randomized, parallel, open‐label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):936A. [CENTRAL: CN‐00747271] FishbaneS , DelmezJ , SukiWN , HariacharSK , HeatonJ , Chasan‐TaberS , et al. A randomized, parallel, open‐label study to compare once‐daily sevelamer carbonate powder dosing with thrice‐daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. American Journal of Kidney Diseases2010;55(2):307‐15. [MEDLINE: 20042256] ">Fishbane 2010</a>; <a href="./references#CD006023-bbs2-0042" title="GreenbergS , ShapiroW , PoruchJG . Calcium acetate (aa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:472. [CENTRAL: CN‐00509217] GreenbergS , ShapiroW , PorushJG . Calcium acetate (caa) vs calcium carbonate (caco) as a phosphorus (p) binder (b) in CAPD patients (pts) [abstract]. Journal of the American Society of Nephrology1994;5(3):492. ">Greenberg 1994</a>; <a href="./references#CD006023-bbs2-0043" title="HervasJG , PradosD , CerezoS . Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney International ‐ Supplement2003;85:69‐72. [MEDLINE: 12753270] ">Hervas 2003</a>; <a href="./references#CD006023-bbs2-0051" title="JespersenB , JensenJD , NielsenHK , LauridsenIN , AndersenMJ , PoulsenJH , et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1‐84), and bone mineral content in dialysis patients. Nephrology Dialysis Transplantation1991;6(2):98‐104. [MEDLINE: 1857534] ">Jespersen 1991</a>; <a href="./references#CD006023-bbs2-0055" title="KoYS , RyuJW , LeeJH , YiJH , HanSW , KimHJ . Efficacy of lanthanum carbonate and calcium carbonate in Korean dialysis patients. Korean Journal of Nephrology2010;29(1):64‐72. [CENTRAL: CN‐01045527] ">Ko 2010</a>; <a href="./references#CD006023-bbs2-0056" title="KoiwaF , YokoyamaK , FukagawaM , TeraoA , AkizawaT . Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrology2017;22(4):293‐300. [MEDLINE: 27496336] ">Koiwa 2017</a>; <a href="./references#CD006023-bbs2-0062" title="LinHH , LiouHH , WuMS , HuangCC . Factors associated with serum fetuin‐A concentrations after long‐term use of different phosphate binders in hemodialysis patients. BMC Nephrology2016;17:33. [MEDLINE: 27007989] LinHH , LiouHH , WuMS , LinCY , HuangCC . Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology2014;19(11):672‐8. [MEDLINE: 25113414] ">Lin 2014a</a>; <a href="./references#CD006023-bbs2-0063" title="HuangC , YuC , LiuY . Effect of sevelamer on homocysteinemia and lipid profile in patients undergoing maintenance hemodialysis ‐ a randomized clinical trial [abstract no: F‐PO610]. Journal of the American Society of Nephrology2005;16:467A. [CENTRAL: CN‐00756400] LiuYL , LinHH , YuCC , KuoHL , YangYF , ChouCY , et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Renal Failure2006;28(8):701‐7. [MEDLINE: 17162430] ">Liu 2006</a>; <a href="./references#CD006023-bbs2-0067" title="Navarro‐GonzalezJF , Mora‐FernandezC , Muros de FuentesM , Donate‐CorreaJ , Cazana‐PerezV , Garcia‐PerezJ . Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2011;6(9):2272‐9. [MEDLINE: 21784820] ">Navarro‐Gonzalez 2011</a>; <a href="./references#CD006023-bbs2-0069" title="LengletA , LiabeufS , ElEsperN , BrissetS , MansourJ , Lemaire‐HurtelAS , et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation2017;32(5):870‐9. [MEDLINE: 24599830] ">NICOREN 2017</a>; <a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a>; <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a>; <a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a>; <a href="./references#CD006023-bbs2-0075" title="RoxeDM , MistovichM , BarchDH . Phosphate‐binding effects of sucralfate in patients with chronic renal failure. American Journal of Kidney Diseases1989;13(3):194‐9. [MEDLINE: 2919600] ">Roxe 1989</a>; <a href="./references#CD006023-bbs2-0076" title="RudnickiM , HyldstrupL , PetersenLJ , HojstedJ , TranbolI . Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double‐blind placebo‐controlled study. Mineral &amp; Electrolyte Metabolism1994;20(3):130‐4. [MEDLINE: 7816001] ">Rudnicki 1994</a>; <a href="./references#CD006023-bbs2-0078" title="SadekT , MazouzH , BahlouH , OprisiuR , ElEsperN , ElEsperI , et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open‐label, randomized study. Nephrology Dialysis Transplantation2003;18(3):582‐9. [MEDLINE: 12584283] ">Sadek 2003</a>; <a href="./references#CD006023-bbs2-0083" title="ShaheenA , AkeelNM , BadawiLS , SouqiyyehMZ . Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Medical Journal2004;25(6):785‐91. [MEDLINE: 15195212] ">Shaheen 2004</a>; <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a>; <a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a>; <a href="./references#CD006023-bbs2-0089" title="SikoleA , SpasovskiG , GelevS , AmitovV , StojcevN , GrozdanovskiR . Lanthanum carbonate ‐ a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v95‐6. SikoleA , SpasovskiG , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]. Nephrology Dialysis Transplantation2002;17(Suppl 12):67. [CENTRAL: CN‐00509481] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients ‐ single center experience [abstract no: w436]. Nephrology Dialysis Transplantation2003;18(Suppl 4):685‐6. [CENTRAL: CN‐00447817] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]. International Journal of Artificial Organs2003;26(7):630. [CENTRAL: CN‐00583691] SpasovskiG , SikoleA , GelevS , MasinJ , FreemontT , WebsterI , et al. The evolution of renal bone disease in dialysis patients ‐ comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105‐6. [CENTRAL: CN‐00509488] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , GrozdanovskiR , et al. Comparative, bone biopsy‐based, 3 years follow‐up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]. Nephrology Dialysis Transplantation2005;20(6 Suppl):v376. [CENTRAL: CN‐00583693] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , PolenakovicB , WebsterI , et al. The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA‐PO842]. Journal of the American Society of Nephrology2005;16(Oct):741A. [CENTRAL: CN‐00583697] SpasovskiGB , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]. Hemodialysis International2003;7(1):87. [CENTRAL: CN‐00461778] SpasovskiGB , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , WebsterI , et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow‐up. Nephrology Dialysis Transplantation2006;21(8):2217‐24. [MEDLINE: 16595583] ">Spasovski 2006</a>; <a href="./references#CD006023-bbs2-0091" title="SpragueS , FinnW , AbboudH , QiuP , SPD405‐206 Study Investigators. Lanthanum carbonate reduces phosphate burden in patients with CKD stages 3 and 4: results from a randomized multicenter trial [abstract no: 252]. American Journal of Kidney Diseases2008;51(4):A90. [CENTRAL: CN‐00757113] SpragueSM , AbboudH , QuiP , DauphinM , ZhangP , FinnW . Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):178‐85. [MEDLINE: 19056618] SpragueSM , FinnWF , QiuP , Study 206 Investigators. Hyperphosphatemia in chronic kidney disease stages 3 and 4: findings from a randomized, multi‐center trial [abstract no: PUB442]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):927A. [CENTRAL: CN‐00756891] ">Sprague 2009a</a>; <a href="./references#CD006023-bbs2-0092" title="TakaharaY , MatsudaY , TakahashiS , ShigematsuT , Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre‐dialysis CKD patients with hyperphosphatemia: a randomized trial. Clinical Nephrology2014;82(3):181‐90. [MEDLINE: 25079863] ">Takahara 2014</a>; <a href="./references#CD006023-bbs2-0102" title="YoungDO , ChengSC , DelmezJA , CoyneDW . The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International2009;29(5):562‐7. [MEDLINE: 19776051] ">Young 2009a</a>). It was unclear whether the remaining 21 studies had other sources of bias. </p> </section> </section> <section id="CD006023-sec-0098"> <h3 class="title" id="CD006023-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD006023-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: Sevelamer versus placebo/usual care</a>; <a href="./full#CD006023-tbl-0002"><b>Summary of findings 2</b> Summary of findings: Lanthanum versus placebo/usual care</a>; <a href="./full#CD006023-tbl-0003"><b>Summary of findings 3</b> Summary of findings: Iron versus placebo/usual care</a>; <a href="./full#CD006023-tbl-0004"><b>Summary of findings 4</b> Summary of findings: Calcium versus placebo/usual care</a>; <a href="./full#CD006023-tbl-0005"><b>Summary of findings 5</b> Summary of findings: Sevelamer versus calcium</a>; <a href="./full#CD006023-tbl-0006"><b>Summary of findings 6</b> Summary of findings ‐ Lanthanum versus calcium</a> </p> <section id="CD006023-sec-0099"> <h4 class="title">Sevelamer versus placebo or usual care</h4> <p>The major outcomes for the comparison of sevelamer with placebo or usual care are shown in the <a href="./full#CD006023-tbl-0001">summary of findings Table for the main comparison</a>. Evidence was generally restricted to people with CKD G2 to G5 not requiring dialysis. </p> <p>No study was designed to evaluate death or cardiovascular events. In the three studies comparing sevelamer with placebo or usual care, deaths were reported as reasons for drop‐out from study follow‐up. A single study reported one or more deaths during a median of 10 months (<a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a>). In very low certainty evidence, sevelamer had uncertain effects on death (all causes) (RR 2.16, 95% CI 0.20 to 22.84) (<a href="./references#CD006023-fig-0003" title="">Analysis 1.1</a>). No studies reported whether deaths due to cardiovascular events occurred. Two studies each reported one participant experiencing a myocardial infarction (<a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a>; <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a>), while a third posted zero events on a studies registry web site (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>). Whether sevelamer prevents myocardial infarction is uncertain due to very low certainty evidence (<a href="./references#CD006023-fig-0004" title="">Analysis 1.2</a> RR 1.00, 95% CI 0.11 to 9.35). A single study reported one stroke event in the sevelamer group on www.ClinicalTrials.gov (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>) (<a href="./references#CD006023-fig-0005" title="">Analysis 1.3</a>). One study reported no difference in the number of patients requiring hospitalisation during follow‐up (<a href="./references#CD006023-bbs2-0026" title="ChueCD , TownendJN , MoodyWE , ZehnderD , WallNA , HarperL , et al. Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology2013;24(5):842‐52. [MEDLINE: 23599381] ChueCD , TownendJN , SteedsRP , FerroCJ . Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB‐PHOS randomised controlled trial. Trials [Electronic Resource]2011;12(1):30. [MEDLINE: 21288351] ">CRIB‐PHOS 2011</a>) (<a href="./references#CD006023-fig-0006" title="">Analysis 1.4</a>). </p> <p><a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> reported two fracture events in the control group (<a href="./references#CD006023-fig-0007" title="">Analysis 1.5</a>) and one participant experienced pruritus during follow‐up in the control group (<a href="./references#CD006023-fig-0008" title="">Analysis 1.6</a>). </p> <p>With respect to adverse events, nausea was reported in three studies (370 participants) in a meta‐analysis marked by substantial heterogeneity. In very low certainty evidence, sevelamer had uncertain risks of nausea (<a href="./references#CD006023-fig-0009" title="">Analysis 1.7</a>: RR 1.27, 95% CI 0.07 to 22.42; I<sup>2</sup> = 71%). In low‐ or very‐low certainty evidence, sevelamer had uncertain risks of vomiting (<a href="./references#CD006023-fig-0010" title="">Analysis 1.8</a> (2 studies, 165 participants): RR 2.09, 95% CI 0.26 to 16.57; I<sup>2</sup> = 0%), abdominal pain (<a href="./references#CD006023-fig-0011" title="">Analysis 1.9</a> (3 studies, 370 participants): RR 0.38, 95% CI 0.13 to 1.14; I<sup>2</sup> = 0%), and diarrhoea (<a href="./references#CD006023-fig-0013" title="">Analysis 1.11</a> (2 studies, 1965 participants): RR 2.02, 95% CI 0.13 to 31.62; I<sup>2</sup> = 66%). <a href="./references#CD006023-bbs2-0060" title="LiabeufS , BennisY , RomezinJ , RyckelynckJ , ElEsperN , UrenaP , et al. The impact of sevelamer on gut derived uremic toxins levels: results from a multicenter, double blind, randomized, placebo controlled clinical trial [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii199. [EMBASE: 617290697] LiabeufS , RyckelynckJP , ElEsperN , UrenaP , CombeC , DussolB , et al. Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD. Clinical Journal of The American Society of Nephrology: CJASN2017;12(12):1930‐40. [MEDLINE: 29074818] ">Liabeuf 2017</a> reported no difference in abdominal bloating between the two groups (<a href="./references#CD006023-fig-0014" title="">Analysis 1.12</a>). Compared with placebo or usual care, sevelamer may lead to an increased risk of constipation (<a href="./references#CD006023-fig-0012" title="">Analysis 1.10</a> (4 studies, 430 participants): RR 6.92, 95% CI 2.24 to 21.38; I<sup>2</sup> = 0%; <i>low certainty evidence</i>). </p> <p>Two studies reported ESKD; <a href="./references#CD006023-bbs2-0074" title="RiccioE , SabbatiniM , BruzzeseD , GrumettoL , MarchetielloC , AmiconeM , et al. Plasma p‐cresol lowering effect of sevelamer in non‐dialysis CKD patients: evidence from a randomized controlled trial. Clinical &amp; Experimental Nephrology2018;22(3):529‐38. [MEDLINE: 29159529] ">Riccio 2018</a> reported no events during treatment while <a href="./references#CD006023-bbs2-0059" title="LemosMM , WatanabeR , CarvalhoAB , JancikicAD , SanchesFM , ChristofaloDM , et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clinical Nephrology2013;80(1):1‐8. [MEDLINE: 23442255] ">Lemos 2013</a> reported 12 events (7 in the sevelamer group and 5 in the placebo group). In very low certainty evidence, sevelamer had uncertain effects on the need for renal replacement therapy (<a href="./references#CD006023-fig-0015" title="">Analysis 1.13</a> (2 studies, 139 participants): RR 1.51, 95% CI 0.52 to 4.36; I<sup>2</sup> = 0%). </p> <p>At 24 months, the mean coronary artery calcium score measured by multislice computed tomography was 434 with placebo or usual care and 70 points lower (362 lower to 222 higher) with sevelamer (<a href="./references#CD006023-fig-0016" title="">Analysis 1.14</a> (2 studies, 155 participants): MD ‐70.19, 95% CI ‐362.44 to 222.06; I<sup>2</sup> = 0%; <i>very low certainty evidence</i>). </p> <p>With respect to biochemical responses to therapy, at a median of 3 months the mean serum phosphate level was 0.28 mg/dL (0.09 mmol/L) lower (0.94 mg/dL lower to 0.39 mg/dL higher (‐0.30 to 0.13 mmol/L) with sevelamer (<a href="./references#CD006023-fig-0017" title="">Analysis 1.15</a>) in an analysis characterised by substantial heterogeneity (I<sup>2</sup> = 95%) (leading to <i>very low certainty</i>). Compared with placebo or usual care, sevelamer did not have clinically important effects on serum calcium (MD 0.03 mg/dL (0.0085 mmol/L), 95% CI ‐0.08 to 0.14 (0.02 to 0.04 mmol/L); I<sup>2</sup> = 72%) (<a href="./references#CD006023-fig-0018" title="">Analysis 1.16</a>). The impact of treatment on hypercalcaemia (<a href="./references#CD006023-fig-0019" title="">Analysis 1.17</a>) was uncertain. Sevelamer had uncertain effects on the serum calcium‐by‐phosphate product (MD 2.66 mg<sup>2</sup>/dL<sup>2</sup>, 95% CI ‐5.52 to 10.84; I<sup>2</sup> = 98%) (<a href="./references#CD006023-fig-0020" title="">Analysis 1.18</a>), serum iPTH (MD ‐6.55 pg/mL (0.74 pmol/L), 95% CI ‐21.16 to 8.07 (‐2.41 to 0.92 pmol/L); I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0021" title="">Analysis 1.19</a>), serum alkaline phosphatase (<a href="./references#CD006023-fig-0022" title="">Analysis 1.20</a>), serum bicarbonate (MD 0.12 mEq/L, 95% CI ‐1.30 to 1.54; I<sup>2</sup> = 82%) (<a href="./references#CD006023-fig-0023" title="">Analysis 1.21</a>), eGFR (MD ‐0.45 mL/min, 95% CI ‐4.74 to 3.85; I<sup>2</sup> = 45%) (<a href="./references#CD006023-fig-0024" title="">Analysis 1.22</a>), and bone mineral density measured at the hip or spine (<a href="./references#CD006023-fig-0025" title="">Analysis 1.23</a>; <a href="./references#CD006023-fig-0026" title="">Analysis 1.24</a>). Serum FGF23 levels were not reported in a format that was extractable for meta‐analysis. <a href="./references#CD006023-bbs2-0026" title="ChueCD , TownendJN , MoodyWE , ZehnderD , WallNA , HarperL , et al. Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology2013;24(5):842‐52. [MEDLINE: 23599381] ChueCD , TownendJN , SteedsRP , FerroCJ . Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB‐PHOS randomised controlled trial. Trials [Electronic Resource]2011;12(1):30. [MEDLINE: 21288351] ">CRIB‐PHOS 2011</a> reported no difference in Klotho levels between the two groups (<a href="./references#CD006023-fig-0027" title="">Analysis 1.25</a>). </p> </section> <section id="CD006023-sec-0100"> <h4 class="title">Lanthanum versus placebo or usual care</h4> <p>The major outcomes for the comparison of lanthanum with placebo or usual care are shown in the <a href="./full#CD006023-tbl-0002">summary of findings Table 2</a>. </p> <p>None of the seven studies were designed to measure death or cardiovascular events. Studies generally involved people with CKD G2 to G5 not requiring dialysis. </p> <p>Three studies reported death as either a reason for study drop‐out or as an adverse event. <a href="./references#CD006023-bbs2-0072" title="Ureña‐TorresP , PriéD , KeddadK , PrestonP , WildeP , WanH , et al. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo‐controlled trial. BMC Nephrology2014;15:71. [MEDLINE: 24885942] ">PREFECT 2014</a> reported a single death in the lanthanum group. Compared with placebo or usual care, it was uncertain whether lanthanum made any difference to the risk of death (all causes) (<a href="./references#CD006023-fig-0028" title="">Analysis 2.1</a> (3 studies, 214 participants): RR 1.63, 95% CI 0.07 to 37.12; I<sup>2</sup> = 100%) after a median study follow‐up of 3 months. No study reported cardiovascular deaths. Three studies reported myocardial infarction as an adverse treatment event, with only two events reported in the lanthanum group. Lanthanum had very uncertain effects on myocardial infarction (<a href="./references#CD006023-fig-0029" title="">Analysis 2.2</a> (3 studies, 239 participants): RR 1.61, 95% CI 0.17 to 14.97; I<sup>2</sup> = 0%). There were no reports of stroke in <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> (<a href="./references#CD006023-fig-0030" title="">Analysis 2.3</a>), <a href="./references#CD006023-bbs2-0047" title="IsakovaT , Barchi‐ChungA , EnfieldG , SmithK , VargasG , HoustonJ , et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 Levels in CKD. Clinical Journal of The American Society of Nephrology: CJASN2013;8(6):1009‐18. [MEDLINE: 23471131] IsakovaT , Barchi‐ChungA , EnfieldG , SmithKT , VargasGS , HoustonJ , et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR‐OR068]. Journal of the American Society of Nephrology2012;23:45A. ">Isakova 2013</a> reported no difference in hospitalisation events (<a href="./references#CD006023-fig-0031" title="">Analysis 2.4</a>), and <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> reported no difference in fractures (<a href="./references#CD006023-fig-0032" title="">Analysis 2.5</a>). </p> <p>Lanthanum treatment had uncertain effects on the risk of pruritus measured as a discrete outcome (<a href="./references#CD006023-fig-0033" title="">Analysis 2.6</a> (3 studies, 345 participants): RR 1.09, 95% CI 0.14 to 8.45; I<sup>2</sup> = 37%) or as a continuous pruritus score (<a href="./references#CD006023-bbs2-0099" title="WangXH , ZhangX , MuCJ , HeY , PengQP , YangGS , et al. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients. Journal of Huazhong University of Science and Technology. Medical Sciences2015;35(4):508‐13. [MEDLINE: 26223918] ">Wang 2015b</a>) (<a href="./references#CD006023-fig-0034" title="">Analysis 2.7</a>). </p> <p>Adverse events were measured over a median of two to three months. In low or moderate certainty evidence, lanthanum may have led to nausea (<a href="./references#CD006023-fig-0035" title="">Analysis 2.8</a> (4 studies, 383 participants): RR 3.72, 95% CI 1.36 to 10.18; I<sup>2</sup> = 0%) and probably leads to an increased risk of constipation (RR 2.98, 95% CI 1.21 to 7.30) (<a href="./references#CD006023-fig-0038" title="">Analysis 2.11</a>). Lanthanum had uncertain risks of abdominal pain (RR 0.23, 95% CI 0.03 to 1.96) (<a href="./references#CD006023-fig-0037" title="">Analysis 2.10</a>) and diarrhoea (RR 0.68, 95% CI 0.13 to 3.68; I<sup>2</sup> = 71%) (<a href="./references#CD006023-fig-0039" title="">Analysis 2.12</a>). </p> <p>Single studies reported no difference in treatment effects of lanthanum on ESKD (<a href="./references#CD006023-fig-0040" title="">Analysis 2.13</a>), coronary artery calcification (<a href="./references#CD006023-fig-0041" title="">Analysis 2.14</a>), or vascular calcification (<a href="./references#CD006023-fig-0042" title="">Analysis 2.15</a>). </p> <p>After a median of 3 months, the average serum phosphate level was 0.48 mg/dL (0.16 mmol/L) lower (0.05 lower to 0.90 mg/dL lower (‐0.02 to 0.29), <i>low certainty</i>) (<a href="./references#CD006023-fig-0058" title="">Analysis 3.8</a>). Lanthanum did not lead to clinically‐important effects on serum calcium (MD 0.03 mg/dL (0.008 mmol/L), 95% CI ‐0.18 to 0.23 mg/dL (‐0.04 to 0.06 mmol/L)) (<a href="./references#CD006023-fig-0044" title="">Analysis 2.17</a>), and the risk of hypercalcaemia were uncertain in one study (<a href="./references#CD006023-fig-0045" title="">Analysis 2.18</a>). The effects of sevelamer were uncertain for the outcomes of serum calcium by phosphate product (2 studies, 194 participants: MD ‐4.36 mg<sup>2</sup>/dL<sup>2</sup>, 95% CI ‐9.96 to 1.24; I<sup>2</sup> = 77%) (<a href="./references#CD006023-fig-0046" title="">Analysis 2.19</a>), serum iPTH (4 studies, 253 participants: MD 10.07 pg/mL (1.15 pmol/L), 95% CI ‐10.69 to 30.83 pg/mL (‐1.22 to 3.52 pmol/L); I<sup>2</sup> = 61%) (<a href="./references#CD006023-fig-0047" title="">Analysis 2.20</a>), eGFR (2 studies, 128 participants: MD 0.13 mL/min, 95% CI ‐1.80 to 2.07; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0048" title="">Analysis 2.21</a>), bone mineral density at the lumbar spine measured as a Z‐score (<a href="./references#CD006023-fig-0049" title="">Analysis 2.22</a>), and serum FGF23 levels (2 studies, 50 participants: SMD 0.32, 95% CI ‐0.81 to 1.45; I<sup>2</sup> = 73%) (<a href="./references#CD006023-fig-0050" title="">Analysis 2.23</a>). </p> </section> <section id="CD006023-sec-0101"> <h4 class="title">Iron versus placebo or usual care</h4> <p>The major outcomes for the comparison of iron with placebo or usual care are shown in the <a href="./full#CD006023-tbl-0003">summary of findings Table 3</a>. </p> <p>In the three studies comparing iron‐based binders with placebo or usual care, one involved dialysis patients and two involved patients with CKD G2 to G5 not requiring dialysis. The studies were not designed to measure the effects of treatment on death or cardiovascular events. Death (all causes) was reported in two studies. At 2.75 to 3 months, iron‐based binders had uncertain effects on death (all causes) (2 studies, 239 participants: RR 0.52, 95% CI 0.06 to 4.65; I<sup>2</sup> = 0%; <i>very low certainty evidence</i>) (<a href="./references#CD006023-fig-0051" title="">Analysis 3.1</a>). Cardiovascular death, myocardial infarction, and stroke were not reported. <a href="./references#CD006023-bbs2-0012" title="BlockG , ChertowG , FishbaneS , RodriguezM , ChenM , ShemeshS , et al. Ferric citrate reduces fibroblast growth factor 23 levels in patients with moderate chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii156. [EMBASE: 71491881] BlockG , FishbaneS , ShemeshS , SharmaA , WolfM , ChertowG . A double‐blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron‐deficiency anemia and reduction of serum phosphate in patients with non‐dialysis dependent chronic kidney disease [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii151. [EMBASE: 71491866] BlockGA , ChertowGM , FishbaneS , LoramLC , WolfM . Auryxia (ferric citrate) effectively reduces serum phosphate and fibroblast growth factor 23 (FGF23) levels in patients with stages 3‐5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A23. [EMBASE: 71875026] BlockGA , FishbaneS , RodriguezM , SmitsG , ShemeshS , PergolaPE , et al. A 12‐week, double‐blind, placebo‐controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3‐5. American Journal of Kidney Diseases2015;65(5):728‐36. [MEDLINE: 25468387] BlockGA , FishbaneS , ShemeshS , SharmaA , ChertowGM . ZerenexTM (ferric citrate) for the treatment of iron‐deficiency anemia and reduction of serum phosphate in non‐dialysis dependent CKD [abstract]. American Journal of Kidney Diseases2014;63(5):A118. [EMBASE: 71448667] ChertowGM , BlockGA , NeylanJF , PergolaPE , UhligK , FishbaneS . Safety and efficacy of ferric citrate in patients with nondialysis‐dependent chronic kidney disease. PLoS ONE [Electronic Resource]2017;12(11):e0188712. [MEDLINE: 29186198] FishbaneS , BlockGA , LoramLC , ChertowGM . Auryxia (ferric citrate), an oral iron‐based phosphate binder significantly improves serum iron measures in patients with stage 3, 4 and 5 chronic kidney disease (CKD) [abstract]. American Journal of Kidney Diseases2015;65(4):A35. [EMBASE: 71875070] ">Block 2015</a> reported no differences in the risks of fracture (<a href="./references#CD006023-fig-0052" title="">Analysis 3.2</a>), pruritus (<a href="./references#CD006023-fig-0053" title="">Analysis 3.3</a>), or nausea (<a href="./references#CD006023-fig-0054" title="">Analysis 3.4</a>). Outcome data for vascular calcification and bone‐related outcomes could not be extracted for analysis. </p> <p>Iron‐based binders had clinically uncertain risks for abdominal pain (2 studies, 332 participants: RR 1.20, 95% CI 0.34 to 4.27) (<a href="./references#CD006023-fig-0057" title="">Analysis 3.7</a>), while probably increasing the risk of constipation (3 studies, 422 participants: RR 2.66, 95% CI 1.15 to 6.12; I<sup>2</sup> = 0%; <i>moderate certainty evidence</i>) (<a href="./references#CD006023-fig-0055" title="">Analysis 3.5</a>) and diarrhoea (3 studies, 422 participants: RR 2.81, 95% CI 1.18 to 6.68; I<sup>2</sup> = 25%) (<a href="./references#CD006023-fig-0056" title="">Analysis 3.6</a>). </p> <p>Iron‐based binders lowered serum phosphate levels (3 studies, 301 participants: MD ‐1.33 mg/dL (‐0.43 mmol/L), 95% CI ‐2.25 to ‐0.41 mg/dL (‐0.73 to ‐0.13 mmol/L); I<sup>2</sup> = 91%) in an analysis possessing substantial between‐study heterogeneity (<a href="./references#CD006023-fig-0058" title="">Analysis 3.8</a>). Iron‐based binder therapy may be associated with higher serum calcium levels (3 studies, 301 participants: MD 0.21 mg/dL (0.05 mmol/L), 95% CI 0.09 to 0.33 mg/dL (0.02 to 0.08 mmol/L); I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0059" title="">Analysis 3.9</a>) while singles studies reported uncertain effects on serum calcium‐by‐phosphate product (<a href="./references#CD006023-fig-0060" title="">Analysis 3.10</a>), alkaline phosphatase (<a href="./references#CD006023-fig-0061" title="">Analysis 3.11</a>), and serum bicarbonate (<a href="./references#CD006023-fig-0062" title="">Analysis 3.12</a>). Iron‐based binders had uncertain effects on eGFR (2 studies, 239 participants: MD ‐0.67 mL/min, 95% CI ‐2.97 to 1.64; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0063" title="">Analysis 3.13</a>). Outcome data for serum FGF23 levels could not be extracted for analysis. </p> </section> <section id="CD006023-sec-0102"> <h4 class="title">Calcium versus placebo or usual care</h4> <p>The major outcomes for the comparison of calcium‐based binders compared with usual care are shown in the <a href="./full#CD006023-tbl-0004">summary of findings Table 4</a>. </p> <p>Evidence was generally restricted to people with CKD G2 to G5 not requiring dialysis. Meta‐analyses involved two studies (or three for biochemical outcomes). As a result, evidence certainty was either low, very low, or absent. No study was specifically designed to measure death or cardiovascular complications. Treatment endpoints were measured during nine months of therapy. </p> <p><a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a> reported no difference in the number of deaths between calcium and placebo (<a href="./references#CD006023-fig-0064" title="">Analysis 4.1</a>). Death due to cardiovascular events was not reported by any study. It is uncertain whether calcium‐based binders make any difference to the risk of myocardial infarction (2 studies, 147 participants: RR 1.36, 95% CI 0.09 to 21.71; I<sup>2</sup> = 35%) (<a href="./references#CD006023-fig-0065" title="">Analysis 4.2</a>). Two studies reported stroke; there were no reports of stoke in <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>, while <a href="./references#CD006023-bbs2-0073" title="QunibiW , WinkelmayerWC , SolomonR , MoustafaM , KesslerP , HoCH , et al. A randomized, double‐blind, placebo‐controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non‐dialysis‐dependent chronic kidney disease. BMC Nephrology2011;12:9. [MEDLINE: 21324193] ">Qunibi 2011</a> reported one stroke in the calcium group. The summary estimate for stroke was extremely imprecise (<a href="./references#CD006023-fig-0066" title="">Analysis 4.3</a>). <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> reported two fractures in the placebo group (<a href="./references#CD006023-fig-0067" title="">Analysis 4.4</a>). The effect of calcium‐based binders on pruritus was very uncertain in two studies (2 studies, 197 participants: RR 1.19, 95% CI 0.29 to 4.81; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0068" title="">Analysis 4.5</a>). </p> <p>In low‐ or very low‐certainty evidence, calcium‐based binders had uncertain risks on adverse events including nausea (2 studies, 197 participants: RR 0.58, 95% CI 0.15 to 2.18; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0069" title="">Analysis 4.6</a>), abdominal pain (2 studies, 197 participants: RR 0.66, 95% CI 0.13 to 3.34; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0071" title="">Analysis 4.8</a>), constipation (2 studies, 197 participants: RR 2.44, 95% CI 0.32 to 18.42; I<sup>2</sup> = 53%) (<a href="./references#CD006023-fig-0072" title="">Analysis 4.9</a>), and diarrhoea (2 studies, 197 participants: RR 0.94, 95% CI 0.39 to 2.28; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0073" title="">Analysis 4.10</a>). <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> reported one vomiting event in the placebo group (<a href="./references#CD006023-fig-0070" title="">Analysis 4.7</a>). </p> <p><a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a> reported no differences between the two groups in coronary artery calcium score at 2 years (<a href="./references#CD006023-fig-0074" title="">Analysis 4.11</a>). </p> <p>In very low certainty evidence, calcium‐based binders had uncertain effects on serum phosphate (3 studies, 151 participants: MD ‐0.18 mg/dL (‐0.06 mmol/L), 95% CI ‐1.30 to 0.95 mg/dL (‐0.42 to 0.31 mmol/L); I<sup>2</sup> = 85%) (<a href="./references#CD006023-fig-0075" title="">Analysis 4.12</a>) and serum calcium (3 studies, 151 participants: MD 0.33 mg/dL (0.08 mmol/L), 95% CI ‐0.26 to 0.92 (‐0.07 to 0.23 mmol/L); I<sup>2</sup> = 85%) (<a href="./references#CD006023-fig-0076" title="">Analysis 4.13</a>) in meta‐analyses with by substantial heterogeneity. Hypercalcaemia was reported as an adverse event in three studies after 12 weeks, 3 months, and 9 months of treatment. There was no uniform definition of hypercalcaemia. In low certainty evidence, calcium‐based binders may increase the risk of hypercalcaemia (3 studies, 215 participants: RR 7.28, 95% CI 1.64 to 32.29; I<sup>2</sup> = 0%)) (<a href="./references#CD006023-fig-0077" title="">Analysis 4.14</a>). </p> <p>Calcium‐based binders had uncertain effects on serum iPTH (2 studies, 133 participants: MD ‐80.15 pg/mL (‐9.14 pmol/L), 95% CI ‐305.46 to 145.16 pg/mL (‐34.8 to 16.5 pmol/L); I<sup>2</sup> = 94%) (<a href="./references#CD006023-fig-0079" title="">Analysis 4.16</a>) and alkaline phosphatase (2 studies, 78 participants: MD 34.86 IU/L, 95% CI ‐21.47 to 91.20; I<sup>2</sup> = 60%) (<a href="./references#CD006023-fig-0080" title="">Analysis 4.17</a>). Calcium binders may lead to a small clinical reduction in serum bicarbonate (2 studies 138 participants: MD ‐1.85 mEq/L, 95% CI ‐3.12 to ‐0.59) (<a href="./references#CD006023-fig-0081" title="">Analysis 4.18</a>). <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a> reported no differences between calcium and placebo in serum calcium‐by‐phosphate product or eGFR (<a href="./references#CD006023-fig-0078" title="">Analysis 4.15</a>; <a href="./references#CD006023-fig-0082" title="">Analysis 4.19</a>). Outcome data for serum FGF23 levels could not be extracted for analysis. </p> </section> <section id="CD006023-sec-0103"> <h4 class="title">Bixalomer versus placebo or usual care</h4> <p><a href="./references#CD006023-bbs2-0004" title="AkizawaT , OrigasaH , KameokaC , TsukadaJ , KuroishiK , YamaguchiY . Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Therapeutic Apheresis &amp; Dialysis2016;20(6):588‐97. [MEDLINE: 27896908] ">Akizawa 2016</a> evaluated bixalomer versus placebo for 12 weeks among people with an eGFR &lt; 60 mL/min per 1.73 m<sup>2</sup>. This study reported no differences in death (<a href="./references#CD006023-fig-0083" title="">Analysis 5.1</a>), ESKD (<a href="./references#CD006023-fig-0084" title="">Analysis 5.2</a>), nausea (<a href="./references#CD006023-fig-0085" title="">Analysis 5.3</a>), abdominal pain (<a href="./references#CD006023-fig-0086" title="">Analysis 5.4</a>), constipation (<a href="./references#CD006023-fig-0087" title="">Analysis 5.5</a>), and diarrhoea (<a href="./references#CD006023-fig-0088" title="">Analysis 5.6</a>). </p> </section> <section id="CD006023-sec-0104"> <h4 class="title">Nicotinamide versus placebo or usual care</h4> <p>Four studies evaluated nicotinamide or placebo or usual care in patients with CKD G5D treated with dialysis. Studies were between 1.8 and 3 months in duration. The studies were not designed to measure the effects of treatment on death or cardiovascular events. <a href="./references#CD006023-bbs2-0086" title="TanK , VardeshD , RamanP , PetrieJ . The SLO‐NIACIN trial: a double‐blind placebo controlled trial of low dose slow‐release niacin to lower phosphate in haemodialysis patients [abstract no: 010]. Nephrology2013;18(Suppl 1):17. ">SLO‐NIACIN 2013</a> reported one death as a study drop‐out (<a href="./references#CD006023-fig-0089" title="">Analysis 6.1</a>). There were no reported cardiovascular deaths. <a href="./references#CD006023-bbs2-0102" title="YoungDO , ChengSC , DelmezJA , CoyneDW . The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International2009;29(5):562‐7. [MEDLINE: 19776051] ">Young 2009a</a> reported no differences in the risk of pruritus (<a href="./references#CD006023-fig-0090" title="">Analysis 6.2</a>). </p> <p>Constipation was reported in one study at 2.75 months (<a href="./references#CD006023-bbs2-0007" title="AramwitP , SrisawadwongR , SupasyndhO . Effectiveness and safety of extended‐release nicotinic acid for reducing serum phosphorus in hemodialysis patients. Journal of Nephrology2012;25(3):354‐62. [MEDLINE: 21748722] ">Aramwit 2012</a>) (<a href="./references#CD006023-fig-0091" title="">Analysis 6.3</a>). It was very uncertain whether nicotinamide increased risks of diarrhoea (RR 1.61, 95% CI 0.06 to 40.36) (<a href="./references#CD006023-fig-0092" title="">Analysis 6.4</a>). </p> <p>There was no evidence that nicotinamide had clinically‐important effects on serum phosphate (3 studies, 98 participants: MD ‐0.56 mg/dL (‐0.18 mmol/L), 95% CI ‐1.24 to 0.12 mg/dL (‐0.40 to 0.04 mmol/L); I<sup>2</sup> = 61%), in an analysis with moderate heterogeneity (<a href="./references#CD006023-fig-0093" title="">Analysis 6.5</a>). Nicotinamide had uncertain effects on serum calcium (3 studies, 98 participants: MD 0.07 mg/dL (0.02 mmol/L), 95% CI ‐0.30 to 0.44 mg/dL (‐0.06 to 0.11 mmol/L); I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0094" title="">Analysis 6.6</a>), and may lower serum calcium‐by‐phosphate product (2 studies, 74 participants: MD ‐7.81 mg<sup>2</sup>/dL<sup>2</sup>, 95% CI ‐13.36 to ‐2.25) (<a href="./references#CD006023-fig-0096" title="">Analysis 6.8</a>). <a href="./references#CD006023-bbs2-0005" title="AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadministration of nicotinamide and calcium‐based phosphate binder on hyperphosphatemia in patients undergoing hemodialysis. Advances in Natural Science2012;5(1):1‐9. [DOI: 10.3968/j.ans.1715787020120501.1001] AllamS , El‐HamamsyM , El‐SharkwayM . The effect of coadminstration of nicotinamide and calcium‐based phosphate binder on hyperphophatemia in patients undergoing hemodialysis [abstract]. Value in Health2012;15(4):A152. [EMBASE: 70763798] ElSharkawyMM , KamelM , ElhamamsyM , AllamS . Lowdose nicotinamide as an adjunctive therapy to calcium carbonate for control of hyperphosphatemia in hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i253. [EMBASE: 71075759] ">Allam 2012</a> reported on difference in serum PTH (<a href="./references#CD006023-fig-0095" title="">Analysis 6.7</a>). </p> </section> <section id="CD006023-sec-0105"> <h4 class="title">Colestilan versus placebo or usual care</h4> <p>Data from a single placebo‐controlled, multiple fixed‐dose study in patients treated with dialysis was available (<a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a>). This study reported no differences between colestilan and placebo in death (<a href="./references#CD006023-fig-0097" title="">Analysis 7.1</a>), abdominal pain (<a href="./references#CD006023-fig-0099" title="">Analysis 7.3</a>), diarrhoea (<a href="./references#CD006023-fig-0100" title="">Analysis 7.4</a>), and constipation (<a href="./references#CD006023-fig-0101" title="">Analysis 7.5</a>). <a href="./references#CD006023-bbs2-0064" title="DimkovicN . A multi‐centre, double‐blind, randomised, placebo‐controlled, multiple fixed‐dose study of colestilan (MCI‐196) versus placebo in chronic kidney disease stage 5 subjects on dialysis (CKD 5D) with hyperphosphataemia and dyslipidaemia (DL): safety results [abstract no: SAP575]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii503‐4. [EMBASE: 70766811] LocatelliF , DimkovicN , SpasovskiG . Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo‐controlled, multiple fixed‐dose trial. Nephrology Dialysis Transplantation2013;28(7):1874‐88. [MEDLINE: 23610100] ">Locatelli 2013</a> reported more nausea in the placebo group (<a href="./references#CD006023-fig-0098" title="">Analysis 7.2</a>). </p> </section> <section id="CD006023-sec-0106"> <h4 class="title">Sevelamer versus calcium</h4> <p>The major outcomes for the comparison of sevelamer with calcium are shown in the <a href="./full#CD006023-tbl-0005">summary of findings Table 5</a>. </p> <p>Studies comparing sevelamer with calcium were dominated by those evaluating therapy in participants with CKD G5D treated with dialysis. Death (all causes) was reported in sixteen studies. Of these, zero events were reported in four studies (<a href="./references#CD006023-bbs2-0009" title="BleyerAJ , BurkeSK , DillonM , GarrettB , KantKS , LynchD , et al. A comparison of the calcium‐free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. American Journal of Kidney Diseases1999;33(4):694‐701. [MEDLINE: 10196011] BleyerAJ , GarrettB , KantKS , LynchD , RahmanN , SchoenfeldP , et al. An open label, cross‐over study of the new phosphate binder renagel in the management of hyperphosphatemia in ESRD patients [abstract]. Journal of the American Society of Nephrology1997;8(Program &amp; Abstracts):548a. [CENTRAL: CN‐00444452] ">Bleyer 1999</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0035" title="FerreiraA , FrazãoJM , Monier‐FaugereMC , GilC , GalvaoJ , OliveiraC , et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. Journal of the American Society of Nephrology2008;19(2):405‐12. [MEDLINE: 18199805] ">Ferreira 2008</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>), deaths were reported as reasons for drop‐out from study follow‐up in six studies (<a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0019" title="BudoffMJ , KesslerP , GaoYL , QunibiW , MoustafaM , MaoSS . The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)‐2 study. Academic Radiology2008;15(1):58‐61. [MEDLINE: 18078907] QunibiW , HorwithG , KesslerP , MoustafaM , CARE‐2 Investigators. Cardiovascular calcification (CVC) in hemodialysis (HD) patients: study design and preliminary mineral data of the calcium acetate sevelamer evaluation‐2 (CARE‐2) study [abstract no: PUB386]. Journal of the American Society of Nephrology2005;16(Oct Abstracts Issue):866A. [CENTRAL: CN‐00602064] QunibiW , MoustafaM , KesslerP , BortleyE , MuenzL , BudoffM . Progression of coronary artery calcification (CAC) in hemodialysis patients (HDP) despite excellent control of LDL cholesterol: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study [abstract no: FP386]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi148. [CENTRAL: CN‐00691160] QunibiW , MoustafaM , KesslerP , MuenzLR , BudoffM . Coronary artery calcification (CAC) in hemodialysis patients (HDP): preliminary results from the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: TH‐PO845]. Journal of the American Society of Nephrology2006;17(Abstracts):286A. [CENTRAL: CN‐00602067] QunibiW , MoustafaM , MuenzLR , HeDY , KesslerPD , Diaz‐BuxoJA , et al. A 1‐year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation‐2 (CARE‐2) study. American Journal of Kidney Diseases2008;51(6):952‐65. [MEDLINE: 18423809] QunibiW , MuenzLR , Diaz‐BuxoJA . The CARE‐2 study results: setting the record straight. Nephrology Dialysis Transplantation2008;23(12):4081‐2. [MEDLINE: 18820282] QunibiWY , MoustafaM , KesslerP , BorteyE , MuenzLR , BudoffM . Coronary artery calcification (CAC) progression in hemodialysis patients (HDP) treated with atorvastatin: the calcium acetate renagel evaluation‐2 (CARE‐2) study [abstract no: S‐PO‐0376]. 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21‐25; Rio de Janeiro, Brazil. 2007:150. QunibiWY , MoustafaM , KesslerP , MuenzLR , Diaz‐BuxoJ , BudoffM , et al. Progression of aorta calcification (AoC) in hemodialysis patients (HDP) treated with calcium acetate (CaA) or sevelamer (SV) with comparable lipid control: the calcium acetate renegal evaluation‐2 (CARE‐2) study [abstract no: TH‐FC043]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):10A. ">CARE‐2 2008</a>; <a href="./references#CD006023-bbs2-0043" title="HervasJG , PradosD , CerezoS . Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney International ‐ Supplement2003;85:69‐72. [MEDLINE: 12753270] ">Hervas 2003</a>; <a href="./references#CD006023-bbs2-0062" title="LinHH , LiouHH , WuMS , HuangCC . Factors associated with serum fetuin‐A concentrations after long‐term use of different phosphate binders in hemodialysis patients. BMC Nephrology2016;17:33. [MEDLINE: 27007989] LinHH , LiouHH , WuMS , LinCY , HuangCC . Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology2014;19(11):672‐8. [MEDLINE: 25113414] ">Lin 2014a</a>; <a href="./references#CD006023-bbs2-0078" title="SadekT , MazouzH , BahlouH , OprisiuR , ElEsperN , ElEsperI , et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open‐label, randomized study. Nephrology Dialysis Transplantation2003;18(3):582‐9. [MEDLINE: 12584283] ">Sadek 2003</a>; <a href="./references#CD006023-bbs2-0097" title="VlassaraH , UribarriJ , CaiW , GoodmanS , PyzikR , PostJ , et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2012;7(6):934‐42. [MEDLINE: 22461535] Yubero‐SerranoEM , WoodwardM , PoretskyL , VlassaraH , StrikerGE . Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro‐oxidant status in patients with diabetic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN2015;10(5):759‐66. [MEDLINE: 25710801] ">Vlassara 2012</a>), and were reported as adverse events in two studies (<a href="./references#CD006023-bbs2-0025" title='AsmusHG , BraunJ , KrauseR , BrunkhorstR , HolzerH , SchulzW , et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrology Dialysis Transplantation2005;20(8):1653‐61. [MEDLINE: 15930018] BommerJ , AsmusG , BraunJ , BrunkhorstR , HolzerH , KrauseR , et al. Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]. Nephrology Dialysis Transplantation2002;17(Suppl 1):32. [CENTRAL: CN‐00509096] BommerJ , European Renagel Investigators Group. Lipid lowering effect of renagel, a novel phosphate binder [abstract]. Nephrology Dialysis Transplantation2001;16(6):A122. [CENTRAL: CN‐00444477] BraunJ , AsmusHG , HolzerH , BrunkhorstR , KrauseR , SchulzW , et al. Long‐term comparison of a calcium‐free phosphate binder and calcium carbonate‐‐phosphorus metabolism and cardiovascular calcification. Clinical Nephrology2004;62(2):104‐15. [MEDLINE: 15356967] ChertowGM , BurkeSK , RaggiP , Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International2002;62(1):245‐52. [MEDLINE: 12081584] ChertowGM , Chasan‐TaberS , RaggiP . The "tip of the iceberg" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):433a. [CENTRAL: CN‐00444789] ChertowGM , DillonMA , AminN , BommerJ , BurkeSK . Sevelamer is more effective at controlling disorders of mineral metabolism than calcium‐based phosphate binders in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):195‐6A. [CENTRAL: CN‐00444790] ChertowGM , GoodmanWG , TotoRD , RaggiP . In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL‐C, APO‐B, and HS‐CRP compared with calcium acetate (PHOSLO) [abstract no: SA‐PO603]. Journal of the American Society of Nephrology2002;13(Sept, Program &amp; Abstracts):386a. [CENTRAL: CN‐00444791] ChertowGM , RaggiP , Chasan‐TaberS , BommerJ , HolzerH , BurkeSK . Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation2004;19(6):1489‐96. [MEDLINE: 15102961] ChertowGM , RaggiP , McCarthyJT , SchulmanG , SilberzweigJ , KuhlikA , et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. American Journal of Nephrology2003;23(5):307‐14. [MEDLINE: 12915774] FerramoscaE , BurkeS , Chasan‐TaberS , RattiC , ChertowGM , RaggiP . Potential antiatherogenic and anti‐inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal2005;149(5):820‐5. [MEDLINE: 15894962] GargJP , Chasan‐TaberS , BlairA , PloneM , BommerJ , RaggiP , et al. Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis &amp; Rheumatism2005;52(1):290‐5. [MEDLINE: 15641045] JamesG , RaggiP , BoulayA , BurkeS , Chasan‐TaberS , ChertowG , et al. Thoracic vertebral bone density increases with renagel and decreases with calcium‐based phosphate binder therapy ‐ a two year study [abstract no: W423]. Nephrology Dialysis Transplantation2003;18(Suppl 4):681. [CENTRAL: CN‐00445894] RaggiP , BommerJ , ChertowGM . Valvular calcification in hemodialysis patients randomized to calcium‐based phosphorus binders or sevelamer. Journal of Heart Valve Disease2004;13(1):134‐41. [MEDLINE: 14765851] RaggiP , BurkeS , Chasen‐TaberS , ChertowG , HolzerH , BommerJ . Sevelamer preserves trabecular bone mineral density [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:103‐4. [CENTRAL: CN‐00509430] RaggiP , BurkeSK , Chasen‐TaberS , ChertowGM , HolzerH , BommerJ . Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA‐PO924]. Journal of the American Society of Nephrology2003;14(Nov):502A. [CENTRAL: CN‐00583411] RaggiP , BurkeSK , DillonMA , AminN , BommerJ , ChertowGM . Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):239A. [CENTRAL: CN‐00447325] RaggiP , JamesG , BurkeSK , BommerS , Chasan‐TaberS , HolzerH , et al. Decrease in thoracic vertebral bone attenuation with calcium‐based phosphate binders in hemodialysis. Journal of Bone &amp; Mineral Research2005;20(5):764‐72. [MEDLINE: 15824849] '>Chertow 2002</a>; <a href="./references#CD006023-bbs2-0081" title="SezerS , KarakanS , AcarNO . Sevelamer improves serum electrolyte profile, metabolic and cardiovascular markers and survival in ESRD patients on hemodialysis treatment [abstract no: Sa473]. NDT Plus2010;3(Suppl 3):iii196. [EMBASE: 70483939] ">Sezer 2010</a>). In four studies, all‐cause or cause‐specific death was a pre‐specified primary or secondary outcome (<a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0046" title="BellasiA , CozzolinoM , RussoD , MolonyD , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology2016;86(9):113‐24. [MEDLINE: 27443567] BellasiA , CozzolinoM , RussoD , MolonyDA , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii588. [EMBASE: 72207961] DiIorioB . In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'. American Journal of Kidney Diseases2014;63(1):164‐5. [MEDLINE: 24377649] DiIorioB , MolonyD , BellC , CuccinielloE , BellizziV , RussoD , et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. American Journal of Kidney Diseases2013;62(4):771‐8. [MEDLINE: 23684755] DiIorioBR , CuccinielloE , BellizziV . Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan‐Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar‐Apr;26(2):419]. Journal of Nephrology2009;22(6):694‐8. [MEDLINE: 19967647] MolonyD , BellasiA , BellizziV , RussoD , DiIorioB . Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii54. [EMBASE: 70765453] ObiY , HamanoT . The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. American Journal of Kidney Diseases2014;63(1):164. [MEDLINE: 24377650] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593‐602; PMID: 25027030]. Journal of Nephrology2014;27(6):717. [MEDLINE: 25098354] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]. Journal of Nephrology2015;28(5):593‐602. [MEDLINE: 25027030] ">INDEPENDENT‐HD 2009</a>). In low certainty evidence downgraded for study limitations and evidence of important statistical heterogeneity, sevelamer may reduce death (all causes) compared with calcium‐based binders (16 studies, 4266 participants: RR 0.53, 95% CI 0.30 to 0.91; I<sup>2</sup> = 78%) (<a href="./references#CD006023-fig-0102" title="">Analysis 8.1</a>). It was not possible to evaluate for presence of publication bias due to the important statistical heterogeneity. </p> <p>In very low certainty evidence, whether sevelamer made any difference to cardiovascular death was uncertain (6 studies, 2904 participants: RR 0.45, 95% CI 0.11 to 1.77; I<sup>2</sup> = 73%) (<a href="./references#CD006023-fig-0103" title="">Analysis 8.2</a>), with important statistical heterogeneity in the analysis. Myocardial infarction (2 studies, 177 participants: RR 1.02, 95% CI 0.11 to 9.59; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0104" title="">Analysis 8.3</a>) and stroke (2 studies, 102 participants: RR 3.00, 95% CI 0.32 to 27.90; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0105" title="">Analysis 8.4</a>) were reported for a single patient in each of two studies leading to a very imprecise risk estimates. Two studies reported hospitalisation, with the evidence dominated by a single study with a large number of reported events in both groups (2 studies, 242 participants: RR 0.78, 95% CI 0.56 to 1.08; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0106" title="">Analysis 8.5</a>). <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> reported no differences in fracture events between the two groups (<a href="./references#CD006023-fig-0107" title="">Analysis 8.6</a>). </p> <p>In low certainty evidence involving studies with a median follow‐up of 5.5 months, sevelamer may have similar risks of nausea compared with calcium (4 studies, 365 participants: RR 0.98, 95% CI 0.56 to 1.71; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0108" title="">Analysis 8.7</a>). Based on two studies in low certainty evidence, there was no clinical difference in the risk of vomiting between sevelamer and calcium (2 studies, 263 participants: RR 0.95, 95% CI 0.54 to 1.69; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0109" title="">Analysis 8.8</a>). There was no evidence of important differences in treatments for the risk of abdominal pain (4 studies, 363 participants: RR 1.77, 95% CI 0.68 to 4.63; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0110" title="">Analysis 8.9</a>), constipation (6 studies, 2652 participants: RR 1.35, 95% CI 0.71 to 2.57; I<sup>2</sup> = 2%) (<a href="./references#CD006023-fig-0111" title="">Analysis 8.10</a>), diarrhoea (3 studies, 315 participants: RR 0.98, 95% CI 0.55 to 1.75; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0112" title="">Analysis 8.11</a>), or abdominal bloating (2 studies, 112 participants: RR 4.85, 95% CI 0.87 to 27.03; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0113" title="">Analysis 8.12</a>). </p> <p>In very low certainty evidence with important statistical heterogeneity in the analysis, sevelamer may result in markedly less hypercalcaemia compared with calcium‐based binders (19 studies, 4084 participants: RR 0.30, 95% CI 0.20 to 0.43; I<sup>2</sup> = 49%) (<a href="./references#CD006023-fig-0114" title="">Analysis 8.13</a>). <a href="./references#CD006023-bbs2-0028" title="StPeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO846]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602069] StPeterWL , FanQ , WeinhandlE , LiuJ . Economic evaluation of sevelamer versus calcium‐based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare &amp; Medicaid services data. Clinical Journal of the American Society of Nephrology: CJASN2009;4(12):1954‐61. [MEDLINE: 19833904] StPeterWL , LiuJ , WeinhandlE , FanQ . A comparison of sevelamer and calcium‐based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. American Journal of Kidney Diseases2008;51(3):445‐54. [MEDLINE: 18295060] StPeterWL , LiuJ , WeinhandlED , FanQ . Linking Centers for Medicare &amp; Medicaid Services data with prospective DCOR trial data: methods and data comparison results. Hemodialysis International2008;12(4):480‐91. [MEDLINE: 19090871] St.PeterW , LiuJ , FanQ , WeinhandlE , Chronic Disease Research Group. DCOR Study: assessing economic impact of sevelamer vs calcium binders on hospitalization and morbidity in hemodialysis patients using CMS data [abstract no: TH‐PO847]. Journal of the American Society of Nephrology2006;17(Abstracts):287A. [CENTRAL: CN‐00602068] SukiW , ZabanehR , CangianoJ , ReedJ , FischerD , GarrettL , et al. A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients ‐ the DCOR trial [abstract no: SP392]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv145. [CENTRAL: CN‐00602070] SukiWN , ZabanehR , CangianoJ , ReedJ , SwanS , FischerD , et al. The DCOR trial ‐ a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract no: TH‐PO745]. Journal of the American Society of Nephrology2005;16:281A. SukiWN , ZabanehR , CangianoJL , ReedJ , FischerD , GarrettL , et al. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients. Kidney International2007;72(9):1130‐7. [MEDLINE: 17728707] SukiWN , Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium‐based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition2008;18(1):91‐8. [MEDLINE: 18089452] ">DCOR 2007</a> reported no difference in the comparative effect of sevelamer and calcium on calciphylaxis (<a href="./references#CD006023-fig-0115" title="">Analysis 8.14</a>). There was no evidence that the coronary artery calcium score at 12 or 24 months was different for sevelamer or calcium use (4 studies, 517 participants: MD ‐24.89, 95% CI ‐75.66 to 25.88; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0116" title="">Analysis 8.15</a>). </p> <p>Among twenty‐three studies involving 4360 participants, the mean serum phosphate at end of treatment was clinically similar between treatment groups (MD 0.06 mg/dL (0.02 mmol/L), 95% CI ‐0.11 to 0.23 mg/dL (‐0.04 to 0.07 mmol/L); I<sup>2</sup> = 78%) (<a href="./references#CD006023-fig-0117" title="">Analysis 8.16</a>), although there was important statistical heterogeneity between the studies. Sevelamer may provide a small clinical impact on serum calcium compared with a calcium‐based binder (22 studies, 4313: MD ‐0.38 mg/dL (‐0.10 mmol/L), 95% CI ‐0.54 to ‐0.21 mg/dL (‐0.14 to ‐0.05 mmol/L); I<sup>2</sup> = 92%), in an analysis showing substantial statistical heterogeneity (<a href="./references#CD006023-fig-0118" title="">Analysis 8.17</a>). Sevelamer may have similar clinical effects on the serum calcium‐by‐phosphate product (13 studies, 2983 participants: MD 0.36 mg<sup>2</sup>/dL<sup>2</sup>, 95% CI ‐0.57 to 1.28; I<sup>2</sup> = 25%) (<a href="./references#CD006023-fig-0119" title="">Analysis 8.18</a>), while sevelamer was possibly associated with a clinically increased serum iPTH levels (16 studies, 1420 participants: MD 44.24 pg/mL (5.04 pmol/L), 95% CI 10.93 to 77.55 (1.24 to 8.84 pmol/L); I<sup>2</sup> = 71%) (<a href="./references#CD006023-fig-0120" title="">Analysis 8.19</a>). Calcium‐based treatment may decrease serum alkaline phosphatase compared to placebo (7 studies, 611 participants: MD 17.64 IU/L, 95% CI ‐0.16 to 35.43; I<sup>2</sup> = 68%) although the confidence interval included the possibility of no difference (<a href="./references#CD006023-fig-0121" title="">Analysis 8.20</a>). Sevelamer use may result in lower serum bicarbonate levels (7 studies, 695 participants: MD ‐1.57 mEq/L, 95% CI ‐2.15 to ‐1.00; I<sup>2</sup> = 24%) (<a href="./references#CD006023-fig-0122" title="">Analysis 8.21</a>). <a href="./references#CD006023-bbs2-0077" title="RussoD , MirandaI , RuoccoC , BattagliaY , BuonannoE , ManziS , et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney International2007;72(10):1255‐61. [MEDLINE: 17805238] ">Russo 2007</a> reported no difference in eGFR between the groups at the end of treatment (<a href="./references#CD006023-fig-0123" title="">Analysis 8.22</a>). <a href="./references#CD006023-bbs2-0062" title="LinHH , LiouHH , WuMS , HuangCC . Factors associated with serum fetuin‐A concentrations after long‐term use of different phosphate binders in hemodialysis patients. BMC Nephrology2016;17:33. [MEDLINE: 27007989] LinHH , LiouHH , WuMS , LinCY , HuangCC . Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology2014;19(11):672‐8. [MEDLINE: 25113414] ">Lin 2014a</a> reported no differences between the groups for serum FGF23 (<a href="./references#CD006023-fig-0124" title="">Analysis 8.23</a>) and soluble Klotho levels (<a href="./references#CD006023-fig-0125" title="">Analysis 8.24</a>). </p> </section> <section id="CD006023-sec-0107"> <h4 class="title">Lanthanum versus calcium</h4> <p>The major outcomes for the comparison of lanthanum with calcium are shown in the <a href="./full#CD006023-tbl-0006">summary of findings Table 6</a>. </p> <p>Nearly all studies evaluated therapy in patients with CKD G5D treated with peritoneal dialysis or haemodialysis. None of the studies were designed to evaluate treatment effects on death or cardiovascular endpoints. Death (all causes) was reported in six studies. Of these, zero events were reported in two studies (<a href="./references#CD006023-bbs2-0027" title="D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International ‐ Supplement2003;85:S73‐8. [MEDLINE: 12753271] D'HaesePC , SpasovskiGB , SikoleA , HutchinsonA , FreemontTJ , SulkovaS , et al. Multi‐centre study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients [abstract no: PS1‐15]. Nephrology2003;8(Suppl 1):A28. DeBroeME , D'HaesePC , FreemontTJ , WebsterI , GillM , SpasovskiGB . Comparative effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients: results from a large, long‐term clinical trial [abstract]. Nephrology Dialysis Transplantation2003;18(Suppl 4):682. [CENTRAL: CN‐00445015] FreemontA . The effects of lanthanum carbonate and calcium carbonate on bone in patients with chronic kidney disease [abstract no: 33]. American Journal of Kidney Diseases2004;43(4):A23. [CENTRAL: CN‐00644282] FreemontA , JonesC . The effects of the phosphate binders lanthanum carbonate and calcium carbonate on bone: a comparative study in patients with chronic kidney disease [abstract no:SP270]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:106. [CENTRAL: CN‐00509202] FreemontAJ , HoylandJA , DentonJ , Lanthanum Carbonate SPD405‐303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end‐stage renal disease. Clinical Nephrology2005;64(6):428‐37. [MEDLINE: 16370155] FreemontT , MallucheHH . Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clinical Nephrology2005;63(2):138‐45. [MEDLINE: 15730056] TorresA , DeBroeME , D'HaesePC , HutchisonA , JonesC . One‐year, randomized, open‐label study comparing the safety and efficacy of lanthanum carbonate (Fosrenol®) and calcium carbonate in dialysis patients [abstract no: SU‐PO1041]. Journal of the American Society of Nephrology2003;14(Nov):764A. [CENTRAL: CN‐00583261] WebsterI . Lanthanum carbonate, a novel phosphate binder, has similar efficacy and tolerability to calcium carbonate over one year of treatment [abstract]. Nephrology Nursing Journal2004;31(2):146. WilsonR . Spica Consultants Ltd. Personal communication2005. WilsonR , CopleyJB , PooleL . Lower serum phosphorus can be attained by increasing the dose of lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii496. [EMBASE: 70766788] ">D'Haese 2003</a>; <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a>), and seven events were reported among the remaining four studies (<a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a>; <a href="./references#CD006023-bbs2-0089" title="SikoleA , SpasovskiG , GelevS , AmitovV , StojcevN , GrozdanovskiR . Lanthanum carbonate ‐ a novel phosphate binder in maintenance dialysis patients [abstract no: SP228]. Nephrology Dialysis Transplantation2005;20(Suppl 5):v95‐6. SikoleA , SpasovskiG , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The use of lanthanum carbonate as a novel phosphate binder in maintenance dialysis patients [abstract no: M63]. Nephrology Dialysis Transplantation2002;17(Suppl 12):67. [CENTRAL: CN‐00509481] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaeseP , et al. The impact of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients ‐ single center experience [abstract no: w436]. Nephrology Dialysis Transplantation2003;18(Suppl 4):685‐6. [CENTRAL: CN‐00447817] SpasovskiG , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. The beneficial effect of lanthanum carbonate on low turnover bone disease in dialysis patients [abstract no: P40]. International Journal of Artificial Organs2003;26(7):630. [CENTRAL: CN‐00583691] SpasovskiG , SikoleA , GelevS , MasinJ , FreemontT , WebsterI , et al. The evolution of renal bone disease in dialysis patients ‐ comparative effects of lanthanum carbonate and calcium carbonate treatment [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:105‐6. [CENTRAL: CN‐00509488] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , GrozdanovskiR , et al. Comparative, bone biopsy‐based, 3 years follow‐up study in dialysis patients during and after 1 year treatment with lanthanum carbonate [abstract no: TO14]. Nephrology Dialysis Transplantation2005;20(6 Suppl):v376. [CENTRAL: CN‐00583693] SpasovskiG , SikoleA , GelevS , Masin‐SpasovskaJ , PolenakovicB , WebsterI , et al. The evolution of renal osteodystrophy in dialysis patients: comparative effects of lanthanum carbonate and calcium carbonate [abstract no: SA‐PO842]. Journal of the American Society of Nephrology2005;16(Oct):741A. [CENTRAL: CN‐00583697] SpasovskiGB , SikoleA , GelevS , GrozdanovskiR , AmitovV , D'HaesePC , et al. Lanthanum carbonate in the management of renal osteodystrophy in dialysis patients [abstract]. Hemodialysis International2003;7(1):87. [CENTRAL: CN‐00461778] SpasovskiGB , SikoleA , GelevS , Masin‐SpasovskaJ , FreemontT , WebsterI , et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow‐up. Nephrology Dialysis Transplantation2006;21(8):2217‐24. [MEDLINE: 16595583] ">Spasovski 2006</a>; <a href="./references#CD006023-bbs2-0095" title="ToussaintN , LauK , PolkinghorneK , KerrP . Attenuation of aortic calcification with lanthanum carbonate vs calcium‐based phosphate binders in haemodialysis ‐ a randomized controlled trial [abstract no: 167]. Nephrology2010;15(Suppl 4):70. ToussaintND , LauKK , PolkinghorneKR , KerrPG . Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology2011;16(3):290‐8. [MEDLINE: 21342323] ToussaintND , LauKK , StraussBJ , PolkinghorneKR , KerrPG . Determination and validation of aortic calcification measurement from lateral bone densitometry in dialysis patients. Clinical Journal of The American Society of Nephrology: CJASN2009;4(1):119‐27. [MEDLINE: 18945998] ">Toussaint 2009</a>; <a href="./references#CD006023-bbs2-0098" title="WadaK , WadaY . Evaluation of aortic calcification with lanthanum carbonate vs. calcium‐based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open‐label randomized controlled trial. Therapeutic Apheresis &amp; Dialysis2014;18(4):353‐60. [MEDLINE: 24417760] ">Wada 2014</a>) at between 6 and 18 months of therapy. In low certainty evidence, the effect of lanthanum treatment on death (all causes) was uncertain (6 studies, 5050 participants: RR 0.76, 95% CI 0.18 to 3.11; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0126" title="">Analysis 9.1</a>). Endpoints for cardiovascular death, myocardial infarction, and stroke were not reported in any of the studies. Based on two studies, there was no evidence of a clinically‐important effect of lanthanum on hospitalisation (2 studies, 88 participants: RR 0.80, 95% CI 0.34 to 1.93; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0127" title="">Analysis 9.2</a>). <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> reported not differences between lanthanum and calcium for fracture (<a href="./references#CD006023-fig-0128" title="">Analysis 9.3</a>) and pruritus (<a href="./references#CD006023-fig-0129" title="">Analysis 9.4</a>). <a href="./references#CD006023-bbs2-0070" title="OhtakeT , FuruyaR , IwagamiM , TsutsumiD , MochidaY , IshiokaK , et al. Lanthanum carbonate delays the progression of coronary artery calcification compared with calcium‐based phosphate binder in patients on hemodialysis [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii229. [EMBASE: 70765964] OhtakeT , KobayashiS , OkaM , FuruyaR , IwagamiM , TsutsumiD , et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium‐based phosphate binders in patients on hemodialysis: a pilot study. Journal of Cardiovascular Pharmacology &amp; Therapeutics2013;18(5):439‐46. [MEDLINE: 23615577] ">Ohtake 2013</a> reported no difference between the two treatments on coronary artery calcium score (<a href="./references#CD006023-fig-0136" title="">Analysis 9.11</a>). </p> <p>Evidence for treatment adverse effects was low‐ or very low‐certainty. Lanthanum may lead to nausea (5 studies, 1191 participants: RR 1.65, 95% CI 0.95 to 2.89; I<sup>2</sup> = 20%), although the estimate included the possibility of no difference (<a href="./references#CD006023-fig-0130" title="">Analysis 9.5</a>). Lanthanum had uncertain effects on vomiting (2 studies, 1058 participants: RR 3.88, 95% CI 0.48 to 31.74; I<sup>2</sup> = 77%) with important statistical heterogeneity in the analysis (<a href="./references#CD006023-fig-0131" title="">Analysis 9.6</a>). There was no evidence of different effects for lanthanum and calcium on abdominal pain (2 studies, 137 participants: RR 0.24, 95% CI 0.03 to 1.94; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0132" title="">Analysis 9.7</a>), constipation (5 studies, 1213 participants: RR 0.79, 95% CI 0.50 to 1.26; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0133" title="">Analysis 9.8</a>), or diarrhoea (2 studies, 858 participants: RR 2.44, 95% CI 0.34 to 17.35; I<sup>2</sup> = 56%) (<a href="./references#CD006023-fig-0134" title="">Analysis 9.9</a>). <a href="./references#CD006023-bbs2-0085" title="ShigematsuT , Lanthanum Carbonate Group. Multicenter prospective randomized, double‐blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clinical Nephrology2008;70(5):404‐10. [MEDLINE: 19000540] ">Shigematsu 2008</a> reported no differences in abdominal bloating between the two groups (<a href="./references#CD006023-fig-0135" title="">Analysis 9.10</a>). </p> <p>In very low certainty evidence with important statistical heterogeneity in the analysis, lanthanum may result in markedly less hypercalcaemia compared with calcium‐based binders (8 studies, 1347 participants: RR 0.16, 95% CI 0.06 to 0.43; I<sup>2</sup> = 59%) (<a href="./references#CD006023-fig-0137" title="">Analysis 9.12</a>). </p> <p>Lanthanum and calcium‐based binders had clinically similar effects on serum phosphate (9 studies, 400 participants: MD ‐0.02 mg/dL (0.006 mmol/L), 95% CI ‐0.45 to 0.41 (‐0.15 to 0.13 pmol/L); I<sup>2</sup> = 76%), in an analysis with marked statistical heterogeneity (<a href="./references#CD006023-fig-0138" title="">Analysis 9.13</a>). Lanthanum treatment may have a small clinical effect on serum calcium levels, although the estimated effect included the possibility of no difference (8 studies, 350 participants: MD ‐0.28 mg/dL (‐0.07 mmol/L), 95% CI ‐0.59 to 0.02 mg/dL (‐0.15 to 0.005 mmol/L); I<sup>2</sup> = 81%), in an analysis with important statistical heterogeneity (<a href="./references#CD006023-fig-0139" title="">Analysis 9.14</a>). Lanthanum may have reduced the serum calcium‐by‐phosphate product (5 studies, 1007 participants: MD ‐2.67 mg<sup>2</sup>/dL<sup>2</sup>, 95% CI ‐5.01 to ‐0.34; I<sup>2</sup> = 26%) (<a href="./references#CD006023-fig-0140" title="">Analysis 9.15</a>). There was no evidence of clinical differences in end of treatment serum PTH (8 studies, 597 participants: MD 33.78 pg/mL(3.85 pmol/L), 95% CI ‐9.03 to 76.60 pg/mL (‐1.03 to 8.73 pmol/L); I<sup>2</sup> = 73%) (<a href="./references#CD006023-fig-0141" title="">Analysis 9.16</a>) or serum alkaline phosphatase (3 studies, 856 participants: MD 20.03 IU/L, 95% CI ‐3.69 to 43.75; I<sup>2</sup> = 88%) (<a href="./references#CD006023-fig-0142" title="">Analysis 9.17</a>). <a href="./references#CD006023-bbs2-0088" title="SorianoS , OjedaR , RodriguezM , AlmadenY , RodriguezM , Martin‐MaloA , et al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clinical Nephrology2013;80(1):17‐22. [MEDLINE: 23391319] ">Soriano 2013</a> reported a higher eGFR at the end of treatment with lanthanum (<a href="./references#CD006023-fig-0143" title="">Analysis 9.18</a>). Lanthanum had uncertain effects on serum FGF23 levels compared with calcium‐based binders (2 studies, 116 participants: SMD ‐0.85, 95% CI ‐2.33 to 0.63; I<sup>2</sup> = 90%) (<a href="./references#CD006023-fig-0144" title="">Analysis 9.19</a>). </p> </section> <section id="CD006023-sec-0108"> <h4 class="title">Iron versus calcium</h4> <p>No studies were identified that provided a head‐to‐head comparison of iron‐ versus calcium‐based binders. </p> </section> <section id="CD006023-sec-0109"> <h4 class="title">Magnesium versus calcium</h4> <p><a href="./references#CD006023-bbs2-0090" title="SpiegelDM , FarmerB . Long‐term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodialysis International2009;13(4):453‐9. [MEDLINE: 19469885] SpiegelDM , FarmerB , ChoncholM . Magnesium carbonate ‐ an effective phosphate binder [abstract no: 152]. American Journal of Kidney Diseases2006;47(4):A56. [CENTRAL: CN‐00653706] SpiegelDM , FarmerB , SmitsG , ChoncholM . Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. Journal of Renal Nutrition2007;17(6):416‐22. [MEDLINE: 17971314] ">Spiegel 2007</a> reported no differences in hospitalisation (<a href="./references#CD006023-fig-0145" title="">Analysis 10.1</a>), constipation (<a href="./references#CD006023-fig-0146" title="">Analysis 10.2</a>), and diarrhoea (<a href="./references#CD006023-fig-0147" title="">Analysis 10.3</a>) between magnesium and calcium‐based binders. </p> </section> <section id="CD006023-sec-0110"> <h4 class="title">Aluminium versus calcium</h4> <p>Two studies evaluated aluminium compared with calcium (<a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a>; <a href="./references#CD006023-bbs2-0051" title="JespersenB , JensenJD , NielsenHK , LauridsenIN , AndersenMJ , PoulsenJH , et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1‐84), and bone mineral content in dialysis patients. Nephrology Dialysis Transplantation1991;6(2):98‐104. [MEDLINE: 1857534] ">Jespersen 1991</a>), however data could not be extracted from <a href="./references#CD006023-bbs2-0051" title="JespersenB , JensenJD , NielsenHK , LauridsenIN , AndersenMJ , PoulsenJH , et al. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1‐84), and bone mineral content in dialysis patients. Nephrology Dialysis Transplantation1991;6(2):98‐104. [MEDLINE: 1857534] ">Jespersen 1991</a>. <a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a> reported lower serum alkaline phosphatase with calcium‐based binders (<a href="./references#CD006023-fig-0148" title="">Analysis 11.1</a>). </p> </section> <section id="CD006023-sec-0111"> <h4 class="title">Magnesium plus calcium versus calcium</h4> <p>Combined magnesium and calcium‐based binders were compared with calcium alone in four studies (<a href="./references#CD006023-bbs2-0029" title="DelmezJA , KelberJ , NorwoodKY , GilesKS , SlatopolskyE . The clinical evaluation of magnesium carbonate (MgCo3) as a phosphorous (P) binder in the suppression of secondary hyperparathyroidism [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:416. DelmezJA , KelberJ , NorwordKY , GilesKS , SlatopolskyE . Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney International1996;49(1):163‐7. [MEDLINE: 8770963] ">Delmez 1996</a>; <a href="./references#CD006023-bbs2-0032" title="DeuberH . Effective reduction of serum phosphate by a calcium and magnesium containing phosphate binder without induction of hypermagnesemia [abstract no: W422]. Nephrology Dialysis Transplantation2003;18(Suppl 4):680‐1. [CENTRAL: CN‐00445085] DeuberHJ . Combined use of calcium acetate and magnesium carbonate as phosphate binder [Kombinierter einsatz von kalziumazetat und magnesiumkarbonat als orale phosphatbinder]. Nieren und Hochdruckkrankheiten2004;33(8):403‐8. [EMBASE: 39150178] ">Deuber 2004</a>; <a href="./references#CD006023-bbs2-0034" title="EvsanaaB , LiuI , AliazardehB , MahdaviS , BajwaG , GulaJ , et al. MgCaCO3 versus CaCO3 in peritoneal dialysis patients‐‐a cross‐over pilot trial. Peritoneal Dialysis International2015;35(1):31‐4. [MEDLINE: 24584605] ">Evsanaa 2015</a>; <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a>). The studies were not designed to evaluate death or cardiovascular endpoints. <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a> reported no difference between the two groups for death as a reason for drop‐out from the study during follow‐up (<a href="./references#CD006023-fig-0149" title="">Analysis 12.1</a>). </p> <p>The clinical effects of magnesium plus calcium compared with calcium alone on serum phosphate levels (2 studies, 109 participants: MD ‐1.26 mg/dL (‐0.41 mmol/L), 95% CI ‐3.52 to 1.00 mg/dL (‐1.14 to 0.32 mmol/L), I<sup>2</sup> = 93%) (<a href="./references#CD006023-fig-0150" title="">Analysis 12.2</a>) and serum calcium levels (2 studies, 109 participants: MD ‐0.92 mg/dL (‐0.23 mmol/L), 95% CI ‐2.39 to 0.55 mg/dL (‐0.60 to 0.14 mmol/L); I<sup>2</sup> = 96%) (<a href="./references#CD006023-fig-0151" title="">Analysis 12.3</a>) were uncertain in analyses with important statistical heterogeneity. <a href="./references#CD006023-bbs2-0096" title="TzanakisIP , StamatakiEE , PapadakiAN , GiannakisN , DamianakisNE , OreopoulosDG . Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. International Urology &amp; Nephrology2014;46(11):2199‐205. [MEDLINE: 25118610] ">Tzanakis 2014</a> reported no differences in serum calcium‐by‐phosphate product (<a href="./references#CD006023-fig-0152" title="">Analysis 12.4</a>) or iPTH (<a href="./references#CD006023-fig-0153" title="">Analysis 12.5</a>) between the two groups. </p> </section> <section id="CD006023-sec-0112"> <h4 class="title">Sevelamer versus lanthanum</h4> <p>Clinical endpoints for the comparison of sevelamer versus lanthanum were reported in two groups of a four‐arm study (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>). <a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a> reported no difference between the two groups for myocardial infarction (<a href="./references#CD006023-fig-0154" title="">Analysis 13.1</a>), stroke (<a href="./references#CD006023-fig-0155" title="">Analysis 13.2</a>), fracture (<a href="./references#CD006023-fig-0156" title="">Analysis 13.3</a>), pruritis (<a href="./references#CD006023-fig-0157" title="">Analysis 13.4</a>), nausea (<a href="./references#CD006023-fig-0158" title="">Analysis 13.5</a>), vomiting (<a href="./references#CD006023-fig-0159" title="">Analysis 13.6</a>), abdominal pain (<a href="./references#CD006023-fig-0160" title="">Analysis 13.7</a>), constipation (<a href="./references#CD006023-fig-0161" title="">Analysis 13.8</a>), diarrhoea (<a href="./references#CD006023-fig-0162" title="">Analysis 13.9</a>), abdominal bloating (<a href="./references#CD006023-fig-0163" title="">Analysis 13.10</a>), and hypercalcaemia (<a href="./references#CD006023-fig-0164" title="">Analysis 13.11</a>). Data from two other studies could not be extracted for meta‐analysis (<a href="./references#CD006023-bbs2-0053" title="KasaiS , SatoK , MurataY , KinoshitaY . Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis. Therapeutic Apheresis &amp; Dialysis2012;16(4):341‐9. [EMBASE: 2012432570] ">Kasai 2012</a>; <a href="./references#CD006023-bbs2-0071" title="PrattR , SmythM . Effective reduction of serum phosphorus using carbonate, with fewer tablets than sevelamer hydrochloride [abstract no: FP486]. Nephrology Dialysis Transplantation2007;22(Suppl 6):vi183. ">Pratt 2007</a>). </p> </section> <section id="CD006023-sec-0113"> <h4 class="title">Sevelamer versus iron</h4> <p>Sevelamer was compared with iron‐based binders in four studies that reported outcomes during three to six months of follow‐up (<a href="./references#CD006023-bbs2-0020" title="ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: a 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology2011;16(8):743‐50. [MEDLINE: 21854503] ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08‐08]. Nephrology2010;15(Suppl 3):51. [EMBASE: 70467427] ChenJB , ChiangSS , HenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]. NDT Plus2010;3(Suppl 3):iii238. [EMBASE: 70484048] ">Chen 2011b</a>; <a href="./references#CD006023-bbs2-0037" title="CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Comparison of safety profiles of PA21 and sevelamer carbonate in a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii153. [EMBASE: 71491873] CovicA , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Efficacy and safety of PA21 and sevelamer carbonate in haemodialysis patients with or without diabetes: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491869] CovicAC , FloegeJ , KettelerM , SpragueSM , LiskL , RakovV , et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation2017;32(8):1330‐8. [MEDLINE: 27342579] FloegeJ , BothaJ , ChongE , SpragueSM . PA21 does not interact with oral vitamin D receptor agonists: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii157. [EMBASE: 71491885] FloegeJ , CovicA , KettelerM , RastogiA , ChongE , LiskL , et al. Regional analysis of baseline characteristics in a phase 3 study of PA21, a novel iron‐based phosphate binder [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155. [EMBASE: 71075446] FloegeJ , CovicAC , KettelerM , MannJ , RastogiA , SpinowitzB , et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation2017;32(11):1918‐26. [MEDLINE: 28339993] FloegeJ , CovicAC , KettelerM , MannJF , RastogiA , SpinowitzB , et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation2015;30(6):1037‐46. [MEDLINE: 25691681] FloegeJ , CovicAC , KettelerM , RastogiA , ChongEM , GaillardS , et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney International2014;86(3):638‐47. [MEDLINE: 24646861] FloegeJ , KettelerM , RastogiA , SpinowitzB , SpragueSM , BothaJ , et al. Post hoc analysis of safety profiles by patient age in a phase 3 study of PA21 and sevelamer carbonate [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii152. [EMBASE: 71491870] FloegeJ , SpragueS , CovicA , RastogiA , SpinowitzB , LarroqueS , et al. Sucroferric oxyhydroxide does not impact the iPTH‐lowering effects of oral vdras or cinacalcet: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i461. [EMBASE: 72327216] FloegeJ , SpragueS , RastogiA , KettelerM , CovicA , RakovV , et al. Characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i466. [EMBASE: 72327232] KettelerM , FloegeJ , RastogiA , SpragueS , GaillardS , LopfeM , et al. PA21, a novel iron‐based phosphate binder, showed no interaction with fat‐soluble vitamins in a phase 3 study [abstract]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i155‐6. [EMBASE: 71075447] RastogiA , CovicA , FloegeJ , KettelerM , ChongE , GaillardS , et al. PA21 ‐ a novel iron‐based phosphate binder with a low pill burden: tolerance in dialysis patients [abstract]. American Journal of Kidney Diseases2013;61(4):A81. [EMBASE: 71024085] RastogiA , CovicA , FloegeJ , KettelerM , SpinowitzB , BothaJ , et al. No clinically relevant changes in vitamin D concentrations with PA21, a novel iron‐based phosphate binder, over 52 weeks [abstract]. American Journal of Kidney Diseases2014;63(5):A94. [EMBASE: 71448568] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , GaillardS , et al. Concomitant intravenous iron use drives changes in iron indices in a phase 3 study of PA21 [abstract]. American Journal of Kidney Diseases2014;63(5):A105. [EMBASE: 71448614] SpragueSM , CovicA , FloegeJ , KettelerM , SpinowitzB , RakovV , et al. Post HOC analysis of antianemic agent use over 1 year in a phase 3 study of sucroferric oxyhydroxide [abstract]. American Journal of Kidney Diseases2015;65(4):A80. [EMBASE: 71875231] SpragueSM , CovicAC , FloegeJ , KettelerM , BothaJ , ChongEM , et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. American Journal of Nephrology2016;44(2):104‐12. [MEDLINE: 27434393] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. 1‐year efficacy and safety of sucroferric oxyhydroxide in a sub‐population of African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313644] SpragueSM , RastogiA , KettelerM , CovicA , FloegeJ , RakovV , et al. FGF‐23 and CKD‐MBD indices after 1 year of treatment with sucroferric oxyhydroxide in African American dialysis patients [abstract]. American Journal of Kidney Diseases2016;67(5):A104. [EMBASE: 72313645] TumlinJ , ChongE , GaillardS , FloegeJ . Evaluating the management of hyperphosphatemia with PA21 in dialysis patients‐rationale and design of an open‐label, randomised, active‐controlled phase 3 study [abstract]. Blood Purification2012;33(1‐3):212‐3. [EMBASE: 70723735] ">Floege 2014</a>; <a href="./references#CD006023-bbs2-0056" title="KoiwaF , YokoyamaK , FukagawaM , TeraoA , AkizawaT . Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrology2017;22(4):293‐300. [MEDLINE: 27496336] ">Koiwa 2017</a>; <a href="./references#CD006023-bbs2-0100" title="YokoyamaK , HirakataH , AkibaT , FukagawaM , NakayamaM , SawadaK , et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis‐dependent CKD. Clinical Journal of The American Society of Nephrology: CJASN2014;9(3):543‐52. [MEDLINE: 24408120] ">Yokoyama 2014</a>). In three of the four studies, participants were treated with haemodialysis or peritoneal dialysis. The studies were not designed to evaluate death or cardiovascular endpoints. Deaths were reported as a reason for drop‐out from follow‐up or as an adverse event in two studies. In very‐low certainty evidence, sevelamer had uncertain effects on the risk of death (all causes) (4 studies, 1683 participants: RR 1.07, 95% CI 0.38 to 2.98; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0165" title="">Analysis 14.1</a>). <a href="./references#CD006023-bbs2-0020" title="ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: a 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride. Nephrology2011;16(8):743‐50. [MEDLINE: 21854503] ChenJB , ChiangSS , ChenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, effectively controls hyperphosphatemia in Asian patients on hemodialysis versus sevelamer [abstract no: FP08‐08]. Nephrology2010;15(Suppl 3):51. [EMBASE: 70467427] ChenJB , ChiangSS , HenHC , ObayashiS , NagasawaM , HexhamJM , et al. SBR759, a novel phosphate binder, is superior to sevelamer HCL in controlling hyperphosphatemia in Asian patients on hemodialysis [abstract no: Sa582]. NDT Plus2010;3(Suppl 3):iii238. [EMBASE: 70484048] ">Chen 2011b</a> reported no differences between the groups for the risk of cardiovascular death (<a href="./references#CD006023-fig-0166" title="">Analysis 14.2</a>), myocardial infarction (<a href="./references#CD006023-fig-0167" title="">Analysis 14.3</a>), and fractures (<a href="./references#CD006023-fig-0168" title="">Analysis 14.4</a>). </p> <p>Compared with iron‐based binders, the risk of nausea (2 studies, 1257 participants: RR 3.86, 95% CI 0.33 to 44.86; I<sup>2</sup> = 68%) (<a href="./references#CD006023-fig-0169" title="">Analysis 14.5</a>), abdominal pain (2 studies, 431 participants: RR 0.42, 95% CI 0.02 to 9.01; I<sup>2</sup> = 79%) (<a href="./references#CD006023-fig-0170" title="">Analysis 14.6</a>), constipation (4 studies, 1699 participants: RR 4.96, 95% CI 1.96 to 12.55; I<sup>2</sup> = 71%) (<a href="./references#CD006023-fig-0171" title="">Analysis 14.7</a>), and diarrhoea (4 studies, 1699 participants: RR 0.28, 95% CI 0.15 to 0.54; I<sup>2</sup> = 51%) (<a href="./references#CD006023-fig-0172" title="">Analysis 14.8</a>) with sevelamer was uncertain in analyses with important statistical heterogeneity. </p> <p>Based on two studies, whether sevelamer had different effects on serum phosphate levels compared with iron‐based binders was uncertain in an analysis within substantial statistical heterogeneity (2 studies, 417 participants: MD 0.19 mg/dL (0.06 mmol/L), 95% CI ‐0.06 to 0.43 mg/dL (‐0.02 to 0.14 mmol/L); I<sup>2</sup> = 28%) (<a href="./references#CD006023-fig-0173" title="">Analysis 14.9</a>). Sevelamer may slightly decrease serum calcium (2 studies, 417 participants: MD ‐0.16 mg/dL (‐0.04 mmol/L, 95% CI ‐0.29 to ‐0.04 mg/dL (‐0.07 to ‐0.01 mmol/L); I<sup>2</sup> = 0%) compared with iron (<a href="./references#CD006023-fig-0174" title="">Analysis 14.10</a>). <a href="./references#CD006023-bbs2-0101" title="YokoyamaK , AkibaT , FukagawaM , NakayamaM , SawadaK , KumagaiY , et al. A randomized trial of JTT‐751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology Dialysis Transplantation2014;29(5):1053‐60. [MEDLINE: 24376274] ">Yokoyama 2014a</a> reported serum bicarbonate levels were lower in the sevelamer group (<a href="./references#CD006023-fig-0175" title="">Analysis 14.11</a>). </p> </section> <section id="CD006023-sec-0114"> <h4 class="title">Sevelamer versus bixalomer</h4> <p><a href="./references#CD006023-bbs2-0003" title="AkizawaT , OrigasaH , KameokaC , KanekoY , KawasakiS , Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Therapeutic Apheresis &amp; Dialysis2014;18(2):122‐31. [MEDLINE: 24720402] ">Akizawa 2014a</a> reported no differences between sevelamer and bixalomer for death (<a href="./references#CD006023-fig-0176" title="">Analysis 15.1</a>), fracture (<a href="./references#CD006023-fig-0177" title="">Analysis 15.2</a>), pruritis (<a href="./references#CD006023-fig-0178" title="">Analysis 15.3</a>), nausea (<a href="./references#CD006023-fig-0179" title="">Analysis 15.4</a>), vomiting (<a href="./references#CD006023-fig-0180" title="">Analysis 15.5</a>), abdominal pain (<a href="./references#CD006023-fig-0181" title="">Analysis 15.6</a>), constipation (<a href="./references#CD006023-fig-0182" title="">Analysis 15.7</a>), abdominal bloating (<a href="./references#CD006023-fig-0183" title="">Analysis 15.8</a>), serum phosphate (<a href="./references#CD006023-fig-0184" title="">Analysis 15.9</a>), serum calcium (<a href="./references#CD006023-fig-0185" title="">Analysis 15.10</a>), and serum calcium‐by‐phosphate product (<a href="./references#CD006023-fig-0186" title="">Analysis 15.11</a>). <a href="./references#CD006023-bbs2-0003" title="AkizawaT , OrigasaH , KameokaC , KanekoY , KawasakiS , Bixalomer Study Group. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Therapeutic Apheresis &amp; Dialysis2014;18(2):122‐31. [MEDLINE: 24720402] ">Akizawa 2014a</a> reported serum iPTH (<a href="./references#CD006023-fig-0187" title="">Analysis 15.12</a>) and serum bicarbonate (<a href="./references#CD006023-fig-0188" title="">Analysis 15.13</a>) were lower in the sevelamer group. </p> </section> <section id="CD006023-sec-0115"> <h4 class="title">Sevelamer versus nicotinamide</h4> <p><a href="./references#CD006023-bbs2-0069" title="LengletA , LiabeufS , ElEsperN , BrissetS , MansourJ , Lemaire‐HurtelAS , et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation2017;32(5):870‐9. [MEDLINE: 24599830] ">NICOREN 2017</a> reported no differences between sevelamer and nicotinamide for death (<a href="./references#CD006023-fig-0189" title="">Analysis 16.1</a>), stroke (<a href="./references#CD006023-fig-0190" title="">Analysis 16.2</a>), vomiting (<a href="./references#CD006023-fig-0191" title="">Analysis 16.3</a>), serum calcium (<a href="./references#CD006023-fig-0192" title="">Analysis 16.4</a>), serum iPTH (<a href="./references#CD006023-fig-0193" title="">Analysis 16.5</a>), and serum alkaline phosphatase <a href="./references#CD006023-fig-0194" title="">Analysis 16.6</a>). </p> </section> <section id="CD006023-sec-0116"> <h4 class="title">Sevelamer versus colestilan</h4> <p>Clinical outcomes for the comparison of sevelamer versus colestilan were reported in three studies (<a href="./references#CD006023-bbs2-0048" title="ItohK , TanakaM , HashiguchiJ , FunakoshiS , NakanoH , KuboH , et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp; Dialysis2008;12(2):126‐32. [MEDLINE: 18387160] ">Itoh 2008</a>; <a href="./references#CD006023-bbs2-0065" title="LocatelliF , SpasovskiG , DimkovicN , WannerC , DellannaF , PontorieroG . The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1‐year prospective randomized study. Nephrology Dialysis Transplantation2014;29(5):1061‐73. [MEDLINE: 24302608] ">Locatelli 2014</a>; <a href="./references#CD006023-bbs2-0068" title="NCT00542815 . A study of MCI‐196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia. ClinicalTrials.gov/show/NCT00542815 (first received 12 October 2007). ">NCT00542815</a>). In moderate certainty evidence, sevelamer may reduce death (all causes) compared with colestilan (2 studies, 536 participants: RR 0.30, 95% CI 0.10 to 0.96; I<sup>2</sup> = 0%) during follow‐up ranging from 1.9 to 12 months (<a href="./references#CD006023-fig-0195" title="">Analysis 17.1</a>). <a href="./references#CD006023-bbs2-0068" title="NCT00542815 . A study of MCI‐196 in chronic kidney disease stage V subjects on dialysis with hyperphosphatemia. ClinicalTrials.gov/show/NCT00542815 (first received 12 October 2007). ">NCT00542815</a> reported no differences between sevelamer and colestilan for cardiovascular death (<a href="./references#CD006023-fig-0196" title="">Analysis 17.2</a>), myocardial infarction (<a href="./references#CD006023-fig-0197" title="">Analysis 17.3</a>), stroke (<a href="./references#CD006023-fig-0198" title="">Analysis 17.4</a>), pruritis (<a href="./references#CD006023-fig-0199" title="">Analysis 17.5</a>), nausea (<a href="./references#CD006023-fig-0200" title="">Analysis 17.6</a>), vomiting (<a href="./references#CD006023-fig-0201" title="">Analysis 17.7</a>), abdominal pain (<a href="./references#CD006023-fig-0202" title="">Analysis 17.8</a>), constipation (<a href="./references#CD006023-fig-0203" title="">Analysis 17.9</a>), and diarrhoea (<a href="./references#CD006023-fig-0204" title="">Analysis 17.10</a>). <a href="./references#CD006023-bbs2-0048" title="ItohK , TanakaM , HashiguchiJ , FunakoshiS , NakanoH , KuboH , et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp; Dialysis2008;12(2):126‐32. [MEDLINE: 18387160] ">Itoh 2008</a> reported no differences between the groups for serum phosphate (<a href="./references#CD006023-fig-0205" title="">Analysis 17.11</a>), serum calcium (<a href="./references#CD006023-fig-0206" title="">Analysis 17.12</a>), and serum calcium‐by‐phosphate product (<a href="./references#CD006023-fig-0207" title="">Analysis 17.13</a>). <a href="./references#CD006023-bbs2-0048" title="ItohK , TanakaM , HashiguchiJ , FunakoshiS , NakanoH , KuboH , et al. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Therapeutic Apheresis &amp; Dialysis2008;12(2):126‐32. [MEDLINE: 18387160] ">Itoh 2008</a> reported serum iPTH (<a href="./references#CD006023-fig-0208" title="">Analysis 17.14</a>) and serum alkaline phosphatase (<a href="./references#CD006023-fig-0209" title="">Analysis 17.15</a>) were lower in the sevelamer group. </p> </section> <section id="CD006023-sec-0117"> <h4 class="title">Sevelamer versus aluminium</h4> <p><a href="./references#CD006023-bbs2-0054" title="KatopodisKP , AndrikosEK , GouvaCD , BairaktariET , NikolopoulosPM , TakouliLK , et al. Sevelamer hydrochloride versus aluminum hydroxide: Effect on serum phosphorus and lipids in CAPD patients. Peritoneal Dialysis International2006;26(3):320‐7. [MEDLINE: 16722024] ">Katopodis 2006</a> reported no differences between sevelamer and aluminium for nausea (<a href="./references#CD006023-fig-0210" title="">Analysis 18.1</a>), constipation (<a href="./references#CD006023-fig-0211" title="">Analysis 18.2</a>), serum phosphate (<a href="./references#CD006023-fig-0212" title="">Analysis 18.3</a>), serum calcium (<a href="./references#CD006023-fig-0213" title="">Analysis 18.4</a>), and serum iPTH (<a href="./references#CD006023-fig-0214" title="">Analysis 18.5</a>). </p> </section> <section id="CD006023-sec-0118"> <h4 class="title">Sevelamer versus magnesium</h4> <p><a href="./references#CD006023-bbs2-0104" title="ZwiechR , DryjaP , LacinaD , KroliczakV , ChrulS , KacprzykF . The influence of short‐term magnesium carbonate treatment on calcium‐phosphorus balance in dialysis patients [Wplyw krotkoterminowego leczenia weglanem magnezu na gospodarke wapniowo‐fosforanowa u chorych przewlekle hemodializowanych]. Wiadomosci Lekarskie2011;64(1):9‐14. [MEDLINE: 21812357] ">Zwiech 2011</a> reported serum phosphate (<a href="./references#CD006023-fig-0215" title="">Analysis 19.1</a>) and serum calcium‐by‐phosphate product (<a href="./references#CD006023-fig-0217" title="">Analysis 19.3</a>) were lower with magnesium; serum calcium (<a href="./references#CD006023-fig-0216" title="">Analysis 19.2</a>) was lower with sevelamer; and there was no difference between the groups for iPTH (<a href="./references#CD006023-fig-0218" title="">Analysis 19.4</a>). </p> </section> <section id="CD006023-sec-0119"> <h4 class="title">Sevelamer versus sevelamer plus calcium</h4> <p><a href="./references#CD006023-bbs2-0024" title="ChertowGM , DillonM , BurkeSK , StegM , BleyerAJ , GarrettBN , et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clinical Nephrology1999;51(1):18‐26. [MEDLINE: 9988142] ">Chertow 1999</a> reported no differences between sevelamer and combination sevelamer plus calcium‐based binders for hypercalcaemia (<a href="./references#CD006023-fig-0219" title="">Analysis 20.1</a>) and serum calcium‐by‐phosphate product (<a href="./references#CD006023-fig-0220" title="">Analysis 20.2</a>). </p> </section> <section id="CD006023-sec-0120"> <h4 class="title">Sevelamer versus calcium plus magnesium</h4> <p><a href="./references#CD006023-bbs2-0016" title="CovicA , Passlick‐DeetjenJ , KroczakM , Buschges‐SeraphinB , GhenuA , PonceP , et al. A comparison of calcium acetate/magnesium carbonate and sevelamer‐hydrochloride effects on fibroblast growth factor‐23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation2013;28(9):2383‐92. [MEDLINE: 23787550] PaschA , deFranciscoALM , CovicA , MarzellB , ArensHJ , Passlick‐DeetjenJ , et al. Serum calcification propensity of HD patients is therapeutically improved by a calcium acetate/ magnesium carbonate containing phosphate binder [abstract]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii40. [EMBASE: 71491561] deFranciscoAL , LeidigM , CovicAC , KettelerM , Benedyk‐LorensE , MircescuGM , et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrology Dialysis Transplantation2010;25(11):3707‐17. [MEDLINE: 20530499] ">CALMAG 2010</a> reported no differences between sevelamer and combination calcium plus magnesium for serum phosphate (<a href="./references#CD006023-fig-0221" title="">Analysis 21.1</a>), serum calcium (<a href="./references#CD006023-fig-0222" title="">Analysis 21.2</a>), and serum iPTH (<a href="./references#CD006023-fig-0223" title="">Analysis 21.3</a>). Serum alkaline phosphate was reported to be lower with calcium plus magnesium (<a href="./references#CD006023-fig-0224" title="">Analysis 21.4</a>), and serum bicarbonate was reported to be lower with sevelamer (<a href="./references#CD006023-fig-0225" title="">Analysis 21.5</a>). </p> </section> <section id="CD006023-sec-0121"> <h4 class="title">Lanthanum versus iron</h4> <p><a href="./references#CD006023-bbs2-0040" title="FujimoriA , OhkawaS , OkadaS , MizobuchiN , SakaiM , HasuikeY , et al. Comparison of the suppressive effects on fibroblast growth factor 23 between ferric citrate and lanthanum carbonate [abstract]. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii244‐5. [EMBASE: 617291229] ">Fujimori 2017</a> compared lanthanum to ferric citrate however data could not be extracted. </p> </section> <section id="CD006023-sec-0122"> <h4 class="title">Sevelamer hydrochloride versus sevelamer carbonate</h4> <p><a href="./references#CD006023-bbs2-0036" title="FishbaneS , DelmezJ , SukiW , HariacharS , MoeS , HeatonJ . Sevelamer carbonate powder dosed once per day and sevelamer hydrochloride tablets dosed three times per day: a randomized, parallel, open‐label study in chronic kidney disease patients on hemodialysis [abstract no: M621]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. FishbaneS , DelmezJ , SukiWN , HariacharS , MoeS . A randomized, parallel, open‐label study to compare once per day sevelamer carbonate powder dosing with three times per day sevelamer hydrochloride tablet dosing in chronic kidney disease patients on hemodialysis [abstract no: PUB556]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):936A. [CENTRAL: CN‐00747271] FishbaneS , DelmezJ , SukiWN , HariacharSK , HeatonJ , Chasan‐TaberS , et al. A randomized, parallel, open‐label study to compare once‐daily sevelamer carbonate powder dosing with thrice‐daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. American Journal of Kidney Diseases2010;55(2):307‐15. [MEDLINE: 20042256] ">Fishbane 2010</a> reported no differences between sevelamer hydrochloride and sevelamer carbonate for death (<a href="./references#CD006023-fig-0226" title="">Analysis 22.1</a>), nausea (<a href="./references#CD006023-fig-0227" title="">Analysis 22.2</a>), vomiting (<a href="./references#CD006023-fig-0228" title="">Analysis 22.3</a>), constipation (<a href="./references#CD006023-fig-0229" title="">Analysis 22.4</a>), and diarrhoea (<a href="./references#CD006023-fig-0230" title="">Analysis 22.5</a>). </p> </section> <section id="CD006023-sec-0123"> <h4 class="title">Calcium acetate versus calcium carbonate</h4> <p>Data for the comparison of calcium acetate compared with calcium carbonate were reported in four studies (<a href="./references#CD006023-bbs2-0006" title="AlmirallJ , VecianaL , LlibreJ . Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):976. [CENTRAL: CN‐00260851] AlmirallJ , VecianaL , LlibreJ . Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. American Journal of Nephrology1994;14(3):192‐6. [MEDLINE: 7977479] ">Almirall 1994</a>; <a href="./references#CD006023-bbs2-0017" title="CaravacaF , SantosI , CuberoJJ , EsparragoJF , ArrobasM , PizarroJL , et al. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron1992;60(4):423‐7. [MEDLINE: 1584317] CaravacaF , SantosI , RoblesR , CuberoJ , EsparragoJ , ArrobasM , et al. Calcium acetate versus calcium carbonate as phosphate binders in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1990;5(8):729. [CENTRAL: CN‐00260555] ">Caravaca 1992</a>; <a href="./references#CD006023-bbs2-0038" title="ForasterA , GonzalezMT , CarrerasJ , PrietoML , SampietroJ , BonninR , et al. Calcium acetate. A good alternative to calcium carbonate for treating hyperphosphoremia in chronic hemodialysis patients with high risk of hypercalcemia [Acetato calcico. Una buena alternativa al carbonato calcico, como quelante del fosforo, en los pacientes en hemodialisis con riesgo de hipercalcemia]. Nefrologia1998;18(4):296‐301. [EMBASE: 1998302471] ">Foraster 1998</a>; <a href="./references#CD006023-bbs2-0050" title="JanssenMJ , van derKuyA , ter WeePM , vanBovenWP . Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clinical Nephrology1996;45(2):111‐9. [MEDLINE: 8846523] ">Janssen 1996</a>). The studies were not designed to evaluate death or cardiovascular endpoints. It was uncertain whether calcium acetate prevents death because the certainty of the evidence was very low (2 studies, 74 participants: RR 1.13, 95% CI 0.07 to 17.30; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0231" title="">Analysis 23.1</a>). Calcium acetate may lower the risk of hypercalcaemia compared with calcium carbonate (2 studies, 92 participants: RR 0.66, 95% CI 0.45 to 0.97; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0232" title="">Analysis 23.2</a>). Adverse events for the treatment comparison could not be extracted for meta‐analysis. </p> <p>Calcium acetate may make little or no difference to serum phosphate levels (3 studies, 98 participants: MD ‐0.24 mg/dL (‐0.08 mmol/L), 95% CI ‐0.74 to 0.26 mg/dL (‐0.24 to 0.08 mmol/L); I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0233" title="">Analysis 23.3</a>), serum calcium (3 studies, 98 participants: MD ‐0.21 mg/dL (‐0.05 mmol/L), 95% CI ‐0.45 to 0.04 mg/dL (‐0.11 to 0.01 mmol/L); I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0234" title="">Analysis 23.4</a>), or serum alkaline phosphatase (2 studies, 35 participants: MD 1.77 IU/L, 95% CI ‐8.80 to 12.35; I<sup>2</sup> = 0%) (<a href="./references#CD006023-fig-0237" title="">Analysis 23.7</a>). <a href="./references#CD006023-bbs2-0006" title="AlmirallJ , VecianaL , LlibreJ . Ca acetate versus Ca carbonate for the control of serum phosphate in haemodialysis patients [abstract]. Nephrology Dialysis Transplantation1993;8(9):976. [CENTRAL: CN‐00260851] AlmirallJ , VecianaL , LlibreJ . Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. American Journal of Nephrology1994;14(3):192‐6. [MEDLINE: 7977479] ">Almirall 1994</a> reported no difference between the groups for calcium‐by‐phosphate product (<a href="./references#CD006023-fig-0235" title="">Analysis 23.5</a>) and <a href="./references#CD006023-bbs2-0038" title="ForasterA , GonzalezMT , CarrerasJ , PrietoML , SampietroJ , BonninR , et al. Calcium acetate. A good alternative to calcium carbonate for treating hyperphosphoremia in chronic hemodialysis patients with high risk of hypercalcemia [Acetato calcico. Una buena alternativa al carbonato calcico, como quelante del fosforo, en los pacientes en hemodialisis con riesgo de hipercalcemia]. Nefrologia1998;18(4):296‐301. [EMBASE: 1998302471] ">Foraster 1998</a> reported no difference in serum iPTH (<a href="./references#CD006023-fig-0236" title="">Analysis 23.6</a>). </p> </section> <section id="CD006023-sec-0124"> <h4 class="title">Investigation for sources of heterogeneity</h4> <section id="CD006023-sec-0125"> <h5 class="title">Subgroup analysis</h5> <p>We pre‐planned subgroup analysis by age (greater or less than 60 years old), CKD GFR categories (G2 to G5 or G5D), baseline serum phosphate level (above or below 4.5 mg/dL (1.5 mmol/L)), study duration (above and below 12 months), and methodological quality (low risk of bias for allocation concealment and high or unclear risk of bias). There was no evidence of different treatment effects based on these factors (<a href="./references#CD006023-fig-0238" title="">Analysis 24.1</a>; <a href="./references#CD006023-fig-0239" title="">Analysis 24.2</a>; <a href="./references#CD006023-fig-0240" title="">Analysis 24.3</a>; <a href="./references#CD006023-fig-0241" title="">Analysis 24.4</a>; <a href="./references#CD006023-fig-0242" title="">Analysis 24.5</a>). Subgroup analyses based on different serum phosphate levels at baseline were not possible. Subgroup analyses based on CKD GFR category were limited in statistical power as placebo or usual care controlled studies primarily involved participants with CKD G2 to G5, and those comparing calcium‐free with calcium‐based binders involved participants with GFR G5D. </p> </section> <section id="CD006023-sec-0126"> <h5 class="title">Sensitivity analysis</h5> <p>Due to the low certainty of the comparison of sevelamer versus calcium on death (all causes) because of study limitations and evidence of important statistical heterogeneity, we did a sensitivity analysis restricting the comparison to studies with a low risk of selection bias. Limiting analysis to include the six studies at low risk of bias for this treatment comparison (<a href="./references#CD006023-bbs2-0010" title="BlockG , RaggiP , BellasiA , EhrlichJ , ChoncholM , SpiegelD . Increased mortality associated with coronary artery calcium scores and calcium containing phosphate binders: long term results from a randomized controlled trial in new dialysis patients [abstract no: MO020]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv294. BlockGA , RaggiP , BellasiA , KooiengaL , SpiegelDM . Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International2007;71(5):438‐41. [MEDLINE: 17200680] BlockGA , SpiegelDM , EhrlichJ , MehtaR , LindberghJ , DreisbachA , et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International2005;68(4):1815‐24. [MEDLINE: 16164659] D'MarcoLG , BellasiA , KimS , ChenZ , BlockGA , RaggiP . Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation2013;28(10):2586‐95. [MEDLINE: 23904396] GalassiA , SpiegelD , NewboldC , BlockG , RaggiP . Accelerated vascular calcification in diabetic patients new to hemodialysis treated with calcium salts as compared to sevelamer [abstract no: SA‐PO818]. Journal of the American Society of Nephrology2005;16:735A. [CENTRAL: CN‐00583849] GalassiA , SpiegelDM , BellasiA , BlockGA , RaggiP . Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation2006;21(11):3215‐22. [MEDLINE: 16877490] KoSM , ZhangC , ChenZ , D'MarcoL , BellasiA , StillmanAE , et al. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium‐based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology2016;29(5):683‐90. [MEDLINE: 27102490] SpiegelDM , RaggiP , MehtaR , LindbergJS , ChoncholM , EhrlichJ , et al. Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International2004;8(3):265‐72. [EMBASE: 2005331550] SpiegelDM , RaggiP , SmitsG , BlockGA . Factors associated with mortality in patients new to haemodialysis. Nephrology Dialysis Transplantation2007;22(12):3568‐72. [MEDLINE: 17617651] ">Block 2005</a>; <a href="./references#CD006023-bbs2-0013" title="AraujoMJ , KarohlC , EliasRM , BarretoFC , BarretoDV , CanzianiME , et al. The pitfall of treating low bone turnover: effects on cortical porosity. Bone2016;91:75‐80. [MEDLINE: 27424935] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , CendorogloM , DraibeSA , et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia‐related risk factors.[Erratum appears in Kidney Int. 2005 May;67(5):2085‐7]. Kidney International2005;67(4):1576‐82. [MEDLINE: 15780114] BarretoDV , BarretoFC , CarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.[Erratum appears in Am J Kidney Dis. 2009 Jan;53(1):181]. American Journal of Kidney Diseases2008;52(6):1139‐50. [MEDLINE: 18824289] BarretoDV , BarretoFC , deCarvalhoAB , CuppariL , DraibeSA , DalboniMA , et al. Phosphate binder impact on bone remodeling and coronary calcification ‐ results from the BRiC study. Nephron2008;110(4):c273‐83. [MEDLINE: 19001830] BarretoFC , BarretoDV , MoysesRM , DiasCB , JorgettiV , DraibeSA , et al. Sevelamer and calcium acetate effects on bone histology in hemodialysis patients: one‐year follow‐up [abstract no: SA‐PO831]. Journal of the American Society of Nephrology2005;16:738A. [CENTRAL: CN‐00676033] BarretoFC , BarretoDV , MoysesRM , NevesKR , CanzianiME , DraibeSA , et al. K/DOQI‐recommended intact PTH levels do not prevent low‐turnover bone disease in hemodialysis patients. Kidney International2008;73(6):771‐7. [MEDLINE: 18185506] CancelaAL , OliveiraRB , GraciolliFG , dos ReisLM , BarretoF , BarretoDV , et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron2011;117(1):c74‐82. [MEDLINE: 20689328] CanzianiME , MoysesRM , BarettoDV , BarretoFC , Cendoroglo‐NetoM , BlairA , et al. Bone and the relationship with inflammation and coronary calcification (BRIC) study [abstract no: SU‐PO723]. Journal of the American Society of Nephrology2003;14(Nov):694A. [CENTRAL: CN‐00677751] OliveiraRB , BarretoF , BarretoDV , GraciolliFG , CancelaALE , CuppariL , et al. Sevelamer (SEV), but not calcium acetate (CA), decreases serum fibroblast growth factor 23 (FGF23) in hemodialysis patients [abstract no: SA‐PO863]. Journal of the American Society of Nephrology2007;18(Abstracts):532A. [CENTRAL: CN‐00776229] PeresAT , DalboniMA , CanzianiME , ManfrediSR , CarvalhoJT , BatistaMC , et al. Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients. Hemodialysis International2009;13(3):271‐7. [CENTRAL: CN‐00747277] ">BRiC 2005</a>; <a href="./references#CD006023-bbs2-0018" title="NolanCR , HootkinsRE , ClevelandMB , PelhamRW , QunibiWY . Treatment of hyperphosphatemia in dialysis patients: results of the calcium acetate renegel evaluation (CARE Study) [abstract no: F‐PO664]. Journal of the American Society of Nephrology2003;14(Nov):207A. QunibiWY , HootkinsRE , McDowellLL , MeyerMS , SimonM , GarzaRO , et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney International2004;65(5):1914‐26. [MEDLINE: 15086935] ">CARE 2004</a>; <a href="./references#CD006023-bbs2-0025" title='AsmusHG , BraunJ , KrauseR , BrunkhorstR , HolzerH , SchulzW , et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrology Dialysis Transplantation2005;20(8):1653‐61. [MEDLINE: 15930018] BommerJ , AsmusG , BraunJ , BrunkhorstR , HolzerH , KrauseR , et al. Sevelamer is more effective than calcium in the management of mineral metabolism and arterial calcification [abstract no: O106]. Nephrology Dialysis Transplantation2002;17(Suppl 1):32. [CENTRAL: CN‐00509096] BommerJ , European Renagel Investigators Group. Lipid lowering effect of renagel, a novel phosphate binder [abstract]. Nephrology Dialysis Transplantation2001;16(6):A122. [CENTRAL: CN‐00444477] BraunJ , AsmusHG , HolzerH , BrunkhorstR , KrauseR , SchulzW , et al. Long‐term comparison of a calcium‐free phosphate binder and calcium carbonate‐‐phosphorus metabolism and cardiovascular calcification. Clinical Nephrology2004;62(2):104‐15. [MEDLINE: 15356967] ChertowGM , BurkeSK , RaggiP , Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International2002;62(1):245‐52. [MEDLINE: 12081584] ChertowGM , Chasan‐TaberS , RaggiP . The "tip of the iceberg" matters: exposure to high normal serum calcium concentration leads to accelerated coronary artery and aortic calcification in hemodialysis patients treated with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2002;13(September, Program &amp; Abstracts):433a. [CENTRAL: CN‐00444789] ChertowGM , DillonMA , AminN , BommerJ , BurkeSK . Sevelamer is more effective at controlling disorders of mineral metabolism than calcium‐based phosphate binders in hemodialysis patients [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):195‐6A. [CENTRAL: CN‐00444790] ChertowGM , GoodmanWG , TotoRD , RaggiP . In hemodialysis patients, sevelamer (renagel) attenuates coronary artery and aortic calcification and reduces LDL‐C, APO‐B, and HS‐CRP compared with calcium acetate (PHOSLO) [abstract no: SA‐PO603]. Journal of the American Society of Nephrology2002;13(Sept, Program &amp; Abstracts):386a. [CENTRAL: CN‐00444791] ChertowGM , RaggiP , Chasan‐TaberS , BommerJ , HolzerH , BurkeSK . Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation2004;19(6):1489‐96. [MEDLINE: 15102961] ChertowGM , RaggiP , McCarthyJT , SchulmanG , SilberzweigJ , KuhlikA , et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. American Journal of Nephrology2003;23(5):307‐14. [MEDLINE: 12915774] FerramoscaE , BurkeS , Chasan‐TaberS , RattiC , ChertowGM , RaggiP . Potential antiatherogenic and anti‐inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal2005;149(5):820‐5. [MEDLINE: 15894962] GargJP , Chasan‐TaberS , BlairA , PloneM , BommerJ , RaggiP , et al. Effects of sevelamer and calcium‐based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis &amp; Rheumatism2005;52(1):290‐5. [MEDLINE: 15641045] JamesG , RaggiP , BoulayA , BurkeS , Chasan‐TaberS , ChertowG , et al. Thoracic vertebral bone density increases with renagel and decreases with calcium‐based phosphate binder therapy ‐ a two year study [abstract no: W423]. Nephrology Dialysis Transplantation2003;18(Suppl 4):681. [CENTRAL: CN‐00445894] RaggiP , BommerJ , ChertowGM . Valvular calcification in hemodialysis patients randomized to calcium‐based phosphorus binders or sevelamer. Journal of Heart Valve Disease2004;13(1):134‐41. [MEDLINE: 14765851] RaggiP , BurkeS , Chasen‐TaberS , ChertowG , HolzerH , BommerJ . Sevelamer preserves trabecular bone mineral density [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:103‐4. [CENTRAL: CN‐00509430] RaggiP , BurkeSK , Chasen‐TaberS , ChertowGM , HolzerH , BommerJ . Sevelamer preserves and calcium reduces trabecular bone mineral density [abstract no: SA‐PO924]. Journal of the American Society of Nephrology2003;14(Nov):502A. [CENTRAL: CN‐00583411] RaggiP , BurkeSK , DillonMA , AminN , BommerJ , ChertowGM . Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium‐based phosphate binders [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):239A. [CENTRAL: CN‐00447325] RaggiP , JamesG , BurkeSK , BommerS , Chasan‐TaberS , HolzerH , et al. Decrease in thoracic vertebral bone attenuation with calcium‐based phosphate binders in hemodialysis. Journal of Bone &amp; Mineral Research2005;20(5):764‐72. [MEDLINE: 15824849] '>Chertow 2002</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0052" title="KakutaT , HyodoT , TanakaR , MiyamotoY , KanaiG , SuzukiH , et al. Sevelamer attenuates the progression of coronary calcification and serum pentosidine content (an AGE) by HPLC assay in haemodialysis patients [abstract no: SU‐PO569]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):708A. KakutaT , TanakaR , HyodoT , SuzukiH , KanaiG , NagaokaM , et al. Effect of sevelamer and calcium‐based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.[Erratum appears in Am J Kidney Dis. 2011 May;57(5):804]. American Journal of Kidney Diseases2011;57(3):422‐31. [MEDLINE: 21239096] ">Kakuta 2011</a>) resulted in evidence of decreased death (all causes) with sevelamer compared with calcium‐based binders in an analysis without evidence of important statistical heterogeneity (RR 0.58, 95% CI 0.36 to 0.94; I<sup>2</sup> = 7%; <i>high certainty evidence</i>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006023-sec-0127" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006023-sec-0127"></div> <section id="CD006023-sec-0128"> <h3 class="title" id="CD006023-sec-0128">Summary of main results</h3> <p>In this updated review, 69 new studies have been added to the 2011 Cochrane review and 23 were removed to provide a total of 104 studies involving 13,744 adults. Studies comparing phosphate binders (sevelamer, lanthanum, calcium, and ferric citrate) to placebo or usual care without binder administration were largely limited to adult patients with CKD G2 to G5 not requiring dialysis (15/25 studies involving 1467 participants), Head‐to‐head studies including those comparing non‐calcium‐ and calcium‐based binders were predominantly conducted among participants with CKD G5D treated with dialysis (74/81 studies involving 10,364 participants). </p> <p>Overall, the superiority of phosphate binders to placebo has not been demonstrated across the range of GFR categories. The addition of new studies has led to the updated conclusion that sevelamer may decrease death (all causes) in studies involving people with CKD G5D when compared with calcium‐based binders. When restricted to higher quality studies, high certainty evidence suggested that sevelamer lead to lower death (all causes) when compared to calcium‐based binders. Despite over one hundred studies eligible for this review, only three were designed to examine non‐fatal cardiovascular events and all‐cause and cardiovascular death as primary or important secondary outcomes. Currently, the evidence for effects of phosphate binders on cardiovascular events and cardiovascular death is uncertain due to a paucity of data. The effects of treatment on fracture and rare outcomes such as calciphylaxis were very uncertain because of a lack of studies reporting these outcomes. </p> <section id="CD006023-sec-0129"> <h4 class="title">Phosphate binders versus placebo or usual care</h4> <p>Placebo‐ or usual care‐controlled studies predominantly involved participants who had moderate CKD (CKD G2 to G5 not requiring dialysis) and were of short duration (generally three months or less). These studies generally involved few participants, with nearly all involving &lt; 200 adults. All but two placebo‐controlled studies had been published since 2008. </p> <p>No placebo‐controlled study was designed to evaluate treatment effects on death (all causes) or individual major cardiovascular outcomes, such as stroke or myocardial infarction. Based on a limited number of short‐term studies, whether phosphate binders prevented all‐cause or cardiovascular death in adults with CKD G2 to G5 was uncertain. There is currently no high‐certainty evidence that phosphate binders prevent myocardial infarction or stroke when compared with placebo or usual care. Sevelamer may incur nausea while lanthanum may lead to nausea and constipation, and iron‐based binders may lead to diarrhoea or constipation. </p> <p>We were uncertain whether phosphate binders impacted on coronary artery calcium scores, fracture risk, or calciphylaxis when compared to placebo in adults with CKD G2 to 5, although the follow‐up duration was very short. Not unexpectedly, calcium‐based binders incurred substantially increased risks of hypercalcaemia. </p> </section> <section id="CD006023-sec-0130"> <h4 class="title">Non‐calcium‐based binders versus calcium‐based binders</h4> <p>Unlike placebo‐controlled studies which were conducted in the setting of CKD G2 to 5, active comparator studies evaluating treatment against calcium‐based binders were generally conducted among adults with CKD G5D treated with dialysis. Studies involved generally few participants with the median sample size of 70 adults. Follow‐up ranged between 1.8 and 36 months, with a median of 6 months. Three studies were designed to evaluate all‐cause or cause‐specific death as a pre‐specified primary or secondary outcome. </p> <p>In low certainty evidence, sevelamer may prevent death (all causes) when compared with calcium‐based binders. This finding was robust when evaluated in an analyses restricted to higher quality studies, leading to higher certainty in the result. It is unclear from this observation whether sevelamer leads to lower death, calcium‐binders cause excess death, or both these observations are true. </p> <p>It was uncertain whether lanthanum decreased death (all causes) compared with calcium‐based binders, and comparative data for iron‐based binders were absent. There was no evidence that non‐calcium phosphate binders improved fracture, pruritus, calciphylaxis, or coronary artery calcification. Sevelamer and lanthanum may have similar risks of nausea, vomiting or constipation compared with calcium‐based binders. Not unexpectedly, sevelamer and lanthanum may incur less hypercalcaemia than calcium‐based binders. There was no evidence that non‐calcium and calcium‐based binders had different effects on serum phosphate levels. </p> </section> <section id="CD006023-sec-0131"> <h4 class="title">Non‐calcium‐based binder versus non‐calcium‐based binder</h4> <p>Head‐to‐head studies of sevelamer, lanthanum, iron, and other non‐calcium phosphate binders were extremely limited. No available studies were designed to evaluate death or cardiovascular events. The effects of treatment on other outcomes were obscured by the paucity of data including for adverse treatment events. </p> <p>Overall, there was insufficient evidence to conduct subgroup analyses based on CKD GFR category and to assess individual phosphate binder agents within drug classes. </p> </section> </section> <section id="CD006023-sec-0132"> <h3 class="title" id="CD006023-sec-0132">Overall completeness and applicability of evidence</h3> <p>This review included evidence from 104 RCTs from 29 different countries or global regions, to evaluate the effects of phosphate binders versus placebo or usual care or other phosphate binder. In general, placebo‐ and usual care studies were more recently published and involved adults with CKD who do not require dialysis therapy. Active comparator studies were mostly conducted among dialysis patients. Therefore, there is a paucity of placebo‐controlled studies in the dialysis setting. </p> <p>In general, study follow‐up was short and very few studies were designed to evaluate death endpoints, specifically for lanthanum and iron‐based binders compared with calcium‐based agents for dialysis patients. An ongoing study (<a href="./references#CD006023-bbs2-0209" title="OgataH , FugakawaM , HidekiH , KanedaH , KagimuraT , AkizawaT , et al. Design and baseline characteristics of the LANDMARK study. Clinical &amp; Experimental Nephrology2017;21(3):531‐7. [MEDLINE: 27405619] ">LANDMARK 2017</a>) of lanthanum carbonate compared with calcium carbonate has completed recruitment of 2309 participants treated with haemodialysis and is due to report in July 2018. The primary outcome of the <a href="./references#CD006023-bbs2-0209" title="OgataH , FugakawaM , HidekiH , KanedaH , KagimuraT , AkizawaT , et al. Design and baseline characteristics of the LANDMARK study. Clinical &amp; Experimental Nephrology2017;21(3):531‐7. [MEDLINE: 27405619] ">LANDMARK 2017</a> is survival free from a composite of cardiovascular death and nonfatal cardiovascular events, and may provide new information relevant to death outcomes for phosphate binders in CKD G5D. A further placebo‐controlled study of lanthanum among 278 participants with an eGFR between 15 to 44 mL/ min/1.73m<sup>2</sup> is due to complete follow‐up in December 2018 (<a href="./references#CD006023-bbs2-0208" title="ToussaintND , PedagogosE . IMPROVE: IMpact of Phosphate Reduction On Vascular End‐points in chronic kidney disease. www.anzctr.org.au/trial_view aspx?id=335812 (first received 10 August 2010). ">IMPROVE‐CKD 2012</a>) with the primary outcome of arterial compliance. This may provide additional data for surrogate outcomes in CKD G2 to G5 not requiring dialysis. </p> <p>A key limitation in the evidence is the lack of standardisation of outcome reporting in the available studies. As a result, many outcomes, such as cardiovascular events, hospitalisation, itch, calciphylaxis, and fracture were reported in few studies. For many of these outcomes, the data were available on the study registry database rather than reporting within primary journal publication. In future phosphate binder studies, standardisation of outcome reporting, as prioritised by the Standardised Outcomes in Nephrology (SONG) by patients, caregivers and health professionals may assist to improve the evidence base. In the haemodialysis setting, this would include the compulsory reporting of endpoints for fatigue, cardiovascular disease, vascular access, and death (<a href="http://songinitiative.org/projects/song-hd/" target="_blank">SONG‐HD</a>). Based on <a href="http://songinitiative.org/projects/song-hd/" target="_blank">SONG‐HD</a>, additional core outcomes for studies of phosphate binders might include mobility, pain, hospitalisation, bone health, calcium, itching, nausea/vomiting, serum phosphate levels, restless legs syndrome, and financial impact. </p> <p>Complications from phosphate binders reported in the included studies were principally gastrointestinal adverse events. However, as the event rates in available studies were often low, we could not be certain whether there were between‐group differences for many of the adverse outcomes. Potential adverse events such as severe bowel complications, or fractures related to suppressed bone turnover (from calcium‐based binders) and microfracture accumulation are not well understood based on existing studies. </p> <p>Based on epidemiological data, there is evidence that higher serum phosphate levels are consistently associated with death for people with CKD (<a href="./references#CD006023-bbs2-0210" title="BlockGA , Hulbert‐ShearonTE , LevinNW , PortFK . Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. American Journal of Kidney Diseases1998;31(4):607‐17. [MEDLINE: 9531176] ">Block 1998</a>; <a href="./references#CD006023-bbs2-0211" title="BlockGA , KlassenPS , LazarusJM , OfsthunN , LowrieEG , ChertowGM . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology2004;15(8):2208‐18. [MEDLINE: 15284307] ">Block 2004</a>; <a href="./references#CD006023-bbs2-0236" title="PalmerSC , HayenA , MacaskillP , PellegriniF , CraigJC , ElderGJ , et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta‐analysis. JAMA2011;305(11):1119‐27. [MEDLINE: 21406649] ">Palmer 2011</a>). This evidence generates the biological plausibility for use of phosphate binders to improve clinical outcomes, and generates the ongoing clinical equipoise needed for the further conduct of RCTs with sufficient power to detect patient‐level outcomes. Based on the data in this review, evidence for outcomes such as death, cardiovascular events, fracture, pain, and health‐related quality of life are required to support decision‐making for phosphate binder uses in CKD G2 to G5, and data for cardiovascular events and skeletal symptoms would assist decision‐making for patients with CKD 5D, particularly for regimens restricting the use of calcium‐based binders and less stringent serum phosphate control. </p> </section> <section id="CD006023-sec-0133"> <h3 class="title" id="CD006023-sec-0133">Quality of the evidence</h3> <p>The overall certainty of the evidence for most outcomes was low or very low, meaning that future research is likely to have an important impact on our knowledge of the benefits and harms of phosphate binders according to the GRADE approach (<a href="./references#CD006023-bbs2-0215" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). Key methodological limitations included attrition from follow‐up due to events that may have been related to the clinical outcomes of interest, differences between treatment groups, or relatively larger proportions of randomised participants. Methods for random sequence generation and allocation concealment were insufficiently reported in most studies, preventing judgement of the risks of bias for these parameters. Empirical evidence suggests that treatment effects may be exaggerated when allocation concealment and blinding are not reported within studies, although this is particularly relevant for subjective outcomes including symptoms and adverse events (<a href="./references#CD006023-bbs2-0253" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [MEDLINE: 18316340] ">Wood 2008</a>). Study limitations led to the downgrading of all evidence by one level (from high to moderate). Minimisation of selection and detection bias in future research studies would increase the certainty of treatment benefits and harms. </p> <p>The relative impact of sevelamer and calcium‐based binders on death was downgraded due to important statistical heterogeneity (I<sup>2</sup> = 74%), leading to low certainty in the evidence. This heterogeneity could not be explained by pre‐specified subgroup analyses including subgroups based on age, stage of CKD, duration or follow‐up or study risk of bias. When this analysis was restricted to the six studies (1053 participants) at low risk of bias for random sequence generation or allocation concealment, we found that there was moderate‐to‐high certainty of lower death with sevelamer compared with calcium‐based binders (RR 0.55, 95% CI 0.36 to 0.82; I<sup>2</sup> = 4%). This meta‐analysis that was restricted to lower risk studies provided a similar magnitude of effect as the full meta‐analysis of all available studies, and had no important statistical heterogeneity. </p> <p>Evidence for adverse events was frequently low or very low certainty, due to substantial imprecision in treatment estimates and study limitations including selective reporting of outcomes. </p> </section> <section id="CD006023-sec-0134"> <h3 class="title" id="CD006023-sec-0134">Potential biases in the review process</h3> <p>This review was carried out using standard Cochrane methods. Each step was completed independently by at least two authors including selection of studies, data management, and risk of bias assessment, thus reducing the risks of errors in identification of eligible studies and adjudication of evidence certainty. A highly sensitive search of the Cochrane Kidney Transplant Specialised Registry was completed without language restriction in November 2017, with a final search undertaken in just prior to publication in July 2018. The Registry contains hand‐searched literature and conference proceedings, maximising the inclusion of grey literature in this review. Most studies did not report key outcomes in a format available for meta‐analysis. This potentially introduced bias in our review and may have been a source of publication bias. We identified three studies (<a href="./references#CD006023-bbs2-0204" title="RoeS . Efficacy and safety study of magnesium iron hydroxycarbonate for the reduction of high blood phosphate in hemodialysis patients. www.clinicalTrials.gov/show/NCT00317694 (first received 25 April 2006). ">NCT00317694</a>; <a href="./references#CD006023-bbs2-0205" title="SaluskyIB . Regulation of bone formation in renal osteodystrophy. www.clinicaltrials.gov/show/NCT00560300 (first received 19 November 2007). ">NCT00560300</a>; <a href="./references#CD006023-bbs2-0206" title="NCT01968759 . Sevelamer in proteinuric CKD. www.clinicalTrials.gov/show/NCT01968759 (first received 24 October 2013). ">NCT01968759</a>) that had completed based on study registry information but for which we could not obtain results despite attempted contact with investigators. These studies may be a potential source of bias. Formal assessment for publication bias through visualisation of asymmetry in funnel plots was precluded for many treatments and outcomes because of few studies. </p> </section> <section id="CD006023-sec-0135"> <h3 class="title" id="CD006023-sec-0135">Agreements and disagreements with other studies or reviews</h3> <p>Numerous systematic reviews with meta‐analysis of RCTs investigating phosphate binders in CKD have been published including our own (<a href="./references#CD006023-bbs2-0237" title="PalmerSC , GardnerS , TonelliM , MavridisD , JohnsonDW , CraigJC , et al. Phosphate‐binding agents in adults with CKD: a network meta‐analysis of randomized controlled trials.[Erratum appears in Am J Kidney Dis. 2017 Sep;70(3):452; PMID: 28676197]. American Journal of Kidney Diseases2016;68(5):691‐702. [MEDLINE: 27461851] ">Palmer 2016</a>), and others (<a href="./references#CD006023-bbs2-0212" title="Bravo‐SotoG , MadridT . Sevelamer versus calcium‐based phosphate binders for chronic kidney disease? [Sevelamer comparado con quelantes de fosforo en base a calcio para la insuficiencia renal cronica]. Medwave2017;17(Suppl 2):e6942. [MEDLINE: 28525528] ">Bravo‐Soto 2017</a>; <a href="./references#CD006023-bbs2-0213" title="BurkeSK , DillonMA , HemkenDE , RezabekMS , BalwitJM . Meta‐analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Advances in Renal Replacement Therapy2003;10(2):133‐45. [MEDLINE: 12879374] ">Burke 2003</a>; <a href="./references#CD006023-bbs2-0221" title="HabbousS , PrzechS , AcedilloR , SarmaS , GargAX . The efficacy and safety of sevelamer and lanthanum versus calcium‐containing and iron‐based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta‐analysis. Nephrology Dialysis Transplantation2017;32(1):111‐25. [MEDLINE: 27651467] ">Habbous 2017</a>; <a href="./references#CD006023-bbs2-0226" title="JamalSA , FitchettD , LokCE , MendelssohnDC , TsuyukiRT . The effects of calcium‐based versus non‐calcium‐based phosphate binders on mortality among patients with chronic kidney disease: a meta‐analysis. Nephrology Dialysis Transplantation2009;24(10):3168‐74. [MEDLINE: 19622572] ">Jamal 2009</a>; <a href="./references#CD006023-bbs2-0227" title="JamalSA , VandermeerB , RaggiP , MendelssohnDC , ChatterleyT , DorganM , et al. Effect of calcium‐based versus non‐calcium‐based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta‐analysis. Lancet2013;382(9900):1268‐77. [MEDLINE: 23870817] ">Jamal 2013</a>; <a href="./references#CD006023-bbs2-0234" title="MannsB , StevensL , MiskulinD , OwenWFJr , WinkelmayerWC , TonelliM . A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney International2004;66(3):1239‐47. [MEDLINE: 15327423] ">Manns 2004</a>; <a href="./references#CD006023-bbs2-0238" title="PatelL , BernardLM , ElderGJ . Sevelamer versus calcium‐based binders for treatment of hyperphosphatemia in CKD: a meta‐analysis of randomized controlled trials. Clinical Journal of The American Society of Nephrology: CJASN2016;11(2):232‐44. [MEDLINE: 26668024] ">Patel 2016</a>; <a href="./references#CD006023-bbs2-0242" title="SekerciogluN , ThabaneL , Díaz MartínezJP , NesrallahG , LongoCJ , BusseJW , et al. Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta‐analysis. PLoS ONE (Electronic Resource]2016;11(6):e0156891. [MEDLINE: 27276077] ">Sekercioglu 2016</a>; <a href="./references#CD006023-bbs2-0243" title="SekerciogluN , Angeliki VeronikiA , ThabaneL , BusseJW , Akhtar‐DaneshN , IorioA , et al. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. PLoS ONE (Electronic Resource]2017;12(3):e0171028. [MEDLINE: 28248961] ">Sekercioglu 2017</a>; <a href="./references#CD006023-bbs2-0250" title="TonelliM , WiebeN , CulletonB , LeeH , KlarenbachS , ShriveF , et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrology Dialysis Transplantation2007;22(10):2856‐66. [MEDLINE: 17906326] ">Tonelli 2007</a>; <a href="./references#CD006023-bbs2-0252" title="WangC , LiuX , ZhouY , LiS , ChenY , WangY , et al. New conclusions regarding comparison of sevelamer and calcium‐based phosphate binders in coronary‐artery calcification for dialysis patients: a meta‐analysis of randomized controlled trials. PLoS ONE (Electronic Resource]2015;10(7):e0133938. [MEDLINE: 26230677] ">Wang 2015</a>; <a href="./references#CD006023-bbs2-0254" title="ZhangQ , LiM , LuY , LiH , GuY , HaoC , et al. Meta‐analysis comparing sevelamer and calcium‐based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron2010;115(4):c259‐67. [MEDLINE: 20424476] ">Zhang 2010</a>). Most existing reviews have focused on the comparison between calcium‐based and non‐calcium‐based phosphate binders because of the concern that excess exogenous calcium may accelerate vascular calcification and cardiovascular complications and calciphylaxis, and due to emerging evidence of higher death with calcium‐based treatments (<a href="./references#CD006023-bbs2-0226" title="JamalSA , FitchettD , LokCE , MendelssohnDC , TsuyukiRT . The effects of calcium‐based versus non‐calcium‐based phosphate binders on mortality among patients with chronic kidney disease: a meta‐analysis. Nephrology Dialysis Transplantation2009;24(10):3168‐74. [MEDLINE: 19622572] ">Jamal 2009</a>). Essentially the current Cochrane review is consistent with the findings of earlier reviews that have identified lower death for sevelamer treatment compared with calcium‐based binders although few existing analyses have incorporated judgement of evidence certainty. The reported relative risk for death (all causes) with sevelamer compared with calcium‐based phosphate binders have ranged between 0.54 and 0.78. In the review by <a href="./references#CD006023-bbs2-0212" title="Bravo‐SotoG , MadridT . Sevelamer versus calcium‐based phosphate binders for chronic kidney disease? [Sevelamer comparado con quelantes de fosforo en base a calcio para la insuficiencia renal cronica]. Medwave2017;17(Suppl 2):e6942. [MEDLINE: 28525528] ">Bravo‐Soto 2017</a> including studies available in existing systematic reviews, the authors used the GRADE process. They downgraded evidence certainty for death by three grades to very low due to risks of bias (two downgrades) and inconsistency between studies. </p> <p>The present Cochrane review update is consistent with existing systematic reviews demonstrating there is little or no evidence for beneficial treatment effects on cardiovascular death for non‐calcium versus calcium‐based binders, a marked reduction in risks of hypercalcaemia with non‐calcium binders, and variable hazards of gastrointestinal adverse effects with specific agents. </p> <p>A previous review has focused on the available evidence with respect to coronary artery calcification (<a href="./references#CD006023-bbs2-0254" title="ZhangQ , LiM , LuY , LiH , GuY , HaoC , et al. Meta‐analysis comparing sevelamer and calcium‐based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron2010;115(4):c259‐67. [MEDLINE: 20424476] ">Zhang 2010</a>). The findings of that review are broadly consistent with ours that it is not possible to establish whether or not specific phosphate binders alter progression of coronary artery calcification scores. </p> <p>Notably in our and other reviews, robust long‐term study data for lanthanum or iron‐based binders compared with either placebo or calcium‐based binders on death outcomes and adverse events are lacking. </p> <p>The findings of this updated review are consistent with the Kidney Disease Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the evaluation, prevention and treatment of CKD‐MBD (<a href="./references#CD006023-bbs2-0231" title="Kidney Disease: Improving Glogal Outcomes (KDIGO) CKD‐MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD). Kidney International ‐ Supplement2017;7(3):1‐59. [EMBASE: 617012703] ">KDIGO 2017</a>) that suggest that the dose of calcium‐based phosphate binders is restricted among adult patients receiving phosphate‐lowering treatment. This updated guideline removes the more restrictive qualifier present in the earlier 2009 KDIGO guideline that calcium‐based phosphate‐binders be avoided in patients with hypercalcaemia, known arterial calcification, adynamic bone disease, or low serum PTH levels (<a href="./references#CD006023-bbs2-0229" title="Kidney Disease: Improving Global Outcomes (KDIGO) CKD‐MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease‐mineral and bone disorder (CKD‐MBD). Kidney International ‐ Supplement 209;76(113):S1‐130. [MEDLINE: 19644521] ">KDIGO 2009</a>), and is updated based on the additional death data available from three new studies (<a href="./references#CD006023-bbs2-0011" title="BlockGA , PerskyMS , KettelerM , KestenbaumB , ThadhaniR , KooiengaL , et al. A randomized double‐blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodialysis International2009;13(3):360‐2. [EMBASE: 2009454718] BlockGA , WheelerDC , PerskyMS , KestenbaumB , KettelerM , SpiegelDM , et al. Effects of phosphate binders in moderate CKD. Journal of the American Society of Nephrology2012;23(8):1407‐15. [MEDLINE: 22822075] JovanovichA , IsakovaT , BlockG , StubbsJ , SmitsG , ChoncholM , et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. American Journal of Kidney Diseases2018;71(1):27‐34. [MEDLINE: 28801122] Robinson‐CohenC , IxJH , SmitsG , PerskyM , ChertowGM , BlockGA , et al. Estimation of 24‐hour urine phosphate excretion from spot urine collection: development of a predictive equation. Journal of Renal Nutrition2014;24(3):194‐9. [MEDLINE: 24759300] WeberCI , Duchateau‐NguyenG , SolierC , Schell‐StevenA , HermosillaR , NogocekeE , et al. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4. Clinical Kidney Journal2014;7(2):167‐73. [MEDLINE: 24683472] ">Block 2009</a>; <a href="./references#CD006023-bbs2-0045" title="DiIorioB , BellasiA , PotaA , RussoL , RussoD . Effect of phosphate binder therapy on mortality in pre‐dialysis patients [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii127. [EMBASE: 70765659] DiIorioB , BellasiA , RussoD , INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study.[Erratum appears in Clin J Am Soc Nephrol. 2012 Aug;7(8):1370‐1]. Clinical Journal of The American Society of Nephrology: CJASN2012;7(3):487‐83. [MEDLINE: 22241819] RuggeriM , CiprianiF , BellasiA , RussoD , DiIorioB . Sevelamer is cost‐saving vs. calcium carbonate in non‐dialysis‐dependent CKD patients in Italy: a patient‐level cost‐effectiveness analysis of the INDEPENDENT study. Blood Purification2014;37(4):316‐24. [MEDLINE: 25171148] RussoD , BellasiA , PotaA , RussoL , DiIorioB . Effects of phosphorus‐restricted diet and phosphate‐binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology2015;28(1):73‐80. [MEDLINE: 24599830] ThompsonM , Bartko‐WintersS , BernardL , FentonA , HutchisonC , DiIorioB . Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. Journal of Medical Economics2013;16(6):744‐55. [MEDLINE: 23550810] delPinoMD , PonsR , Rodriguez‐CarmonaA , RubioLM , SubiraR . Cost‐effectiveness of sevelamer versus calcium carbonate in non‐dialysis dependent chronic kidney disease patients in Spain [Analisis coste‐efectividad de sevelamero frente a carbonato calcico en pacientes con enfermedad renal cronica no dependientes de dialisis en Espana]. Pharmacoeconomics ‐ Spanish Research Articles2016;13(2):49‐56. [EMBASE: 610467965] ">INDEPENDENT‐CKD 2012</a>; <a href="./references#CD006023-bbs2-0046" title="BellasiA , CozzolinoM , RussoD , MolonyD , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology2016;86(9):113‐24. [MEDLINE: 27443567] BellasiA , CozzolinoM , RussoD , MolonyDA , DiIorioB . Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study [abstract]. Nephrology Dialysis Transplantation2015;30(Suppl 3):iii588. [EMBASE: 72207961] DiIorioB . In reply to 'The change history of the INDEPENDENT Study in the ClinicalTrials.gov database'. American Journal of Kidney Diseases2014;63(1):164‐5. [MEDLINE: 24377649] DiIorioB , MolonyD , BellC , CuccinielloE , BellizziV , RussoD , et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. American Journal of Kidney Diseases2013;62(4):771‐8. [MEDLINE: 23684755] DiIorioBR , CuccinielloE , BellizziV . Vascular calcification and QT interval in incident hemodialysis patients.[Erratum appears in J Nephrol. 2010 Jan‐Feb;23(1):124], [Erratum appears in J Nephrol. 2013 Mar‐Apr;26(2):419]. Journal of Nephrology2009;22(6):694‐8. [MEDLINE: 19967647] MolonyD , BellasiA , BellizziV , RussoD , DiIorioB . Sevelamer attenuates CV mortality in incident hemodialysis patients: open label, randomized clinical trial of efficacy and safety (INDEPENDENT study) [abstract]. Nephrology Dialysis Transplantation2012;27(Suppl 2):ii54. [EMBASE: 70765453] ObiY , HamanoT . The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. American Journal of Kidney Diseases2014;63(1):164. [MEDLINE: 24377650] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum for J Nephrol. 2015 Oct;28(5):593‐602; PMID: 25027030]. Journal of Nephrology2014;27(6):717. [MEDLINE: 25098354] RuggeriM , BellasiA , CiprianiF , MolonyD , BellC , RussoD , et al. Sevelamer is cost effective versus calcium carbonate for the first‐line treatment of hyperphosphatemia in new patients to hemodialysis: a patient‐level economic evaluation of the INDEPENDENT‐HD study.[Erratum appears in J Nephrol. 2014 Dec;27(6):717; PMID: 25098354]. Journal of Nephrology2015;28(5):593‐602. [MEDLINE: 25027030] ">INDEPENDENT‐HD 2009</a>). It should be noted that current evidence does not allow us to discern whether the increased possible hazard for death with calcium‐based binders compared with sevelamer is caused by calcium‐containing medications. A placebo‐controlled study of calcium‐based phosphate binders could address this question but such a study is unlikely to be conducted. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006023-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD006023-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006023-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 1 Death (all causes)." data-id="CD006023-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 2 Myocardial infarction." data-id="CD006023-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 2 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 3 Stroke." data-id="CD006023-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 3 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 4 Hospitalisation." data-id="CD006023-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 4 Hospitalisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 5 Fracture." data-id="CD006023-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 5 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 6 Pruritus." data-id="CD006023-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 6 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 7 Nausea." data-id="CD006023-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 7 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 8 Vomiting." data-id="CD006023-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 8 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 9 Abdominal pain." data-id="CD006023-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 9 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 10 Constipation." data-id="CD006023-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 10 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 11 Diarrhoea." data-id="CD006023-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 11 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 12 Abdominal bloating." data-id="CD006023-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 12 Abdominal bloating.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 13 End‐stage kidney disease." data-id="CD006023-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 13 End‐stage kidney disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 14 Coronary artery calcium score." data-id="CD006023-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 14 Coronary artery calcium score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 15 Serum phosphate." data-id="CD006023-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 15 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 16 Serum calcium." data-id="CD006023-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 16 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 17 Hypercalcaemia." data-id="CD006023-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 17 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 18 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 18 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 19 Serum iPTH." data-id="CD006023-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 19 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 20 Serum alkaline phosphatase." data-id="CD006023-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 20 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 21 Serum bicarbonate." data-id="CD006023-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 21 Serum bicarbonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 22 eGFR." data-id="CD006023-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 22 eGFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 23 Bone mineral density: lumbar spine." data-id="CD006023-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 23 Bone mineral density: lumbar spine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 24 Bone mineral density: hip." data-id="CD006023-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 24 Bone mineral density: hip. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Sevelamer versus placebo or usual care, Outcome 25 Klotho." data-id="CD006023-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Sevelamer versus placebo or usual care, Outcome 25 Klotho.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 1 Death (all causes)." data-id="CD006023-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 2 Myocardial infarction." data-id="CD006023-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 2 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 3 Stroke." data-id="CD006023-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 3 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 4 Hospitalisation." data-id="CD006023-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 4 Hospitalisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 5 Fracture." data-id="CD006023-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 5 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 6 Pruritus." data-id="CD006023-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 6 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 7 Pruritus." data-id="CD006023-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 7 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 8 Nausea." data-id="CD006023-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 8 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 9 Vomiting." data-id="CD006023-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 9 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 10 Abdominal pain." data-id="CD006023-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 10 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 11 Constipation." data-id="CD006023-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 11 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 12 Diarrhoea." data-id="CD006023-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 12 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 13 End‐stage kidney disease." data-id="CD006023-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 13 End‐stage kidney disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 14 Coronary artery calcification score." data-id="CD006023-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 14 Coronary artery calcification score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 15 Vascular calcification score." data-id="CD006023-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 15 Vascular calcification score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 16 Serum phosphate." data-id="CD006023-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 16 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 17 Serum calcium." data-id="CD006023-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 17 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 18 Hypercalcaemia." data-id="CD006023-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 18 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 19 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 19 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 20 Serum iPTH." data-id="CD006023-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 20 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 21 eGFR." data-id="CD006023-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 21 eGFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 22 Bone mineral density: lumbar spine." data-id="CD006023-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 22 Bone mineral density: lumbar spine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Lanthanum versus placebo or usual care, Outcome 23 Serum FGF23." data-id="CD006023-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Lanthanum versus placebo or usual care, Outcome 23 Serum FGF23.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 1 Death (all causes)." data-id="CD006023-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 2 Fracture." data-id="CD006023-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 2 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 3 Pruritus." data-id="CD006023-fig-0053" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 3 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 4 Nausea." data-id="CD006023-fig-0054" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 4 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 5 Constipation." data-id="CD006023-fig-0055" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 5 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 6 Diarrhoea." data-id="CD006023-fig-0056" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 6 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 7 Abdominal pain." data-id="CD006023-fig-0057" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 7 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 8 Serum phosphate." data-id="CD006023-fig-0058" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 8 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 9 Serum calcium." data-id="CD006023-fig-0059" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 9 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 10 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0060" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 10 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 11 Serum alkaline phosphatase." data-id="CD006023-fig-0061" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 11 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 12 Serum bicarbonate." data-id="CD006023-fig-0062" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 12 Serum bicarbonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron versus placebo or usual care, Outcome 13 eGFR." data-id="CD006023-fig-0063" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Iron versus placebo or usual care, Outcome 13 eGFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 1 Death (all causes)." data-id="CD006023-fig-0064" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 2 Myocardial infarction." data-id="CD006023-fig-0065" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 2 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 3 Stroke." data-id="CD006023-fig-0066" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 3 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 4 Fracture." data-id="CD006023-fig-0067" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 4 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 5 Pruritus." data-id="CD006023-fig-0068" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 5 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 6 Nausea." data-id="CD006023-fig-0069" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 6 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 7 Vomiting." data-id="CD006023-fig-0070" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 7 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 8 Abdominal pain." data-id="CD006023-fig-0071" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 8 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 9 Constipation." data-id="CD006023-fig-0072" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 9 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 10 Diarrhoea." data-id="CD006023-fig-0073" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 10 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 11 Coronary artery calcification score." data-id="CD006023-fig-0074" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 11 Coronary artery calcification score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 12 Serum phosphate." data-id="CD006023-fig-0075" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 12 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 13 Serum calcium." data-id="CD006023-fig-0076" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 13 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 14 Hypercalcaemia." data-id="CD006023-fig-0077" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 14 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 15 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0078" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 15 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 16 Serum iPTH." data-id="CD006023-fig-0079" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 16 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 17 Serum alkaline phosphatase." data-id="CD006023-fig-0080" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 17 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 18 Serum bicarbonate." data-id="CD006023-fig-0081" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 18 Serum bicarbonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Calcium versus placebo or usual care, Outcome 19 eGFR." data-id="CD006023-fig-0082" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Calcium versus placebo or usual care, Outcome 19 eGFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bixalomer versus placebo or usual care, Outcome 1 Death (all causes)." data-id="CD006023-fig-0083" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Bixalomer versus placebo or usual care, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bixalomer versus placebo or usual care, Outcome 2 End‐stage kidney disease." data-id="CD006023-fig-0084" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Bixalomer versus placebo or usual care, Outcome 2 End‐stage kidney disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bixalomer versus placebo or usual care, Outcome 3 Nausea." data-id="CD006023-fig-0085" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Bixalomer versus placebo or usual care, Outcome 3 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bixalomer versus placebo or usual care, Outcome 4 Abdominal pain." data-id="CD006023-fig-0086" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Bixalomer versus placebo or usual care, Outcome 4 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bixalomer versus placebo or usual care, Outcome 5 Constipation." data-id="CD006023-fig-0087" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Bixalomer versus placebo or usual care, Outcome 5 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bixalomer versus placebo or usual care, Outcome 6 Diarrhoea." data-id="CD006023-fig-0088" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Bixalomer versus placebo or usual care, Outcome 6 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 1 Death (all causes)." data-id="CD006023-fig-0089" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 2 Pruritus." data-id="CD006023-fig-0090" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 2 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 3 Constipation." data-id="CD006023-fig-0091" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 3 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 4 Diarrhoea." data-id="CD006023-fig-0092" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 4 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 5 Serum phosphate." data-id="CD006023-fig-0093" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 5 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 6 Serum calcium." data-id="CD006023-fig-0094" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 6 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 7 Serum iPTH." data-id="CD006023-fig-0095" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 7 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Nicotinamide versus placebo or usual care, Outcome 8 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0096" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Nicotinamide versus placebo or usual care, Outcome 8 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Colestilan versus placebo or usual care, Outcome 1 Death (all causes)." data-id="CD006023-fig-0097" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Colestilan versus placebo or usual care, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Colestilan versus placebo or usual care, Outcome 2 Nausea." data-id="CD006023-fig-0098" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Colestilan versus placebo or usual care, Outcome 2 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Colestilan versus placebo or usual care, Outcome 3 Abdominal pain." data-id="CD006023-fig-0099" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Colestilan versus placebo or usual care, Outcome 3 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Colestilan versus placebo or usual care, Outcome 4 Diarrhoea." data-id="CD006023-fig-0100" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Colestilan versus placebo or usual care, Outcome 4 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Colestilan versus placebo or usual care, Outcome 5 Constipation." data-id="CD006023-fig-0101" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Colestilan versus placebo or usual care, Outcome 5 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 1 Death (all causes)." data-id="CD006023-fig-0102" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 2 Cardiovascular death." data-id="CD006023-fig-0103" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 3 Myocardial infarction." data-id="CD006023-fig-0104" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 3 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 4 Stroke." data-id="CD006023-fig-0105" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 4 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 5 Hospitalisation." data-id="CD006023-fig-0106" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 5 Hospitalisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 6 Fracture." data-id="CD006023-fig-0107" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 6 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 7 Nausea." data-id="CD006023-fig-0108" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 7 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 8 Vomiting." data-id="CD006023-fig-0109" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 8 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 9 Abdominal pain." data-id="CD006023-fig-0110" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 9 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 10 Constipation." data-id="CD006023-fig-0111" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 10 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 11 Diarrhoea." data-id="CD006023-fig-0112" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 11 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 12 Abdominal bloating." data-id="CD006023-fig-0113" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 12 Abdominal bloating.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 13 Hypercalcaemia." data-id="CD006023-fig-0114" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 13 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 14 Calciphylaxis." data-id="CD006023-fig-0115" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.14</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 14 Calciphylaxis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 15 Coronary artery calcium score." data-id="CD006023-fig-0116" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.15</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 15 Coronary artery calcium score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 16 Serum phosphate." data-id="CD006023-fig-0117" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.16</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 16 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 17 Serum calcium." data-id="CD006023-fig-0118" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.17</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 17 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 18 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0119" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.18</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 18 Serum calcium‐by‐phosphate product.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 19 Serum iPTH." data-id="CD006023-fig-0120" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.19</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 19 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 20 Serum alkaline phosphatase." data-id="CD006023-fig-0121" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.20</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 20 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 21 Serum bicarbonate." data-id="CD006023-fig-0122" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.21</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 21 Serum bicarbonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 22 eGFR." data-id="CD006023-fig-0123" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.22</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 22 eGFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 23 Serum FGF23." data-id="CD006023-fig-0124" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.23</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 23 Serum FGF23.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-008-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-008-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sevelamer versus calcium, Outcome 24 Soluble Klotho." data-id="CD006023-fig-0125" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.24</div> <div class="figure-caption"> <p>Comparison 8 Sevelamer versus calcium, Outcome 24 Soluble Klotho.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-008-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 1 Death (all causes)." data-id="CD006023-fig-0126" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 2 Hospitalisation." data-id="CD006023-fig-0127" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 2 Hospitalisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 3 Fracture." data-id="CD006023-fig-0128" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 3 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 4 Pruritus." data-id="CD006023-fig-0129" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 4 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 5 Nausea." data-id="CD006023-fig-0130" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 5 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 6 Vomiting." data-id="CD006023-fig-0131" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 6 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 7 Abdominal pain." data-id="CD006023-fig-0132" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 7 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 8 Constipation." data-id="CD006023-fig-0133" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 8 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 9 Diarrhoea." data-id="CD006023-fig-0134" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 9 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 10 Abdominal bloating." data-id="CD006023-fig-0135" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 10 Abdominal bloating.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 11 Coronary artery calcium score." data-id="CD006023-fig-0136" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 11 Coronary artery calcium score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 12 Hypercalcaemia." data-id="CD006023-fig-0137" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 12 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 13 Serum phosphate." data-id="CD006023-fig-0138" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 13 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 14 Serum calcium." data-id="CD006023-fig-0139" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 14 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 15 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0140" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 15 Serum calcium‐by‐phosphate product.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 16 Serum iPTH." data-id="CD006023-fig-0141" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.16</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 16 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 17 Serum alkaline phosphatase." data-id="CD006023-fig-0142" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.17</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 17 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 18 eGFR." data-id="CD006023-fig-0143" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.18</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 18 eGFR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-009-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-009-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Lanthanum versus calcium, Outcome 19 Serum FGF23." data-id="CD006023-fig-0144" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.19</div> <div class="figure-caption"> <p>Comparison 9 Lanthanum versus calcium, Outcome 19 Serum FGF23.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-009-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Magnesium versus calcium, Outcome 1 Hospitalisation." data-id="CD006023-fig-0145" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Magnesium versus calcium, Outcome 1 Hospitalisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Magnesium versus calcium, Outcome 2 Constipation." data-id="CD006023-fig-0146" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Magnesium versus calcium, Outcome 2 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Magnesium versus calcium, Outcome 3 Diarrhoea." data-id="CD006023-fig-0147" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Magnesium versus calcium, Outcome 3 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Aluminium versus calcium, Outcome 1 Serum alkaline phosphatase." data-id="CD006023-fig-0148" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Aluminium versus calcium, Outcome 1 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Magnesium plus calcium versus calcium, Outcome 1 Death (all causes)." data-id="CD006023-fig-0149" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Magnesium plus calcium versus calcium, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Magnesium plus calcium versus calcium, Outcome 2 Serum phosphate." data-id="CD006023-fig-0150" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Magnesium plus calcium versus calcium, Outcome 2 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Magnesium plus calcium versus calcium, Outcome 3 Serum calcium." data-id="CD006023-fig-0151" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Magnesium plus calcium versus calcium, Outcome 3 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Magnesium plus calcium versus calcium, Outcome 4 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0152" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Magnesium plus calcium versus calcium, Outcome 4 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Magnesium plus calcium versus calcium, Outcome 5 Serum iPTH." data-id="CD006023-fig-0153" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Magnesium plus calcium versus calcium, Outcome 5 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 1 Myocardial infarction." data-id="CD006023-fig-0154" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 1 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 2 Stroke." data-id="CD006023-fig-0155" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 2 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 3 Fracture." data-id="CD006023-fig-0156" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 3 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 4 Pruritus." data-id="CD006023-fig-0157" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 4 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 5 Nausea." data-id="CD006023-fig-0158" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 5 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 6 Vomiting." data-id="CD006023-fig-0159" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 6 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 7 Abdominal pain." data-id="CD006023-fig-0160" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 7 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 8 Constipation." data-id="CD006023-fig-0161" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 8 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 9 Diarrhoea." data-id="CD006023-fig-0162" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.9</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 9 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 10 Abdominal bloating." data-id="CD006023-fig-0163" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.10</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 10 Abdominal bloating.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-013-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-013-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sevelamer versus lanthanum, Outcome 11 Hypercalcaemia." data-id="CD006023-fig-0164" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.11</div> <div class="figure-caption"> <p>Comparison 13 Sevelamer versus lanthanum, Outcome 11 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-013-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 1 Death (all causes)." data-id="CD006023-fig-0165" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 2 Cardiovascular death." data-id="CD006023-fig-0166" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 3 Myocardial infarction." data-id="CD006023-fig-0167" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 3 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 4 Fracture." data-id="CD006023-fig-0168" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 4 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 5 Nausea." data-id="CD006023-fig-0169" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 5 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 6 Abdominal pain." data-id="CD006023-fig-0170" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 6 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 7 Constipation." data-id="CD006023-fig-0171" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.7</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 7 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 8 Diarrhoea." data-id="CD006023-fig-0172" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.8</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 8 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 9 Serum phosphate." data-id="CD006023-fig-0173" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.9</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 9 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 10 Serum calcium." data-id="CD006023-fig-0174" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.10</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 10 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-014-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-014-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sevelamer versus iron, Outcome 11 Serum bicarbonate." data-id="CD006023-fig-0175" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.11</div> <div class="figure-caption"> <p>Comparison 14 Sevelamer versus iron, Outcome 11 Serum bicarbonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-014-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 1 Death (all causes)." data-id="CD006023-fig-0176" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 2 Fracture." data-id="CD006023-fig-0177" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 2 Fracture.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 3 Pruritus." data-id="CD006023-fig-0178" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 3 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 4 Nausea." data-id="CD006023-fig-0179" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 4 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 5 Vomiting." data-id="CD006023-fig-0180" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 5 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 6 Abdominal pain." data-id="CD006023-fig-0181" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 6 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 7 Constipation." data-id="CD006023-fig-0182" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.7</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 7 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 8 Abdominal bloating." data-id="CD006023-fig-0183" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.8</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 8 Abdominal bloating.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 9 Serum phosphate." data-id="CD006023-fig-0184" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.9</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 9 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 10 Serum calcium." data-id="CD006023-fig-0185" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.10</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 10 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 11 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0186" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.11</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 11 Serum calcium‐by‐phosphate product.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 12 Serum iPTH." data-id="CD006023-fig-0187" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.12</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 12 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-015-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-015-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sevelamer versus bixalomer, Outcome 13 Serum bicarbonate." data-id="CD006023-fig-0188" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.13</div> <div class="figure-caption"> <p>Comparison 15 Sevelamer versus bixalomer, Outcome 13 Serum bicarbonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-015-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Sevelamer versus nicotinamide, Outcome 1 Death (all causes)." data-id="CD006023-fig-0189" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Sevelamer versus nicotinamide, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Sevelamer versus nicotinamide, Outcome 2 Stroke." data-id="CD006023-fig-0190" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 Sevelamer versus nicotinamide, Outcome 2 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Sevelamer versus nicotinamide, Outcome 3 Vomiting." data-id="CD006023-fig-0191" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 Sevelamer versus nicotinamide, Outcome 3 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-016-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-016-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Sevelamer versus nicotinamide, Outcome 4 Serum calcium." data-id="CD006023-fig-0192" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16 Sevelamer versus nicotinamide, Outcome 4 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-016-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-016-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Sevelamer versus nicotinamide, Outcome 5 Serum iPTH." data-id="CD006023-fig-0193" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16 Sevelamer versus nicotinamide, Outcome 5 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-016-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-016-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Sevelamer versus nicotinamide, Outcome 6 Serum alkaline phosphatase." data-id="CD006023-fig-0194" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16 Sevelamer versus nicotinamide, Outcome 6 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-016-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 1 Death (all causes)." data-id="CD006023-fig-0195" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 2 Cardiovascular death." data-id="CD006023-fig-0196" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 2 Cardiovascular death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 3 Myocardial infarction." data-id="CD006023-fig-0197" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 3 Myocardial infarction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 4 Stroke." data-id="CD006023-fig-0198" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 4 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 5 Pruritus." data-id="CD006023-fig-0199" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 5 Pruritus.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 6 Nausea." data-id="CD006023-fig-0200" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 6 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 7 Vomiting." data-id="CD006023-fig-0201" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 7 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 8 Abdominal pain." data-id="CD006023-fig-0202" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.8</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 8 Abdominal pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 9 Constipation." data-id="CD006023-fig-0203" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.9</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 9 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 10 Diarrhoea." data-id="CD006023-fig-0204" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.10</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 10 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 11 Serum phosphate." data-id="CD006023-fig-0205" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.11</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 11 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 12 Serum calcium." data-id="CD006023-fig-0206" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.12</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 12 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 13 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0207" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.13</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 13 Serum calcium‐by‐phosphate product.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 14 Serum iPTH." data-id="CD006023-fig-0208" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.14</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 14 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-017-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-017-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sevelamer versus colestilan, Outcome 15 Serum alkaline phosphatase." data-id="CD006023-fig-0209" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.15</div> <div class="figure-caption"> <p>Comparison 17 Sevelamer versus colestilan, Outcome 15 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-017-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sevelamer versus aluminium, Outcome 1 Nausea." data-id="CD006023-fig-0210" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Sevelamer versus aluminium, Outcome 1 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-018-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-018-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sevelamer versus aluminium, Outcome 2 Constipation." data-id="CD006023-fig-0211" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18 Sevelamer versus aluminium, Outcome 2 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-018-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-018-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sevelamer versus aluminium, Outcome 3 Serum phosphate." data-id="CD006023-fig-0212" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18 Sevelamer versus aluminium, Outcome 3 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-018-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-018-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sevelamer versus aluminium, Outcome 4 Serum calcium." data-id="CD006023-fig-0213" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18 Sevelamer versus aluminium, Outcome 4 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-018-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-018-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sevelamer versus aluminium, Outcome 5 Serum iPTH." data-id="CD006023-fig-0214" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18 Sevelamer versus aluminium, Outcome 5 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-018-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Sevelamer versus magnesium, Outcome 1 Serum phosphate." data-id="CD006023-fig-0215" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Sevelamer versus magnesium, Outcome 1 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Sevelamer versus magnesium, Outcome 2 Serum calcium." data-id="CD006023-fig-0216" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 Sevelamer versus magnesium, Outcome 2 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-019-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-019-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Sevelamer versus magnesium, Outcome 3 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0217" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19 Sevelamer versus magnesium, Outcome 3 Serum calcium‐by‐phosphate product.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-019-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-019-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Sevelamer versus magnesium, Outcome 4 Serum iPTH." data-id="CD006023-fig-0218" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19 Sevelamer versus magnesium, Outcome 4 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-019-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Sevelamer versus sevelamer + calcium, Outcome 1 Hypercalcaemia." data-id="CD006023-fig-0219" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Sevelamer versus sevelamer + calcium, Outcome 1 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-020-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-020-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Sevelamer versus sevelamer + calcium, Outcome 2 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0220" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-020-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 Sevelamer versus sevelamer + calcium, Outcome 2 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-020-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Sevelamer versus calcium + magnesium, Outcome 1 Serum phosphate." data-id="CD006023-fig-0221" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Sevelamer versus calcium + magnesium, Outcome 1 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-021-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-021-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Sevelamer versus calcium + magnesium, Outcome 2 Serum calcium." data-id="CD006023-fig-0222" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21 Sevelamer versus calcium + magnesium, Outcome 2 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-021-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-021-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Sevelamer versus calcium + magnesium, Outcome 3 Serum iPTH." data-id="CD006023-fig-0223" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21 Sevelamer versus calcium + magnesium, Outcome 3 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-021-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-021-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Sevelamer versus calcium + magnesium, Outcome 4 Serum alkaline phosphatase." data-id="CD006023-fig-0224" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.4</div> <div class="figure-caption"> <p>Comparison 21 Sevelamer versus calcium + magnesium, Outcome 4 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-021-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-021-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Sevelamer versus calcium + magnesium, Outcome 5 Serum bicarbonate." data-id="CD006023-fig-0225" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.5</div> <div class="figure-caption"> <p>Comparison 21 Sevelamer versus calcium + magnesium, Outcome 5 Serum bicarbonate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-021-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 1 Death (all causes)." data-id="CD006023-fig-0226" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 1 Death (all causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 2 Nausea." data-id="CD006023-fig-0227" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 2 Nausea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-022-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-022-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 3 Vomiting." data-id="CD006023-fig-0228" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 3 Vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-022-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-022-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 4 Constipation." data-id="CD006023-fig-0229" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.4</div> <div class="figure-caption"> <p>Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 4 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0230"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-022-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-022-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 5 Diarrhoea." data-id="CD006023-fig-0230" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.5</div> <div class="figure-caption"> <p>Comparison 22 Sevelamer hydrochloride versus sevelamer carbonate, Outcome 5 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0230">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-022-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0231"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Calcium acetate versus calcium carbonate, Outcome 1 Death (all causes)." data-id="CD006023-fig-0231" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Calcium acetate versus calcium carbonate, Outcome 1 Death (all causes).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0231">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0232"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-023-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-023-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Calcium acetate versus calcium carbonate, Outcome 2 Hypercalcaemia." data-id="CD006023-fig-0232" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23 Calcium acetate versus calcium carbonate, Outcome 2 Hypercalcaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0232">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0233"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-023-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-023-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Calcium acetate versus calcium carbonate, Outcome 3 Serum phosphate." data-id="CD006023-fig-0233" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23 Calcium acetate versus calcium carbonate, Outcome 3 Serum phosphate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0233">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0234"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-023-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-023-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Calcium acetate versus calcium carbonate, Outcome 4 Serum calcium." data-id="CD006023-fig-0234" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.4</div> <div class="figure-caption"> <p>Comparison 23 Calcium acetate versus calcium carbonate, Outcome 4 Serum calcium.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0234">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0235"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-023-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-023-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Calcium acetate versus calcium carbonate, Outcome 5 Serum calcium‐by‐phosphate product." data-id="CD006023-fig-0235" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.5</div> <div class="figure-caption"> <p>Comparison 23 Calcium acetate versus calcium carbonate, Outcome 5 Serum calcium‐by‐phosphate product. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0235">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0236"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-023-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-023-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Calcium acetate versus calcium carbonate, Outcome 6 Serum iPTH." data-id="CD006023-fig-0236" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.6</div> <div class="figure-caption"> <p>Comparison 23 Calcium acetate versus calcium carbonate, Outcome 6 Serum iPTH.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0236">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0237"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-023-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-023-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Calcium acetate versus calcium carbonate, Outcome 7 Serum alkaline phosphatase." data-id="CD006023-fig-0237" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.7</div> <div class="figure-caption"> <p>Comparison 23 Calcium acetate versus calcium carbonate, Outcome 7 Serum alkaline phosphatase.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0237">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-023-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0238"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Subgroup: sevelamer versus calcium, Outcome 1 Death (all causes): age." data-id="CD006023-fig-0238" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Subgroup: sevelamer versus calcium, Outcome 1 Death (all causes): age.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0238">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0239"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-024-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-024-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Subgroup: sevelamer versus calcium, Outcome 2 Death (all causes): CKD GFR category." data-id="CD006023-fig-0239" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24 Subgroup: sevelamer versus calcium, Outcome 2 Death (all causes): CKD GFR category. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0239">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0240"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-024-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-024-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Subgroup: sevelamer versus calcium, Outcome 3 Cardiovascular death: CKD GFR category." data-id="CD006023-fig-0240" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.3</div> <div class="figure-caption"> <p>Comparison 24 Subgroup: sevelamer versus calcium, Outcome 3 Cardiovascular death: CKD GFR category. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0240">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0241"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-024-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-024-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Subgroup: sevelamer versus calcium, Outcome 4 Death (all causes): study duration." data-id="CD006023-fig-0241" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.4</div> <div class="figure-caption"> <p>Comparison 24 Subgroup: sevelamer versus calcium, Outcome 4 Death (all causes): study duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0241">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006023-fig-0242"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/urn:x-wiley:14651858:media:CD006023:CD006023-CMP-024-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_t/tCD006023-CMP-024-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Subgroup: sevelamer versus calcium, Outcome 5 Death (all causes): random sequence generation and allocation concealment." data-id="CD006023-fig-0242" src="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.5</div> <div class="figure-caption"> <p>Comparison 24 Subgroup: sevelamer versus calcium, Outcome 5 Death (all causes): random sequence generation and allocation concealment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-fig-0242">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/media/CDSR/CD006023/image_n/nCD006023-CMP-024-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006023-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Sevelamer versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Sevelamer versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> most studies involved people with CKD not requiring dialysis </p> <p><b>Intervention:</b> sevelamer versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sevelamer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Death (all causes)</p> <p>Follow‐up: 3 to 24 months (median 10 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.16</b> </p> <p>(0.20 to 22.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>248 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>A single study reported 1 or more events. The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>17 per 1000</b> </p> <p>(2 to 183)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.90 (0.12 to 29.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported 1 event in each group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p>Follow‐up: 2 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>30 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> <p>(2 to 673)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b> </p> <p>(0.07 to 22.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>370 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 2.8 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> </p> <p>(3 to 173)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.09</b> </p> <p>(0.26 to 16.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 2 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> <p>(23 to 218)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 6.92</b> </p> <p>(2.24 to 21.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>430 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 2 to 10 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>4.48 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the sevelamer group was<br/> <b>0.28 mg/dL lower</b> (0.39 higher to 0.94 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>483 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> <p>Follow‐up: 24 months (both studies)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcium score in the placebo group was <b>945</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcium score in the sevelamer group was</p> <p><b>70 lower</b> (362 lower to 222 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: Sevelamer versus placebo/usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006023-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: Lanthanum versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Lanthanum versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> most studies involved people with CKD not requiring dialysis </p> <p><b>Intervention:</b> lanthanum versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or standard care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lanthanum</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Death (all causes)</p> <p>Follow‐up: 1.8 to 12 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.63</b> </p> <p>(0.07 to 37.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>214 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5,6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>A single death was reported among three studies. The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p>Follow‐up: 1.8 to 12 months (median 2 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>87 per 1000</b> </p> <p>(32 to 237)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.72</b> </p> <p>(1.36 to 10.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 1.8 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>89 per 1000</b> </p> <p>(13 to 601)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.76</b> </p> <p>(0.41 to 18.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 1.8 to 9 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>35 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>104 per 1000</b> </p> <p>(42 to 255)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.98</b> </p> <p>(1.21 to 7.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>299 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 1.8 to 12 months (median 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>4.7 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the lanthanum group was <b>0.48 mg/dL lower</b> </p> <p>(0.05 to 0.90 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the placebo group was <b>23 mm<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the lanthanum group was<b>3 mm<sup>3</sup> higher</b> (9.86 lower to 15.86 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: Lanthanum versus placebo/usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006023-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: Iron versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Iron versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> dialysis (1 study) and CKD (2 studies) </p> <p><b>Intervention:</b> iron versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or standard care</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Iron</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (all causes)</p> <p>Follow‐up: 2.75 to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>19 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> <p>(1 to 89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.52</b> </p> <p>(0.06 to 4.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypercalcaemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>68 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>67 per 1000</b> </p> <p>(20 to 221)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> (0.30 to 3.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 1.8 to 3 months (median 2.75 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>114 per 1000</b> </p> <p>(49 to 262)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.66</b> </p> <p>(1.15 to 6.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 1.8 to 3 months (median 2.75 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>5.8 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate in the iron group was</p> <p><b>1.33 mg/dL lower</b> </p> <p>(0.41 to 2.25 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: Iron versus placebo/usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006023-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: Calcium versus placebo/usual care</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Calcium versus placebo or usual care for preventing and treating bone disease in people chronic kidney disease (CKD) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting:</b> Most studies involved people with CKD not requiring dialysis </p> <p><b>Intervention</b>: calcium versus placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Calcium</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death (all causes)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>22 per 1000</b> </p> <p>(2 to 203)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.46</b> </p> <p>(0.05 to 4.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 3 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>56 per 1000</b> </p> <p>(13 to 248)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 7.28</b> </p> <p>(1.64 to 32.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p>Follow‐up: 3 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>38 per 1000</b> </p> <p>(10 to 144)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.58</b> </p> <p>(0.15 to 2.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> <p>Follow‐up: 3 to 9 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>161 per 1000</b> </p> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.44</b> </p> <p>(0.32 to 18.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 5.5 to 24 months (median 9 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the placebo group was <b>5.0 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean serum phosphate level in the calcium group was <b>0.18 mg/dL lower</b> (0.95 higher to 1.30 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies were predominantly in CKD G2 to G5. Therefore, the evidence certainty for patients treated with dialysis (GFR 5D) is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcification score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the placebo group was <b>473</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean coronary artery calcification score in the calcium group was <b>74 lower</b> (443 lower to 295 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A single study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of included studies</p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: Calcium versus placebo/usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006023-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: Sevelamer versus calcium</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sevelamer versus calcium for preventing and treating bone disease people with in chronic kidney disease (CKD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with CKD </p> <p><b>Setting</b>: most studies involved people treated with dialysis </p> <p><b>Intervention:</b> sevelamer versus calcium </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Calcium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Sevelamer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Death (all causes)</b> </p> <p>Follow‐up: 1.8 to 36 months (median 5.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Low risk population (CKD G2 to G5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>RR 0.53</b> </p> <p>(0.30 to 0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>3688 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>124 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> <p>(27 to 227)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High risk population (CKD G5D)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>210 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>105 per 1000</b> </p> <p>(55 to 199)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cardiovascular death</b> </p> <p>Follow‐up: 3 to 36 months (median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk population (CKD G2 to G5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> </p> <p>(0.11 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2829 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>92 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 1000</b> </p> <p>(1 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>High risk population (CKD G5D)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>132 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>112 per 1000</b> </p> <p>(11 to 177)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 1.8 to 36 months (median 5.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b><br/> (28 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.30</b> </p> <p>(0.20 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4084 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> <p>Follow‐up: 2 to 12 months (median 9 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>123 per 1000</b><br/> (70 to 214) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> </p> <p>(0.56 to 1.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>365 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 9 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>158 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>150 per 1000</b> </p> <p>(85 to 267)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.95</b> </p> <p>(0.54 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Constipation</b> </p> <p>Follow‐up: 2 to 20 months (median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/> (9 to 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.35</b> </p> <p>(0.71 to 2.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2652 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 1.8 to 36 months (median 5.5 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the calcium group was <b>5.39 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the sevelamer group was<br/> <b>0.06 mg/dL higher</b> </p> <p>(0.11 lower to 0.23 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4360 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coronary artery calcium score</b> </p> <p>Follow‐up: 12‐24 months (median 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the calcium group was <b>923</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the sevelamer group was</p> <p><b>25 lower</b> (76 lower to 26 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the median incidence of the event in the control arm of included studies. Where there was a wide range of reported incidence (for example, Death (all causes) ranged from 10 per 1000 to 340 per 1000), two levels of risk (high and low) were generated for calculation of absolute risks </p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: Sevelamer versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006023-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings ‐ Lanthanum versus calcium</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lanthanum versus calcium for preventing and treating bone disease people with in chronic kidney disease (CKD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with CKD </p> <p><b>Setting</b>: most studies involved people treated with dialysis </p> <p><b>Intervention:</b> lanthanum versus calcium </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Calcium</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lanthanum</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death (all causes)</p> <p>Follow‐up: 1.8 to 18 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk population (CKD G5D)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> </p> <p>(0.18 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>505 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The studies were in CKD G5D</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> <p>(3 to 48)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiovascular</b> death </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data observations</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypercalcaemia</b> </p> <p>Follow‐up: 1.8 to 12 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/> (14 to 103) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.16</b> </p> <p>(0.06 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1347 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> <p>Follow‐up: 1.8 to 12 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>88 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b><br/> (84 to 254) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b> </p> <p>(0.95 to 2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1191 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> <p>Follow‐up: 1.8 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b> </p> <p>(37 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.88</b> </p> <p>(0.48 to 31.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1058 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,3,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Constipation</b> </p> <p>Follow‐up: 1.8 to 18 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><br/> (33 to 84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p>(0.50 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1213 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>1,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum phosphate level</b> </p> <p>Follow‐up: 3 to 12 months (median 6 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the calcium group was <b>5.39 mg/dL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum phosphate level in the lanthanum group was<br/> <b>0.01 mg/dL lower</b><br/> (0.42 higher to 0.43 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to assess for publication bias due to substantial between‐study heterogeneity. The studies were predominantly in CKD G5D Therefore, the evidence certainty for patients with CKD G2 to G5 is very low </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary artery calcium score</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the calcium group was <b>1640</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean coronary artery calcium score in the lanthanum group was <b>57</b> lower (1308 lower to 5 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>6</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A single study reported 1 or more events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk is the event rate per annum in the control arm of the control arm of included studies. Where there was a wide range of reported incidence (for example, Death (all causes) ranged from 10 per 1000 to 340 per 1000), two levels of risk (high and low) were generated for calculation of absolute risks. </p> <p><sup>1</sup> Evidence certainty was downgraded by one level due to study limitations. Most studies had unclear risks for random sequence generation and allocation concealment and were not blinded (participants or investigators) </p> <p><sup>2</sup> Evidence certainty was downgraded by one level due to moderate or substantial between‐study heterogeneity </p> <p><sup>3</sup> Evidence certainty was downgraded by one level due to imprecision </p> <p><sup>4</sup> Evidence certainty was downgraded by one level due to publication bias </p> <p><sup>5</sup> Evidence certainty was downgraded by two levels due to severe imprecision </p> <p><sup>6</sup> Data came from only one study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings ‐ Lanthanum versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/full#CD006023-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sevelamer versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.20, 22.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.11, 9.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.07, 22.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.26, 16.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.13, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.92 [2.24, 21.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.13, 31.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Abdominal bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 End‐stage kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.52, 4.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Coronary artery calcium score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐70.19 [‐362.44, 222.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.94, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.08, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.23 [‐26.52, 18.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.55 [‐21.16, 8.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Serum bicarbonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐1.30, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐4.74, 3.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Bone mineral density: lumbar spine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Bone mineral density: hip <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Klotho <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sevelamer versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lanthanum versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.07, 37.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.17, 14.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.14, 8.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.72 [1.36, 10.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.41, 18.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.03, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [1.21, 7.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.13, 3.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 End‐stage kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Coronary artery calcification score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Vascular calcification score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.90, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.18, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.36 [‐9.96, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.07 [‐10.69, 30.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐1.80, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Bone mineral density: lumbar spine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Serum FGF23 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.81, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lanthanum versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Iron versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.06, 4.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [1.15, 6.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.18, 6.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.34, 4.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.33 [‐2.25, ‐0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.09, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serum bicarbonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐2.97, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Iron versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Calcium versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.09, 21.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [0.17, 99.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.29, 4.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.15, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.13, 3.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.32, 18.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.39, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Coronary artery calcification score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐1.30, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.26, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.28 [1.64, 32.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐80.15 [‐305.46, 145.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>34.86 [‐21.47, 91.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Serum bicarbonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.85 [‐3.12, ‐0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Calcium versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bixalomer versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 End‐stage kidney disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bixalomer versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Nicotinamide versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.06, 40.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.24, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.30, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.81 [‐13.36, ‐2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Nicotinamide versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Colestilan versus placebo or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Colestilan versus placebo or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sevelamer versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.30, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.11, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.11, 9.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.32, 27.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.56, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.56, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.54, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.68, 4.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.71, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.55, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Abdominal bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.85 [0.87, 27.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.20, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Calciphylaxis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Coronary artery calcium score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐24.89 [‐75.66, 25.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.11, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.54, ‐0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐0.57, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.24 [10.93, 77.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.64 [‐0.16, 35.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Serum bicarbonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.57 [‐2.15, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Serum FGF23 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Soluble Klotho <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sevelamer versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Lanthanum versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.18, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.34, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.95, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.88 [0.48, 31.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.50, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.34, 17.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Abdominal bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Coronary artery calcium score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.06, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.42, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.59, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.67 [‐5.01, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.78 [‐9.03, 76.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.03 [‐3.69, 43.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 eGFR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Serum FGF23 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐2.33, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Lanthanum versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Magnesium versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Magnesium versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Aluminium versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Aluminium versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Magnesium plus calcium versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.26 [‐3.52, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐2.39, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Magnesium plus calcium versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sevelamer versus lanthanum</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Abdominal bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sevelamer versus lanthanum</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Sevelamer versus iron</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.38, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.86 [0.33, 44.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.02, 9.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.96 [1.96, 12.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.06, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.29, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum bicarbonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Sevelamer versus iron</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Sevelamer versus bixalomer</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Abdominal bloating <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serum bicarbonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Sevelamer versus bixalomer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Sevelamer versus nicotinamide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Sevelamer versus nicotinamide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Sevelamer versus colestilan</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Abdominal pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Sevelamer versus colestilan</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Sevelamer versus aluminium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Sevelamer versus aluminium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Sevelamer versus magnesium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Sevelamer versus magnesium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Sevelamer versus sevelamer + calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Sevelamer versus sevelamer + calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Sevelamer versus calcium + magnesium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum bicarbonate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Sevelamer versus calcium + magnesium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Sevelamer hydrochloride versus sevelamer carbonate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Sevelamer hydrochloride versus sevelamer carbonate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Calcium acetate versus calcium carbonate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.07, 17.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.45, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.74, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum calcium <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.45, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum calcium‐by‐phosphate product <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum iPTH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serum alkaline phosphatase <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [‐8.80, 12.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Calcium acetate versus calcium carbonate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006023-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Subgroup: sevelamer versus calcium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all causes): age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.30, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mean study age above 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.31, 7.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mean study age 60 years or below</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death (all causes): CKD GFR category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.30, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Stage 2‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.22, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Stage 5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.26, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular death: CKD GFR category <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.11, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Stage 2 to 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.01, 13.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Stage 5D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.46, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Death (all causes): study duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.32, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Less than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.34, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Equal to or longer than 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Death (all causes): random sequence generation and allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.34, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.36, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Unclear/high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.27, 1.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Subgroup: sevelamer versus calcium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006023.pub3/references#CD006023-tbl-0030">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006023.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006023-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006023-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD006023-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006023-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD006023-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006023-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006023\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006023\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006023\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006023\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006023\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006023.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006023.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006023.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006023.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006023.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725740873"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006023.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725740876"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006023.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8297bf87936d',t:'MTc0MDcyNTc0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 